var images_info;if (!images_info) images_info =[]; images_info["114"]={"114001":{"type":"graphic_table","displayName":"Categorization of Hirschsprung-associated enterocolitis","title":"Suggested categorization and management of patients with suspected or established Hirschsprung-associated enterocolitis (HAEC)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested categorization and management of patients with suspected or established Hirschsprung-associated enterocolitis (HAEC)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">APSA categorization</td> <td class=\"subtitle1\">Typical presenting symptoms</td> <td class=\"subtitle1\">Typical radiographic features</td> <td class=\"subtitle1\">Recommended treatment <br /> (do all of the following)</td> <td class=\"subtitle1\">Possible additional measures</td> </tr> <tr> <td>Possible HAEC (Grade I)</td> <td>Anorexia, diarrhea, mild abdominal distention</td> <td>Normal radiograph, or mild signs of ileus</td> <td> <ul> <li>Oral hydration </li> <li>Oral metronidazole </li> </ul> </td> <td> <ul> <li>Rectal irrigations </li> </ul> </td> </tr> <tr> <td>Definite HAEC (Grade II)</td> <td>One or more of the following:* <ul class=\"decimal_heading\"> <li>Explosive diarrhea </li> <li>Fever, tachycardia, or lethargy </li> <li>Moderate abdominal distention and/or tenderness </li> <li>Explosive gas/stool on rectal examination </li> </ul> </td> <td>May include: <ul class=\"decimal_heading\"> <li>Signs of ileus, including air-fluid levels and dilated loops of bowel </li> <li>Distension of the proximal colon, with rectosigmoid cutoff<sup>&#182;</sup> </li> </ul> </td> <td> <ul> <li>Clear liquids or hold feeds </li> <li>IV hydration </li> <li>Metronidazole (oral or IV) </li> <li>Broad spectrum antibiotic coverage<sup>&#916;</sup> (in addition to metronidazole) </li> <li>Rectal irrigations </li> </ul> </td> <td> <ul> <li>Nasogastric decompression<sup>&#9674;</sup> </li> </ul> </td> </tr> <tr> <td>Severe HAEC (Grade III)</td> <td>Symptoms of Grade II (above), PLUS: <ul class=\"decimal_heading\"> <li>Obstipation </li> <li>Poor perfusion </li> <li>Hypotension </li> <li>Altered consciousness/mentation </li> <li>Marked abdominal distension </li> <li>Signs of peritonitis </li> </ul> </td> <td>Signs of Grade II (above), PLUS possible: <ul class=\"decimal_heading\"> <li>Pneumatosis intestinalis </li> <li>Pneumoperitoneum (rare) </li> </ul> </td> <td> <ul> <li>Hold feeds </li> <li>Metronidazole (IV), AND </li> <li>Broad-spectrum IV antibiotics<sup>&#916;</sup> </li> <li>Rectal irrigations </li> </ul> </td> <td> <ul> <li>Nasogastric decompression<sup>&#9674;</sup> </li> <li>Possible surgical intervention<sup>&#167;</sup> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HAEC: Hirschsprung-associated enterocolitis; APSA: American Pediatric Surgical Association; IV: intravenous.<br />* A particularly high suspicion for HAEC is appropriate for patients with a prior history of this disorder.<br />¶ On plain radiograph, HAEC is specifically suggested by distension of the proximal colon and absence of air in the distal rectosigmoid colon, with an abrupt cut-off at the level of the pelvic brim.<br />Δ Broad spectrum antibiotic coverage might consist of IV ampicillin with gentamicin, or IV piperacillin/tazobactam.<br /><FONT class=lozenge>◊</FONT> Patients with marked abdominal distension should be treated with nasogastric decompression as well as holding of feeds.<br />§ Patients who develop pneumoperitoneum may require surgical exploration. Patients with severe HAEC who fail to improve with maximal medical management may require surgery with proximal bowel diversion.</div><div class=\"graphic_reference\">Adapted from Gosain A, Frykman PK, Cowles RA, et al. Guidelines for the diagnosis and management of Hirschsprung-associated enterocolitis. Pediatr Surg Int 2017; 33:517.</div><div id=\"graphicVersion\">Graphic 114001 Version 1.0</div></div></div>"},"114010":{"type":"graphic_table","displayName":"Operationalized definitions for PSP diagnosis","title":"Operationalized definitions of core clinical features, supportive clinical clues, and supportive imaging findings for the diagnosis of progressive supranuclear palsy (PSP)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Operationalized definitions of core clinical features, supportive clinical clues, and supportive imaging findings for the diagnosis of progressive supranuclear palsy (PSP)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"30%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Domain</td> <td class=\"subtitle1\">Feature</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Ocular motor dysfunction</td> </tr> <tr> <td class=\"indent1\">O1</td> <td>Vertical supranuclear gaze palsy</td> <td>A clear limitation of the range of voluntary gaze in the vertical more than in the horizontal plane, affecting both upgaze and downgaze, more than expected for age, which is overcome by activation with the vestibulo-ocular reflex; at later stages, the vestibulo-ocular reflex may be lost, or the maneuver prevented by nuchal rigidity.</td> </tr> <tr> <td class=\"indent1\">O2</td> <td>Slow velocity of vertical saccades</td> <td>Decreased velocity (and amplitude) of vertical greater than horizontal saccadic eye movements; this may be established by quantitative measurements of saccades, such as infrared oculography, or by bedside testing; gaze should be assessed by command (\"Look at the flicking finger\") rather than by pursuit (\"Follow my finger\"), with the target &#62;20 degrees from the position of primary gaze; to be diagnostic, saccadic movements are slow enough for the examiner to see their movement (eye rotation), rather than just initial and final eye positions in normal subjects; a delay in saccade initiation is not considered slowing; findings are supported by slowed or absent fast components of vertical optokinetic nystagmus (ie, only the slow following component may be retained).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">O3</td> <td>Frequent macro square wave jerks or \"eyelid opening apraxia\"</td> <td>Macro square wave jerks are rapid involuntary saccadic intrusions during fixation, displacing the eye horizontally from the primary position, and returning it to the target after 200 to 300 milliseconds; most square wave jerks are &#60;1 degree in amplitude and rare in healthy controls, but up to 3 to 4 degrees and more frequent (&#62;10/minute) in PSP.<sup>[1]</sup> \"Eyelid opening apraxia\" is an inability to voluntarily initiate eyelid opening after a period of lid closure in the absence of involuntary forced eyelid closure (ie, blepharospasm); the term is written in quotation marks because the inability to initiate eyelid opening is often attributed to activation of the pretarsal component of the orbicularis oculi (ie, pretarsal blepharospasm) rather than failure to activate the levator palpebrae.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Postural instability</td> </tr> <tr> <td class=\"indent1\">P1</td> <td>Repeated unprovoked falls within 3 years</td> <td>Spontaneous loss of balance while standing, or history of more than one unprovoked fall, within 3 years after onset of PSP-related features.</td> </tr> <tr> <td class=\"indent1\">P2</td> <td>Tendency to fall on the pull-test within 3 years</td> <td>Tendency to fall on the pull-test if not caught by examiner, within 3 years after onset of PSP-related features. The test examines the response to a quick, forceful pull on the shoulders with the examiner standing behind the patient and the patient standing erect with eyes open and feet comfortably apart and parallel, as described in the MDS-UPDRS item 3.12.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">P3</td> <td>More than two steps backward on the pull-test within 3 years</td> <td>More than two steps backward, but unaided recovery, on the pull-test, within 3 years after onset of PSP-related features.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Akinesia</td> </tr> <tr> <td class=\"indent1\">A1</td> <td>Progressive gait freezing within 3 years</td> <td>Sudden and transient motor blocks or start hesitation are predominant within 3 years after onset of PSP-related symptoms, progressive and not responsive to levodopa; in the early disease course, akinesia may be present, but limb rigidity, tremor, and dementia are absent or mild.</td> </tr> <tr> <td class=\"indent1\">A2</td> <td>Parkinsonism, akinetic-rigid, predominantly axial and levodopa resistant</td> <td>Bradykinesia and rigidity with axial predominance, and levodopa resistance (refer to Clinical Clue CC1 for operationalized definition).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">A3</td> <td>Parkinsonism, with tremor and/or asymmetric and/or levodopa responsive</td> <td>Bradykinesia with rigidity and/or tremor, and/or asymmetric predominance of limbs, and/or levodopa responsiveness (refer to Clinical Clue CC1 for operationalized definition).</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Cognitive dysfunction</td> </tr> <tr> <td class=\"indent1\">C1</td> <td>Speech/language disorder</td> <td>Defined as at least one of the following features, which has to be persistent (rather than transient): <ol> <li>Nonfluent/agrammatic variant of primary - Loss of grammar and/or telegraphic speech or writing progressive aphasia (nfaPPA) or </li> <li>Progressive apraxia of speech (AOS) - Effortful, halting speech with inconsistent speech sound errors and distortions or slow syllabically segmented prosodic speech patterns with spared single-word comprehension, object knowledge, and word retrieval during sentence repetition. </li> </ol> </td> </tr> <tr> <td class=\"indent1\">C2</td> <td>Frontal cognitive/behavioral presentation</td> <td>Defined as at least three of the following features, which have to be persistent (rather than transient): <ol> <li>Apathy - Reduced level of interest, initiative, and spontaneous activity; clearly apparent to informant or patient. </li> <li>Bradyphrenia - Slowed thinking; clearly apparent to informant or patient. </li> <li>Dysexecutive syndrome - Eg, reverse digit span, Trails B or Stroop test, Luria sequence (at least 1.5 standard deviations below mean of age- and education-adjusted norms). </li> <li>Reduced phonemic verbal fluency - Eg, \"D, F, A, or S\" words per minute (at least 1.5 standard deviations below mean of age- and education-adjusted norms). </li> <li>Impulsivity, disinhibition, or perseveration - Eg, socially inappropriate behaviors, overstuffing the mouth when eating, motor recklessness, applause sign, palilalia, echolalia. </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">C3</td> <td>CBS</td> <td>Defined as at least one sign each from the following two groups (may be asymmetric or symmetric): <ol> <li>Cortical signs <ol style=\"list-style-type: lower-alpha;\"> <li>Orobuccal or limb apraxia. </li> <li>Cortical sensory deficit. </li> <li>Alien limb phenomena (more than simple levitation.) </li> </ol> </li> <li>Movement disorder signs <ol style=\"list-style-type: lower-alpha;\"> <li>Limb rigidity. </li> <li>Limb akinesia. </li> <li>Limb myoclonus. </li> </ol> </li> </ol> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Clinical clues</td> </tr> <tr> <td class=\"indent1\">CC1</td> <td>Levodopa resistance</td> <td>Levodopa resistance is defined as improvement of the MDS-UPDRS motor scale by &#8804;30%; to fulfill this criterion patients should be assessed having been given at least 1000 mg (if tolerated) at least 1 month OR once patients have received this treatment they could be formally assessed following a challenge dose of at least 200 mg.</td> </tr> <tr> <td class=\"indent1\">CC2</td> <td>Hypokinetic, spastic dysarthria</td> <td>Slow, low volume and pitch, harsh voice.</td> </tr> <tr> <td class=\"indent1\">CC3</td> <td>Dysphagia</td> <td>Otherwise unexplained difficulty in swallowing, severe enough to request dietary adaptations.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">CC4</td> <td>Photophobia</td> <td>Intolerance to visual perception of light attributed to adaptative dysfunction.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Imaging findings</td> </tr> <tr> <td class=\"indent1\">IF1</td> <td>Predominant midbrain atrophy or hypometabolism</td> <td>Atrophy or hypometabolism predominant in midbrain relative to pons, as demonstrated, eg, by MRI or [<sup>18</sup>F]DG-PET.</td> </tr> <tr> <td class=\"indent1\">IF2</td> <td>Postsynaptic striatal dopaminergic degeneration</td> <td>Postsynaptic striatal dopaminergic degeneration, as demonstrated, eg, by [<sup>123</sup>I]IBZM-SPECT or [<sup>18</sup>F]-DMFP-PET.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Otero-Millan J, Serra A, Leigh RJ, et al. Distinctive features of saccadic intrusions and microsaccades in progressive supranuclear palsy. J Neurosci 2011; 31:4379.</li>&#xD;&#xA;</ol>&#xD;&#xA;From: H&ouml;glinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: The Movement Disorder Society criteria. Mov Disord 2017; 32:853. <a href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1002/mds.26987/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/wol1/doi/10.1002/mds.26987/abstract</a>. Copyright &copy; 2017 International Parkinson and Movement Disorder Society. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 114010 Version 1.0</div></div></div>"},"114011":{"type":"graphic_picture","displayName":"Anal fissure","title":"Anal fissure","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Anal fissure</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/PC/114011_Anal_fissure_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 114011 Version 1.0</div></div></div>"},"114012":{"type":"graphic_table","displayName":"Degrees of diagnostic certainty for PSP","title":"Degrees of diagnostic certainty for progressive supranuclear palsy (PSP), obtained by combinations of clinical features and clinical clues","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Degrees of diagnostic certainty for progressive supranuclear palsy (PSP), obtained by combinations of clinical features and clinical clues</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Diagnostic certainty</td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Combinations of clinical features and clinical clues</td> <td class=\"subtitle1\">Predominance type</td> <td class=\"subtitle1\">Abbreviation</td> </tr> <tr class=\"divider_bottom\"> <td>Definite PSP</td> <td>Gold standard defining the disease entity.</td> <td>Neuropathological diagnosis</td> <td>Any clinical presentation</td> <td>Definite PSP</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Probable PSP</td> <td class=\"divider_bottom\" rowspan=\"4\"> <p>Highly specific, but not very sensitive for PSP.</p> <em>Suitable for therapeutic and biological studies.</em></td> <td>(O1 or O2) + (P1 or P2)</td> <td>PSP with Richardson's syndrome (PSP-RS)</td> <td>Probable PSP-RS</td> </tr> <tr> <td>(O1 or O2) + A1</td> <td>PSP with progressive gait freezing (PSP-PGF)</td> <td>Probable PSP-PGF</td> </tr> <tr> <td>(O1 or O2) + (A2 or A3)</td> <td>PSP with predominant parkinsonism (PSP-P)</td> <td>Probable PSP-P</td> </tr> <tr class=\"divider_bottom\"> <td>(O1 or O2) + C2</td> <td>PSP with predominant frontal presentation (PSP-F)</td> <td>Probable PSP-F</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Possible PSP</td> <td class=\"divider_bottom\" rowspan=\"5\"> <p>Substantially more sensitive, but less specific for PSP.</p> <em>Suitable for descriptive epidemiological studies and clinical care.</em></td> <td>O1</td> <td>PSP with predominant ocular motor dysfunction (PSP-OM)</td> <td>Possible PSP-OM</td> </tr> <tr> <td>O2 + P3</td> <td>PSP-RS</td> <td>Possible PSP-RS</td> </tr> <tr> <td>A1</td> <td>PSP-PGF</td> <td>Possible PSP-PGF</td> </tr> <tr> <td>(O1 or O2) + C1</td> <td>PSP with predominant speech/language disorder (PSP-SL)*</td> <td>Possible PSP-SL</td> </tr> <tr class=\"divider_bottom\"> <td>(O1 or O2) + C3</td> <td>PSP with predominant corticobasal syndrome (PSP-CBS)*</td> <td>Possible PSP-CBS</td> </tr> <tr> <td rowspan=\"7\">Suggestive of PSP</td> <td rowspan=\"7\"> <p>Suggestive of PSP, but not passing the threshold for possible or probable PSP.</p> <em>Suitable for early identification.</em></td> <td>O2 or O3</td> <td>PSP-OM</td> <td>Suggestive of PSP-OM</td> </tr> <tr> <td>P1 or P2</td> <td>PSP with predominant postural instability (PSP-PI)</td> <td>Suggestive of PSP-PI</td> </tr> <tr> <td>O3 + (P2 or P3)</td> <td>PSP-RS</td> <td>Suggestive of PSP-RS</td> </tr> <tr> <td>(A2 or A3) + (O3, P1, P2, C1, C2, CC1, CC2, CC3, or CC4)</td> <td>PSP-P</td> <td>Suggestive of PSP-P</td> </tr> <tr> <td>C1</td> <td>PSP-SL</td> <td>Suggestive of PSP-SL</td> </tr> <tr> <td>C2 + (O3 or P3)</td> <td>PSP-F</td> <td>Suggestive of PSP-F</td> </tr> <tr> <td>C3</td> <td>PSP-CBS</td> <td>Suggestive of PSP-CBS</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The basic features (mandatory inclusion and exclusion criteria, and context-dependent exclusion criteria; refer to UpToDate text for details) apply for all probable, possible, and suggestive degrees of certainty. <STRONG>Core clinical features</STRONG> are defined by their functional domain (ocular motor dysfunction [O], postural instability [P], akinesia [A], and cognitive dysfunction [C]), and stratified by presumed levels of certainty (1 = highest, 2 = middle, 3 = lowest) that contribute to the diagnosis of PSP. <STRONG>Supportive clinical clues</STRONG> are described in the UpToDate text. Operationalized definitions of clinical features and clinical clues are described in a separate UpToDate table.</div><div class=\"graphic_footnotes\">CC1: levodopa resistance; CC2: hypokinetic, spastic dysarthria; CC3: dysphagia; CC4: photophobia.<br />* Probable 4R-tauopathy (ie, either PSP or corticobasal degeneration).</div><div class=\"graphic_reference\">From: Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: The Movement Disorder Society criteria. Mov Disord 2017; 32:853. <A href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1002/mds.26987/abstract\" target=_blank>http://onlinelibrary.wiley.com/wol1/doi/10.1002/mds.26987/abstract</A>. Copyright © 2017 International Parkinson and Movement Disorder Society. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 114012 Version 1.0</div></div></div>"},"114013":{"type":"graphic_picture","displayName":"Scanning EM in HE","title":"Scanning electron micrograph showing abnormal RBC morphology in hereditary elliptocytosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scanning&nbsp;electron micrograph showing abnormal&nbsp;RBC morphology in hereditary elliptocytosis</div><div class=\"cntnt\"><img style=\"width:379px; height:290px;\" src=\"images/HEME/114013_Abnormal_RBC_morphology_HE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scanning&nbsp;electron micrograph of the peripheral blood of a patient with HE and severe anemia. Note the abnormal RBC morphology with elliptocytes, poikilocytes, and fragmented RBCs. Original magnification ×10,000. Refer to UpToDate for our approach to the evaluation of individuals with suspected HE.</div><div class=\"graphic_footnotes\">RBC: red blood cell; HE: hereditary elliptocytosis.</div><div class=\"graphic_reference\">From: An X, Mohandas N. Disorders of red cell membrane. Br J Haematol 2008; 141:367. <a href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2008.07091.x/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2008.07091.x/abstract</a>. Copyright &copy; 2008. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 114013 Version 1.0</div></div></div>"},"114016":{"type":"graphic_picture","displayName":"Pyogenic granuloma of pregnancy","title":"Pyogenic granuloma of pregnancy","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Pyogenic granuloma of pregnancy</div><div class=\"cntnt\"><img style=\"width:720px; height:575px;\" src=\"images/OBGYN/114016_Pyogenic_granuloma_preg.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Aldulaimi S, Saenz A. A bleeding oral mass in a pregnant woman. JAMA 2017; 318(3):293-294. Copyright © 2017 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 114016 Version 1.0</div></div></div>"},"114017":{"type":"graphic_table","displayName":"Thalassemia monitoring checklist","title":"Checklist for routine monitoring in individuals with thalassemia major","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Checklist for routine monitoring in individuals with&nbsp;thalassemia major</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\"><span class=\"subtitle1\" style=\"background-color: #eeeeee;\">Category</span></td> <td class=\"subtitle1\">Measurement&nbsp;</td> <td class=\"subtitle1\">Interval</td> </tr> <tr> <td rowspan=\"6\">Growth and development</td> <td>Height</td> <td>Monthly</td> </tr> <tr> <td>Sitting height</td> <td>Every&nbsp;three months in children</td> </tr> <tr> <td>Weight</td> <td>Monthly</td> </tr> <tr> <td>Growth velocity</td> <td>Annually</td> </tr> <tr> <td>Tanner stage</td> <td>Every&nbsp;six months in children and adolescents</td> </tr> <tr> <td>Head circumference</td> <td>Every other month in infants</td> </tr> <tr> <td rowspan=\"4\">Hematology</td> <td>CBC, reticulocytes</td> <td>Monthly</td> </tr> <tr> <td>Blood type and antibody screen</td> <td>Monthly</td> </tr> <tr> <td>Coombs (direct)</td> <td>As clinically indicated</td> </tr> <tr> <td>Serum transferrin receptor</td> <td>As clinically indicated</td> </tr> <tr> <td rowspan=\"7\">General</td> <td>HLA typing</td> <td>At initial evaluation</td> </tr> <tr> <td>DNA mapping (alpha and beta)</td> <td>At initial evaluation</td> </tr> <tr> <td>Red blood cell phenotype</td> <td>At initial evaluation</td> </tr> <tr> <td>Volume of packed red blood cells transfused</td> <td>Every 6 to 12 months</td> </tr> <tr> <td>Chemistry panel including calcium level</td> <td>Every&nbsp;three months</td> </tr> <tr> <td>Urinalysis</td> <td>Every&nbsp;six months</td> </tr> <tr> <td>Dental</td> <td>Every 6 to 12 months</td> </tr> <tr> <td rowspan=\"7\">Iron and toxicity</td> <td>Ferritin</td> <td>Every&nbsp;three months</td> </tr> <tr> <td>Liver iron</td> <td>Annually</td> </tr> <tr> <td>Audiology evaluation</td> <td>Annually in children</td> </tr> <tr> <td>Vision screen</td> <td>Every&nbsp;three months</td> </tr> <tr> <td>Ophthalmology evaluation</td> <td>Annually</td> </tr> <tr> <td>Iron, TIBC</td> <td>As clinically indicated</td> </tr> <tr> <td>Transferrin saturation</td> <td>As clinically indicated</td> </tr> <tr> <td rowspan=\"6\">Liver function and disease</td> <td>AST, ALT</td> <td>Every&nbsp;three months</td> </tr> <tr> <td>Bilirubin (direct and total)</td> <td>Every&nbsp;three months</td> </tr> <tr> <td>Hepatitis A, B, and C&nbsp;serology</td> <td>Annually</td> </tr> <tr> <td>Hepatitis B and C PCR</td> <td>As clinically indicated</td> </tr> <tr> <td>PT, aPTT</td> <td>As clinically indicated</td> </tr> <tr> <td>Albumin</td> <td>Annually</td> </tr> <tr> <td rowspan=\"8\">Endocrine</td> <td>T3, free T4, TSH</td> <td>Annually starting at age&nbsp;five years</td> </tr> <tr> <td>PTH</td> <td>Annually starting at age&nbsp;five years</td> </tr> <tr> <td>Calcium, ionized calcium</td> <td>Annually starting at age&nbsp;five years</td> </tr> <tr> <td>Diabetes screening (fasting glucose, HbA1c, or oral glucose tolerance test)*</td> <td>At ages 10, 12, 14, and 16 years</td> </tr> <tr> <td>IGF-1, IGF BP-3</td> <td>As clinically indicated (eg, growth delay)</td> </tr> <tr> <td>LH-ICMA</td> <td>As clinically indicated (eg, delayed puberty)</td> </tr> <tr> <td>FSH</td> <td>As clinically indicated (eg, delayed puberty)</td> </tr> <tr> <td>Estradiol</td> <td>As clinically indicated (eg, delayed puberty)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This is a general timetable for clinical and laboratory evaluations; clinical judgment is used to determine the appropriate interval for all testing and the specific testing and timetable in thalassemia intermedia phenotypes. Evaluations for delayed puberty are generally done for girls at age 12 years and for boys at age 14 years. Refer to UpToDate for additional details of the management of thalassemia.</div><div class=\"graphic_footnotes\">*If there is a concern that hemolysis may falsely lower the HbA1c, the other methods (fasting glucose or oral glucose tolerance test) may be preferred.<br />CBC: complete blood count; HLA: human leukocyte antigen; TIBC: total iron binding capacity; AST: aspartate aminotransferase; ALT: alanine aminotransferase; PCR: polymerase chain reaction; PT: prothrombin time; aPTT: activated partial thromboplastin time; TSH: thyroid-stimulating hormone; PTH: parathyroid hormone; HbA1c: glycosylated hemoglobin; IGF: insulin-like growth factor; BP: binding protein; LH-ICMA: luteinizing hormone-immunochemiluminometric assay; FSH: follicle-stimulating hormone.</div><div class=\"graphic_reference\">Modified with permission from: UCSF Benioff Children's Hospital Oakland, Northern California Comprehensive Thalassemia Center. Treating Thalassemia: Checklist.&nbsp;Available at: <A spellcheck=true href=\"http://thalassemia.com/treatment-checklist.aspx\"target=_blank>http://thalassemia.com/treatment-checklist.aspx</A> (Accessed on July 20, 2017). Copyright © 2017 Children's Hospital &amp; Research Center Oakland.</div><div id=\"graphicVersion\">Graphic 114017 Version 2.0</div></div></div>"},"114021":{"type":"graphic_table","displayName":"High-risk breast lesions and management","title":"High-risk breast lesions and management","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">High-risk breast lesions and management</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Diagnosis</td> <td class=\"subtitle1\">Management after core needle biopsy<sup>[1]</sup></td> <td class=\"subtitle1\">Upgrade rate with excision</td> <td class=\"subtitle1\">Management of margins after excision</td> <td class=\"subtitle1\">Relative risk for invasive cancer</td> <td class=\"subtitle1\">Risk reduction with active surveillance and chemoprevention</td> </tr> <tr> <td>Atypical ductal hyperplasia (ADH)</td> <td>Found on biopsy performed for microcalcifications on screening mammogram</td> <td>Surgical excision for most patients</td> <td>10 to 20%<sup>[2]</sup></td> <td>No re-excision for margins</td> <td>3.1 to 4.7<sup>[2]</sup></td> <td>Yes</td> </tr> <tr> <td>Atypical lobular hyperplasia (ALH)</td> <td>Incidental finding on biopsy performed for other reasons</td> <td> <p>Surgical excision for discordance or presence of other high-risk lesion</p> Observation for other lesions </td> <td>&#60;3% for concordant, small-volume disease<sup>[2]</sup></td> <td>No re-excision for margins</td> <td>3.1 to 5.9<sup>[2]</sup></td> <td>Yes</td> </tr> <tr> <td>Lobular carcinoma in situ (LCIS)</td> <td>Incidental finding on biopsy performed for other reasons</td> <td> <p>Surgical excision for non-classic features (pleomorphic, comedo necrosis, signet ring, or apocrine), or for discordance</p> Observation for concordant classic LCIS </td> <td>&#60;5% for concordant, small-volume disease<sup>[2]</sup></td> <td> <p>Re-excision to negative margins for pleomorphic LCIS</p> No re-excision for margins for classic LCIS </td> <td>6.9 to 11<sup>[2]</sup></td> <td>Yes</td> </tr> <tr> <td>Flat epithelial atypia (FEA)</td> <td>Found on biopsy performed for microcalcifications on screening mammogram</td> <td> <p>Surgical excision for discordance or FEA associated with residual microcalcification</p> Observation for concordant pure FEA </td> <td>0 to 3.2% for pure FEA<sup>[2]</sup></td> <td>No re-excision for margins</td> <td>1.47<sup>[3]</sup></td> <td>No for pure FEA (return to routine surveillance)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li><a href=\"https://www.breastsurgeons.org/new_layout/about/statements/PDF_Statements/Concordance_and_High%20RiskLesions.pdf\" target=\"_blank\">https://www.breastsurgeons.org/new_layout/about/statements/PDF_Statements/Concordance_and_High%20RiskLesions.pdf</a> (Accessed on June 29, 2017). </li>&#xD;&#xA;    <li>Morrow M, Schnitt SJ, Norton L. Current management of lesions associated with an increased risk of breast cancer. Nat Rev Clin Oncol 2015; 12:227. </li>&#xD;&#xA;    <li>Boulos FI, Dupont WD, Simpson JF, et al. Histologic associations and long-term cancer risk in columnar cell lesions of the breast: a retrospective cohort and a nested case-control study. Cancer 2008; 113:2415. </li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 114021 Version 1.0</div></div></div>"},"114025":{"type":"graphic_table","displayName":"Marijuana Withdrawal Checklist","title":"Marijuana Withdrawal Checklist<SUP>[1,2]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Marijuana Withdrawal Checklist<SUP>[1,2]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"5\">Please indicate whether or not you have experienced these symptoms and rate their severity since&nbsp;<strong>you stopped using marijuana</strong>.</td> </tr> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">None</td> <td class=\"subtitle1\">Mild</td> <td class=\"subtitle1\">Moderate</td> <td class=\"subtitle1\">Severe</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Mood</td> </tr> <tr> <td class=\"indent1\">Depression</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Irritability</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Nervousness</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Increased anger</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Increased aggression</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Behavioral</td> </tr> <tr> <td class=\"indent1\">Decreased appetite</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Sleep difficulty</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Cravings to smoke marijuana</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Restlessness</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Strange dreams</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Physical</td> </tr> <tr> <td class=\"indent1\">Shakiness</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Nausea</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Sweating</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Headaches</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Stomach pains</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Each item is scored for intensity on a 0 to 3 scale. Higher total scores indicate greater intensity of withdrawal. The 10-item Withdrawal Discomfort Score omits items increased aggression, shakiness, nausea, sweating, and stomach pains.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Budney AJ, Novy PL, Hughes JR. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 1999; 94:1311.</li>&#xD;&#xA;    <li>Budney AJ, Moore BA, Vandrey RG, Hughes JR. The time course and significance of cannabis withdrawal. J Abnorm Psychology 2003; 112:393.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: Available at: <a href=\"https://www.phenxtoolkit.org/index.php?pageLink=browse.si.all&amp;saa=true\" target=\"_blank\">https://www.phenxtoolkit.org/index.php?pageLink=browse.si.all&amp;saa=true</a> (accessed on July 21, 2017).</div><div id=\"graphicVersion\">Graphic 114025 Version 1.0</div></div></div>"},"114026":{"type":"graphic_table","displayName":"CMS quality measures for skilled nursing facilities","title":"CMS quality measures for skilled nursing facilities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">CMS quality measures for skilled nursing facilities</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Short-stay quality measures</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Percent of residents who self-report moderate to severe pain</li> <li>Percent of residents with pressure ulcers that are new or worsened</li> <li>Percent of residents who were assessed and appropriately given the influenza vaccine</li> <li>Percent of residents who were assessed and appropriately given the pneumococcal vaccine</li> <li>Percent of residents who newly received an antipsychotic medication</li> <li>Percent of residents who were successfully discharged to the community</li> <li>Percent of residents who have had an outpatient emergency department visit</li> <li>Percent of residents who were re-hospitalized after an SNF admission</li> <li>Percent of residents who made improvements in function</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Long-stay quality measures</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Percent of residents who self-report moderate to severe pain</li> <li>Percent of high-risk* patients with pressure ulcers</li> <li>Percent of residents experiencing one or more falls with major injury</li> <li>Percent of residents who were assessed and appropriately given the influenza vaccine</li> <li>Percent of residents who were assessed and appropriately given the pneumococcal vaccine</li> <li>Percent of residents who received an antipsychotic medication</li> <li>Percent of residents who received an anxiety or hypnotic medication</li> <li>Percent of residents with a urinary tract infection</li> <li>Percent of low-risk<sup>&#182;</sup> residents who lose control of their bowels or bladder</li> <li>Percent of residents who have/had a catheter inserted and left in their bladder</li> <li>Percent of residents who were physically restrained</li> <li>Percent of residents whose need for help with activities of daily living has increased</li> <li>Percent of residents whose ability to move independently worsened</li> <li>Percent of residents who lose too much weight<sup>&#916;</sup></li> <li>Percent of residents who have depressive symptoms</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CMS: Centers for Medicare and Medicaid Services; SNF: skilled nursing facility.<br />* High risk for pressure ulcers: Impaired in bed mobility, comatose, or suffering from malnutrition.<br />¶ Low risk for loss of control of bladder/bowel: Lack of severe cognitive impairment or not totally dependent in mobility related activities of daily living.<br />Δ Weight loss: 5% in last month or 10% in last six months.</div><div id=\"graphicVersion\">Graphic 114026 Version 1.0</div></div></div>"},"114028":{"type":"graphic_table","displayName":"Amount of blood to transfuse","title":"Calculation of the amount of blood to transfuse based on the hematocrit of packed RBCs and the desired increase in hemoglobin level","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Calculation of the amount of blood to transfuse based on the hematocrit of packed RBCs and the desired increase in hemoglobin level</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Desired&nbsp;increase in hemoglobin</td> <td class=\"subtitle1\" colspan=\"4\">Hematocrit of donor red cells</td> </tr> <tr> <td class=\"subtitle2\">50%</td> <td class=\"subtitle2\">60%</td> <td class=\"subtitle2\">75%</td> <td class=\"subtitle2\">80%</td> </tr> <tr> <td class=\"centered\">2 g/dL</td> <td class=\"centered\">12 mL/kg</td> <td class=\"centered\">10 mL/kg</td> <td class=\"centered\">8 mL/kg</td> <td class=\"centered\">7.5 mL/kg</td> </tr> <tr> <td class=\"centered\">3 g/dL</td> <td class=\"centered\">18 mL/kg</td> <td class=\"centered\">15 mL/kg</td> <td class=\"centered\">12 mL/kg</td> <td class=\"centered\">11.2 mL/kg</td> </tr> <tr> <td class=\"centered\">4 g/dL</td> <td class=\"centered\">24 mL/kg</td> <td class=\"centered\">20 mL/kg</td> <td class=\"centered\">16 mL/kg</td> <td class=\"centered\">15 mL/kg</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The amount of blood (volume or number of units) depends on the starting hemoglobin level, desired increase, hematocrit of the packed RBCs, and size of the patient, and requires some empirical dose-finding for each individual. Units&nbsp;with CPD-A tend to have hematocrits close to 75%; units with additive solutions tend to have lower hematocrits.&nbsp;As an example calculation, to raise hemoglobin level by 4 g/dL in a patient weighing 40 kg and receiving blood with the AS1 additive (with a hematocrit of 60%) would require 800 mL. This calculation assumes a blood volume of 70 mL/kg body weight. In many cases, it may be easier to order a certain number of units rather than a volume of blood, especially for adults.</div><div class=\"graphic_footnotes\">RBCs: Red blood cells.</div><div class=\"graphic_reference\">Reproduced with permission from: Trompeter S, Cohen A. Blood transfusion. In: Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT), 3rd ed, Cappellini MD, Cohen A, Porter J, et al (Eds), Thalassaemia International Federation 2014. p.28. Copyright &copy; 2014 Thalassaemia International Federation. All rights reserved.</div><div id=\"graphicVersion\">Graphic 114028 Version 2.0</div></div></div>"},"114030":{"type":"graphic_figure","displayName":"Newborn assessment of ocular distance","title":"Newborn assessment of ocular distance","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Newborn assessment of ocular distance</div><div class=\"cntnt\"><img style=\"width:506px; height:416px;\" src=\"images/PEDS/114030_Newborn_assessment_of_ocular_distance.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distance between the eyes should be measured in newborn infants if the eye spacing appears abnormal. The standard values for the newborn include:<br />Arrow A. Outer canthal distance ranges from 5.2 to 7.3 cm (2 to 2.9 inches). <br />Arrow B. Inner canthal distance ranges from 1.5 to 2.55 cm (0.6 to 1 inch).<br />Arrow C. Interpupillary distance ranges from 3.25 to 4.5 cm (1.3 to 1.8 inches).</div><div class=\"graphic_reference\">Modified from: Feingold M, Bossert WH. Normal values for selected physical parameters: an aid to syndrome delineation. Birth Defects Orig Artic Ser 1974; 10:1.</div><div id=\"graphicVersion\">Graphic 114030 Version 1.0</div></div></div>"},"114031":{"type":"graphic_table","displayName":"Shared decision making","title":"Shared decision making","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Shared decision making</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Patient is informed of all medical issues </li> </ul> </td> </tr> <tr> <td> <ul> <li>Patient is informed of recommendations and all options for care </li> </ul> </td> </tr> <tr> <td> <ul> <li>Patient is aware of the&nbsp;benefits and risks of the options of care </li> </ul> </td> </tr> <tr> <td> <ul> <li>Patient's personal expectations and concerns are considered </li> </ul> </td> </tr> <tr> <td> <ul> <li>Providers consider the patient's viewpoint </li> </ul> </td> </tr> <tr> <td> <ul> <li>Providers answer all the patient's questions </li> </ul> </td> </tr> <tr> <td> <ul> <li>Patient actively participates in all decisions </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Flierler WJ, N&uuml;bling M, Kasper J, Heidegger T. Implementation of shared decision making in anaesthesia and its influence on patient satisfaction. Anaesthesia 2013; 68:713.</div><div id=\"graphicVersion\">Graphic 114031 Version 2.0</div></div></div>"},"114035":{"type":"graphic_table","displayName":"Causes of and contributing factors to blepharitis","title":"Causes of and contributing factors to blepharitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of and contributing factors to blepharitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Inflammatory skin conditions</td> </tr> <tr> <td class=\"indent1\">Rosacea</td> <td> <ul> <li>More commonly causes posterior blepharitis </li> <li>May be associated with facial redness or flushing </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Seborrheic dermatitis</td> <td> <ul> <li>More commonly causes anterior blepharitis </li> <li>Characterized by flaking and greasy scales at base of eyelids </li> <li>May be associated with scalp dandruff and other manifestations </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Atopic dermatitis (eczema)</td> <td> <ul> <li>Characterized by edema, hyperemia, and scaling of lash line of lid margins </li> <li>May be associated with other manifestations (eg, chronic pruritic erythematous rash involving skin creases) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Psoriasis</td> <td> <ul> <li>Characterized by flaking or crusting of the eyelashes and swollen eyelids </li> <li>May be associated with other manifestations (eg, well-defined erythematous plaques with scale involving elbows and knees) </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Infections</td> </tr> <tr> <td class=\"indent1\">Bacterial \"over-colonization\"</td> <td> <ul> <li>Most commonly causes anterior blepharitis </li> <li>Characterized by fibrinous scales and crust around the eyelashes </li> <li><em>Staphylococcus aureus</em> and coagulase-negative staphylococci are the most common organisms </li> <li>Other lid-colonizing bacteria (eg, <em>Corynebacterium</em> species, <em>Cutibacterium acnes</em>) may play a role </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Parasitic infestation (<em>Demodex</em> species)</td> <td> <ul> <li>Inhabit eyelid follicles (<em>Demodex folliculorum</em>) and meibomian glands (<em>Demodex brevis</em>) </li> <li>Characterized by follicular pustules or papules </li> <li>Scales may form \"collarettes\" (cylindrical dandruff around the lash base) </li> <li>Not all patients with <em>Demodex</em> infestation develop blepharitis </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Irritants and allergens (contact blepharitis)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cosmetics, cigarette smoke, contact lenses/contact lens solution</td> <td> <ul> <li>Characterized by erythematous, swollen, and itchy eyelids </li> <li>Reaction to local irritant </li> <li>Improves with removal/avoidance of offending agent </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Medications</td> </tr> <tr> <td class=\"indent1\">Retinoids (eg, isotretinoin), chemotherapeutic agents (eg, 5-fluorouracil)</td> <td> <ul> <li>Typically causes posterior blepharitis (meibomian gland dysfunction) </li> <li>Commonly associated with dry eye </li> <li>Generally resolves after discontinuing medication </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 114035 Version 2.0</div></div></div>"},"114036":{"type":"graphic_table","displayName":"Questions to identify an association between fungus and symptoms","title":"Questions that can be asked to identify an association between fungus exposure and increased symptoms*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Questions that can be asked to identify an association between fungus exposure and increased symptoms*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Do your symptoms get worse when you are in an environment with visible mold? </li> </ul> </td> </tr> <tr> <td> <ul> <li>Do your symptoms get worse when you visit an old house or building? </li> </ul> </td> </tr> <tr> <td> <ul> <li>Do your symptoms get worse when you enter a basement or other damp environment? </li> </ul> </td> </tr> <tr> <td> <ul> <li>Do your symptoms get worse after rain storms? </li> </ul> </td> </tr> <tr> <td> <ul> <li>Do your symptoms get worse after you mow the lawn, rake leaves, or work with compost or hay? </li> </ul> </td> </tr> <tr> <td> <ul> <li>Do your symptoms get worse when you are in buildings with a moldy or musty smell? </li> </ul> </td> </tr> <tr> <td> <ul> <li>Do your symptoms get worse during the late summer and fall? </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* While the predictive value of these questions has not been validated in clinical trials, they do make sense given our knowledge of fungus exposure in certain types of environments.</div><div class=\"graphic_reference\">Reproduced from: Larenas-Linnemann D, Baxi S, Phipatanakul W, et al. Clinical evaluation and management of patients with suspected fungus sensitivity. J Allergy Clin Immunol Pract 2016; 4:405. Table used with the permission of Elsevier, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 114036 Version 1.0</div></div></div>"},"114038":{"type":"graphic_table","displayName":"Antibiotics for treatment of MRSA bacteremia in adults","title":"Antibiotics for treatment of bacteremia due to methicillin-resistant <EM>Staphylococcus aureus</EM> (MRSA) in adults<SUP>[1-3]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antibiotics for treatment of bacteremia due to methicillin-resistant <EM>Staphylococcus aureus</EM> (MRSA) in adults<SUP>[1-3]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Adult dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Antibiotics of choice</td> </tr> <tr> <td class=\"indent1\">Vancomycin</td> <td>15 to 20 mg/kg/dose IV every 8 to 12 hours, not to exceed 2 g per dose</td> </tr> <tr> <td class=\"indent1\">Daptomycin</td> <td>6 to 10 mg/kg IV once daily*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Teicoplanin</td> <td>6 to 12 mg/kg IV once daily</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Alternative agents</td> </tr> <tr> <td class=\"indent1\">Ceftaroline</td> <td>600 mg IV every 12 hours</td> </tr> <tr> <td class=\"indent1\">Telavancin</td> <td>10 mg/kg IV once daily</td> </tr> <tr> <td class=\"indent1\">Linezolid</td> <td>600 mg IV (or orally) twice daily</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenously.<br />* Standard daptomycin dosing (as approved by the US Food and Drug Administration) for treatment of bacteremia or osteomyelitis is 6 mg/kg IV once daily. Because daptomycin exhibits concentration-dependent killing, some experts recommend doses of up to 8 to 10 mg/kg IV once daily, which appear safe; further study is needed.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009; 49:177.</LI>&#xD;&#xA;<LI>Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Ther Chemother 2006; 50:3245.</LI>&#xD;&#xA;<LI>Lui C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:285.</LI></OL></div><div id=\"graphicVersion\">Graphic 114038 Version 2.0</div></div></div>"},"114040":{"type":"graphic_figure","displayName":"Fick angle of the foot","title":"Fick angle of the foot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fick angle of the foot</div><div class=\"cntnt\"><img style=\"width:421px; height:664px;\" src=\"images/SM/114040_Frickangleofthefoot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Fick Angle reflects foot external rotation relative to the line of direct forward progress during gait. Its normal range is 5 to 18 degrees. </div><div id=\"graphicVersion\">Graphic 114040 Version 1.0</div></div></div>"},"114041":{"type":"graphic_table","displayName":"Pediatric systemic UFH nomogram","title":"Protocol for systemic unfractionated heparin administration and adjustment for pediatric patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Protocol for systemic unfractionated heparin administration and adjustment for pediatric patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"6\"> <ol class=\"numbers_no_heading\"> <li>UFH loading dose: 75 units/kg IV over 10 minutes. </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"6\"> <ol class=\"numbers_no_heading\" start=\"2\"> <li>Initial maintenance dose: <ul class=\"decimal_heading\"> <li>Infants &#60;1 year: 28 units/kg per hour </li> <li>Children &#8805;1 year: 20 units/kg per hour </li> </ul> </li> </ol> </td> </tr> <tr> <td colspan=\"6\"> <ol class=\"numbers_no_heading\" start=\"3\"> <li> <p>Adjust UFH to maintain anti-factor Xa activity 0.35 to 0.7 units/mL. In most children, this corresponds to a goal aPTT of 60 to 85 seconds.</p> <p>aPTT testing can be used to facilitate dose adjustments, but only after establishing that the aPTT range corresponds to the target anti-factor Xa range in the individual patient.</p> Initial testing is performed 4 to 6 hours after starting the infusion. </li> </ol> </td> </tr> <tr> <td class=\"centered highlight_gray_text\"><strong>Anti-Xa<br /> (units/mL)</strong></td> <td class=\"centered highlight_gray_text\"><strong>aPTT<br /> (seconds)</strong></td> <td class=\"centered highlight_gray_text\"><strong>Bolus<br /> (units/kg)</strong></td> <td class=\"centered highlight_gray_text\"><strong>Hold infusion<br /> (minutes)</strong></td> <td class=\"centered highlight_gray_text\"><strong>Rate change</strong></td> <td class=\"centered highlight_gray_text\"><strong>Repeat<br /> anti-Xa/aPTT</strong></td> </tr> <tr> <td class=\"centered\">&#8804;0.1</td> <td class=\"centered\">&#60;50</td> <td class=\"centered\">50</td> <td class=\"centered\">0</td> <td class=\"centered\">Increase 10%</td> <td class=\"centered\">4 hours</td> </tr> <tr> <td class=\"centered\">0.11 to 0.34</td> <td class=\"centered\">50 to 59</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">Increase 10%</td> <td class=\"centered\">4 hours</td> </tr> <tr> <td class=\"centered\">0.35 to 0.7</td> <td class=\"centered\">60 to 85</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">No change</td> <td class=\"centered\">4 hours, then daily once 2 consecutive values are in range</td> </tr> <tr> <td class=\"centered\">0.71 to 0.99</td> <td class=\"centered\">86 to 95</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">Decrease 10%</td> <td class=\"centered\">4 hours</td> </tr> <tr> <td class=\"centered\">1.0 to 1.19</td> <td class=\"centered\">96 to 120</td> <td class=\"centered\">0</td> <td class=\"centered\">30</td> <td class=\"centered\">Decrease 10%</td> <td class=\"centered\">4 hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">&#8805;1.2</td> <td class=\"centered\">&#62;120</td> <td class=\"centered\">0</td> <td class=\"centered\">60</td> <td class=\"centered\">Decrease 15%</td> <td class=\"centered\">4 hours</td> </tr> <tr> <td colspan=\"6\"> <ol class=\"numbers_no_heading\" start=\"4\"> <li>When anti-Xa/aPTT values are therapeutic, monitor anti-Xa/aPTT and CBC daily. </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">UFH: unfractionated heparin; IV: intravenous; aPTT: activated partial thromboplastin time.<br /><br />* If both anti-Xa activity and aPTT&nbsp;are&nbsp;monitored and&nbsp;there is a disconnect between the two values&nbsp;such that&nbsp;the aPTT is &gt;150 yet the anti-Xa level is subtherapeutic, the UFH should <STRONG>not</STRONG> be increased to achieve the&nbsp;desired therapeutic anti-Xa level since there are reports of bleeding complications occurring in this setting,&nbsp;particularly in neonates. Consultation with a pediatric hematologist is recommended in such cases.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Monagle P, Chan AK, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e737S.</li>&#xD;&#xA;    <li>Trucco M, Lehmann CU, Mollenkopf N, et al. Retrospective cohort study comparing activated partial thromboplastin time versus anti-factor Xa activity nomograms for therapeutic unfractionated heparin monitoring in pediatrics. J Thromb Haemost 2015; 13:788.</li>&#xD;&#xA;</ol>&#xD;&#xA;Original table modified for this publication. From: Michelson AD, Bovill E, Andrew M. Antithrombotic therapy in Children. Chest 1995; 108:506S. Table used with the permission of Elsevier, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 114041 Version 2.0</div></div></div>"},"114042":{"type":"graphic_movie","displayName":"Running gait: Sagittal and rear view","title":"Running gait: Sagittal and rear view","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Running gait: Sagittal and rear view</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SM/114042_Rungaitsiderearviewvid.mp4\" style=\"width:704px;height:416px\"></div><img style=\"width:756px; height:540px;\" src=\"images/SM/114042_Rungaitsiderearviewimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video clip shows the rear and sagittal perspectives for assessing running gait.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114042 Version 1.0</div></div></div>"},"114043":{"type":"graphic_movie","displayName":"Running gait: Front and rear views","title":"Running gait: Front and rear views","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Running gait: Front and rear views</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SM/114043_Rungaitfrntrearviewvid.mp4\" style=\"width:704px;height:416px\"></div><img style=\"width:756px; height:531px;\" src=\"images/SM/114043_Rungaitfrntrearviewimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video clip shows the front and rear perspectives for assessing running gait.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114043 Version 1.0</div></div></div>"},"114044":{"type":"graphic_movie","displayName":"Arm swing during running gait","title":"Arm swing during running gait","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Arm swing during running gait</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SM/114044_Armswingrunninggaitvid.mp4\" style=\"width:704px;height:416px\"></div><img style=\"width:756px; height:679px;\" src=\"images/SM/114044_Armswingrunninggaitimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arm swing provides counterbalance to the lower extremities during running gait. Ideally, this swing is symmetric and well synchronized. The runner in this video clip demonstrates mild asymmetries, which can be appreciated by comparing the excursion of each arm relative to the white lines drawn on the image.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114044 Version 1.0</div></div></div>"},"114045":{"type":"graphic_figure","displayName":"Pathogenesis of urinary tuberculosis","title":"Pathogenesis of urinary tuberculosis","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Pathogenesis of urinary tuberculosis</div><div class=\"cntnt\"><img style=\"width:543px; height:881px;\" src=\"images/ID/114045_Pathogenss_urinary_tubrclss.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Visweswaran RK, Bhat S. Tuberculosis of the urinary tract. In: Comprehensive Clinical Nephrology, 5th edition, Johnson R, Feehally J (Eds). Elsevier Saunders, Philadelphia, PA 2015. Illustration used with the permission of Elsevier, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 114045 Version 1.0</div></div></div>"},"114046":{"type":"graphic_table","displayName":"Pediatric warfarin nomogram","title":"Protocol for warfarin administration and adjustment to maintain INR between 2 and 3 for pediatric patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Protocol for warfarin administration and adjustment to maintain INR between 2 and 3 for pediatric patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"2\"> <ol class=\"numbers_to_nine\"> <li><strong>Day 1 </strong><span style=\"font-family: Calibri; color: #1f497d;\">&ndash;</span> If the baseline INR is 1.0 to 1.3, initial dose of warfarin is 0.2 mg/kg orally in a single dose* </li> </ol> </td> </tr> <tr> <td colspan=\"2\"> <ol class=\"numbers_to_nine\" start=\"2\"> <li><strong>Days 2 to 4<strong>&nbsp;</strong><span style=\"font-family: Calibri; color: #1f497d;\">&ndash;</span> </strong>Adjust warfarin dose according to INR: </li> </ol> </td> </tr> <tr> <td class=\"indent2\">INR 1.1 to 1.3</td> <td>Give same dose as on day 1</td> </tr> <tr> <td class=\"indent2\">INR 1.4 to 3.0</td> <td>Give 50% of day 1 dose</td> </tr> <tr> <td class=\"indent2\">INR 3.1 to 3.5</td> <td>Give 25% of day 1 dose</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">INR &#62;3.5</td> <td>Hold warfarin until INR &#60;3.5, then restart at 50% reduced dose</td> </tr> <tr> <td colspan=\"2\"> <ol class=\"numbers_to_nine\" start=\"3\"> <li><strong>Maintenance dose<strong>&nbsp;</strong><span style=\"font-family: Calibri; color: #1f497d;\">&ndash;</span> </strong>Adjust warfarin dose according to INR: </li> </ol> </td> </tr> <tr> <td class=\"indent2\">INR 1.1 to 1.4</td> <td>Increase dose by 20%</td> </tr> <tr> <td class=\"indent2\">INR 1.5 to 1.9</td> <td>Increase dose by 10%</td> </tr> <tr> <td class=\"indent2\">INR 2.0 to 3.0</td> <td>No change</td> </tr> <tr> <td class=\"indent2\">INR 3.1 to 3.5</td> <td>Decrease dose by 10%</td> </tr> <tr> <td class=\"indent2\">INR &#62;3.5</td> <td>Hold warfarin until INR &#60;3.5, then restart at 20% reduced dose</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">INR: international normalized ratio.<br />* In patients with mild liver dysfunction and/or elevated baseline prothrombin time, a lower initial dose should be used (eg, 0.1 mg/kg). Warfarin should be avoided in patients with severe liver failure.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Monagle P, Chan AK, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e737S.</li>&#xD;&#xA;    <li>Trucco M, Lehmann CU, Mollenkopf N, et al. Retrospective cohort study comparing activated partial thromboplastin time versus anti-factor Xa activity nomograms for therapeutic unfractionated heparin monitoring in pediatrics. J Thromb Haemost 2015; 13:788.</li>&#xD;&#xA;</ol>&#xD;&#xA;Original table modified for this publication. From: Michelson AD, Bovill E, Andrew M. Antithrombotic therapy in Children. Chest 1995; 108:506S. Table used with the permission of Elsevier, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 114046 Version 2.0</div></div></div>"},"114047":{"type":"graphic_picture","displayName":"Erythema nodosum leprosum on face and extremity","title":"Erythema nodosum leprosum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema nodosum leprosum</div><div class=\"cntnt\"><img style=\"width:368px; height:358px;\" src=\"images/DERM/114047_Erythm_ndsm_lprsm_fc_xtrmty.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dr. Samuel L Moschella, MD, FAAD, FACP.</div><div id=\"graphicVersion\">Graphic 114047 Version 1.0</div></div></div>"},"114048":{"type":"graphic_movie","displayName":"Running with symmetric pelvic movement","title":"Running with symmetric pelvic movement","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Running with symmetric pelvic movement</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SM/114048_Runsymmtrcpelvcmvmntvid.mp4\" style=\"width:704px;height:416px\"></div><img style=\"width:756px; height:677px;\" src=\"images/SM/114048_Runsymmtrcpelvcmvmntimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this video clip, the runner demonstrates a smooth running gait with symmetric, unexaggerated pelvic motion.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114048 Version 1.0</div></div></div>"},"114049":{"type":"graphic_movie","displayName":"Running gait: Knee at crossover","title":"Running gait: Knee at crossover","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Running gait: Knee at crossover</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SM/114049_RungaitKneecrossovervid.mp4\" style=\"width:704px;height:416px\"></div><img style=\"width:756px; height:537px;\" src=\"images/SM/114049_RungaitKneecrossoverimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">One way to look for valgus knee alignment during running gait is to watch as one knee passes the other. The video clips presented here show both normal and valgus positioning at this moment.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114049 Version 1.0</div></div></div>"},"114050":{"type":"graphic_movie","displayName":"Phases of running gait","title":"Phases of running gait","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Phases of running gait</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SM/114050_Phasesrunninggaitvid.mp4\" style=\"width:704px;height:416px\"></div><img style=\"width:756px; height:677px;\" src=\"images/SM/114050_Phasesrunninggaitimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video clip shows the major phases of running gait.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114050 Version 1.0</div></div></div>"},"114051":{"type":"graphic_movie","displayName":"Foot pronation during running gait","title":"Foot pronation during running gait","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Foot pronation during running gait</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SM/114051_Footpronationrungaitvid.mp4\" style=\"width:704px;height:416px\"></div><img style=\"width:756px; height:709px;\" src=\"images/SM/114051_Footpronationrungaitimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video clip demonstrates maximum foot pronation at midstance. Both feet pronate excessively at midstance, but the left foot is worse.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114051 Version 1.0</div></div></div>"},"114052":{"type":"graphic_movie","displayName":"Normal walking gait slow motion","title":"Normal walking gait slow motion","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Normal walking gait slow motion</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SM/114052_Normalwalkinggaitvid.mp4\" style=\"width:704px;height:416px\"></div><img style=\"width:756px; height:531px;\" src=\"images/SM/114052_Normalwalkinggaitimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video clip shows a normal walking gait with smooth, symmetric movements through all phases.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114052 Version 2.0</div></div></div>"},"114053":{"type":"graphic_movie","displayName":"Stridor audio","title":"Stridor audio","html":"<div class=\"graphic normal\"><div style=\"width: 1300px\" class=\"figure\"><div class=\"ttl\">Stridor audio</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/114053_Stridoraudiovid.mp4\" style=\"width:1280px;height:432px\"></div><img style=\"width:571px; height:345px;\" src=\"images/PEDS/114053_Stridoraudioimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">7 month old infant with&nbsp;high-pitched inspiratory stridor.</div><div class=\"graphic_reference\">Audio recorded on a Thinklabs Digital Stethoscope. Reproduced with permission from ThinkLabs Medical, LLC. Copyright &copy; 2004-2017. <a href=\"http://www.thinklabs.com/\" target=\"_blank\">www.thinklabs.com</a>.</div><div id=\"graphicVersion\">Graphic 114053 Version 1.0</div></div></div>"},"114060":{"type":"graphic_table","displayName":"Assessment non-traumatic forefoot pain","title":"Assessment non-traumatic forefoot pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Assessment non-traumatic forefoot pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Questions to guide&nbsp;assessment of&nbsp;non-trauma-related forefoot pain:</td> </tr> <tr> <td class=\"subtitle2_single\"> <ol class=\"numbers_to_nine\"> <li>Are there localized findings? </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol style=\"list-style-type: upper-alpha;\"> <li>Findings isolated to the great toe? </li> </ol> </td> </tr> <tr> <td class=\"indent2\"> <ul class=\"decimal_heading\"> <li>Valgus deviation. &#8212; Bunion (hallux valgus). </li> <li>Varus deviation. &#8212; Hallux varus. </li> <li>Irregularity and enlargement of first MTP. &#8212; Suggests osteoarthritis, gout, or other degenerative condition of first MTP joint. </li> <li>Limited passive extension of first toe. &#8212; Hallux limitus or hallux rigidus. </li> <li>Redness and swelling with intense pain and tenderness of acute onset. &#8212; Suggests gout, or less commonly, pseudogout or septic joint. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ol style=\"list-style-type: upper-alpha;\" start=\"2\"> <li>Changes in lesser toes? </li> </ol> </td> </tr> <tr> <td class=\"indent2\"> <ul class=\"decimal_heading\"> <li>Dorsiflexion of proximal phalanx at the MTP joint, flexion of PIP joint and a neutral DIP joint. &#8212; Hammertoe. </li> <li>Dorsiflexion of proximal phalanx on MTP and plantar flexion of PIP and DIP. &#8212; Claw toe. </li> <li>Rotation and prominence of the fifth toe and MTP. &#8212; Bunionette. </li> <li>Flexion contracture of the DIP joint. &#8212; Mallet toe. </li> <li>Flexion of the MTP, PIP, and DIP joints. &#8212; Curly toes. </li> <li>Toes that rotate over or under other toes. &#8212; Crossover toes. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ol style=\"list-style-type: upper-alpha;\" start=\"3\"> <li>Does one or more of the toes appear significantly shortened?* </li> </ol> </td> </tr> <tr> <td class=\"indent2\"> <ul class=\"decimal_heading\"> <li>Is there first MT brachymetatarsia? </li> <li>Is there fourth MT brachymetatarsia?<sup>&#182;</sup> </li> <li>With multiple involved toes, is there evidence of a congenital injury or complex genetic disorder?<sup>&#916;</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ol style=\"list-style-type: upper-alpha;\" start=\"4\"> <li>Are there changes to the skin or nails in the forefoot? </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul class=\"decimal_heading\"> <li>Large callus over the plantar surface of the second MT head. &#8212; Suggests Morton callus indicating likely metatarsalgia. </li> <li>Multiple calluses over plantar surfaces of MT heads. &#8212; Suggests metatarsalgia with drop of transverse arch or neurogenic conditions causing peripheral neuropathy. </li> <li>Callus that appears to have a central core. &#8212; Suggests a corn. </li> <li>Callus on the dorsum of the PIP. &#8212; Suggests friction from shoe surface in patient with hammer toe or curly toe. </li> <li>Callus-like skin changes with dark dots after shaving surface. &#8212; Plantar wart. </li> <li>Inflammatory reaction along lateral nail bed. &#8212; Suggests ingrown toenail. </li> <li>Abnormal nail appearance. &#8212; Nail dystrophy (multiple causes). </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\"> <ol class=\"numbers_to_nine\" start=\"2\"> <li>Are there generalized changes to the MTP or PIP joints? </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Is there evidence of rheumatoid arthritis? </li> <li>Is there evidence of osteoarthritis? </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\"> <ol class=\"numbers_to_nine\" start=\"3\"> <li>Is there forefoot pain without obvious changes in the appearance of the foot? </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Pain over the distal MT shafts. &#8212; Suggests metatarsalgia. </li> <li>Pain localized to the area between MTs, or worse when the sides of the foot are squeezed together. &#8212; Suggests Morton neuroma. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MTP: metatarsophalangeal; PIP: proximal interphalangeal; DIP: distal interphalangeal; MT: metatarsal.<br />* Rare condition with enlargement of one or more toes is called macrodactyly.<br />¶ Amniotic band syndrome can lead to shortening, partial amputation, or other malformations of toes.<br />Δ Some congenital problems affecting toes: Holt Oram Syndrome, triphalangeal thumb and brachyectrodactyly, Rubinstein-Taybi Syndrome, Iso-Kikuchi Syndrome, Split hand-split foot malformation (Lobster Claw deformity).</div><div id=\"graphicVersion\">Graphic 114060 Version 1.0</div></div></div>"},"114061":{"type":"graphic_table","displayName":"Assessment traumatic forefoot pain","title":"Assessment traumatic forefoot pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Assessment traumatic forefoot pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\">Five questions to guide assessment of trauma-related forefoot pain:</td> </tr> <tr> <td> <ol> <li>Does the patient recall acute hyperextension of the great toe followed by immediate or slightly delayed pain and swelling? &#8212; Suggests first MTP sprain (\"turf toe\"). </li> </ol> </td> </tr> <tr> <td> <ol start=\"2\"> <li>Does the patient have persistent pain under the first MTP joint and a history of overuse or pressure in that region from shoes? &#8212; Suggests sesamoid injury or painful corn or callus (rarely, stress fracture of distal first metatarsal). </li> </ol> </td> </tr> <tr> <td> <ol start=\"3\"> <li>Is there discoloration and pain under the nail following direct trauma to the toe? &#8212; Subungual hematoma, possibly accompanied by fracture. </li> </ol> </td> </tr> <tr> <td> <ol start=\"4\"> <li>Is there tenderness, discoloration, and possibly malalignment of a toe following trauma? &#8212; Suggests toe fracture (or dislocation). </li> </ol> </td> </tr> <tr> <td> <ol start=\"5\"> <li>Is there swelling and tenderness over the dorsum of the forefoot (proximal to toes) after trauma or overuse? &#8212; Suggests metatarsal fracture or stress fracture. </li> </ol> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 114061 Version 1.0</div></div></div>"},"114063":{"type":"graphic_figure","displayName":"Natalizumab-associated PML risk factors and resulting risks","title":"Combination of validated progressive multifocal leukoencephalopathy (PML) risk factors and resulting risks for natalizumab-associated PML","html":"<div class=\"graphic\"><div style=\"width: 631px\" class=\"figure\"><div class=\"ttl\">Combination of validated progressive multifocal leukoencephalopathy (PML) risk factors and resulting risks for natalizumab-associated PML</div><div class=\"cntnt\"><img style=\"width:611px; height:416px;\" src=\"images/NEURO/114063_Ntlzmb_ac_PML_rsk_fctr_rslt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Integrated datasets: based on the official PML data from December 2014, 2015, and 2016<sup>[1]</sup>:&#xD;&#xA;<ol>&#xD;&#xA;    <li>PML incidence 4.22/1000 treated patients (2016).</li>&#xD;&#xA;    <li>57.6% of patients are treated for more than two years (2014).</li>&#xD;&#xA;    <li>55% of treated patients are JC virus (JCV+).</li>&#xD;&#xA;    <li>14% of PML cases occur during the first two years of treatment (2015).</li>&#xD;&#xA;    <li>42% of PML cases have been immunosuppressed prior to natalizumab treatment (2014).</li>&#xD;&#xA;    <li>Approximately 1% of PML cases were JCV&ndash; before developing PML (2016).</li>&#xD;&#xA;    <li>95.6% of (JCV+) non-immunosuppressed PML cases had an index value of &gt;0.9 before PML (2015).</li>&#xD;&#xA;</ol>&#xD;&#xA;Own data:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Rate of immunosuppression was &le;15% in 2014.</li>&#xD;&#xA;    <li>&le;14% of patients are JCV+, but have an index value of &lt;0.9. Shown is the calculated risk tree of 100,000 hypothetical patients under treatment with natalizumab and resulting 422 cases of PML (4.22/1000), grouped according to the risk factors JCV serostatus, treatment duration, prior immunosuppression, and JCV index. Given are the number of patients in the particular population, the number of PML cases in that population, and the resulting PML incidence/risk. This representation is supposed to allow the reader to weigh the effect of different risk parameters and help with decision making. As a thought and calculation exercise solely based on published statistics, this tree is not meant to be a replacement for actual patient numbers and data from clinical studies.</li>&#xD;&#xA;</ol></div><div class=\"graphic_footnotes\">IS: immunosuppression; JCV: JC virus; MS: multiple sclerosis.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Biogen Idec. Biogen Idec MedInfo. Available at: medinfo.biogenidec.com (Accessed on June 4, 2016).</li>&#xD;&#xA;</ol>&#xD;&#xA;From: Schwab N, Schneider-Hohendorf T, Melzer N, et al. Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification. Neurology 2017; 88:1197. DOI: <a href=\"http://www.neurology.org/content/88/12/1197\" target=\"_blank\">10.1212/WNL.0000000000003739</a>. Copyright &copy; 2017 American Academy of Neurology. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 114063 Version 1.0</div></div></div>"},"114067":{"type":"graphic_algorithm","displayName":"Lab testing for Zika virus in asymptomatic pregnant women","title":"Updated interim testing recommendations*<SUP>¶</SUP><SUP>Δ</SUP> and interpretation of results<SUP>◊</SUP><SUP>§</SUP> for asymptomatic pregnant women with possible Zika virus exposure<SUP>¥</SUP><SUP>‡</SUP><SUP>†</SUP> – United States, 2017","html":"<div class=\"graphic\"><div style=\"width: 826px\" class=\"figure\"><div class=\"ttl\">Updated interim testing recommendations*<SUP>¶</SUP><SUP>Δ</SUP> and interpretation of results<SUP>◊</SUP><SUP>§</SUP> for asymptomatic pregnant women with possible Zika virus exposure<SUP>¥</SUP><SUP>‡</SUP><SUP>†</SUP>&nbsp;– United States, 2017</div><div class=\"cntnt\"><img style=\"width:806px; height:412px;\" src=\"images/OBGYN/114067_Lab_test_Zika_asympt_preg.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NAT: nucleic acid test; IgM: immunoglobulin M; PRNT: plaque reduction neutralization test.<br />* Ask about type and duration of Zika virus exposure before and during the current pregnancy. Exposure before the current pregnancy might limit interpretation of Zika virus IgM results; pretest counseling can help inform testing decisions.<br />¶ Zika virus testing is not routinely recommended for pregnant women with a previous diagnosis of laboratory-confirmed Zika virus infection by either NAT or serology (positive/equivocal Zika virus or dengue virus IgM and Zika virus PRNT ≥10 and dengue virus PRNT &lt;10 results).<br />Δ The interval for Zika virus NAT testing during pregnancy is unknown. Preliminary data suggest that NAT might remain positive for several weeks after infection in some pregnant women. For women without a prior <EM>laboratory-confirmed</EM> diagnosis of Zika virus, NAT testing should be offered at the initiation of prenatal care, and if Zika virus RNA is not detected on clinical specimens, two additional tests should be offered during the course of the pregnancy coinciding with prenatal visits. The proportion of fetuses and infants with Zika virus-associated birth defects is highest among women with first and early second trimester infections; therefore, conducting all NAT testing during the first and second trimesters might be considered to help identify infections early in pregnancy. However, adverse outcomes have been associated with infection diagnosed in the third trimester; therefore, testing every trimester might be considered.<br /><FONT class=lozenge>◊</FONT> Despite the high specificity of NAT, false-positive NAT results have been reported. <STRONG>If both serum and urine specimens are NAT-positive, interpretation should be acute Zika virus infection.</STRONG> If NAT is only positive on serum or urine, testing should be repeated on the original NAT-positive specimen. <STRONG>If repeat NAT is positive, results should be interpreted as evidence of acute Zika virus infection.</STRONG> If repeat NAT testing is negative, results are indeterminate and health care providers should perform IgM testing on a specimen collected ≥2 weeks after initial specimen collection. For laboratory interpretation, refer to <A href=\"https://www.cdc.gov/zika/pdfs/lab-table.pdf\" target=_blank>https://www.cdc.gov/zika/pdfs/lab-table.pdf</A>.<br />§ A negative Zika virus NAT result does not exclude infection during pregnancy because it represents a single point in time. Zika virus RNA levels decline over time, and the duration of the presence of Zika virus RNA in serum and urine following infection varies among pregnant women. Despite Zika virus IgM antibody test limitations (eg, cross-reactivity with other flaviviruses and prolonged detection for months, presenting challenges in determining the timing of infection), which should be discussed as part of pretest counseling, patients may still choose to receive Zika virus IgM testing.<br />¥ Possible Zika virus exposure includes travel to or residence in an area with risk for Zika virus transmission (<A href=\"https://wwwnc.cdc.gov/travel/page/zika-travel-information\" target=_blank>https://wwwnc.cdc.gov/travel/page/zika-travel-information</A>) during pregnancy or the periconceptional period (8 weeks before conception [6 weeks before the last menstrual period]), or sex without a condom, during pregnancy or the periconceptional period, with a partner who traveled to, or resides in an area with risk for Zika virus transmission.<br />‡ Persons <EM>with ongoing</EM> possible Zika virus exposure include those who reside in or frequently travel (eg, daily or weekly) to an area with risk for Zika virus transmission.<br />† For the purposes of this guidance, recent possible Zika virus exposure or Zika virus/flavivirus infection is defined as a possible exposure or infection during the current pregnancy or periconceptional period.</div><div class=\"graphic_reference\">From: Oduyebo T, Polen KD, Walke HT, et al. Update: Interim guidance for health care providers caring for pregnant women with possible Zika virus exposure — United States (including U.S. territories), July 2017. MMWR 2017; 66:1.</div><div id=\"graphicVersion\">Graphic 114067 Version 2.0</div></div></div>"},"114068":{"type":"graphic_picture","displayName":"Covered, self-expandable, metal stent for pancreatic drainage","title":"Use of a large-caliber, fully covered, self-expandable metal stent for the management of walled-off pancreatic necrosis","html":"<div class=\"graphic\"><div style=\"width: 781px\" class=\"figure\"><div class=\"ttl\">Use of a large-caliber, fully covered, self-expandable metal stent for the management of walled-off pancreatic necrosis</div><div class=\"cntnt\"><img style=\"width:761px; height:329px;\" src=\"images/GAST/114068_Cvrslxpdbmtsttpcrtdrn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Endoscopic image showing pus originating from walled-off pancreatic necrosis and draining through a large-caliber, fully covered, self-expandable metal stent (AXIOS).<br />(B) Endoscopic image showing pancreatic fluid draining through a large-caliber, fully covered, self-expandable metal stent (AXIOS).</div><div id=\"graphicVersion\">Graphic 114068 Version 1.0</div></div></div>"},"114069":{"type":"graphic_table","displayName":"Testing fetal and placental tissue for Zika virus","title":"Interim guidance for Zika virus testing* of formalin-fixed, paraffin-embedded placental, fetal, or infant autopsy tissues<SUP>¶</SUP> for completed pregnancies with possible Zika virus exposure<SUP>Δ</SUP> during pregnancy<SUP>◊</SUP> – United States","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interim guidance for Zika virus testing* of formalin-fixed, paraffin-embedded placental, fetal, or infant autopsy tissues<SUP>¶</SUP> for completed pregnancies with possible Zika virus exposure<SUP>Δ</SUP> during pregnancy<SUP>◊</SUP>&nbsp;– United States</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16.66%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Pregnancy outcome</td> <td class=\"subtitle1\" colspan=\"5\">Maternal Zika virus test results on nontissue clinical specimens (eg, serum, urine)</td> </tr> <tr> <td class=\"subtitle2\">Acute Zika virus infection<sup>&#167;</sup></td> <td class=\"subtitle2\">Zika virus infection; timing of infection cannot be determined<sup>&#165;</sup></td> <td class=\"subtitle2\">Flavivirus infection; timing of infection cannot be determined</td> <td class=\"subtitle2\">&#62;12 weeks after symptom onset or exposure,<sup>&#135;</sup> with either negative maternal Zika virus IgM, or no maternal testing conducted</td> <td class=\"subtitle2\">No evidence of Zika virus infection<sup>&#134;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Testing of placental tissues</td> </tr> <tr> <td class=\"indent1\">Live birth, possible Zika virus-associated birth defects**</td> <td>Not indicated<sup>&#182;&#182;</sup></td> <td colspan=\"3\">Should be considered to aid in maternal diagnosis</td> <td>Not indicated<sup>&#182;&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Live birth, no obvious Zika virus-associated birth defects at birth</td> <td>Not indicated</td> <td colspan=\"3\">May be considered to aid in maternal diagnosis on a case-by-case and jurisdictional basis. Not routinely recommended for asymptomatic women with possible Zika virus exposure but <em>without ongoing</em> possible exposure</td> <td>Not indicated</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Testing of placental and fetal tissues</td> </tr> <tr> <td class=\"indent1\">Pregnancy loss, possible Zika virus-associated birth defects</td> <td>May be considered to aid in fetal diagnosis</td> <td colspan=\"3\">May be considered to aid in fetal and maternal diagnosis</td> <td>Not indicated<sup>&#182;&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pregnancy loss, no obvious Zika virus-associated birth defects</td> <td>May be considered to aid in fetal diagnosis</td> <td colspan=\"3\">May be considered to aid in fetal and maternal diagnosis</td> <td>Not indicated<sup>&#182;&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Testing of placental and infant autopsy tissues</td> </tr> <tr> <td class=\"indent1\">Infant death following live birth</td> <td>Should be considered to aid in infant diagnosis</td> <td colspan=\"3\">Should be considered to aid in infant and maternal diagnosis</td> <td>Not indicated<sup>&#182;&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgM: immunoglobulin M; CDC: Centers for Disease Control and Prevention; RT-PCR: reverse-transcription polymerase chain reaction; IHC: immunohistochemistry; NAT: nucleic acid test.<br />* Zika virus testing on formalin-fixed, paraffin embedded tissue specimens is conducted at CDC's Infectious Diseases Pathology Branch (IDPB) and includes Zika virus RT-PCR on placental and fetal/infant tissues. Zika virus IHC may be performed on placental tissues into the second trimester, fetal tissues from any gestational age, and infant autopsy tissues.<br />¶ Placental tissues include placental disc, umbilical cord, and fetal membranes. Zika virus RNA can be focal within placental tissues, and testing of three sections of placenta, one section of umbilical cord, and one section of fetal membrane is recommended (<A href=\"https://www.cdc.gov/zika/laboratories/test-specimens-tissues.html\" target=_blank>https://www.cdc.gov/zika/laboratories/test-specimens-tissues.html</A>). For pregnancy losses and infant deaths, submission of placental tissues in addition to fetal or infant autopsy tissues, if available, is preferred, but if not available will not preclude placental testing.<br />Δ Possible Zika virus exposure includes travel to or residence in an area with risk for Zika virus transmission (<A href=\"https://www.cdc.gov/zika/geo/index.html\" target=_blank>https://www.cdc.gov/zika/geo/index.html</A>) during pregnancy or the periconceptional period (8 weeks before conception [6 weeks before the last menstrual period]), or sex without a condom, during pregnancy or the periconceptional period, with a partner who traveled to, or resides in an area with risk for Zika virus transmission.<br /><FONT class=lozenge>◊</FONT> Zika virus testing is not routinely recommended for asymptomatic pregnant women with recent possible Zika virus exposure but <EM>without ongoing</EM> exposure and who have a fetus or infant without Zika virus-associated birth defects.<br />§ In the event of a confirmed maternal acute Zika virus infection or confirmed congenital Zika virus infection in the infant (eg, a positive NAT), placental testing from live births is not indicated. Currently, placental testing does not routinely provide additional diagnostic information in the setting of a maternal or infant diagnosis of acute or congenital Zika virus infection, respectively.<br />¥ For women with no possible Zika virus exposure before the current pregnancy, a positive IgM result likely represents acute Zika virus infection, and placental testing is not indicated.<br />‡ All or part of possible maternal Zika virus exposure, or symptom onset occurred &gt;12 weeks before maternal serum specimen was collected.<br />† Includes pregnant women with negative Zika virus NAT and negative Zika virus IgM ≤12 weeks after symptom onset or exposure.<br />** Possible Zika virus-associated birth defects that meet the CDC surveillance case definition include the following: Brain abnormalities and/or microcephaly, intracranial calcifications, ventriculomegaly, neural tube defects and other early brain malformations, eye abnormalities, or other consequences of central nervous system dysfunction including arthrogryposis (joint contractures), congenital hip dysplasia, and congenital deafness (<A href=\"https://www.cdc.gov/zika/geo/pregnancy-outcomes.html\" target=_blank>https://www.cdc.gov/zika/geo/pregnancy-outcomes.html</A>). In all cases, infants or fetuses with possible Zika virus-associated birth defects should also be evaluated for other etiologies of congenital anomalies.<br />¶¶ Testing may be considered on a case-by-case basis, consult CDC for case-specific questions at <A href=\"https://www.cdc.gov/zika/laboratories/test-specimens-tissues.html\" target=_blank>https://www.cdc.gov/zika/laboratories/test-specimens-tissues.html</A>.</div><div class=\"graphic_reference\">From: Oduyebo T, Polen KD, Walke HT, et al. Update: Interim guidance for health care providers caring for pregnant women with possible Zika virus exposure — United States (including U.S. territories), July 2017. MMWR 2017; 66:1.</div><div id=\"graphicVersion\">Graphic 114069 Version 1.0</div></div></div>"},"114074":{"type":"graphic_picture","displayName":"Lateral pelvic tilt at mid-stance during gait","title":"Lateral pelvic tilt at mid-stance during gait","html":"<div class=\"graphic\"><div style=\"width: 779px\" class=\"figure\"><div class=\"ttl\">Lateral pelvic tilt at mid-stance during gait</div><div class=\"cntnt\"><img style=\"width:759px; height:697px;\" src=\"images/SM/114074_Lateralplvctltmaxmdstnc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During gait, lateral pelvic tilt reaches its maximum extent&nbsp;at mid-stance. The side of the pelvis in the midst of the swing phase lowers, while the hip abductors on the stance side&nbsp;control this descent. The white line extending across the top of the pelvis shows the degree of pelvic tilt. A normal degree of pelvic tilt is shown above.<br /><br />(A) Right side stance.<br />(B) Left side stance.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114074 Version 2.0</div></div></div>"},"114075":{"type":"graphic_picture","displayName":"Tibial tilt","title":"Tibial tilt","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Tibial tilt</div><div class=\"cntnt\"><img style=\"width:550px; height:734px;\" src=\"images/SM/114075_Tibialtilt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above shows a subtle outward tibial tilt to the left leg compared to the right.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114075 Version 1.0</div></div></div>"},"114076":{"type":"graphic_table","displayName":"Atypical antidepressants adverse effects in overdose","title":"Atypical antidepressants adverse effects in overdose","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Atypical antidepressants adverse effects in overdose</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Effects</td> </tr> <tr> <td>Bupropion</td> <td>Agitation, tremor, seizures, tachydysrhythmia, hypertension</td> </tr> <tr> <td>Venlafaxine</td> <td>Sedation, seizures, serotonergic symptoms, tachydysrhythmia</td> </tr> <tr> <td>Desvenlafaxine</td> <td>Tachycardia, mild CNS depression</td> </tr> <tr> <td>Duloxetine</td> <td>Sedation, gastrointestinal symptoms</td> </tr> <tr> <td>Mirtazapine</td> <td>Sedation, tachycardia</td> </tr> <tr> <td>Milnacipran</td> <td>Serotonergic symptoms, cardiac dysfunction (rare), rash (rare)</td> </tr> <tr> <td>Vilazodone</td> <td>Sedation, seizures, tachycardia, vomiting, serotonergic symptoms</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">CNS: central nervous system.</div><div id=\"graphicVersion\">Graphic 114076 Version 1.0</div></div></div>"},"114078":{"type":"graphic_figure","displayName":"LV wall stress-dimension loops compensated and decompensated MR","title":"Left ventricular meridional wall stress-dimension loops from patients with compensated and decompensated chronic mitral regurgitation","html":"<div class=\"graphic\"><div style=\"width: 811px\" class=\"figure\"><div class=\"ttl\">Left ventricular meridional wall stress-dimension loops from patients with compensated and decompensated chronic mitral regurgitation</div><div class=\"cntnt\"><img style=\"width:791px; height:476px;\" src=\"images/CARD/114078_LV_wll_strss-dim_loops_MR.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left ventricular meridional wall stress-dimension loops from patients with compensated (A) and decompensated (B) chronic mitral regurgitation. The calculated coordinates of stress and dimension are shown by <STRONG>squares;</STRONG> <STRONG>connecting lines</STRONG> are shown schematically. Preoperatively, the loops are displaced well to the right of normal. In panel A, the postoperative loop is near normal (but, in contrast to aortic regurgitation, shortening fell significantly); in panel B, chamber dilatation persists.</div><div class=\"graphic_reference\">Reproduced from: Zile MR, Gaasch WH, Levine HJ. Left ventricular stress-dimension-shortening relations before and after correction of chronic aortic and mitral regurgitation. Am J Cardiol 1985; 56:99. Illustration used with the permission of Elsevier, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 114078 Version 1.0</div></div></div>"},"114079":{"type":"graphic_algorithm","displayName":"Evaluation of SRBD in COPD","title":"Evaluation of sleep-related breathing disorders in COPD","html":"<div class=\"graphic\"><div style=\"width: 1025px\" class=\"figure\"><div class=\"ttl\">Evaluation of sleep-related breathing disorders in COPD</div><div class=\"cntnt\"><img style=\"width:1005px; height:646px;\" src=\"images/PULM/114079_Evaluation_SRBD_COPD.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">OSA: obstructive sleep apnea; COPD: chronic obstructive pulmonary disease; HSAT: home sleep apnea test; GOLD: Global Initiative for Chronic Obstructive Lung Disease; NREM/REM: nonrapid eye movement/rapid eye movement; PaCO<sub>2</sub>: arterial partial pressure of carbon dioxide; PSG: polysomnography; AHI: apnea-hypopnea index; SpO<sub>2</sub>: pulse oxygen saturation; CPAP: continuous-positive airway pressure; APAP: auto(titrating)-positive airway pressure; PAP: positive airway pressure; SRBD: sleep-related breathing disorders; BPAP: bilevel-positive airway pressure; ASV: adaptive servo-ventilation; CPAP: continuous-positive airway pressure.<br />* Most of the conditions that make HSAT not appropriate are also reasons for a full-night PSG study.<br />&para; These conditions increase the likelihood of nonobstructive sleep-disordered breathing, which is not adequately evaluated on HSAT.<br />&Delta; For uncomplicated OSA, a split-night protocol is preferred, assuming moderate to severe OSA is noted during a minimum of two hours of recording AND at least three hours are available for CPAP titration.<br /><span class=\"lozenge\">&loz;</span> Refer to UpToDate content on sleep-related breathing disturbances and on initiation and titration of positive airway pressure.<br />&sect; Refer to UpToDate content on snoring, excessive daytime sleepiness.</div><div id=\"graphicVersion\">Graphic 114079 Version 1.0</div></div></div>"},"114080":{"type":"graphic_algorithm","displayName":"Treatment of vernal keratoconjunctivitis","title":"Treatment of vernal keratoconjunctivitis","html":"<div class=\"graphic\"><div style=\"width: 867px\" class=\"figure\"><div class=\"ttl\">Treatment of vernal keratoconjunctivitis</div><div class=\"cntnt\"><img style=\"width:847px; height:890px;\" src=\"images/ALLRG/114080_Trtmt_vernl_keratocnjnctvts.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">VKC: vernal keratoconjunctivitis.<br />* Topical dual-acting mast cell stabilizers/antitistamines include olopatadine, azelastine hydrochloride, epinastine, pemirolast potassium, and ketotifen fumarate.<br />¶ Basic eye care and trigger avoidance include the following: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Avoidance of nonspecific triggers, such as wind, heat, salt water, and sunlight whenever possible.</LI>&#xD;&#xA;<LI>Avoidance of known allergens in patients with immunoglobulin E (IgE)-mediated disease (this can be challenging as patients with VKC can react to multiple allergens).</LI>&#xD;&#xA;<LI>Avoidance of eye rubbing as it leads to a mechanical mast-cell degranulation, as well as exacerbation of the allergic process.</LI>&#xD;&#xA;<LI>Artificial tears, especially in patients who develop tear film insufficiency due to the anticholinergic effect of systemic antihistamines.</LI>&#xD;&#xA;<LI>Cool compresses.</LI></UL>Δ Second- and third-generation oral antihistamines include fexofenadine, loratadine, desloratidine, cetirizine, and levocetirizine.<br /><FONT class=lozenge>◊</FONT> Symptoms most commonly occur during the spring pollen season but can extended into other seasons, depending upon allergen levels, and may occur nearly year round.<br />§ Topical ophthalmic corticosteroids include prednisone acetate 1% and dexamethasone 0.1% for severe cases and prednisolone acetate 0.12%, fluorometholone, medrysone, loteprednol, etabonate 0.2 or 0.5%, and rimexolone 1%. Side effects of ophthalmic corticosteroids include cataracts and increased intraocular pressure leading to glaucoma. Thus, dose and duration of therapy should be minimized.<br />¥ A topical ophthalmic calcineurin inhibitor (eg, cyclosporine 2% or tacrolimus) is used instead of a topical corticosteroid if the corneal epithelium is compromised. Additional therapy is used for corneal shield ulcers.<br />‡ The patient is started on allergen immunotherapy if pollens are positive on testing and there are no contraindications. VKC is unlikely if aeroallergen testing to pollens is negative, and the patient should be evaluated for alternative diagnoses including atopic keratoconjunctivitis (AKC) and severe perennial atopic conjunctivitis.<br />† Systemic cyclosporine is limited to those with severe, sight-threatening disease, usually in patients with severe chronic allergic disease with seasonal exacerbation (VKC plus AKC or VKC plus severe perennial atopic conjunctivitis) who may require longer-term treatment.</div><div id=\"graphicVersion\">Graphic 114080 Version 1.0</div></div></div>"},"114082":{"type":"graphic_table","displayName":"Management neuromuscular blockade according to monitoring","title":"Suggested management of neuromuscular blockade according to monitoring","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested management of neuromuscular blockade according to monitoring</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Site</td> <td class=\"subtitle1\">Modality</td> <td class=\"subtitle1\">Response</td> <td class=\"subtitle1\">Interpretation</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Prediction of tracheal intubating conditions</td> </tr> <tr> <td class=\"indent1\">Any site</td> <td>Single twitch, TOF</td> <td>Present</td> <td>Adequate conditions not met</td> <td>Deep blockade is required for intubation</td> </tr> <tr> <td class=\"indent1\">Corrugator supercilii</td> <td>Single twitch, TOF</td> <td>Absent</td> <td>Adequate conditions likely</td> <td>Corrugator supercilii reflects vocal cords and diaphragm</td> </tr> <tr> <td class=\"indent1\">Adductor pollicis</td> <td>Single twitch, TOF</td> <td>Absent</td> <td>Adequate conditions likely only if high dose given</td> <td>Adductor pollicis is more sensitive than vocal cords and diaphragm</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Flexor hallucis (foot)</td> <td>Single twitch, TOF</td> <td>Absent</td> <td>Adequate conditions likely only if high dose given</td> <td>Foot muscles are sensitive and block late</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Intraoperative conditions</td> </tr> <tr> <td class=\"indent1\">Adductor pollicis</td> <td>PTC</td> <td>1 to 2</td> <td>Deep blockade</td> <td>Return of diaphragm movements possible, no TOF response at adductor pollicis</td> </tr> <tr> <td class=\"indent1\">Corrugator supercilii</td> <td>TOF</td> <td>1 to 2</td> <td>Deep blockade</td> <td>Return of abdominal tone possible, no TOF response at adductor polices</td> </tr> <tr> <td class=\"indent1\">Adductor pollicis</td> <td>TOF</td> <td>1 to 2</td> <td>Moderate blockade</td> <td>Usually sufficient for most procedures</td> </tr> <tr> <td class=\"indent1\">Corrugator supercilii</td> <td>TOF</td> <td>4, with or without fade</td> <td>Moderate to shallow blockade</td> <td>Difficult to interpret without adductor pollicis data</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Adductor pollicis</td> <td>TOF</td> <td>4, with or without fade</td> <td>Shallow blockade</td> <td>Additional relaxation might be needed</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Management of recovery</td> </tr> <tr> <td class=\"indent1\">Adductor pollicis</td> <td>PTC</td> <td>0</td> <td>Wait or sugammadex* 16 mg/kg</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Adductor pollicis</td> <td>PTC</td> <td>1 to 2</td> <td>Wait or sugammadex* 4 mg/kg</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Corrugator supercilii</td> <td>TOF</td> <td>1 to 2</td> <td>Wait or sugammadex* 4 mg/kg</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Adductor pollicis</td> <td>TOF</td> <td>2</td> <td>Wait or sugammadex* 2 mg/kg</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Corrugator supercilii</td> <td>TOF</td> <td>4, with or without fade</td> <td>Wait or correlate with adductor pollicis or sugammadex* 4 mg/kg</td> <td> <p>Corrugator supercilii recovers early</p> Correlation with adductor pollicis preferable</td> </tr> <tr> <td class=\"indent1\">Hypothenar eminence (fifth finger)</td> <td>TOF</td> <td>4, with or without fade</td> <td>Observe thumb motion</td> <td>Adductor pollicis recovers later</td> </tr> <tr> <td class=\"indent1\">Adductor pollicis</td> <td>TOF, visual or tactile</td> <td>4, with fade</td> <td>Wait or neostigmine<sup>&#182;</sup> 0.04 to 0.05 mg/kg or sugammadex* 2 mg/kg</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Adductor pollicis</td> <td>TOF, visual or tactile</td> <td>4, without fade</td> <td>Wait or neostigmine<sup>&#182;</sup> 0.020 mg/kg</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Adductor pollicis</td> <td>DBS, visual or tactile</td> <td>Fade</td> <td>Wait or neostigmine<sup>&#182;</sup> 0.02 to 0.05 mg/kg</td> <td>Less neostigmine needed if no TOF fade</td> </tr> <tr> <td class=\"indent1\">Adductor pollicis</td> <td>DBS, visual or tactile</td> <td>No fade</td> <td>Wait or neostigmine<sup>&#182;</sup> 0.020 mg/kg</td> <td>DBS fade detected when TOF ratio = 0.6</td> </tr> <tr> <td class=\"indent1\">Adductor pollicis</td> <td>TOF, quantitative</td> <td>TOF ratio &#60;0.90</td> <td>Wait or neostigmine<sup>&#182;</sup></td> <td>Neostigmine 0.04 to 0.05 mg/kg if TOF ratio &#60;0.4; 0.02 mg/kg if TOF ratio &#62;0.4</td> </tr> <tr> <td class=\"indent1\">Adductor pollicis</td> <td>100 Hz TET</td> <td>No fade</td> <td>No reversal necessary</td> <td>100 Hz TET fade detected when TOF ratio = 0.8 to 0.9</td> </tr> <tr> <td class=\"indent1\">Adductor pollicis</td> <td>TOF, quantitative</td> <td>TOF ratio &#8805;0.9</td> <td>No reversal necessary</td> <td>Full recovery</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Actual management depends on patient, surgical procedure, and previous response to neuromuscular blocking agents.</div><div class=\"graphic_footnotes\">TOF: train of four; PTC: posttetanic count; DBS: double burst stimulation; TET: 5-sec tetanic stimulation.<br />* Sugammadex can be used to reverse only rocuronium or vecuronium.<br />¶ Neostigmine can be used to reverse any nondepolarizing neuromuscular blocking agent.</div><div class=\"graphic_reference\">Reproduced with permission from: Brull SJ. Neuromuscular blocking agents. In: Clinical Anesthesia, 8th ed, Barash PG, Cullen BF, Stoelting RK, et al (Eds), Wolters Kluwer, Philadelphia 2017. Copyright &copy; 2017 Wolters Kluwer.</div><div id=\"graphicVersion\">Graphic 114082 Version 2.0</div></div></div>"},"114083":{"type":"graphic_table","displayName":"Depth of block based on monitoring","title":"Classification of depth of nondepolarizing neuromuscular blockade based on subjective and objective criteria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of depth of nondepolarizing neuromuscular blockade based on subjective and objective criteria</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Depth of block</td> <td class=\"subtitle1\">Posttetanic count (PTC)</td> <td class=\"subtitle1\">Train-of-four count (TOFC)</td> <td class=\"subtitle1\">Subjective train-of-four (TOF) ratio</td> <td class=\"subtitle1\">Measured (actual) train-of-four (TOF) ratio</td> </tr> <tr> <td>Intense (profound) block</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> </tr> <tr> <td>Deep block</td> <td class=\"centered\">&#8805;1</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> </tr> <tr> <td>Moderate block</td> <td class=\"centered\">NA</td> <td class=\"centered\">1 to 3</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> </tr> <tr> <td>Light (shallow) block</td> <td class=\"centered\">NA</td> <td class=\"centered\">4</td> <td class=\"centered\">Fade present</td> <td class=\"centered\">0.1 to 0.4</td> </tr> <tr> <td>Minimal block</td> <td class=\"centered\">NA</td> <td class=\"centered\">4</td> <td class=\"centered\">No fade</td> <td class=\"centered\">&#62;0.4 but &#60;0.9</td> </tr> <tr> <td>Full recovery</td> <td class=\"centered\">NA</td> <td class=\"centered\">4</td> <td class=\"centered\">No fade</td> <td class=\"centered\">&#8805;0.9 to 1.0</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NA: data not available.</div><div class=\"graphic_reference\">Reproduced with permission from: Brull SJ. Neuromuscular blocking agents. In: Clinical Anesthesia, 8th ed, Barash PG, Cullen BF, Stoelting RK, et al (Eds), Wolters Kluwer, Philadelphia 2017. Copyright &copy; 2017 Wolters Kluwer.</div><div id=\"graphicVersion\">Graphic 114083 Version 1.0</div></div></div>"},"114084":{"type":"graphic_algorithm","displayName":"Evaluation of thunderclap headache (TCH)","title":"Evaluation of thunderclap headache (TCH)","html":"<div class=\"graphic\"><div style=\"width: 645px\" class=\"figure\"><div class=\"ttl\">Evaluation of thunderclap headache (TCH)</div><div class=\"cntnt\"><img style=\"width:625px; height:513px;\" src=\"images/NEURO/114084_Eval_TCH.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography; SAH: subarachnoid hemorrhage; LP: lumbar puncture; CSF: cerebrospinal fluid; MRI: magnetic resonance imaging; MRA: magnetic resonance angiography; MRV: magnetic resonance venography; RCVS: reversible cerebral vasoconstriction syndrome; PRES: posterior reversible encephalopathy syndrome, also known as RPLS (reversible posterior leukoencephalopathy syndrome); CTA: computed tomography angiography; CTV: computed tomography venography.<br />* Further evaluation to determine the cause of SAH, including neurovascular imaging, will be needed; refer to appropriate topic reviews.<br />¶ CT is less sensitive than MRI for all of the possible underlying causes of TCH. Follow-up MRI, MRA, and MRV is often indicated even if CT identifies a potential cause of TCH.<br />Δ Obtain brain MRI, MRA, and MRV if LP is contraindicated.<br /><FONT class=lozenge>◊</FONT> Further evaluation for possible SAH may be necessary with CSF spectrophotometry and/or cerebral angiography; refer to appropriate topic reviews.<br />§ Obtain contrast-enhanced MRI of brain and cerebrovascular imaging with MRA and MRV. Obtain contrast-enhanced CT with CTA and CTV if MRI/MRA/MRV are not options.<br />¥ Up to 20% of noninvasive vascular angiograms are negative in RCVS. The existence of primary thunderclap headache is controversial; it is a diagnosis of last resort, reached only when all organic causes have been excluded by expedited and exhaustive search.</div><div id=\"graphicVersion\">Graphic 114084 Version 1.0</div></div></div>"},"114095":{"type":"graphic_movie","displayName":"Mesothelioma pleural plaque","title":"Thoracoscopic view of mesothelioma pleural plaque","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thoracoscopic view of mesothelioma pleural plaque</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PULM/114095_Mesotheliomapleurlplqvid.mp4\" style=\"width:240px;height:192px\"></div><img style=\"width:384px; height:262px;\" src=\"images/PULM/114095_Mesotheliomapleurlplqimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video shows the thoracoscopic view of the pleural cavity involved with mesothelioma revealing a pleural plaque on the parietal surface.</div><div id=\"graphicVersion\">Graphic 114095 Version 1.0</div></div></div>"},"114096":{"type":"graphic_movie","displayName":"Metastatic ovarian cancer","title":"Thoracoscopic view of metastatic ovarian cancer","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thoracoscopic view of metastatic ovarian cancer</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PULM/114096_Metastaticovariancncrvid.mp4\" style=\"width:352px;height:272px\"></div><img style=\"width:384px; height:262px;\" src=\"images/PULM/114096_Metastaticovariancncrvimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video shows the circular motion used by thoracoscopists to comprehensively inspect the pleural space. Multiple metastatic deposits are seen as white patchy deposits on the parietal pleura. These are readily accessible to thoracoscopic biopsy under direct visualization but could be easily missed by closed needle biopsy.</div><div id=\"graphicVersion\">Graphic 114096 Version 1.0</div></div></div>"},"114097":{"type":"graphic_movie","displayName":"TEE video (ME 4-chamber LAX view) showing air in LA and LV","title":"TEE (midesophageal 4-chamber long-axis view) showing air in the LA and LV","html":"<div class=\"graphic normal\"><div style=\"width: 708px\" class=\"figure\"><div class=\"ttl\">TEE (midesophageal 4-chamber long-axis view) showing air in the LA and LV</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/114097_TEEME4CLAXVairLALVvid.mp4\" style=\"width:688px;height:496px\"></div><img style=\"width:766px; height:538px;\" src=\"images/ANEST/114097_TEEME4CLAXVairLALVimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This TEE midesophageal 4-chamber long-axis video recorded prior to weaning from cardiopulmonary bypass shows air in the LA and LV, noted as echo-dense targets in these chambers of the heart. Note that color flow Doppler imaging shows significant tricuspid regurgitation and right atrial distention that result from acute right ventricular dysfunction owing to right coronary artery air embolism.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; ME: midesophageal; LAX: long-axis; LA: left atrium; LV: left ventricle.</div><div class=\"graphic_reference\">Reproduced with permission from Jonathan B Mark, MD.</div><div id=\"graphicVersion\">Graphic 114097 Version 1.0</div></div></div>"},"114098":{"type":"graphic_movie","displayName":"TEE video (ME 4-chamber LAX view) showing residual air (LV apex)","title":"TEE video (midesophageal 4-chamber long-axis view) showing a small amount of residual air in the LV apex","html":"<div class=\"graphic normal\"><div style=\"width: 708px\" class=\"figure\"><div class=\"ttl\">TEE video (midesophageal 4-chamber long-axis view) showing a small amount of residual air in the LV apex</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/114098_TEEME4CLAXVairLVapexvid.mp4\" style=\"width:688px;height:480px\"></div><img style=\"width:756px; height:535px;\" src=\"images/ANEST/114098_TEEME4CLAXVairLVapeximg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This TEE video obtained in the midesophageal 4-chamber long-axis view after weaning from cardiopulmonary bypass demonstrates a small amount of residual air in the LV apex. Note that RV function has improved compared to the TEE video showing air in the LA and LV.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; ME: midesophageal; LAX: long-axis; LV: left ventricle; RV: right ventricle.</div><div class=\"graphic_reference\">Reproduced with permission from Jonathan B Mark, MD.</div><div id=\"graphicVersion\">Graphic 114098 Version 1.0</div></div></div>"},"114099":{"type":"graphic_movie","displayName":"TEE video (ME LAX view) showing air in the LA","title":"TEE video (midesophageal long-axis view) showing air in the LA","html":"<div class=\"graphic normal\"><div style=\"width: 708px\" class=\"figure\"><div class=\"ttl\">TEE video (midesophageal long-axis view) showing air in the LA</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/114099_TEEMELAXviewairLAvid.mp4\" style=\"width:688px;height:496px\"></div><img style=\"width:756px; height:538px;\" src=\"images/ANEST/114099_TEEMELAXviewairLAimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This TEE midesophageal long axis view shows air in the LA, which has layered out along the non-dependent, superior aspect of the LA behind the ascending aorta. The air bubbles are strong echo-reflectors and create a reverberation artifact that appears as linear streaks extending into the scan plane. This artifact is also termed a comet-tail or ring-down artifact.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; ME: midesophageal; LAX: long-axis; LA: left atrium.</div><div class=\"graphic_reference\">Reproduced with permission from Jonathan B Mark, MD.</div><div id=\"graphicVersion\">Graphic 114099 Version 1.0</div></div></div>"},"114100":{"type":"graphic_movie","displayName":"TEE video (ME 4-chamber LAX view) showing residual air in the LV","title":"TEE video (midesophageal 4-chamber long-axis view) showing residual air in the LV and LV apex","html":"<div class=\"graphic normal\"><div style=\"width: 708px\" class=\"figure\"><div class=\"ttl\">TEE video (midesophageal 4-chamber long-axis view) showing residual air in the LV and LV apex</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/114100_TEEME4CLAXviewairLVvid.mp4\" style=\"width:688px;height:528px\"></div><img style=\"width:756px; height:567px;\" src=\"images/ANEST/114100_TEEME4CLAXviewairLVimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After weaning from bypass, this TEE midesophageal 4-chamber long-axis view is recorded and shows residual air in the LV.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; ME: midesophageal; LAX: long-axis; LV: left ventricle.</div><div class=\"graphic_reference\">Reproduced with permission from Jonathan B Mark, MD.</div><div id=\"graphicVersion\">Graphic 114100 Version 1.0</div></div></div>"},"114101":{"type":"graphic_table","displayName":"Micronutrient management after bariatric surgery","title":"Micronutrient management after bariatric surgery<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Micronutrient management after bariatric surgery<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Preoperative prevalence</td> <td class=\"subtitle1\">Postoperative prevalence</td> <td class=\"subtitle1\">Symptoms of deficiency</td> <td class=\"subtitle1\">RDA<sup>[2]</sup></td> <td class=\"subtitle1\">Supplementation</td> <td class=\"subtitle1\">Repletion</td> </tr> <tr> <td>Vitamin A<sup>[1,3]</sup></td> <td>Up to 17%<sup>[3]</sup></td> <td> <p>8 to 11% after RYGB</p> 70% after BPD/DS </td> <td>Early signs: <ul class=\"decimal_heading\"> <li>Night blindness </li> <li>Bitot's spots </li> <li>Hyperkeratinization of skin </li> <li>Loss of taste </li> </ul> <br /> Advanced signs: <ul class=\"decimal_heading\"> <li>Corneal damage </li> <li>Blindness </li> </ul> </td> <td> <p>Men: 900 mcg (3000 IU)</p> Women: 700 mcg (2300 IU) </td> <td> <p>LAGB: 5000 IU daily</p> <p>RYGB or SG: 5000 to 10,000 IU daily</p> BPD/DS: 10,000 IU daily </td> <td> <p>Without corneal changes: 10,000 to 25,000 IU daily orally until clinical improvement (1 to 2 weeks)</p> With corneal changes: 50,000 to 100,000 IU daily IM for 3 days, followed by 50,000 IU daily IM for 2 weeks </td> </tr> <tr> <td>Vitamin D</td> <td>25 to 68%</td> <td>25 to 80%</td> <td>Hypocalcemia, tetany, tingling, cramping, metabolic bone disease, muscle pain</td> <td> <p>General: 600 IU</p> <p>Pregnancy, lactation, or over 71 years of age: 800 IU</p> </td> <td>3000 IU D3 daily from all sources to maintain a 25(OH)D level of &#62;30 ng/mL</td> <td>3000 to 6000 IU of D3 daily (preferred), or 50,000 IU of D2 1 to 3 times per week</td> </tr> <tr> <td>Vitamin E</td> <td>2.2%</td> <td>Uncommon</td> <td>Neuromuscular disorders and hemolysis</td> <td> <p>General: 15 mg (22.4 IU)</p> <p>Lactation: 19 mg (28.4 IU)</p> </td> <td> <p>Adults and adolescents 14 or older: 15 mg (22.4 IU) daily</p> <p>Lactation: 19 mg (28.4 IU) daily </p> </td> <td>90 to 300 mg (100 to 400 IU) daily</td> </tr> <tr> <td>Vitamin K</td> <td>Uncommon</td> <td>Uncommon</td> <td>Impaired coagulation</td> <td>90 to 120 mcg</td> <td> <p>LAGB, RYGB, or SG: 90 to 120 mcg daily</p> <p>BPD/DS: 300 mcg daily </p> </td> <td> <p>Acute malabsorption: 10 mg of parenteral vitamin K </p> <p>Chronic malabsorption: 1 to 2 mg per day orally or 1 to 2 mg per week parenterally </p> </td> </tr> <tr> <td>Vitamin B1 (Thiamine)</td> <td>16 to 29%</td> <td>1 to 49%</td> <td> <p>Numbness, tingling in extremities, gait ataxia, edema, vomiting, confusion</p> Wernicke-Korsakoff syndrome: <ul class=\"decimal_heading\"> <li>Encephalopathy </li> <li>Ataxia </li> <li>Oculomotor dysfunction </li> <li>Confabulation </li> <li>Impaired memory </li> <li>Impaired learning </li> </ul> <br /> Beriberi: <ul class=\"decimal_heading\"> <li>Neuropathy </li> <li>Pain </li> <li>Paresthesia </li> <li>Loss of reflexes </li> </ul> </td> <td>1.5 mg</td> <td> <p>&#62;12 mg daily, preferably 50 to 100 mg daily from a B-complex supplement</p> With IV hydration, 100 mg of thiamine should be added to the solution (should <strong>not</strong> contain glucose if Wernicke encephalopathy is suspected) </td> <td> <p>Oral: 100 mg three times daily until symptoms resolve</p> <p>Intravenous: 200 mg three times daily to 500 mg once or twice daily for 3 to 5 days, followed by 250 mg daily for 3 to 5 days, and subsequent oral maintenance (100 mg daily) indefinitely</p> Intramuscular: 250 mg daily for 3 to 5 days, or 100 to 250 mg monthly </td> </tr> <tr> <td>Vitamin B12</td> <td>0 to 18%</td> <td>33% after RYGB; 4 to 20% after SG</td> <td>Macrocytic (megaloblastic) anemia, mild pancytopenia, neuropsychiatric findings (eg, depression, neuropathy)</td> <td>2.4 mcg</td> <td>Oral dose of 350 to 500 mcg daily, or 1000 mcg IM or SQ monthly, or by nasal spray</td> <td>1000 to 2000 mcg daily until the level is normalized, then resume maintenance dose</td> </tr> <tr> <td>Folate</td> <td>0 to 54%</td> <td>Up to 65% after RYGB; 18% after SG</td> <td>Macrocytic (megaloblastic) anemia, mild pancytopenia, neural tube defects</td> <td>400 mcg</td> <td> <p>General: 400 to 800 mcg daily</p> <p>Women of childbearing age: 800 to 1000 mcg daily</p> <p>Should <strong>not</strong> exceed 1 mg per day</p> </td> <td>1000 mcg daily until the level is normalized, then resume maintenance dose</td> </tr> <tr> <td>Iron</td> <td>0 to 58%</td> <td>LAGB 14%, SG &#60;18%, RYGB 20 to 55%, BPD 13 to 62%, DS 8 to 50%</td> <td> <p>Anemia</p> <p>Pica</p> Impaired learning<br /> </td> <td> <p>Men ages 19 and older and women ages 51 and older: 8 mg per day</p> <p>Women between the ages of 19 to 50: 18 mg per day</p> </td> <td> <p>Males, post-menopausal women, and patients without history of anemia: 18 mg of iron from a multivitamin</p> <p>Menstruating women and men or women who have undergone RYGB, SG, or BPD/DS: &#62;45 to 60 mg of elemental iron daily from all sources* </p> </td> <td> <p>Oral: 150 to 300 mg 2 to 3 times a day</p> <p>Parenteral iron for those who do not respond to oral supplementation</p> </td> </tr> <tr> <td>Zinc</td> <td>24 to 28% overall; 9 to 74% seeking BPD/DS</td> <td>70% after BPD/DS, 40% after RYGB, 19% after SG, 34% after LAGB</td> <td>Growth retardation, delayed sexual maturity, impotence, impaired immune function</td> <td> <p>Women: 8 mg</p> <p>Men: 11 mg </p> </td> <td> <p>BPD/DS: 16 to 22 mg (200% RDA)</p> <p>RYGB: 8 to 22 mg (100 to 200% RDA)</p> <p>SG or LAGB: 8 to 11 mg (100% RDA)</p> <p>Maintain a ratio of 8 to 15 mg of zinc per 1 mg of copper </p> </td> <td> <p>Optimal repletion dose unknown</p> Overdose can be associated with toxicity or copper deficiency </td> </tr> <tr> <td>Copper</td> <td>68% in women seeking BPD</td> <td>90% after BPD/DS, 10 to 20% after RYGB</td> <td>Anemia, neutropenia, ataxia</td> <td>900 mcg</td> <td> <p>BPD/DS or RYGB: 2 mg daily (200% RDA)</p> <p>SG or LAGB: 1 mg daily (100% RDA)</p> <p>Maintain a ratio of 8 to 15 mg of zinc per 1 mg of copper</p> </td> <td> <p>Mild-to-moderate deficiency: 3 to 8 mg copper orally until levels normalize</p> Severe deficiency: 2 to 4 mg intravenous copper for 6 days or until symptoms resolve </td> </tr> <tr> <td>Selenium</td> <td>2%</td> <td>14 to 22% after RYGB and BPD/DS</td> <td>Skeletal muscle dysfunction and cardiomyopathy, mood disorder, impaired immune function, macrocytosis</td> <td>55 mcg</td> <td>Unknown but likely higher than 100 mcg/day<sup>[4]</sup></td> <td>2 mcg/kg/day in patients who develop cardiomyopathy<sup>[5]</sup></td> </tr> <tr> <td>Calcium</td> <td>1 to 10%<sup>[6]</sup></td> <td>3.6% after bariatric surgery (1.9% after RYGB, 9.3% after SG, and 10% after BPD/DS)</td> <td>Bone disease, secondary hyperparathyroidism</td> <td>1000 to 1200 mg</td> <td> <p>RYGB, SG, or LAGB: 1200 to 1500 mg daily in divided doses</p> <p>BPD/DS: 1800 to 2400 mg daily in divided doses</p> </td> <td> <p>RYGB, SG, or LAGB: 1200 to 1500 mg daily in divided doses</p> <p>BPD/DS: 1800 to 2400 mg daily in divided doses</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RDA: Recommended Daily Allowance; RYGB: Roux-en-Y gastric bypass; BPD/DS: biliopancreatic diversion with duodenal switch; IU: international unit; LAGB: laparoscopic adjustable gastric band; SG: sleeve gastrectomy; IM: intramuscular; IV: intravenous; SQ: subcutaneous.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Parrott J, Frank L, Rabena R, et al. American Society for Metabolic and Bariatric Surgery Integrated Health Nutritional Guidelines for the Surgical Weight Loss Patient 2016 Update: Micronutrients. Surg Obes Relat Dis 2017; 13:727.</LI>&#xD;&#xA;<LI>U.S. Department of Health and Human Services and U.S. Department of Agriculture. 2015–2020 Dietary Guidelines for Americans, 8th Edition, December 2015. Available at: <A href=\"http://health.gov/dietaryguidelines/2015/guidelines/\" target=_blank>http://health.gov/dietaryguidelines/2015/guidelines/</A> (Accessed on July 27, 2017).</LI>&#xD;&#xA;<LI>Stein J, Stier C, Raab H, Weiner R. Review article: The nutritional and pharmacological consequences of obesity surgery. Aliment Pharmacol Ther 2014; 40:582.</LI>&#xD;&#xA;<LI>Institute of Medicine (U.S.). Panel on Dietary Antioxidants and Related Compounds. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids, National Academy Press, Washington DC 2000.</LI>&#xD;&#xA;<LI>Al-Matary A, Hussain M, Ali J. Selenium: a brief review and a case report of selenium responsive cardiomyopathy. BMC Pediatr 2013; 13:39.</LI>&#xD;&#xA;<LI>Shah M, Sharma A, Wermers RA, et al. Hypocalcemia after bariatric surgery: Prevalence and associated risk factors. Obes Surg 2017.</LI></OL></div><div id=\"graphicVersion\">Graphic 114101 Version 2.0</div></div></div>"},"114103":{"type":"graphic_picture","displayName":"Tumor studding","title":"Thoracoscopic pleural appearance of tumor studding","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Thoracoscopic pleural appearance of tumor studding</div><div class=\"cntnt\"><img style=\"width:504px; height:765px;\" src=\"images/PULM/114103_Tumorstudding.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) This image depicts tumor studding of the parietal pleura surrounded by normal appearing pleura.<br />(B) This image shows extensive parietal pleural tumor studding which can be readily biopsied under direct visual guidance using a thoracoscope.</div><div class=\"graphic_reference\">Courtesy of Dr. John Beamis.</div><div id=\"graphicVersion\">Graphic 114103 Version 1.0</div></div></div>"},"114104":{"type":"graphic_picture","displayName":"Lymphangitis and tumor studding","title":"Thoracoscopic pleural appearance of lymphangitis and pleural tumor studding","html":"<div class=\"graphic\"><div style=\"width: 671px\" class=\"figure\"><div class=\"ttl\">Thoracoscopic pleural appearance of lymphangitis and pleural tumor studding</div><div class=\"cntnt\"><img style=\"width:651px; height:518px;\" src=\"images/PULM/114104_Lymphangitistumorstudding.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Typical appearance of lymphangitis on the lung surface due to breast cancer.<br />(B and C) Parietal pleural studding.<br />(D) Mesothelioma.</div><div id=\"graphicVersion\">Graphic 114104 Version 1.0</div></div></div>"},"114106":{"type":"graphic_picture","displayName":"Intraductal tubulopapillary neoplasm of the bile duct","title":"Intraductal tubulopapillary neoplasm of the bile duct, a precursor lesion to cholangiocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intraductal tubulopapillary neoplasm of the bile duct, a precursor lesion to cholangiocarcinoma</div><div class=\"cntnt\"><img style=\"width:320px; height:240px;\" src=\"images/ONC/114106_Intdctl_tblpry_nplsm_bl_dct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histology of intraductal tubulopapillary neoplasm: Dilated bile duct with intraductal polypoid mass, composed of back-to-back tubular units and occasional papillary formation. The native bile duct epithelium is preserved.</div><div id=\"graphicVersion\">Graphic 114106 Version 1.0</div></div></div>"},"114108":{"type":"graphic_picture","displayName":"Continuous nasal ventilatory support","title":"Continuous nasal ventilatory support","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Continuous nasal ventilatory support</div><div class=\"cntnt\"><img style=\"width:756px; height:447px;\" src=\"images/PULM/114108_Contnasalventilatryspprt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two individuals (19 and 21 years old) with severe spinal muscular atrophy type 1 who are continuously dependent on noninvasive ventilatory support (via nasal cannulae) since four months of age.</div><div id=\"graphicVersion\">Graphic 114108 Version 1.0</div></div></div>"},"114113":{"type":"graphic_picture","displayName":"PAH pathology","title":"Heath and Edwards pathological classification of pulmonary artery hypertension","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Heath and Edwards pathological classification of pulmonary artery hypertension</div><div class=\"cntnt\"><img style=\"width:764px; height:572px;\" src=\"images/PULM/114113_PAHpathology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panels A and C are from a 38 year-old woman with severe PAH associated with systemic sclerosis. Panels B and D are from a 40 year-old woman with a ventricular septal defect and Eisenmenger syndrome.<br />(A) Grade II lesion depicting intimal hyperplasia and medial hypertrophy.<br />(B) Grade III lesion depicting an \"onion-skin\" appearance and vessel occlusion.<br />(C) Grade IV depicting a plexiform lesion (asterisk).<br />(D) Grade VI lesion depicting a plexiform lesion with fibrinoid necrosis.</div><div class=\"graphic_footnotes\">PAH: pulmonary artery hypertension.</div><div id=\"graphicVersion\">Graphic 114113 Version 1.0</div></div></div>"},"114114":{"type":"graphic_movie","displayName":"TEE (TG LV SAX view) showing hypovolemic shock","title":"TEE (transgastric LV short-axis view) showing hypovolemic shock","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">TEE (transgastric LV short-axis view) showing hypovolemic shock</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/114114_TGLVSAXhypovolshkvid.mp4\" style=\"width:704px;height:544px\"></div><img style=\"width:746px; height:506px;\" src=\"images/ANEST/114114_TGLVSAXhypovolshkimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transgastric LV short-axis view shows a hyperdynamic left ventricle that is small at end-diastole and nearly obliterated at end-systole, consistent with severe hypovolemia.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; TG: transgastric; LV: left ventricular; SAX: short-axis.</div><div id=\"graphicVersion\">Graphic 114114 Version 1.0</div></div></div>"},"114115":{"type":"graphic_movie","displayName":"TEE (TG LV SAX view) showing LV failure","title":"TEE (transgastric LV short-axis view) showing LV failure","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">TEE (transgastric LV short-axis view) showing LV failure</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/114115_TEETGLVSAXLVfailrvid.mp4\" style=\"width:704px;height:544px\"></div><img style=\"width:756px; height:530px;\" src=\"images/ANEST/114115_TEETGLVSAXLVfailrimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A transgastric midpapillary short-axis TEE view showing severe LV dysfunction, with LVEF &lt;20%. Note minimal contraction and inward thickening of the LV globally.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; TG: transgastric; LV: left ventricle; SAX: short-axis; LVEF: left ventricular ejection fraction.</div><div id=\"graphicVersion\">Graphic 114115 Version 1.0</div></div></div>"},"114116":{"type":"graphic_movie","displayName":"TEE (ME 4CV view) showing RV dilation and failure","title":"TEE (midesophageal 4-chamber view) showing RV dilation and failure","html":"<div class=\"graphic normal\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">TEE (midesophageal 4-chamber view) showing RV dilation and failure</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/114116_TEEME4CVRVdltnfailvid.mp4\" style=\"width:592px;height:464px\"></div><img style=\"width:756px; height:567px;\" src=\"images/ANEST/114116_TEEME4CVRVdltnfailimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this video we see a severely hyperkinetic and dilated right ventricle that is nearly twice the size of the left ventricle. Note the codominance of the RV with the LV apex. Also note the severe bowing of the interatrial and interventricular septum toward the left throughout the cardiac cycle, suggesting severe pressure and volume overload.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; ME: midesophageal; 4CV: 4-chamber view; RV: right ventricular; LV: left ventricular.</div><div id=\"graphicVersion\">Graphic 114116 Version 1.0</div></div></div>"},"114118":{"type":"graphic_movie","displayName":"TEE (ME AV SAX view) showing severe AS","title":"TEE (midesophageal aortic valve short-axis view) showing severe AS","html":"<div class=\"graphic normal\"><div style=\"width: 708px\" class=\"figure\"><div class=\"ttl\">TEE (midesophageal aortic valve short-axis view) showing severe AS</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/114118_TEEMEAVSAXsevereASvid.mp4\" style=\"width:688px;height:544px\"></div><img style=\"width:686px; height:530px;\" src=\"images/ANEST/114118_TEEMEAVSAXsevereASimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image of the aortic valve short axis view shows a heavily calcified aortic valve in the center of the screen. Note the bright and poorly mobile leaflets that result in a narrowed aortic valve orifice. Also note that the significant calcification of the aortic valve results in artifacts that limit visualization of the right ventricle and right ventricular outflow tract below the aortic valve in the image.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; ME: midesophageal; AV: aortic valve; SAX: short-axis; AS: aortic stenosis.</div><div id=\"graphicVersion\">Graphic 114118 Version 1.0</div></div></div>"},"114119":{"type":"graphic_movie","displayName":"TEE (ME 4CV of the RV) in a patient with a pulmonary embolus","title":"TEE (midesophageal 4-chamber view of the RV) in a patient with a pulmonary embolus","html":"<div class=\"graphic normal\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">TEE (midesophageal 4-chamber view of the RV) in a patient with a pulmonary embolus</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/114119_TEEME4CVRVpulmemblvid.mp4\" style=\"width:608px;height:480px\"></div><img style=\"width:686px; height:522px;\" src=\"images/ANEST/114119_TEEME4CVRVpulmemblimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this 4-chamber view focused on the right ventricle we see a dilated right atrium and ventricle with RV akinesia with apical sparing, and left ventricular hyperkinesis and underfilling. These findings are consistent with a pulmonary embolus. There is septal shift leftward suggesting right ventricular pressure and volume overload. There is also an echogenic mass in the right ventricle consistent with embolic material. While it is not common to see the embolic material in transit, the other findings shown here are classic for pulmonary embolus.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; ME: midesophageal; 4CV: 4-chamber view; RV right ventricle.</div><div id=\"graphicVersion\">Graphic 114119 Version 1.0</div></div></div>"},"114120":{"type":"graphic_table","displayName":"Adjuvant CAPOX chemotherapy for stage II to III gastric cancer","title":"Adjuvant CAPOX chemotherapy for stage II to III gastric cancer<SUP>[1,2]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adjuvant CAPOX chemotherapy for stage II to III gastric cancer<SUP>[1,2]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days &times; 8 cycles. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Oxaliplatin*</td> <td>130 mg/m<sup>2</sup> IV</td> <td>Dilute in 500 mL 5% dextrose in water (D5W)<sup>&#182;</sup> and administer over two hours.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Capecitabine<sup>&#916;</sup></td> <td>1000 mg/m<sup>2</sup> per dose, by mouth</td> <td>Twice daily (total dose 2000 mg/m<sup>2</sup> per day). Swallow whole with water within 30 minutes after a meal, with each dose as close to 12 hours apart as possible. Do not cut or crush tablets.<sup>&#9674;</sup></td> <td>Day 1 through 14</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin: MODERATE. </li> <li>Oral capecitabine: LOW. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>There is no standard premedication regimen for oxaliplatin. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin is an irritant, but can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>While rates of febrile neutropenia were not reported in the primary reference for this regimen in the adjuvant setting, the rate of grade 3 or 4 neutropenia was 22%, so the decision to use primary prophylaxis with granulocyte-colony stimulating factors should not be routine but individualized based on additional risk factors<sup>[1,2]</sup>. </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy induced neutropenia and conditions other than leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Lower starting doses of oxaliplatin and capecitabine may be needed for renal impairment. </li> <li>Refer to UpToDate topic on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Maneuvers to prevent neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Counsel patients to avoid exposure to cold during and for approximately 48 hours after each infusion. Prolongation of the oxaliplatin infusion time from two to six hours may mitigate acute neurotoxicity. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>Prolongation of the corrected QT (QTc) interval and ventricular arrhythmias have been reported after oxaliplatin. ECG monitoring is recommended if therapy is initiated in patients with heart failure, bradyarrhythmias, coadministration of drugs known to prolong the QTc interval, and electrolyte abnormalities. Avoid oxaliplatin in patients with congenital long QT syndrome. Correct hypokalemia and hypomagnesemia prior to initiating oxaliplatin. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Pulmonary issues</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin has rarely been associated with pulmonary toxicity<sup>[3]</sup>. </li> <li>Refer to UpToDate topics on \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\" and \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Obtain CBC with differential and platelet count prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes (particularly potassium and magnesium) and liver and renal function prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in neurologic function prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess cardiac function at baseline and then as clinically indicated. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for diarrhea and palmar-plantar erythrodysesthesias during treatment. </li> <li>Refer to UpToDate topics on \"Enterotoxicity of chemotherapy agents\" and \"Cutaneous complications of conventional chemotherapy agents\". </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>More frequent anticoagulant response (INR or prothrombin time) monitoring is necessary for patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Cardiotoxicity observed with capecitabine includes myocardial infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac failure, sudden death, electrocardiographic changes, and cardiomyopathy. These adverse reactions may be more common in patients with a prior history of coronary artery disease. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>While the primary reference did not report the protocol-specified alterations for treatment-related toxicity, guidelines are available from trials of this same CAPOX regimen in patients with advanced disease<sup>[4,5]</sup>. A new cycle of treatment should not start until neutrophils recover to &#62;1500/microL and platelets recover to &#62;100,000/microL<sup>[5]</sup>. Some clinicians will initiate a new cycle of therapy if the platelet count is &#62;75,000/microL. Interrupt capecitabine until the next cycle begins for any grade 2 or worse hematologic toxicity and delay treatment until complete recovery or improvement to &#8804;grade 1. After recovery, reduce doses of both drugs by 20% for febrile neutropenia in the preceding cycle<sup>[4]</sup>. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Reduce the dose of oxaliplatin by 25% for persistent (14 days or longer) paresthesia or temporary (7 to 14 days) painful paresthesia or functional impairment<sup>[5]</sup>. For persistent painful paresthesia or functional impairment omit oxaliplatin until recovery and if it completely resolves, restart at 50% of dose<sup>[5]</sup>. Discontinue if toxicities recur despite dose reduction. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Gastrointestinal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Interrupt capecitabine until the initiation of the next cycle and delay oxaliplatin for any grade 2 or worse gastrointestinal toxicity; restart treatment only after complete recovery or improvement to &#8804;grade 1. Reduce the capecitabine dose by 25% in subsequent cycles at the first occurrence of grade 2 gastrointestinal toxicity, or grade 3 or 4 toxicity including mucositis. </li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after capecitabine should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin has rarely been associated with pulmonary toxicity. Withhold oxaliplatin for unexplained pulmonary symptoms until interstitial lung disease or pulmonary fibrosis is excluded<sup>[4]</sup>. </li> <li>Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other toxicity (including hepatotoxicity)</strong></td> <td colspan=\"3\"> <ul> <li>Interrupt capecitabine and delay oxaliplatin for any grade 2 or worse non-neurologic toxicity (except alopecia); restart treatment only after complete recovery or improvement to &#8804;grade 1<sup>[5]</sup>. Reduce the dose of oxaliplatin by 25% for any drug-related grade 3 toxicity other than that described above. Reduce the capecitabine dose by 20 to 30% in subsequent cycles for grade 2 or grade 3 toxicity (including hand-foot syndrome) during a preceding cycle<sup>[4]</sup>. Discontinue capecitabine permanently if, despite dose reduction, a given toxicity occurs for the fourth time at grade 2, third time at grade 3, or a second time at grade 4<sup>[6]</sup>. For transient renal insufficiency in the preceding cycle, reduce doses of both drugs. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\"><strong>Doses of capecitabine that are omitted for toxicity should not be replaced. The patient should resume the planned treatment cycles at the modified dose.</strong></td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; ECG: electrocardiogram; CBC: complete blood count; INR: international normalized ratio.<br />* Many centers routinely infuse oxaliplatin through a central venous catheter because of local pain with infusion into a peripheral vein.<br />¶ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />Δ No capecitabine dose has been shown to be safe in patients with complete dihydropyrimidine dehydrogenase (DPD) deficiency, and data are insufficient to recommend a dose in patients with partial DPD activity.<br /><FONT class=lozenge>◊</FONT> Extemporaneous compounding of liquid dosage forms has been recommended, but IV therapies may be more appropriate for patients with significant swallowing difficulty.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Noh SH, et al. Lancet Oncol 2014; 15:1389.</LI>&#xD;&#xA;<LI>Bang YJ, et al. Lancet 2012; 379:315.</LI>&#xD;&#xA;<LI>Oxaliplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on March 21, 2017).</LI>&#xD;&#xA;<LI>Jatoi A, et al. Ann Oncol 2006; 17:29.</LI>&#xD;&#xA;<LI>Van Meerten E, et al. Br J Cancer 2007; 96:1348.</LI>&#xD;&#xA;<LI>Capecitabine. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on March 21, 2017).</LI></OL></div><div id=\"graphicVersion\">Graphic 114120 Version 2.0</div></div></div>"},"114123":{"type":"graphic_movie","displayName":"Right pleural effusion consistent with hemothorax","title":"Right pleural effusion consistent with hemothorax","html":"<div class=\"graphic normal\"><div style=\"width: 676px\" class=\"figure\"><div class=\"ttl\">Right pleural effusion consistent with hemothorax</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/114123_RightPEhemothoraxvid.mp4\" style=\"width:656px;height:512px\"></div><img style=\"width:746px; height:516px;\" src=\"images/ANEST/114123_RightPEhemothoraximg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this video, the probe has been advanced from a 4-chamber view and rotated past the right ventricle to show a large right pleural effusion consistent with hemothorax. The lung tissue is collapsed and appears to the right of the image.</div><div id=\"graphicVersion\">Graphic 114123 Version 1.0</div></div></div>"},"114124":{"type":"graphic_movie","displayName":"RV failure with codominance of the ventricular apex","title":"Right ventricular failure with codominance of the ventricular apex","html":"<div class=\"graphic normal\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Right ventricular failure with codominance of the ventricular apex</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/114124_RVfailcodmvntrclrapxvid.mp4\" style=\"width:640px;height:496px\"></div><img style=\"width:760px; height:577px;\" src=\"images/ANEST/114124_RVfailcodmvntrclrapximg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this image, we see an enlarged right ventricle with codominance of the ventricular apex. The ventricle is nearly akinetic at the base but does have some apical movement. The right ventricle appears hypertrophied (&gt;0.5 cm thick) and is visually comparable in size and thickness to the left ventricle. The interatrial and interventricular septum also both bow leftward indicating pressure and volume overload of the right heart.</div><div id=\"graphicVersion\">Graphic 114124 Version 1.0</div></div></div>"},"114126":{"type":"graphic_movie","displayName":"TEE image of RA collapse caused by pericardial effusion","title":"TEE image of right atrial collapse caused by pericardial effusion","html":"<div class=\"graphic normal\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">TEE image of right atrial collapse caused by pericardial effusion</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/114126_TEERAcllpsprcrdleffvid.mp4\" style=\"width:640px;height:496px\"></div><img style=\"width:756px; height:566px;\" src=\"images/ANEST/114126_TEERAcllpsprcrdleffimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this midesophageal four-chamber view (ME 4CV) focused on the right atrium, we can see a large effusion compressing the right atrium and resulting in systolic collapse when timed with the ECG, highly suggestive of tamponade physiology.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; RA: right atrial.</div><div id=\"graphicVersion\">Graphic 114126 Version 1.0</div></div></div>"},"114127":{"type":"graphic_movie","displayName":"TEE showing pericardial effusion with RV diastolic collapse","title":"TEE (transgastric midpapillary view of the left and right ventricles) showing pericardial effusion with RV diastolic collapse","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">TEE (transgastric midpapillary view of the left and right ventricles) showing pericardial effusion with RV diastolic collapse</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/114127_TEERVdiastlccollpsvid.mp4\" style=\"width:704px;height:544px\"></div><img style=\"width:766px; height:567px;\" src=\"images/ANEST/114127_TEERVdiastlccollpsimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this videoclip of the transgastric midpapillary view, we see a large pericardial effusion encircling the lateral and inferior left ventricle and also behind the right ventricle. There is clear collapse of the right ventricle in diastole, consistent with tamponade.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; RV: right ventricular.</div><div class=\"graphic_reference\">Reproduced with permission from Dr. Peter Panzica, MD, Beth Israel Deaconess Medical Center.</div><div id=\"graphicVersion\">Graphic 114127 Version 1.0</div></div></div>"},"114132":{"type":"graphic_table","displayName":"Pain assessment tools for older adults with dementia","title":"Pain assessment tools for older adults with dementia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pain assessment tools for older adults with dementia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tool</td> <td class=\"subtitle1\">Type of assessment</td> <td class=\"subtitle1\">Timeframe</td> </tr> <tr class=\"divider_bottom\"> <td>Checklist of Nonverbal Pain Indicators (CNPI)<sup>[1]</sup></td> <td>Six categories of behavioral items <ol> <li>Vocal complaints: nonverbal </li> <li>Facial grimaces </li> <li>Bracing </li> <li>Restlessness </li> <li>Rubbing </li> <li>Vocal complaints: verbal </li> </ol> </td> <td>Approximately five minutes</td> </tr> <tr class=\"divider_bottom\"> <td>Pain Assessment Checklist for Seniors with Limited Ability to Communicate (PACSLAC)<sup>[2]</sup></td> <td>60 items (divided between four areas) <ol> <li>Facial expression </li> <li>Activity/body movement </li> <li>Social/personality/mood </li> <li>Other (psychological changes/eating/sleep/vocal behaviors) </li> </ol> </td> <td>Approximately five minutes with minimal training</td> </tr> <tr class=\"divider_bottom\"> <td>Pain Assessment in Advanced Dementia (PAINAD)<sup>[3]</sup></td> <td>Five categories of behavioral items <ol> <li>Breathing </li> <li>Negative vocalization </li> <li>Facial expression </li> <li>Body language </li> <li>Consolability </li> </ol> </td> <td>Approximately five minutes</td> </tr> <tr class=\"divider_bottom\"> <td>Pain Assessment for the Dementing Elderly scale (PADE)<sup>[4]</sup></td> <td>24 items (divided between three areas) <ol> <li>Physical </li> <li>Global assessment </li> <li>Functional </li> </ol> </td> <td>5 to 10 minutes</td> </tr> <tr> <td>Non-communicative Patients' Pain Assessment Instrument (NOPPAIN)<sup>[5]</sup></td> <td>Activity chart checklist <ol> <li>Situations of daily care </li> <li>Pain behaviors observed </li> <li>Location of pain seen </li> <li>Pain intensity </li> </ol> </td> <td>Five minutes of daily care activities completed prior to observation. Checklist completion less than five minutes.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Feldt KS. The checklist of nonverbal pain indicators (CNPI). Pain Manag Nurs 2000; 1:13.</li>&#xD;&#xA;    <li>Fuchs-Lacelle S, Hadjistavropoulos T. Development and preliminary validation of the pain assessment checklist for seniors with limited ability to communicate (PACSLAC). Pain Manag Nurs 2004; 5:37.</li>&#xD;&#xA;    <li>Warden V, Hurley AC, Volicer L. Development and psychometric evaluation of the Pain Assessment in Advanced Dementia (PAINAD) scale. J Am Med Dir Assoc 2003; 4:9.</li>&#xD;&#xA;    <li>Villanueva MR, Smith TL, Erickson JS, et al. Pain Assessment for the Dementing Elderly (PADE): reliability and validity of a new measure. J Am Med Dir Assoc 2003; 4:1.</li>&#xD;&#xA;    <li>Snow AL, Weber JB, O'Malley KJ, et al. NOPPAIN: a nursing assistant-administered pain assessment instrument for use in dementia. Dement Geriatr Cogn Disord 2004; 17:240.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 114132 Version 1.0</div></div></div>"},"114133":{"type":"graphic_figure","displayName":"Neuromuscular junction","title":"Neuromuscular junction","html":"<div class=\"graphic\"><div style=\"width: 762px\" class=\"figure\"><div class=\"ttl\">Neuromuscular junction</div><div class=\"cntnt\"><img style=\"width:742px; height:622px;\" src=\"images/ANEST/114133_Neuromuscular_junction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The synaptic vesicle exocytosis-endocytosis cycle. After an action potential and Ca<SUP>2+</SUP> influx, phosphorylation of synapsin is activated by calcium-calmodulin activated protein kinases I and II. This results in the mobilization of SVs from the cytomatrix toward the plasma membrane. The formation of the SNARE complex is an essential step for the docking process. After fusion of SVs with the presynaptic plasma membrane, ACh is released into the synaptic cleft. Some of the released acetylcholine molecules bind to the nAChRs on the postsynaptic membrane, while the rest is rapidly hydrolyzed by the AChE present in the synaptic cleft to choline and acetate. Choline is recycled into the terminal by a high-affinity uptake system, making it available for the resynthesis of acetylcholine. Exocytosis is followed by endocytosis in a process dependent on the formation of a clathrin coat and of action of dynamin. After recovering of SV membrane, the coated vesicle uncoats and another cycle starts again.</div><div class=\"graphic_footnotes\">Acetyl CoA: acetylcoenzyme A; CAT: choline acetyltransferase; PK: protein kinase; SVs: synaptic vesicles; ACh: acetylcholine; nAChRs: nicotinic acetylcholine receptors; AChE: acetylcholinesterase.</div><div class=\"graphic_reference\">From: Naguib M, Flood P, McArdle JJ, Brenner HR. Advances in neurobiology of the neuromuscular junction: implications for the anesthesiologist. Anesthesiology 2002; 96:202. Copyright © 2002 American Society of Anesthesiologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 114133 Version 1.0</div></div></div>"},"114136":{"type":"graphic_figure","displayName":"Single twitch stimulation","title":"Single twitch (ST) - Unblocked","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Single twitch (ST) - Unblocked</div><div class=\"cntnt\"><img style=\"width:516px; height:319px;\" src=\"images/ANEST/114136_Pttrnsingletwitchstimltn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Single twitch stimulation involves one supramaximal neurostimulation every 10 seconds. This graphic shows the pattern of ST stimulation (lower panel) and the evoked muscle response during normal (unblocked) neuromuscular function (upper panel). Following establishment of a baseline (control) twitch amplitude at supramaximal current, subsequent single twitches are compared to control to determine an amplitude ratio (ST/STc). In this graphic, without neuromuscular blockade, the ST/STc = 1.0.</div><div class=\"graphic_footnotes\">STc: single twitch control.</div><div class=\"graphic_reference\">Reproduced with permission from: Brull SJ. Neuromuscular blocking agents. In: Clinical Anesthesia, 8th ed, Barash PG, Cullen BF, Stoelting RK, et al (Eds), Wolters Kluwer, Philadelphia 2017. Copyright © 2017 Wolters Kluwer.</div><div id=\"graphicVersion\">Graphic 114136 Version 1.0</div></div></div>"},"114137":{"type":"graphic_figure","displayName":"TOF unblocked","title":"Train-of-four (TOF) - Unblocked","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Train-of-four (TOF) - Unblocked</div><div class=\"cntnt\"><img style=\"width:479px; height:319px;\" src=\"images/ANEST/114137_Rspnsnormneuromsclrfnctn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pattern of TOF stimulation (lower panel) and the evoked muscle response during normal (unblocked) neuromuscular function (upper panel). For further information refer to UpToDate content on monitoring neuromuscular function.</div><div class=\"graphic_footnotes\">TOF: train-of-four; T: twitch.</div><div class=\"graphic_reference\">Reproduced with permission from: Brull SJ. Neuromuscular blocking agents. In: Clinical Anesthesia, 8th ed, Barash PG, Cullen BF, Stoelting RK, et al (Eds), Wolters Kluwer, Philadelphia 2017. Copyright © 2017 Wolters Kluwer.</div><div id=\"graphicVersion\">Graphic 114137 Version 1.0</div></div></div>"},"114138":{"type":"graphic_figure","displayName":"TOF partial block","title":"Train-of-four (TOF) - Partial block","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Train-of-four (TOF) - Partial block</div><div class=\"cntnt\"><img style=\"width:476px; height:318px;\" src=\"images/ANEST/114138_Msclrspnsprtlnrmsclrblk.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pattern of TOF stimulation (lower panel) and the evoked muscle response during partial neuromuscular block (upper panel), with a TOFR of 0.5. For further information, refer to UpToDate content on monitoring neuromuscular function. </div><div class=\"graphic_footnotes\">TOF: train-of-four; TOFR: train-of-four ratio; T: twitch</div><div class=\"graphic_reference\">Reproduced with permission from: Brull SJ. Neuromuscular blocking agents. In: Clinical Anesthesia, 8th ed, Barash PG, Cullen BF, Stoelting RK, et al (Eds), Wolters Kluwer, Philadelphia 2017. Copyright © 2017 Wolters Kluwer.</div><div id=\"graphicVersion\">Graphic 114138 Version 1.0</div></div></div>"},"114139":{"type":"graphic_figure","displayName":"Muscle response during partial (moderate) neuromuscular block","title":"Train-of-four count (TOFC) - Moderate block","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Train-of-four count (TOFC) - Moderate block</div><div class=\"cntnt\"><img style=\"width:479px; height:310px;\" src=\"images/ANEST/114139_Rspns_prt_mod_neurmsclr_blk.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pattern of TOF stimulation (lower panel) and the evoked muscle response during partial (moderate) neuromuscular block (upper panel). Note there is no muscle response to the fourth TOF stimulus. For further information, refer to UpToDate content on monitoring neuromuscular blockade.</div><div class=\"graphic_footnotes\">mA: milliamperes; T<SUB innerHtml>1</SUB>: first twitch in sequence; T<SUB innerHtml>2 </SUB>: second twitch in sequence; T<SUB>3</SUB>: third twitch in sequence; T<SUB>4</SUB>: fourth twitch in sequence; TOF: train-of-four; TOFC: train-of-four count.</div><div id=\"graphicVersion\">Graphic 114139 Version 2.0</div></div></div>"},"114140":{"type":"graphic_figure","displayName":"Tetanus without block","title":"Tetanus (TET) - Unblocked","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tetanus (TET) - Unblocked</div><div class=\"cntnt\"><img style=\"width:435px; height:290px;\" src=\"images/ANEST/114140_Cntrctnnrmneuromsclrfnct.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pattern of TET stimulation (lower panel) and the evoked muscle response (sustained contraction) during normal neuromuscular function (upper panel). The muscle response is maintained at a stable level without fade (S<SUB>5</SUB>/S<SUB>1</SUB> = 1.0). The TOFR is also 1.0. For further information, refer to UpToDate content on monitoring neuromuscular function.</div><div class=\"graphic_footnotes\">TET: tetanic; S<SUB innerHtml>1</SUB>: beginning of&nbsp; tetanus; S<SUB>5</SUB>: end of 5 second tetanus; TOFR: train-of-four ratio; T: twitch.</div><div class=\"graphic_reference\">Reproduced with permission from: Brull SJ. Neuromuscular blocking agents. In: Clinical Anesthesia, 8th ed, Barash PG, Cullen BF, Stoelting RK, et al (Eds), Wolters Kluwer, Philadelphia 2017. Copyright © 2017 Wolters Kluwer.</div><div id=\"graphicVersion\">Graphic 114140 Version 1.0</div></div></div>"},"114141":{"type":"graphic_figure","displayName":"Tetanus with partial block","title":"Tetanus (TET) - Partial block","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tetanus (TET) - Partial block</div><div class=\"cntnt\"><img style=\"width:435px; height:344px;\" src=\"images/ANEST/114141_Cntrctnprtlneuromsclrblk.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pattern of TET stimulation (lower panel) and the evoked muscle response (decreasing muscle contraction; fade) during partial neuromuscular block (upper panel). The ratio of tension at 5 seconds to the tension at the beginning is the tetanic ratio (S<SUB>5</SUB>/S<SUB>1</SUB>) and is the same as the TOFR. For further information refer to UpToDate content on monitoring neuromuscular function.</div><div class=\"graphic_footnotes\">TET: tetanic; T: twitch; TOFR: train-of-four ratio; S<SUB>1</SUB>: beginning of tetanus; S<SUB>5</SUB>: end of 5 second tetanus.</div><div class=\"graphic_reference\">Reproduced with permission from: Brull SJ. Neuromuscular blocking agents. In: Clinical Anesthesia, 8th ed, Barash PG, Cullen BF, Stoelting RK, et al (Eds), Wolters Kluwer, Philadelphia 2017. Copyright © 2017 Wolters Kluwer.</div><div id=\"graphicVersion\">Graphic 114141 Version 1.0</div></div></div>"},"114142":{"type":"graphic_figure","displayName":"Pattern of post-tetanic count stimulation","title":"Post-tetanic count (PTC)","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Post-tetanic count (PTC)</div><div class=\"cntnt\"><img style=\"width:505px; height:319px;\" src=\"images/ANEST/114142_Pttrnposttetaniccntstim.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Post-tetanic count (PTC) consists of a five-second tetanic (50 Hz) stimulus, followed three seconds later by a series of ST stimuli delivered at 1 Hz. In this example, neither TOF nor tetanic stimulation (lower panel) results in evoked muscle response (upper panel). Post tetanic stimulation results in four fading muscle contractions, and a PTC of 4. For further information, refer to UpToDate content on monitoring neuromuscular function.</div><div class=\"graphic_footnotes\">PTC: post-tetanic count; TOF: train-of-four; ST: single twitch.</div><div class=\"graphic_reference\"><FONT id=source data-bind=\"template: 'sourceTemplate'\" __ko__1502800343973=\"ko7\">Reproduced with permission from: Brull SJ. Neuromuscular blocking agents. In: Clinical Anesthesia, 8th ed, Barash PG, Cullen BF, Stoelting RK, et al (Eds), Wolters Kluwer, Philadelphia 2017. Copyright © 2017 Wolters Kluwer.</FONT></div><div id=\"graphicVersion\">Graphic 114142 Version 1.0</div></div></div>"},"114143":{"type":"graphic_figure","displayName":"Double burst stimulation without block","title":"Double burst stimulation - Unblocked","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Double burst&nbsp;stimulation - Unblocked</div><div class=\"cntnt\"><img style=\"width:484px; height:357px;\" src=\"images/ANEST/114143_Pttrndoubleburststimultn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pattern of DBS (lower panel) and the evoked muscle response during normal (unblocked) neuromuscular function (upper panel). The level of blockade (double burst ratio) is the same as the TOF ratio. For further information, refer to UpToDate content on monitoring neuromuscular function.</div><div class=\"graphic_footnotes\">DBS: double burst stimulation; TOF: train-of-four; D<SUB>1</SUB>: first burst; D<SUB>2</SUB>: second burst.</div><div class=\"graphic_reference\"><FONT id=source data-bind=\"template: 'sourceTemplate'\" __ko__1502800343973=\"ko7\"><FONT jQuery1502800342471=\"6982\">Reproduced with permission from: Brull SJ. Neuromuscular blocking agents. In: Clinical Anesthesia, 8th ed, Barash PG, Cullen BF, Stoelting RK, et al (Eds), Wolters Kluwer, Philadelphia 2017. Copyright © 2017 Wolters Kluwer. </FONT></FONT></div><div id=\"graphicVersion\">Graphic 114143 Version 1.0</div></div></div>"},"114144":{"type":"graphic_figure","displayName":"Double burst stimulation and evoked muscle response","title":"Double burst stimulation - Partial block","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Double burst stimulation - Partial block</div><div class=\"cntnt\"><img style=\"width:484px; height:357px;\" src=\"images/ANEST/114144_Dblbrststimltnmsclrspns.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pattern of DBS<SUB> </SUB>(lower panel) and the evoked muscle response during partial neuromuscular block (upper panel). The level of blockade (double burst ratio) is the same as the TOF ratio. For further information, refer to UpToDate content on monitoring neuromuscular blockade.</div><div class=\"graphic_footnotes\">DBS: double burst stimulation; TOF: train-of-four; D<SUB innerHtml>1</SUB>: first burst; D<SUB>2</SUB>: second burst.</div><div class=\"graphic_reference\">Reproduced with permission from: Brull SJ. Neuromuscular blocking agents. In: Clinical Anesthesia, 8th ed, Barash PG, Cullen BF, Stoelting RK, et al (Eds), Wolters Kluwer, Philadelphia 2017. Copyright © 2017 Wolters Kluwer.</div><div id=\"graphicVersion\">Graphic 114144 Version 1.0</div></div></div>"},"114145":{"type":"graphic_figure","displayName":"Subjective eval neuromuscular responses at adductor pollicis","title":"Subjective evaluation of neuromuscular responses at the adductor pollicis<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div style=\"width: 665px\" class=\"figure\"><div class=\"ttl\">Subjective evaluation of neuromuscular responses at the adductor pollicis<SUP>[1]</SUP></div><div class=\"cntnt\"><img style=\"width:645px; height:492px;\" src=\"images/ANEST/114145_Neurmsclr_rspn_addctr_pllcs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subjective (tactile) evaluation of neuromuscular responses at the adductor pollicis (thumb) muscle in response to ulnar nerve stimulation. Note the negative (black) electrode is placed distally.</div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Naguib M, Brull SJ, Johnson KB. Conceptual and technical insights into the basis of neuromuscular monitoring. Anaesthesia 2017; 72 Suppl 1:16.</LI></OL>Reprinted with permission, Cleveland Clinic Center for Medical Art &amp; Photography ©2016-2017. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 114145 Version 1.0</div></div></div>"},"114146":{"type":"graphic_figure","displayName":"Lower extremity monitoring","title":"Lower extremity monitoring<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div style=\"width: 675px\" class=\"figure\"><div class=\"ttl\">Lower extremity monitoring<SUP>[1]</SUP></div><div class=\"cntnt\"><img style=\"width:655px; height:533px;\" src=\"images/ANEST/114146_Lower_extremity_monitoring.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An accelerometer is attached to the plantar surface of the large toe. The stimulating electrodes are placed along the posterior tibial nerve (posterior to the medial malleolus). Stimulation causes plantar flexion of the toes. Note the negative (black) electrode is placed distally.</div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Naguib M, Brull SJ, Johnson KB. Conceptual and technical insights into the basis of neuromuscular monitoring. Anaesthesia 2017; 72 Suppl 1:16.</LI></OL>Reprinted with permission, Cleveland Clinic Center for Medical Art &amp; Photography ©2016-2017. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 114146 Version 1.0</div></div></div>"},"114147":{"type":"graphic_figure","displayName":"Placement of stimulating electrodes for monitoring of eye","title":"Placement of stimulating electrodes for monitoring of eye<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div style=\"width: 665px\" class=\"figure\"><div class=\"ttl\">Placement of stimulating electrodes for monitoring of eye<SUP>[1]</SUP></div><div class=\"cntnt\"><img style=\"width:645px; height:395px;\" src=\"images/ANEST/114147_Stim_plc_elctrds_eye_mntrng.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Suggested placement of stimulating electrodes for monitoring of the eye (orbicularis oculi, corrugator supercilii) muscles. Given the course of the facial nerve, note that the positive (red) electrode is always proximal and the negative (black) electrode always distal.</div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Naguib M, Brull SJ, Johnson KB. Conceptual and technical insights into the basis of neuromuscular monitoring. Anaesthesia 2017; 72 Suppl 1:16.</LI></OL>Reprinted with permission, Cleveland Clinic Center for Medical Art &amp; Photography ©2016-2017. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 114147 Version 1.0</div></div></div>"},"114148":{"type":"graphic_figure","displayName":"Rocuronium recovery chart","title":"Rocuronium recovery chart","html":"<div class=\"graphic\"><div style=\"width: 1327px\" class=\"figure\"><div class=\"ttl\">Rocuronium recovery chart</div><div class=\"cntnt\"><img style=\"width:1307px; height:577px;\" src=\"images/ANEST/114148_Rocuroniumrecoverychart.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Simulations of predicted effect site concentrations, depth of block and duration of block, various modes of monitoring neuromuscular block (TOFC, PTC, TOFR), and the recommended doses of the three most common pharmacological neuromuscular reversal agents (SGX, Neo, and Edro). The top graph represents the predicted effect site concentrations over time for a 0.6 mg.kg<SUP>−1</SUP> rocuronium bolus (black line) based on published pharmacokinetic parameters. The grey lines represent estimated 10% variability in effect site concentrations. The duration in minutes (median and range) in each predicted state of neuromuscular blockade (colored boxes) was adapted from published data. Estimates assume maintenance of anesthesia with propofol, fentanyl, and 66% nitrous oxide. TOFC and PTC can be assessed by subjective (tactile or visual) means using a PNS. In addition to TOFC and PTC, a quantitative monitor measures TOFR. The time range of recovery of clinical signs (eg, head lift) and sustained response to 50 Hz tetanic stimulation is presented in the yellow box. It is important to note that all the clinical signs of recovery from neuromuscular blockade are insensitive and unreliable.</div><div class=\"graphic_footnotes\">TOFC: train-of-four count; PTC, post-tetanic count; TOFR, train-of-four ratio; SGX: sugammadex; Neo: neostigmine; Edro: edrophonium.<br />* At the deeper level, a higher dose of sugammadex (8 mg.kg<SUP>−1</SUP>) may be required 'off-label'.</div><div class=\"graphic_reference\">From: Naguib M, Brull SJ, Johnson KB. Conceptual and technical insights into the basis of neuromuscular monitoring. Anaesthesia 2017; 72 Suppl 1:16. <A href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1111/anae.13738/full\" target=_blank>http://onlinelibrary.wiley.com/wol1/doi/10.1111/anae.13738/full</A>. Copyright © 2017 The Association of Anaesthetists of Great Britain and Ireland. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 114148 Version 2.0</div></div></div>"},"114154":{"type":"graphic_table","displayName":"Patient preoperative history","title":"Patient preoperative history","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient preoperative history</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td><strong>Name:</strong></td> <td><strong>DOB:</strong></td> <td colspan=\"2\"><strong>Preferred daytime phone #:</strong></td> </tr> <tr> <td colspan=\"3\"><strong>Planned surgery:</strong></td> <td><strong>Today's date:</strong></td> </tr> <tr> <td colspan=\"4\"><strong>Surgeon:</strong></td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\"><strong>Primary care physician:</strong></td> <td><strong>PCP phone #:</strong></td> </tr> <tr class=\"divider_top divider_bottom highlight_gray_text\"> <td colspan=\"4\"><strong>Please list all previous surgeries (and approximate dates)</strong></td> </tr> <tr> <td colspan=\"2\">&nbsp;</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td colspan=\"2\">&nbsp;</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">&nbsp;</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"divider_bottom highlight_gray_text\" colspan=\"4\"><strong>Please list any allergies to medications, latex, food, or other (and your reactions to them)</strong></td> </tr> <tr> <td colspan=\"2\">&nbsp;</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">&nbsp;</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"divider_bottom highlight_gray_text\" colspan=\"4\"><strong>List all medications (include over-the-counter drugs, inhalers, herbals, supplements, and aspirin)</strong></td> </tr> <tr class=\"divider_bottom\"> <td><strong>Drug name</strong></td> <td><strong>Dose and how often?</strong></td> <td><strong>Drug name</strong></td> <td><strong>Dose and how often?</strong></td> </tr> <tr> <td colspan=\"2\">1.</td> <td colspan=\"2\">7.</td> </tr> <tr> <td colspan=\"2\">2.</td> <td colspan=\"2\">8.</td> </tr> <tr> <td colspan=\"2\">3.</td> <td colspan=\"2\">9.</td> </tr> <tr> <td colspan=\"2\">4.</td> <td colspan=\"2\">10.</td> </tr> <tr> <td colspan=\"2\">5.</td> <td colspan=\"2\">11.</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">6.</td> <td colspan=\"2\">12.</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\">Weight: (lbs or kg) ____<br /> Height: (inches or cm) ____<br /> (Circle the measurement units you use)</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td colspan=\"4\"><strong>Please check any of the following that apply to your health:</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Heart attack at any time</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Congenital heart disease</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Heart attack within past 60 days</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Hypertension</td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Chest pain or pressure with activity</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Murmur</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Angina</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Valve disorder</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Heart failure</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>LVAD</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Heart surgery</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Heart device</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Heart stent in the last 6 months</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Pacemaker</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Unable to climb 2 flights of stairs or walking 2 blocks because of chest pain or trouble breathing</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Defibrillator</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Heart stent at any time</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Fainted in the last year</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Atrial fibrillation</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Pain in legs while walking</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Arrhythmia</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> None of these</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td colspan=\"4\">&nbsp;</td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Oxygen at home</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>COPD</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Pulmonary hypertension</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Pneumonia in last 2 months</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Trouble breathing at rest or with minimal exertions</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Any problems with your lungs</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Asthma</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Severe cough</strong></td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">&nbsp;</td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> None of these</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td colspan=\"4\">&nbsp;</td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Face, arm, or leg weakness</td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Myasthenia gravis</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Stroke/TIA within past 60 days</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Muscular dystrophy</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Stroke or TIA at any time</td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Spinal cord injury</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Paralysis</td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Brain tumor</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Difficulty speaking</td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Brain aneurysm or AVM</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Dementia</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Epilepsy, blackouts, or seizures</strong></td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Parkinson disease</td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> None of these</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td colspan=\"4\">&nbsp;</td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Hospitalized in last 30 days</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Hypothyroidism</td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Anemia</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Adrenal disorder</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Sickle cell disease</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Pituitary disorder</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Blood transfusion in last 3 months</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Dialysis</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Blood clots/pulmonary embolus</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Lupus</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Diabetes</td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Rheumatoid arthritis</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Cancer: What type? ________</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Scleroderma</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Chemo or radiation last 3 months</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Sjogren's</td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Kidney disease other than stones</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Jehovah's Witness</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Liver disease</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Use illegal drugs (excluding marijuana)</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Cirrhosis</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Kidney failure</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Hepatitis B/C</td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Taking antibiotics for any reason</td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Jaundice</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>HIV</strong></td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Hyperthyroidism</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> None of these</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td colspan=\"4\">&nbsp;</td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Blood thinners or anticoagulants other than aspirin</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Von Willebrands</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Bleeding with surgery or tooth extractions</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Known bleeding disorder</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Hemophilia</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Severe nose bleeds</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">&nbsp;</td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> None of these</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td colspan=\"4\">&nbsp;</td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Malignant hyperthermia (in blood relatives or self) with anesthesia</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Dentures</td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Severe nausea or vomiting from anesthesia</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Problems opening your mouth</td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Difficult airway with anesthesia</td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Loose teeth</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">&nbsp;</td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> None of these</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td colspan=\"4\">&nbsp;</td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Unintentional weight loss &#62;10 lbs</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Difficulty doing your own shopping</td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Difficulty getting out of bed/chair by yourself</td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Feel that everything you did was an effort: ____ days in the last week</td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Difficulty making your own meals</td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Need assistance with eating or bathing or dressing</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Your physical abilities limit your daily activities</td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Fallen in the last 6 months ( ____ times)</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">&nbsp;</td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> None of these</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td colspan=\"4\">&nbsp;</td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Very loud snoring</td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> High blood pressure/hypertension</td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Tired/fall asleep frequently during the day</td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Sleep apnea; NO CPAP</strong></td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Observed to stop breathing during sleep</strong></td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Sleep apnea; use CPAP</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">&nbsp;</td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> None of these</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td colspan=\"4\">&nbsp;</td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Cannot speak and/or understand English</td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Deaf</td> </tr> <tr> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Cannot lie flat for 45 minutes</td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> Blind</td> </tr> <tr> <td colspan=\"4\"><span class=\"primarybox_left\">&nbsp;</span> Currently pregnant. Last menstrual period began: ________</td> </tr> <tr> <td colspan=\"4\"><span class=\"primarybox_left\">&nbsp;</span> Smoker (current or past) ____ packs/day for ____ years. Quit date: ________</td> </tr> <tr> <td colspan=\"4\"><span class=\"primarybox_left\">&nbsp;</span> Drink alcohol. How much each day? ____ beers ____ glasses of wine ____ shots of hard alcohol</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">&nbsp;</td> <td colspan=\"2\"><span class=\"primarybox_left\">&nbsp;</span> None of these</td> </tr> <tr class=\"divider_top\"> <td colspan=\"4\">Please list any medical illness or medications not noted already:<br /> <br /> <br /> <br /> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The graphic shows an example of a form that would be used to start a medical history during evaluation in anticipation of anesthesia. For further information, refer to UpToDate content on preanesthesia evaluation for noncardiac surgery.</div><div class=\"graphic_footnotes\">DOB: date of birth; PCP: primary care physician; COPD: chronic obstructive pulmonary disease; TIA: transient ischemic attack; AVM: arteriovenous malformation; CPAP: continuous positive airway pressure.</div><div id=\"graphicVersion\">Graphic 114154 Version 2.0</div></div></div>"},"114155":{"type":"graphic_table","displayName":"Criteria med conditions preop eval recommended","title":"Criteria and medical conditions for which preoperative evaluation is recommended before the date of surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria and medical conditions for which preoperative evaluation is recommended before the date of surgery</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Medical condition</td> </tr> <tr> <td class=\"indent1\"><strong>General</strong></td> </tr> <tr> <td class=\"indent2\">Normal activity inhibited</td> </tr> <tr> <td class=\"indent2\">Monitoring or medical assistance at home within two months</td> </tr> <tr> <td class=\"indent2\">Hospital admission within two months</td> </tr> <tr> <td class=\"indent2\">Obesity &#62;140% ideal body weight</td> </tr> <tr> <td class=\"indent1\"><strong>Cardiovascular</strong></td> </tr> <tr> <td class=\"indent2\">Coronary artery disease</td> </tr> <tr> <td class=\"indent2\">Arrhythmias</td> </tr> <tr> <td class=\"indent2\">Poorly controlled hypertension</td> </tr> <tr> <td class=\"indent2\">Systolic blood pressure &#62;160 mmHg or diastolic blood pressure &#62;100 mmHg</td> </tr> <tr> <td class=\"indent2\">Heart failure</td> </tr> <tr> <td class=\"indent1\"><strong>Respiratory</strong></td> </tr> <tr> <td class=\"indent2\">Asthma requiring daily medications</td> </tr> <tr> <td class=\"indent2\">COPD with symptoms</td> </tr> <tr> <td class=\"indent2\">Exacerbation or progression of COPD or asthma within two months</td> </tr> <tr> <td class=\"indent2\">Previous airway surgery</td> </tr> <tr> <td class=\"indent2\">Unusual airway anatomy</td> </tr> <tr> <td class=\"indent2\">Airway tumor or obstruction</td> </tr> <tr> <td class=\"indent2\">Home ventilatory assistance or monitoring</td> </tr> <tr> <td class=\"indent1\"><strong>Endocrine</strong></td> </tr> <tr> <td class=\"indent2\">Diabetes</td> </tr> <tr> <td class=\"indent2\">Adrenal disorders</td> </tr> <tr> <td class=\"indent2\">Active thyroid disease</td> </tr> <tr> <td class=\"indent1\"><strong>Neuromuscular</strong></td> </tr> <tr> <td class=\"indent2\">Seizure disorder</td> </tr> <tr> <td class=\"indent2\">CNS disease (eg, multiple sclerosis)</td> </tr> <tr> <td class=\"indent2\">Myopathy or other muscle disorders</td> </tr> <tr> <td class=\"indent1\"><strong>Hepatic</strong></td> </tr> <tr> <td class=\"indent2\">Active hepatobiliary disease or compromise</td> </tr> <tr> <td class=\"indent1\"><strong>Renal</strong></td> </tr> <tr> <td class=\"indent2\">Renal insufficiency or failure</td> </tr> <tr> <td class=\"indent1\"><strong>Musculoskeletal</strong></td> </tr> <tr> <td class=\"indent2\">Kyphosis or scoliosis compromising function</td> </tr> <tr> <td class=\"indent2\">Temporomandibular joint disorder limiting mouth opening</td> </tr> <tr> <td class=\"indent2\">Cervical or thoracic spine injury/disease</td> </tr> <tr> <td class=\"indent1\"><strong>Oncology</strong></td> </tr> <tr> <td class=\"indent2\">Chemo- or radiotherapy within last two months</td> </tr> <tr> <td class=\"indent2\">Significant physiologic compromise from disease or treatment</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Criteria</td> </tr> <tr> <td class=\"indent1\"><strong>Age</strong></td> </tr> <tr> <td class=\"indent2\">&#62;65 years, unless surgery is minor (eg, cataract, cystoscopy) and under monitored anesthesia care</td> </tr> <tr> <td class=\"indent1\"><strong>Language</strong></td> </tr> <tr> <td class=\"indent2\">Patient or parent/guardian cannot hear, speak, or understand English</td> </tr> <tr> <td class=\"indent1\"><strong>Anesthesia related</strong></td> </tr> <tr> <td class=\"indent2\">Patient has had previous difficult intubation, paralysis or nerve damage during anesthesia, or patient or family has had previous elevated temperature during anesthesia, is allergic to succinylcholine, has malignant hyperthermia or pseudocholinesterase deficiency&nbsp;</td> </tr> <tr> <td class=\"indent1\"><strong>Procedure related</strong></td> </tr> <tr> <td class=\"indent2\">Intraoperative blood transfusion likely</td> </tr> <tr> <td class=\"indent2\">ICU admission likely</td> </tr> <tr> <td class=\"indent2\">High-risk surgery</td> </tr> <tr> <td class=\"indent1\"><strong>Pregnancy</strong></td> </tr> <tr> <td class=\"indent2\">Patient is pregnant (unless the procedure is termination)</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table shows medical conditions and other patient criteria for preanesthesia evaluation before the day of surgery. For further information, refer to UpToDate content on preanesthesia evaluation for noncardiac surgery.&nbsp;<br />​</div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease; CNS: central nervous system; ICU: intensive care unit.</div><div id=\"graphicVersion\">Graphic 114155 Version 1.0</div></div></div>"},"114156":{"type":"graphic_table","displayName":"Triage guidelines","title":"Triage guidelines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Triage guidelines</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>Patients for low risk procedures typically done with sedation</strong></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>In-person evaluation well before the day of surgery is recommended for patients with any one of the conditions from List 1 </li> </ul> </td> </tr> <tr> <td><strong>Triage guidelines for moderate-high risk procedures</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>In-person evaluation well before the day of surgery is recommended for patients with any one of the conditions from List 1 or List 2 </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td><strong>List 1:</strong></td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\"> <li>Poor historians who do not know their medications or medical history </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"2\"> <li>Unable to lie flat and still for the duration of the procedure </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"3\"> <li>Obstructive sleep apnea without treatment </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"4\"> <li>BMI &#62;40 </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"5\"> <li>Heart failure </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"6\"> <li>Pacemaker or implantable cardiac defibrillator </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"7\"> <li>Hospitalization for medical problems within the last two months </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"8\"> <li>Unable to perform activities of daily living (feeding or dressing oneself) </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"9\"> <li>Myocardial infarction within the last 60 days </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"10\"> <li>Coronary stents within the last six months </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"11\"> <li>Stroke or TIA within the last three months </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"12\"> <li>Use of anticoagulants if these must be stopped for the procedure </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"13\"> <li>Oxygen use </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"14\"> <li>Previous serious problems with anesthesia such as malignant hyperthermia, nerve damage </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"15\"> <li>Dialysis patient </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"16\"> <li>Severe liver disease </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"17\"> <li>Cannot hear, speak, or understand English </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"18\"> <li>Significant dementia or cognitive impairment </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"19\"> <li>Pregnancy (unless procedure is a termination) </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"20\"> <li>Obviously difficult airway or history of same </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"21\"> <li>Poorly controlled hypertension (SBP &#62;160; DBP &#62;100) </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"22\"> <li>Poorly controlled seizure disorder </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"23\"> <li>Pulmonary hypertension </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"24\"> <li>Significant airway abnormalities (goiter, tumors, tracheostomy) </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>25.&nbsp; Hospitalization within the last two months unless the surgery was planned during the hospitalization</p> </td> </tr> <tr class=\"divider_top\"> <td><strong>List 2:</strong></td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\"> <li>Age &#62;65 years </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"2\"> <li>Taking &#62;8 prescription medications </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"3\"> <li>Heart disease of any type </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"4\"> <li>Medical condition inhibiting normal daily activity </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"5\"> <li>Inability to climb one flight of stairs </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"6\"> <li>Conditions necessitating assistance or monitoring at home within last three months </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"7\"> <li>Diabetes mellitus </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"8\"> <li>Chronic pain </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"9\"> <li>Kidney disease </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"10\"> <li>Liver disease </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"11\"> <li>Significant lung disease (use of daily medications) </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"12\"> <li>Likely to require a blood transfusion </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"13\"> <li>Patient refusing blood transfusion </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"14\"> <li>Planned postoperative ICU admission </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"15\"> <li>Previous transplant </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"16\"> <li>Significant spine disease (eg, scoliosis or neurologic symptoms) </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"17\"> <li>Rheumatoid arthritis </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"18\"> <li>Chemotherapy or radiation therapy within the previous three months </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"19\"> <li>Active cancer </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"20\"> <li>Thyroid disease </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"21\"> <li>Adrenal disease </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"22\"> <li>Neurologic disease (seizure, paralysis) </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"23\"> <li>Chronic obstructive lung disease </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_no_heading\" start=\"24\"> <li>Muscular dystrophies </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table shows suggested criteria for triaging patients for preanesthesia evaluation prior to or on the day of surgery. For further information, refer to UpToDate content on preanesthesia evaluation for noncardiac surgery.</div><div class=\"graphic_footnotes\">BMI: body mass index; TIA: transient ischemic attack; SBP: systolic blood pressure; DBP: diastolic blood pressure: ICU: intensive care unit.</div><div id=\"graphicVersion\">Graphic 114156 Version 1.0</div></div></div>"},"114157":{"type":"graphic_table","displayName":"Testing for pts anticipating anesthesia and procedures","title":"Diagnostic testing for patients anticipating anesthesia and procedures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic testing for patients anticipating anesthesia and procedures</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td><strong>Age &#62;65</strong>&nbsp;</td> <td>Albumin, creatinine, hemoglobin&nbsp;</td> </tr> <tr> <td><strong>Alcohol abuse:</strong></td> <td>ECG, electrolytes, hemoglobin, LFTs, platelet count, PT/INR</td> </tr> <tr> <td><strong>Anasarca:</strong></td> <td>Albumin, BUN, creatinine, ECG, electrolytes, TSH, T3, T4</td> </tr> <tr> <td><strong>Anemia:</strong></td> <td>CBC, creatinine, ferritin, iron, transferrin saturation, TSH, T3, T4, Vit B<sub>12</sub></td> </tr> <tr> <td><strong>Bleeding disorder (personal or family history):</strong></td> <td>LFTs, platelet count, PT/INR, PTT</td> </tr> <tr> <td><strong>Blood loss (anticipated) significant:</strong></td> <td>Hemoglobin, type and screen</td> </tr> <tr> <td><strong>BMI &#60;16:</strong></td> <td>Albumin, ECG, electrolytes, hemoglobin, PT/INR, TSH, T3, T4</td> </tr> <tr> <td><strong>BMI &#62;50:</strong></td> <td>ECG, HgA1c/glucose</td> </tr> <tr> <td colspan=\"2\"><strong>Cardiac disease:</strong></td> </tr> <tr> <td class=\"indent1\">Arrhythmias (new or undiagnosed brady, irregular, or tachy):</td> <td>BNP, ECG, electrolytes, hemoglobin, TSH, T3, T4</td> </tr> <tr> <td class=\"indent1\">Chest pain (new or worsening):</td> <td>BNP, ECG, hemoglobin</td> </tr> <tr> <td class=\"indent1\">Heart failure (decompensated or NYHA class 3 or 4):</td> <td>BNP, chest radiograph, creatinine, ECG, electrolytes, hemoglobin</td> </tr> <tr> <td class=\"indent1\">Murmur (undiagnosed):</td> <td>BNP, ECG</td> </tr> <tr> <td><strong>Chemotherapy (within last 30 days):</strong></td> <td>BUN, CBC, creatinine, platelet count</td> </tr> <tr> <td><strong>CIED (pacemaker, ICD):</strong></td> <td>ECG</td> </tr> <tr> <td><strong>Cocaine abuse:</strong></td> <td>ECG</td> </tr> <tr> <td><strong>Contrast dye (anticipated use):</strong></td> <td>Creatinine</td> </tr> <tr> <td><strong>Diabetes:</strong></td> <td>Creatinine, HgA1c/glucose</td> </tr> <tr> <td><strong>Dyspnea (severe and undiagnosed):</strong></td> <td>Albumin, BNP, BUN, chest radiograph, creatinine, ECG, electrolytes, hemoglobin, TSH, T3, T4</td> </tr> <tr> <td><strong>Goiter:</strong></td> <td>T3, T4, TSH</td> </tr> <tr> <td><strong>Hematologic disorders (eg, leukemia, myeloma):</strong></td> <td>CBC, platelet count</td> </tr> <tr> <td><strong>Hepatic disease:</strong></td> <td>Albumin, BUN, creatinine, electrolytes, hemoglobin, LFTs, platelet count, PT/INR</td> </tr> <tr> <td><strong>Hypercoagulable condition (undiagnosed):</strong></td> <td>Platelet count, PTT</td> </tr> <tr> <td><strong>Inflammatory bowel disease:</strong></td> <td>Electrolytes, hemoglobin</td> </tr> <tr> <td><strong>Instrumentation of the urinary tract:</strong></td> <td>Urinalysis</td> </tr> <tr> <td><strong>Malabsorption:</strong></td> <td>Albumin, BUN, CBC, electrolytes, hemoglobin, PT/INR</td> </tr> <tr> <td><strong>Malnutrition:</strong></td> <td>Albumin, BUN, CBC, creatinine, electrolytes, hemoglobin, PT/INR</td> </tr> <tr> <td colspan=\"2\"><strong>Medications:</strong></td> </tr> <tr> <td class=\"indent1\">Amiodarone use:</td> <td>ECG, T3, T4, TSH</td> </tr> <tr> <td class=\"indent1\">Digoxin:</td> <td>ECG, electrolytes</td> </tr> <tr> <td class=\"indent1\">Diuretics:</td> <td>Electrolytes</td> </tr> <tr> <td class=\"indent1\">Heparin (unfractionated):</td> <td>PTT</td> </tr> <tr> <td class=\"indent1\">Steroids (systemic):</td> <td>Electrolytes, HgA1c/glucose</td> </tr> <tr> <td class=\"indent1\">Thyroid replacement:</td> <td>TSH, T3, T4</td> </tr> <tr> <td class=\"indent1\">Warfarin:</td> <td>PT/INR</td> </tr> <tr> <td class=\"indent1\">Planned initiation of warfarin for first time in hospital:</td> <td>PT/INR</td> </tr> <tr> <td><strong>Palpitations:</strong></td> <td>ECG, hemoglobin, T3, T4, TSH</td> </tr> <tr> <td><strong>Positive antibody screen on previous type and screen:</strong></td> <td>Type and screen (except for procedures with <strong>no </strong>blood loss potential)</td> </tr> <tr> <td><strong>Pulmonary disease (eg, cough, severe dyspnea, abnormal findings on chest examination):</strong></td> <td>Chest radiograph</td> </tr> <tr> <td><strong>Pulmonary HTN:</strong></td> <td>ECG</td> </tr> <tr> <td><strong>Radiation therapy (to chest, breasts, lungs, thorax):</strong></td> <td>Chest radiograph, ECG</td> </tr> <tr> <td><strong>Renal disease:</strong></td> <td>BUN, creatinine, electrolytes, hemoglobin</td> </tr> <tr> <td><strong>Suspected pregnancy:</strong></td> <td>B-hCG</td> </tr> <tr> <td><strong>Syncope:</strong></td> <td>BNP, creatinine, ECG, electrolytes, hemoglobin, HgA1c/glucose, TSH, T3, T4</td> </tr> <tr> <td><strong>Thyroid disease:</strong></td> <td>TSH, T3, T4</td> </tr> <tr> <td><strong>Tobacco use + diabetes + age &#62;55 years:</strong></td> <td>Creatinine</td> </tr> <tr> <td><strong>Thrombocytopenia:</strong></td> <td>Platelet count</td> </tr> <tr> <td><strong>Urinary tract infection (suspected):</strong></td> <td>Urinalysis; sample hold for C/S if UA suggestive of infection</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These tests should be done when one either suspects an undiagnosed or worsening condition or when no laboratory values are available and the results will affect perioperative management. Typically these would apply only for intermediate-high risk surgeries. Previously abnormal results predict new or worsening results or may now be normal.</div><div class=\"graphic_footnotes\">ECG: electrocardiogram; LFTs: liver function tests; PT/INR: prothrombin time/international normalized ratio; TSH: thyroid stimulating hormone; CBC: complete blood count; PTT: partial thromboplastin time; T3: liothyronine sodium; T4: thyroxine; HbA1c: glycated hemoglobin; BNP: brain natriuretic peptide; BUN: blood urea nitrogen; CIED: cardiovascular implantable electronic device; ICD: implantable cardioverter-defibrillator; b-hCG: beta human chorionic gonadotropin; C/S: culture and sensitivity; UA: urine analysis.</div><div id=\"graphicVersion\">Graphic 114157 Version 3.0</div></div></div>"},"114163":{"type":"graphic_table","displayName":"Patient-specific baseline testing before anesthesia","title":"Recommendations for patient-specific baseline testing before anesthesia*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for patient-specific baseline testing before anesthesia*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Procedure/patient type</td> <td class=\"subtitle1\">Test</td> </tr> <tr> <td>Injection of contrast dye</td> <td>Creatinine<sup>&#182;</sup></td> </tr> <tr> <td>Potential for significant blood loss</td> <td>Hemoglobin/hematocrit<sup>&#182;</sup></td> </tr> <tr> <td>Likelihood of transfusion requirement</td> <td>Type and screen</td> </tr> <tr> <td>Possibility of pregnancy</td> <td>Pregnancy test<sup>&#916;</sup></td> </tr> <tr> <td>End-stage renal disease</td> <td>Potassium level<sup>&#9674;</sup></td> </tr> <tr> <td>Diabetes</td> <td>Glucose level determination on day of surgery<sup>&#9674;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Not to establish a diagnosis or to guide <STRONG>preoperative </STRONG>management.<br />¶ Results from laboratory tests within three months of surgery are acceptable unless major abnormalities are present or the patient's condition has changed.<br />Δ A routine pregnancy test before surgery is not recommended before the day of surgery, except for gynecologic surgery. A careful history and local practice determine whether a pregnancy test is indicated.<br /><FONT class=lozenge>◊</FONT> No absolute level of either potassium or glucose has been determined to preclude surgery and anesthesia. The benefits of the procedure must be balanced against the risk of proceeding in a patient with abnormal results.<br />For further information, refer to UpToDate content on preanesthesia evaluation for noncardiac surgery.</div><div id=\"graphicVersion\">Graphic 114163 Version 1.0</div></div></div>"},"114164":{"type":"graphic_table","displayName":"Rationale for preop testing","title":"Rationale for preoperative testing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rationale for preoperative testing</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>Preoperative testing is recommended when an abnormal result is suspected based on clinical risk factors and the result will:</strong></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Establish a new diagnosis </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Direct further beneficial preoperative testing or consultation </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Impact decision to postpone or cancel surgery </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Inform preoperative medication use </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Influence type of surgery </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Influence choice of anesthetic technique </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Alter intraoperative monitoring or management </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Change postoperative disposition </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Establish perioperative risk profile for physicians and patient decisions </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 114164 Version 1.0</div></div></div>"},"114167":{"type":"graphic_diagnosticimage","displayName":"Urinary acyclovir crystals","title":"Photomicrograph showing urine sediment of a patient with acyclovir crystalluria","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Photomicrograph showing urine sediment of a patient with acyclovir crystalluria</div><div class=\"cntnt\"><img style=\"width:764px; height:516px;\" src=\"images/NEPH/114167_Urinary_acyclovir_crystals.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Brightfield microscopy.<br />(B) Polarized microscopy.</div><div class=\"graphic_reference\">Courtesy of Mark Perazella, MD, FACP. Reproduced with permission of the American Society of Nephrology. This image originally appeared as the cover photo of the September 2016 issue of CJASN: Clinical Journal of the American Society of Nephrology.</div><div id=\"graphicVersion\">Graphic 114167 Version 1.0</div></div></div>"},"114168":{"type":"graphic_diagnosticimage","displayName":"Urine methotrexate crystals","title":"Photomicrograph showing urine sediment of a patient with methotrexate crystalluria","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Photomicrograph showing urine sediment of a patient with methotrexate crystalluria</div><div class=\"cntnt\"><img style=\"width:720px; height:577px;\" src=\"images/NEPH/114168_Urine_methotrexate_crystals.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Mallipattu SK, Ross MJ. Methotrexate in the urine. Kidney Int 2011; 80:226. Illustration used with the permission of Elsevier, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 114168 Version 1.0</div></div></div>"},"114172":{"type":"graphic_algorithm","displayName":"Diagnosis of PCD","title":"Algorithm for the diagnosis of primary ciliary dysfunction","html":"<div class=\"graphic\"><div style=\"width: 722px\" class=\"figure\"><div class=\"ttl\">Algorithm for the diagnosis of primary ciliary dysfunction</div><div class=\"cntnt\"><img style=\"width:702px; height:667px;\" src=\"images/PULM/114172_Diagnosis_PCD.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PCD: primary ciliary dysfunction; CVID: common variable immunodeficiency; nNO: nasal nitric oxide; HSVA: high-speed videomicroscopy analysis; TEM: transmission electron microscopy.<br />* Testing for cystic fibrosis may include sweat chloride or genetic testing; testing for CVID usually includes quantitative immunoglobulins. Refer to appropriate UpToDate topics.<br />¶ A low value for nNO (eg, ≤30 nL/minute) suggests PCD; exact threshold depends on technique.<br />Δ A bronchial brush can be used to obtain a nasal mucosal sample. If nasal sample is&nbsp;inadequate, bronchial mucosal brushing or biopsy can be obtained&nbsp;via flexible bronchoscopy instead.<br /><FONT class=lozenge>◊</FONT> Cell culture of mucosal cells may improve accuracy of HSVA.</div><div id=\"graphicVersion\">Graphic 114172 Version 1.0</div></div></div>"},"114173":{"type":"graphic_table","displayName":"Checklist optimal preop assessment geriatric surg pt","title":"Checklist for the optimal preoperative assessment of the geriatric surgical patient","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Checklist for the optimal preoperative assessment of the geriatric surgical patient</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>In addition to conducting a complete history and physical examination of the patient, the following assessments are strongly recommended:</strong></td> </tr> <tr> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>Assess the patient's <strong>cognitive ability</strong> and <strong>capacity</strong> to understand the anticipated surgery.</td> </tr> <tr> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>Screen the patient for <strong>depression</strong>.</td> </tr> <tr> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>Identify the patient's risk factors for developing postoperative <strong>delirium</strong>.</td> </tr> <tr> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>Screen for <strong>alcohol</strong> and other <strong>substance abuse/dependence</strong>.</td> </tr> <tr> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>Perform a preoperative <strong>cardiac</strong> evaluation according to the American College of Cardiology/American Heart Association algorithm for patients undergoing noncardiac surgery.</td> </tr> <tr> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>Identify the patient's risk factors for postoperative <strong>pulmonary</strong> complications and implement appropriate strategies for prevention.</td> </tr> <tr> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>Document <strong>functional status</strong> and history of <strong>falls</strong>.</td> </tr> <tr> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>Determine baseline <strong>frailty</strong> score.</td> </tr> <tr> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>Assess patient's <strong>nutritional status</strong> and consider preoperative interventions if the patient is at severe nutritional risk.</td> </tr> <tr> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>Take an accurate and detailed <strong>medication history</strong> and consider appropriate perioperative adjustments. Monitor for <strong>polypharmacy</strong>.</td> </tr> <tr> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>Determine the patient's <strong>treatment goals</strong> and <strong>expectations</strong> in the context of the possible treatment outcomes.</td> </tr> <tr> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>Determine patient's <strong>family</strong> and <strong>social support system.</strong></td> </tr> <tr> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>Order appropriate preoperative <strong>diagnostic tests</strong> focused on elderly patients.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Chow WB, Rosenthal RA, Merkow RP, et al. Optimal preoperative assessment of the geriatric surgical patient: a best practices guideline from the American College of Surgeons National Surgical Quality Improvement Program and the American Geriatrics Society. J Am Coll Surg 2012; 215:453. Table used with the permission of Elsevier, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 114173 Version 1.0</div></div></div>"},"114174":{"type":"graphic_table","displayName":"Preoperative frailty assessment","title":"Preoperative frailty assessment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Preoperative frailty assessment</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup span=\"4\" width=\"10%\"></colgroup><colgroup width=\"5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Frailty criteria</td> <td class=\"subtitle1\">Assessment</td> <td class=\"subtitle1\" colspan=\"4\">Score</td> <td class=\"subtitle1\">Points</td> </tr> <tr class=\"divider_bottom\"> <td>Shrinkage</td> <td>Ask the patient: Have you unintentionally lost &#8805;10 lbs in the past year? <strong>Yes / No</strong></td> <td colspan=\"4\"><em>If <strong>Yes</strong>, add 1 point</em></td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"8\">Weakness (grip strength)</td> <td class=\"divider_bottom\" rowspan=\"8\"> <ol class=\"numbers_to_nine\"> <li>Ask the patient to hold dynamometer in dominant hand with arms parallel to their body without squeezing arms against their body. </li> <li>Adjust the handle to ensure that the middle phalanx rests on the inner handle. </li> <li>Ask the patient to squeeze the handle and record. </li> <li>Perform three trials, and obtain the average value. Record results below: </li> </ol> <br /> <p>Trial 1: ________ kg force</p> <p>Trial 2: ________ kg force</p> <p>Trial 3: ________ kg force</p> <strong>Average:</strong> ________ kg force</td> <td class=\"divider_bottom\" colspan=\"4\">Compare patient's average with the lowest 20th percentile by gender and BMI shown below:</td> <td class=\"centered divider_bottom\" rowspan=\"8\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text centered\" colspan=\"2\"><strong>Men</strong></td> <td class=\"highlight_gray_text centered\" colspan=\"2\"><strong>Women</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered highlight_green_text\"><strong>BMI</strong></td> <td class=\"centered highlight_green_text\"><strong>Kg force</strong></td> <td class=\"centered highlight_green_text\"><strong>BMI</strong></td> <td class=\"centered highlight_green_text\"><strong>Kg force</strong></td> </tr> <tr> <td class=\"centered\">&#8804;24</td> <td class=\"centered\">&#8804;29</td> <td class=\"centered\">&#8804;23</td> <td class=\"centered\">&#8804;17</td> </tr> <tr> <td class=\"centered\">24.1 to 26</td> <td class=\"centered\">&#8804;30</td> <td class=\"centered\">23.1 to 26</td> <td class=\"centered\">&#8804;17.3</td> </tr> <tr> <td class=\"centered\">26.1 to 28</td> <td class=\"centered\">&#8804;31</td> <td class=\"centered\">26.1 to 29</td> <td class=\"centered\">&#8804;18</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">&#62;28</td> <td class=\"centered\">&#8804;32</td> <td class=\"centered\">&#62;29</td> <td class=\"centered\">&#8804;21</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"><em>Add 1 point</em> if the <strong>average</strong> falls within or below the above values</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Exhaustion</td> <td class=\"divider_bottom\" rowspan=\"4\"> <p>Ask the patient the following two questions:</p> <ol> <li>How often in the last week did you feel that everything you did was an effort? ________ </li> <li>How often in the last week did you feel that you could not get going? ________ </li> </ol> </td> <td class=\"divider_bottom\" colspan=\"4\">&nbsp;</td> <td class=\"centered divider_bottom\" rowspan=\"4\">&nbsp;</td> </tr> <tr> <td class=\"divider_bottom highlight_gray_text centered\"><strong>0</strong></td> <td class=\"divider_bottom highlight_gray_text centered\"><strong>1</strong></td> <td class=\"divider_bottom highlight_gray_text centered\"><strong>2</strong></td> <td class=\"divider_bottom highlight_gray_text centered\"><strong>3</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">Rarely or none of the time<br /> (&#60;1 day)</td> <td class=\"centered\">Some or a little of the time<br /> (1 to 2 days)</td> <td class=\"centered\">Moderate amount of the time<br /> (3 to 4 days)</td> <td class=\"centered\">Most of the time<br /> (&#62;4 days)</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"><em>Add 1 point</em> for a score of 2 or 3 for EITHER question</td> </tr> <tr class=\"divider_bottom\"> <td>Low physical activity</td> <td> <p>Ask the patient the following four questions:</p> <ol> <li>Can you get out of bed or chair yourself? <strong>Yes / No</strong> </li> <li>Can you dress and bathe yourself? <strong>Yes / No</strong> </li> <li>Can you make your own meals? <strong>Yes / No</strong> </li> <li>Can you do your own shopping? <strong>Yes / No</strong> </li> </ol> </td> <td colspan=\"4\"><em>Add 1 point</em> for any <strong>No</strong> answer</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Slowness</td> <td class=\"divider_bottom\" rowspan=\"6\"> <ol class=\"numbers_to_nine\"> <li>Ask the patient to stand up and walk toward the tape on the ground. </li> <li>Using a stopwatch, record the time it takes for the patient to walk 15 feet. Record results below: </li> </ol> <br /> Trial: ________ seconds </td> <td class=\"divider_bottom\" colspan=\"4\">&nbsp;</td> <td class=\"centered divider_bottom\" rowspan=\"6\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text centered\" colspan=\"2\"><strong>Men</strong></td> <td class=\"highlight_gray_text centered\" colspan=\"2\"><strong>Women</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered highlight_green_text\"><strong>Height</strong></td> <td class=\"centered highlight_green_text\"><strong>Time</strong></td> <td class=\"centered highlight_green_text\"><strong>Height</strong></td> <td class=\"centered highlight_green_text\"><strong>Time</strong></td> </tr> <tr> <td class=\"centered\">&#8804;173 cm</td> <td class=\"centered\">&#8805;7 seconds</td> <td class=\"centered\">&#8804;159 cm</td> <td class=\"centered\">&#8805;7 seconds</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">&#62;173 cm</td> <td class=\"centered\">&#8805;6 seconds</td> <td class=\"centered\">&#62;159 cm</td> <td class=\"centered\">&#8805;6 seconds</td> </tr> <tr> <td class=\"divider_bottom\" colspan=\"4\"><em>Add 1 point</em> if the&nbsp;trial time&nbsp;falls higher than the above values</td> </tr> <tr> <td class=\"highlight_gray_text\" colspan=\"6\"><strong>Frailty score:</strong></td> <td class=\"centered highlight_gray_text\"><strong>&nbsp;</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Total the <strong>number of points for each criterion</strong> (the total should be 0 to 5) to determine the frailty score.&#xD;&#xA;<ul class=\"decimal_heading\">&#xD;&#xA;    <li>0 to 1: Not frail</li>&#xD;&#xA;    <li>2 to 3: Intermediate (pre-frail)</li>&#xD;&#xA;    <li>4 to 5: Frail</li>&#xD;&#xA;</ul>&#xD;&#xA;<strong>If the patient is in the intermediate frail or frail categories, please notify the surgeon.</strong></div><div class=\"graphic_footnotes\">BMI: body mass index.</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56:M146.</li>&#xD;&#xA;    <li>Frailty. In: Geriatrics Evaluation &amp; Management Tools: Clinical Templates to Support Clinicians and Systems that are Caring for Older Adults, American Geriatrics Society, New York 2013.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 114174 Version 1.0</div></div></div>"},"114175":{"type":"graphic_table","displayName":"Genetic mutations in PH","title":"Genetic mutations associated with pulmonary hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic mutations associated with pulmonary hypertension</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Gene</td> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Inheritance</td> <td class=\"subtitle1\">Function</td> </tr> <tr> <td><em><a href=\"http://www.omim.org/entry/600799\" spellcheck=\"true\" id=\"http://www.omim.org/entry/600799\" target=\"_blank\">BMPR2</a></em></td> <td>IPAH/HPAH</td> <td>Autosomal dominant</td> <td>Type II receptor of TGF-beta family of signaling molecules</td> </tr> <tr> <td><em><a href=\"http://www.omim.org/entry/601284\" spellcheck=\"true\" id=\"http://www.omim.org/entry/601284\" target=\"_blank\">ALK1</a></em></td> <td>HHT</td> <td>Autosomal dominant</td> <td>Type I receptor of TGF-beta family</td> </tr> <tr> <td><em><a href=\"http://www.omim.org/entry/131195\" spellcheck=\"true\" id=\"http://www.omim.org/entry/131195\" target=\"_blank\">ENG</a></em></td> <td>HHT</td> <td>Autosomal dominant</td> <td>Type II receptor of TGF-beta family</td> </tr> <tr> <td><em><a href=\"http://www.omim.org/entry/601595\" spellcheck=\"true\" id=\"http://www.omim.org/entry/601595\" target=\"_blank\">SMAD1</a></em></td> <td>IPAH/HPAH</td> <td>N/A</td> <td>Signal transduction molecule</td> </tr> <tr> <td><em><a href=\"http://www.omim.org/entry/600993\" spellcheck=\"true\" id=\"http://www.omim.org/entry/600993\" target=\"_blank\">SMAD4</a></em></td> <td>HHT</td> <td>Autosomal dominant</td> <td>Signal transduction molecule</td> </tr> <tr> <td><em><a href=\"http://www.omim.org/entry/603295\" spellcheck=\"true\" id=\"http://www.omim.org/entry/603295\" target=\"_blank\">SMAD9</a></em></td> <td>IPAH/HPAH</td> <td>Autosomal dominant</td> <td>Signal transduction molecule</td> </tr> <tr> <td><em><a href=\"http://www.omim.org/entry/603220\" spellcheck=\"true\" id=\"http://www.omim.org/entry/603220\" target=\"_blank\">KCNK3</a></em></td> <td>IPAH/HPAH</td> <td>Autosomal dominant</td> <td>pH-sensitive potassium channel</td> </tr> <tr> <td><em><a href=\"http://www.omim.org/entry/601047\" spellcheck=\"true\" id=\"http://www.omim.org/entry/601047\" target=\"_blank\">CAV1</a></em></td> <td>IPAH/HPAH</td> <td>Autosomal dominant</td> <td>Membrane protein required for formation of caveolae</td> </tr> <tr> <td><em><a href=\"http://www.omim.org/entry/609280\" spellcheck=\"true\" id=\"http://www.omim.org/entry/609280\" target=\"_blank\">EIF2AK4</a></em></td> <td>PVOD/PCH</td> <td>Autosomal recessive</td> <td>Kinase involved in control of angiogenesis</td> </tr> <tr> <td><em><a href=\"http://www.omim.org/entry/601719\" spellcheck=\"true\" id=\"http://www.omim.org/entry/601719\" target=\"_blank\">TBX4</a></em></td> <td>Small patellar syndrome</td> <td>Autosomal dominant</td> <td>T-box transcription factor</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IPAH: idiopathic pulmonary arterial hypertension; HPAH: heritable pulmonary arterial hypertension; TGF: transcription growth factor; HHT: hereditary hemorrhagic telangiectasia; PVOD: pulmonary veno-occlusive disease; PCH: pulmonary capillary hemangiomatosis.</div><div id=\"graphicVersion\">Graphic 114175 Version 1.0</div></div></div>"},"114177":{"type":"graphic_figure","displayName":"Normal and abnormal capnograms","title":"Normal and abnormal capnograms","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal and abnormal capnograms</div><div class=\"cntnt\"><img style=\"width:382px; height:769px;\" src=\"images/ANEST/114177_Normal_and_abnormal_capnograms.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This graphic shows normal and abnormal capnograms, as follows:<br />A. Normal capnogram during positive pressure ventilation<br />B. Normal capnogram during spontaneous ventilation<br />C. Upsloping plateau that might occur with bronchospasm or a kinked or obstructed endotracheal tube<br />D. Notched plateau caused by attempts at spontaneous ventilation during controlled mechanical ventilation<br />E. Progressive decrease and disappearance of capnogram during esophageal intubation<br />F. Rebreathing of carbon dioxide<br />G. Abrupt shortening of plateau phase, as might occur with ruptured endotracheal tube cuff</div><div id=\"graphicVersion\">Graphic 114177 Version 1.0</div></div></div>"},"114182":{"type":"graphic_table","displayName":"Clinical features and epidemiologic exposures","title":"Clinical features and epidemiologic associations with specific pathogens","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features and epidemiologic associations with specific pathogens</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Pathogen</td> <td class=\"subtitle1\">Clinical features and epidemiologic associations</td> </tr> <tr> <td>Influenza virus</td> <td>Acute onset fever, chills, myalgias and cough during influenza season or in patients with known exposure or recent travel</td> </tr> <tr> <td><em>Bordetella pertussis</em></td> <td>Cough lasting &#8805;2 weeks without an apparent cause, with one of the following symptoms: Paroxysms of coughing, inspiratory whoop, or posttussive emesis, particularly during outbreaks or in patients with known exposures</td> </tr> <tr> <td><em>Bordetella bronchiseptica</em></td> <td>Pertussis-like syndrome in a patient with animal exposure, particularly if immunocompromised</td> </tr> <tr> <td><em>Mycoplasma pneumoniae</em></td> <td>No distinguishing clinical features, although outbreaks reported across large geographic regions and among families or persons living in close quarters</td> </tr> <tr> <td><em>Chlamydia pneumoniae</em></td> <td>No distinguishing clinical features, although outbreaks reported in persons living in close quarters</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 114182 Version 2.0</div></div></div>"},"114184":{"type":"graphic_figure","displayName":"E-C clamp technique neonate","title":"E-C clamp technique for a neonate","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">E-C clamp technique for a neonate</div><div class=\"cntnt\"><img style=\"width:537px; height:499px;\" src=\"images/PEDS/114184_ECclamptechniqueneonate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The hand is positioned so that the little, ring, and&nbsp;middle fingers are spread over the mandible from the angle of the jaw forward towards the chin in the configuration of the letter \"E\". The jaw is then lifted, pulling the face into the mask. The thumb and forefinger are placed over the mask in the shape of the letter \"C\". The mask is squeezed onto the face and a seal is formed between the mask and the face. </div><div id=\"graphicVersion\">Graphic 114184 Version 1.0</div></div></div>"},"114185":{"type":"graphic_table","displayName":"Soft tissue lesions of the oral cavity in children","title":"Soft tissue lesions of the oral cavity in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Soft tissue lesions of the oral cavity in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"2\" width=\"37.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Lesion</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Management</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Lesions of the gums</td> </tr> <tr> <td class=\"indent1\">Eruption cyst/hematoma</td> <td> <ul> <li>Normal finding </li> <li>Dome-shaped cyst </li> <li>Associated with eruption of teeth </li> <li>Cyst fluid may be mixed with blood (eruption hematoma) </li> </ul> </td> <td> <ul> <li>No treatment necessary </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Gingival pigmentation</td> <td> <ul> <li>Normal finding in dark-skinned children </li> </ul> </td> <td> <ul> <li>No treatment necessary </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Retrocuspid papillae</td> <td> <ul> <li>Firm, round, pink to red papule </li> <li>2 to 3 mm (0.1 inches) in diameter </li> <li>Located on the inner gum below the lower canines </li> <li>Often bilateral </li> </ul> </td> <td> <ul> <li>Resolves spontaneously </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Parulis (\"gum boil\")</td> <td> <ul> <li>Associated with primary tooth abscess </li> <li>Soft, solitary, reddish papule on the outer gum above or below the abscessed tooth </li> <li>Drainage or pus may be observed </li> </ul> </td> <td> <ul> <li>Complete pulpectomy or extraction of involved tooth </li> </ul> </td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Gingival overgrowth</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Inflammatory </li> </ul> </td> <td> <ul> <li>Associated with longstanding gingivitis or chronic mouth breathing </li> <li>Erythematous gums with shiny, friable surface that bleeds easily </li> <li>Involves the gums between the teeth and at the margins of the teeth </li> </ul> </td> <td> <ul> <li>Often resolves with adequate plaque control </li> <li>May require gingivectomy </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Infiltrative </li> </ul> </td> <td> <ul> <li>Associated with leukemia, particularly AML </li> <li>Edematous and hemorrhagic </li> </ul> </td> <td> <ul> <li>Treatment of underlying disease </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Drug-induced </li> </ul> </td> <td> <ul> <li>Commonly precipitated by phenytoin, nifedipine, and cyclosporine A </li> <li>Painless, firm, fibrous overgrowth </li> <li>Bleeding is uncommon </li> <li>May progress to cover the crown of the tooth </li> </ul> </td> <td> <ul> <li>Meticulous oral hygiene </li> <li>Discontinuation of offending drug, if possible </li> <li>May require gingivectomy </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Hereditary </li> </ul> </td> <td> <ul> <li>Onset in early childhood </li> <li>Progressive nonhemorrhagic fibrous enlargement </li> <li>May be associated with failure or delay of primary or permanent tooth eruption </li> </ul> </td> <td> <ul> <li>Meticulous oral hygiene </li> <li>Gingivectomy </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Vascular (localized juvenile spongiotic gingival hyperplasia </li> </ul> </td> <td> <ul> <li>Localized erythema of the attached gingiva of the front teeth </li> <li>Most common in female adolescents </li> </ul> </td> <td> <ul> <li>Topical corticosteroids </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Gingival recession</td> <td> <ul> <li>Associated with abnormally erupted teeth </li> <li>Narrowing of the gums above and below the teeth </li> </ul> </td> <td> <ul> <li>Orthodontic repositioning of malpositioned teeth </li> <li>Gingival grafting may be necessary for severe recession </li> </ul> </td> </tr> <tr> <td class=\"indent1\">HIV gingivitis (linear gingival erythema)</td> <td> <ul> <li>Brightly inflamed gums at the margins of the teeth </li> <li>Bleeds easily </li> <li>Painful </li> </ul> </td> <td> <ul> <li>Debridement </li> <li>Antibiotics </li> <li>Antibacterial oral rinses </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Other gum lesions: <ul class=\"decimal_heading\"> <li>Hemangiomas </li> <li>Irritant fibromas </li> <li>Peripheral ossifying fibromas </li> <li>Pyogenic granulomas </li> <li>Peripheral giant cell granulomas </li> <li>Traumatic ulcers </li> <li>Aphthous ulcers </li> <li>HSV gingivostomatitis </li> </ul> </td> <td colspan=\"2\">Clinical features and management of these lesions are described in the section on \"Lesions that occur at multiple sites\"</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Lesions of the tongue</td> </tr> <tr> <td class=\"indent1\">Ankyloglossia</td> <td> <ul> <li>Tongue movement is restricted by a short, tight frenum between the tongue and floor of the mouth </li> </ul> </td> <td> <ul> <li>May require frenotomy (refer to UpToDate content on ankyloglossia in children) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Congenital melanotic macules</td> <td> <ul> <li>Present from birth </li> <li>Single or multiple, asymptomatic, hyperpigmented macules </li> <li>Range from 3 mm to 3 cm (0.1 to 1.2 inches) in diameter; size increases proportionally as the child grows </li> <li>No family history of systemic conditions associated with mucosal pigmentation (eg, Peutz-Jeghers syndrome) </li> </ul> </td> <td> <ul> <li>Monitor over time </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Geographic tongue</td> <td> <ul> <li>Pink to red, slightly depressed lesions with irregular, elevated, curvilinear white or yellow borders </li> <li>Pattern of lesions changes continuously </li> </ul> </td> <td> <ul> <li>Does not require treatment </li> <li>Avoidance of acidic foods and beverages is helpful if the lesions are sensitive </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Fissured tongue</td> <td> <ul> <li>Marked central fissure from front to back of tongue </li> <li>Smaller fissures radiate laterally from the central fissure </li> </ul> </td> <td> <ul> <li>Removal of trapped food particles through brushing of the tongue </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Mucoceles</td> <td colspan=\"2\">Clinical feature and management of mucoceles are described in the section on \"Lesions of the lips\"</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Other tongue lesions: <ul class=\"decimal_heading\"> <li>Hemangiomas </li> <li>Lymphangiomas </li> <li>Irritation fibromas&nbsp; </li> <li>Traumatic ulcers </li> <li>Aphthous ulcers </li> <li>Thrush </li> <li>HSV gingivostomatitis </li> <li>HFMD </li> </ul> </td> <td colspan=\"2\">Clinical features and management of these lesions are described in the section on \"Lesions that occur at multiple sites\"</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Lesions of the lips</td> </tr> <tr> <td class=\"indent1\">Herpes labialis (fever blister, cold sore)</td> <td> <ul> <li>Vesicular eruption of skin adjacent to lip </li> <li>Vesicles rupture to form ulcers and crusts </li> <li>Caused by HSV </li> </ul> </td> <td> <ul> <li>Refer to UpToDate content on treatment of HSV type 1 infection for treatment indications and options </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Angular cheilitis (perl&#232;che)</td> <td> <ul> <li>Painful fissuring at the corners of the mouth </li> <li>Usually caused by <em>Candida albicans</em> </li> </ul> </td> <td> <ul> <li>Maintain oral hygiene </li> <li>Apply barrier cream or petrolatum </li> <li>May require antifungal therapy (refer to UpToDate content on angular cheilitis) </li> </ul> </td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Abnormalities of the labial frena</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Persistence of raphe between the upper labial frenum and the palatal papilla </li> </ul> </td> <td> <ul> <li>May lead to widely spaced front teeth (diastema) </li> </ul> </td> <td> <ul> <li>Diastema may require orthodontic treatment </li> <li>May require frenotomy </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Extension of frenum to central incisors </li> </ul> </td> <td> <ul> <li>May lead to gingival recession and bone loss </li> </ul> </td> <td> <ul> <li>May require frenotomy to prevent bone loss </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Absence or hypoplasia </li> </ul> </td> <td> <ul> <li>May be associated with Ehlers-Danlos syndrome </li> <li>May be associated with infantile hypertrophic pyloric stenosis </li> </ul> </td> <td> <ul> <li>No treatment required </li> <li>Monitor for signs and symptoms of Ehlers-Danlos syndrome and infantile hypertrophic pyloric stenosis </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Mucoceles and ranulas</td> <td> <ul> <li>Painless swelling, smooth walled, bluish or translucent </li> <li>Usually &#60;1 cm (0.4 inches) in diameter </li> <li>Usually located on the inside of the lower lip but may occur on the tongue or floor of the mouth&nbsp;(ranula) </li> </ul> </td> <td> <ul> <li>May spontaneously resolve </li> <li>Surgical excision with associated minor salivary gland&nbsp;for mucoceles that interfere with function or cause discomfort </li> <li>Surgical treatment, ranging from incision and drainage to marsupialization to excision for ranulas&nbsp; </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Other lip lesions: <ul class=\"decimal_heading\"> <li>Hemangiomas </li> <li>Lymphangiomas </li> <li>Irritation fibromas </li> <li>Pyogenic granulomas </li> <li>Traumatic ulcers </li> <li>Aphthous ulcers </li> <li>Thrush </li> <li>HSV gingivostomatitis </li> <li>HFMD </li> </ul> </td> <td colspan=\"2\">Clinical features and management of these lesions are described in the section on \"Lesions that occur at multiple sites\"</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Lesions of the palate</td> </tr> <tr> <td class=\"indent1\">Herpangina</td> <td> <ul> <li>Lesions progress from yellow/greyish-white papules to vesicles to shallow ulcerations </li> <li>The lesions most frequently involve the soft palate, tonsils, and uvula </li> <li>Typically occurs in children age 3 to 10 years </li> </ul> </td> <td> <ul> <li>Supportive care to prevent dehydration </li> <li>Symptomatic treatment of pain </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Other palatal lesions: <ul class=\"decimal_heading\"> <li>Irritation fibromas </li> <li>Traumatic ulcers </li> <li>Aphthous ulcers </li> <li>Thrush </li> <li>HSV gingivostomatitis </li> <li>HFMD </li> </ul> </td> <td colspan=\"2\">Clinical features and management of these lesions are described in the section on \"Lesions that occur at multiple sites\"</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Lesions of the buccal mucosa</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Hemangiomas </li> <li>Lymphangiomas </li> <li>Irritation fibromas </li> <li>Aphthous ulcers </li> <li>Traumatic ulcers </li> <li>Thrush </li> <li>HSV gingivostomatitis </li> <li>HFMD </li> </ul> </td> <td colspan=\"2\">Clinical features and management of these lesions are described in the section on \"Lesions that occur at multiple sites\"</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Lesions that occur at multiple sites</td> </tr> <tr> <td class=\"indent1\">Hemangioma</td> <td> <ul> <li>Red or bluish-red, raised, moderately firm to palpation </li> <li>Appear early in life, enlarge during infancy, and regress during childhood </li> <li>May occur on any oral mucosa (eg, gums, tongue, lips, palate, buccal mucosa) </li> </ul> </td> <td> <ul> <li>Refer to UpToDate content on management of infantile hemangiomas </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Lymphangiomas</td> <td> <ul> <li>Pink to reddish-blue, soft, compressible </li> <li>May be present at birth or develop early in life </li> <li>May occur on the tongue, lips, or buccal mucosa </li> </ul> </td> <td> <ul> <li>May require surgical resection or percutaneous chemoablation </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Irritation fibroma</td> <td> <ul> <li><span style=\"color: black;\">Pale, pink, smooth, firm, &#60;1 cm (0.4 inches) in diameter, sessile or pedunculated base </span></li> <li><span style=\"color: black;\">Usually occur on the tongue</span>, lip, palate, or buccal mucosa, but may occur on any mucosal surface </li> </ul> </td> <td> <ul> <li>Surgical excision if it&nbsp;interferes with function </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Peripheral ossifying fibroma</td> <td> <ul> <li>Traumatic overgrowth that contains mineralized tissues (eg, bone, calcifications) </li> <li>Predominantly occurs on the gingiva </li> </ul> </td> <td> <ul> <li>Surgical excision down to the bone </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Pyogenic granuloma (lobular capillary hemangioma)</td> <td> <ul> <li>Bright red lesion with rapid growth, friable surface, easy bleeding<span class=\"_TELERIK_InsertParagraph\">&nbsp; </span></li> <li>May be triggered by trauma </li> <li>More common in females </li> </ul> </td> <td> <ul> <li>Surgical excision </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Peripheral giant cell granuloma</td> <td> <ul> <li>Bluish-purple traumatic overgrowth </li> <li>Typically occur on the gingiva </li> <li>Slightly more common on the lower gums </li> <li>More common in children with mixed dentition and adults between 30 and 40 years of age </li> <li>More common in females </li> </ul> </td> <td> <ul> <li>Surgical excision </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Traumatic ulcers</td> <td> <ul> <li>Occur on the gums, tongue, lips, palate, and buccal mucosa </li> </ul> </td> <td> <ul> <li>Spontaneous healing with removal of source of trauma </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Aphthous ulcer</td> <td> <ul> <li>Localized, shallow, round to oval ulcers with grayish base </li> <li>Occur on the gums, tongue, lips, palate, and buccal mucosa </li> </ul> </td> <td> <ul> <li>Refer to UpToDate content on aphthous ulcerations </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Thrush</td> <td> <ul> <li>White plaques on the tongue, lips, palate, and/or buccal mucosa </li> </ul> </td> <td> <ul> <li>Sterilization/decolonization of items place in the mouth (eg, pacifiers, bottle nipples) </li> <li>Topical or systemic antifungal therapy may be warranted for symptomatic patients </li> <li>Refer to UpToDate content on oropharyngeal candidiasis in children </li> </ul> </td> </tr> <tr> <td class=\"indent1\">HSV gingivostomatitis</td> <td> <ul> <li>Red, edematous marginal gingivae </li> <li>Clusters of small vesicles that become yellow after rupture and are surrounded by a red halo </li> <li>Vesicles occur on the gums, tongue, lips, hard palate, buccal mucosa, and perioral skin </li> </ul> </td> <td> <ul> <li>Supportive care to prevent dehydration </li> <li>Symptomatic pain control </li> <li>Topical barrier cream </li> <li>Oral acyclovir may be warranted (refer to UpToDate content on herpetic gingivostomatitis in young children) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">HFMD</td> <td> <ul> <li>Oral vesicles, small cutaneous lesions on the hands, feet, buttocks, and genitalia </li> </ul> </td> <td> <ul> <li>Supportive care to prevent dehydration </li> <li>Symptomatic pain control </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AML: acute myeloid leukemia; HIV: human immunodeficiency virus; HSV: herpes simplex virus; HFMD: hand, foot, and mouth disease.</div><div id=\"graphicVersion\">Graphic 114185 Version 2.0</div></div></div>"},"114187":{"type":"graphic_diagnosticimage","displayName":"MRI T1-weighted image of bright appendix in pregnancy","title":"MRI T1-weighted image of bright appendix in pregnancy","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">MRI T1-weighted image of bright appendix in pregnancy</div><div class=\"cntnt\"><img style=\"width:494px; height:747px;\" src=\"images/OBGYN/114187_MRIT1wghtdappndxpregncy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Axial T2-weighted magnetic resonance image of a 33-year-old pregnant woman (gestational age: 21 weeks) who presented with right lower quadrant pain. The appendix, located below the right kidney (arrow), is superiorly displaced by the uterus.<br />(B) In the axial T1-weighted image, intraluminal high signal intensity in the appendix (arrow), a typical positive T1 bright appendix sign, was noted. She was discharged after symptom relief, and no residual pain was reported during a follow-up physical examination after a few weeks.</div><div class=\"graphic_reference\">From: European Radiology, T1 bright appendix sign to exclude acute appendicitis in pregnant women, Vol. 27, 2017, p. 3310, Shin I, An C, Lim JS, et al, © European Society of Radiology 2017. With permission of Springer.</div><div id=\"graphicVersion\">Graphic 114187 Version 1.0</div></div></div>"},"114194":{"type":"graphic_picture","displayName":"Horner-Trantas dots","title":"Horner-Trantas dots","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Horner-Trantas dots</div><div class=\"cntnt\"><img style=\"width:546px; height:761px;\" src=\"images/ALLRG/114194_HornerTrantasdots.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A)&nbsp;Right eye&nbsp;- Broad, gelatinous, thickened, opacified, mucoid nodular infiltrates of eosinophils and epithelial debris. Horner-Trantas Dots (punctiform calcified concretions) are at the apices of the nodules.<br />(B)&nbsp;Left&nbsp;eye&nbsp;- Limbal conjunctivitis: broad, gelatinous, thickened, opacification of superior limbus.</div><div class=\"graphic_reference\">Koczman J, Oetting TA. Vernal keratoconjunctivitis: 8-year-old asthmatic male with reduced vision. EyeRounds.org. June 25, 2007. Available from: <A href=\"http://www.eyerounds.org/cases/70-Vernal-Keratoconjunctivitis-Atopic-Asthma.htm\" target=_blank>http://www.EyeRounds.org/cases/70-Vernal-Keratoconjunctivitis-Atopic-Asthma.htm</A>. The authors/editors and publishers acknowledge The University of Iowa and EyeRounds.org for permission to reproduce this copyrighted material.</div><div id=\"graphicVersion\">Graphic 114194 Version 1.0</div></div></div>"},"114199":{"type":"graphic_figure","displayName":"Supplementary suckling technique","title":"Supplementary suckling technique","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Supplementary suckling technique</div><div class=\"cntnt\"><img style=\"width:456px; height:630px;\" src=\"images/PEDS/114199_Supplimentary_suckling_technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Supplementary suckling technique to provide therapeutic milk feeds and simultaneously increase breast milk production. One end of a feeding tube is placed in a cup with therapeutic milk while the other is placed such that the infant latches onto both the feeding tube and the mother’s nipple simultaneously. Frequent daily feedings using this technique are&nbsp;often successful in slowly increasing the mother’s own breast milk production.</div><div class=\"graphic_reference\">Modified from: Vygen SB, Roberfroid D, Captier V, Kolsteren P. Treatment of Severe Acute Malnutrition in Infants Aged &lt;6 Months in Niger. J Pediatr 2003; 162:516.</div><div id=\"graphicVersion\">Graphic 114199 Version 1.0</div></div></div>"},"114204":{"type":"graphic_figure","displayName":"Maternal cardiovascular changes during pregnancy","title":"Maternal cardiovascular changes during pregnancy by trimester","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Maternal cardiovascular changes during pregnancy by trimester</div><div class=\"cntnt\"><img style=\"width:710px; height:356px;\" src=\"images/OBGYN/114204_Mtrnlcrdvsclrchngsprgncy.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SVR: systemic vascular resistance; LV: left ventricular; LVEDD: left ventricular end diastolic diameter.</div><div class=\"graphic_reference\">Adapted from: Ashrafi R, Curtis SL. Heart disease in pregnancy. Cardiol Ther 2017.</div><div id=\"graphicVersion\">Graphic 114204 Version 1.0</div></div></div>"},"114207":{"type":"graphic_table","displayName":"Pharmacokinetic properties aminosteroid nondepolarizing NMBAs","title":"Pharmacokinetic properties of aminosteroid nondepolarizing neuromuscular blocking agents in infants, children, and adults*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacokinetic properties of aminosteroid nondepolarizing neuromuscular blocking agents in infants, children, and adults*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"8\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"4\">Rocuronium</td> <td class=\"subtitle1\" colspan=\"4\">Vecuronium</td> </tr> <tr> <td class=\"subtitle2\">Infant</td> <td class=\"subtitle2\">Child</td> <td class=\"subtitle2\">Adult</td> <td class=\"subtitle2\">Elderly</td> <td class=\"subtitle2\">Infant</td> <td class=\"subtitle2\">Child</td> <td class=\"subtitle2\">Adult</td> <td class=\"subtitle2\">Elderly</td> </tr> <tr> <td><strong>ED<sub>95</sub> (mg/kg)</strong></td> <td class=\"centered\">0.3</td> <td class=\"centered\">0.4</td> <td class=\"centered\">0.3</td> <td class=\"centered\">0.3</td> <td class=\"centered\">0.05</td> <td class=\"centered\">0.08</td> <td class=\"centered\">0.05</td> <td class=\"centered\">0.05</td> </tr> <tr> <td><strong>V<sub>D</sub> (L/kg)</strong></td> <td class=\"centered\">0.2</td> <td class=\"centered\">0.17</td> <td class=\"centered\">0.3 to 0.7</td> <td class=\"centered\">0.2 to 0.6</td> <td class=\"centered\">0.35</td> <td class=\"centered\">0.20</td> <td class=\"centered\">0.4</td> <td class=\"centered\">0.3</td> </tr> <tr> <td><strong>t<sub>&#189;-Beta</sub> (minutes)</strong></td> <td class=\"centered\">50 to 110</td> <td class=\"centered\">25 to 110</td> <td class=\"centered\">100 to 250</td> <td class=\"centered\">110 to 280</td> <td class=\"centered\">65</td> <td class=\"centered\">41.0</td> <td class=\"centered\">65 to 75</td> <td class=\"centered\">70 to 180</td> </tr> <tr> <td><strong>Onset time (minutes)</strong></td> <td class=\"centered\">0.6</td> <td class=\"centered\">1.3</td> <td class=\"centered\">1.5 to 3</td> <td class=\"centered\">2 to 5</td> <td class=\"centered\">1.5</td> <td class=\"centered\">2.4</td> <td class=\"centered\">3 to 4</td> <td class=\"centered\">3 to 4</td> </tr> <tr> <td><strong>Dosing interval (minutes)</strong></td> <td class=\"centered\">42 to 100</td> <td class=\"centered\">27</td> <td class=\"centered\">30 to 70</td> <td class=\"centered\">22 to 73</td> <td class=\"centered\">59</td> <td class=\"centered\">37</td> <td class=\"centered\">25 to 50</td> <td class=\"centered\">49 to 97</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Onset times and dosing intervals are averages for a 2 &times; ED<sub>95</sub> dose. Infant: 0 to 1 year; Child: 1 to 18 years; Adult: 18 to 65 years; Elderly: &gt;65 years.</div><div class=\"graphic_footnotes\">ED<sub>95</sub>: effective dose required to achieve 95% depression in evoked twitch response; V<sub>D</sub>: volume of distribution; t<sub>&frac12;-Beta</sub>: elimination half-life.<br />* The data are averages obtained from published literature and do not account for other influences such as volatile anesthetics, organ dysfunction, etc.</div><div class=\"graphic_reference\">Adapted from: Brull SJ. Neuromuscular blocking agents. In: Clinical Anesthesia, 8th ed, Barash PG, Cullen BF, Stoelting RK, et al (Eds), Wolters Kluwer 2017. p.527.</div><div id=\"graphicVersion\">Graphic 114207 Version 1.0</div></div></div>"},"114209":{"type":"graphic_table","displayName":"Sensitivity to NMBAs neuromuscular disease","title":"Sensitivity of patients with neuromuscular disease to neuromuscular blocking agents ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sensitivity of patients with neuromuscular disease to neuromuscular blocking agents </div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disorder type</td> <td class=\"subtitle1\">Response to succinylcholine</td> <td class=\"subtitle1\">Response to nondepolarizing NMBA</td> </tr> <tr> <td colspan=\"3\"><strong>Myasthenic syndromes</strong></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Myasthenia gravis </li> </ul> </td> <td>Resistant</td> <td>Sensitive</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Lambert-Eaton myasthenic syndrome </li> </ul> </td> <td>Sensitive</td> <td>Sensitive</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Congenital myasthenic syndromes </li> </ul> </td> <td>Variable, not recommended due to potential hyperkalemic response</td> <td>Sensitive</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Malignant hyperthermia, central core disease, King-Denborough syndrome</strong></td> <td>Contraindicated</td> <td>Normal</td> </tr> <tr> <td colspan=\"3\"><strong>Demyelinating diseases</strong></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Multiple sclerosis </li> </ul> </td> <td>Avoid use</td> <td>Sensitive</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Motor neuron diseases </li> </ul> </td> <td>Avoid use</td> <td>Sensitive</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Guillain-Barr&#233; syndrome </li> </ul> </td> <td>Avoid use</td> <td>Sensitive</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Charcot-Marie-Tooth disease (CMTD) </li> </ul> </td> <td>Avoid use</td> <td>Normal</td> </tr> <tr> <td colspan=\"3\"><strong>Primary muscle diseases</strong></td> </tr> <tr> <td class=\"indent1\">Muscular dystrophies</td> <td>Contraindicated</td> <td>Sensitive</td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Duchenne muscular dystrophy </li> </ul> </ul> </td> <td>Contraindicated</td> <td>Sensitive</td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Becker muscular dystrophy </li> </ul> </ul> </td> <td>Contraindicated</td> <td>Sensitive</td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Limb-girdle dystrophy </li> </ul> </ul> </td> <td>Contraindicated</td> <td>Sensitive</td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Congenital muscular dystrophy </li> </ul> </ul> </td> <td>Contraindicated</td> <td>Sensitive</td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Facioscapulohumeral muscular dystrophy </li> </ul> </ul> </td> <td>Contraindicated</td> <td>Sensitive</td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Myotonic dystrophy </li> </ul> </ul> </td> <td>Contraindicated</td> <td>Sensitive*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Mitochondrial myopathies</td> <td>Sensitive</td> <td>Sensitive</td> </tr> <tr> <td colspan=\"3\"><strong>Motor neuron diseases</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Amyotrophic lateral sclerosis (Lou Gehrig's disease)</td> <td>Avoid use</td> <td>Sensitive</td> </tr> <tr> <td colspan=\"3\"><strong>Channelopathies</strong></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Acquired neuromyotonia </li> </ul> </td> <td>Avoid use</td> <td class=\"divider_bottom\" rowspan=\"6\"> <p>Normal*</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Myotonia congenita </li> </ul> </td> <td>Avoid use</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Paramyotonia congenita </li> </ul> </td> <td>Avoid use</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Potassium aggravated myotonia </li> </ul> </td> <td>Avoid use</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Hyperkalemic periodic paralysis </li> </ul> </td> <td>Avoid use</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Hypokalemic periodic paralysis </li> </ul> </td> <td>Avoid use</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Spinal cord injury, stroke, immobility, ICU patients</strong></td> <td>Avoid use</td> <td>Resistant</td> </tr> <tr> <td colspan=\"3\"><strong>Metabolic myopathies</strong></td> </tr> <tr> <td class=\"indent1\">Storage disorders (lipid, glycogen)&#182;</td> <td>Avoid use</td> <td>Variable &ndash; avoid use if possible</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NMBA: neuromuscular blocking agent; ICU: intensive care unit.<br />*&nbsp;Anticholinesterase drugs should be avoided because they may provoke a myotonic reaction.<br />¶&nbsp;Carnitine palmitoyltransferase II (CPT II) deficiency; myophosphorylase deficiency (McArdle disease).</div><div class=\"graphic_reference\">Adapted from: Brull SJ. Neuromuscular blocking agents. In: Clinical Anesthesia, 8th ed, Barash PG, Cullen BF, Stoelting RK, et al (Eds), Wolters Kluwer 2017. p.527.</div><div id=\"graphicVersion\">Graphic 114209 Version 2.0</div></div></div>"},"114210":{"type":"graphic_table","displayName":"Pharmacokin propert benzylisoquinolinium nondepolarizing NMBAs","title":"Pharmacokinetic properties of benzylisoquinolinium nondepolarizing neuromuscular blocking agents in infants, children, and adults*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacokinetic properties of benzylisoquinolinium nondepolarizing neuromuscular blocking agents in infants, children, and adults*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"8\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"4\">Atracurium</td> <td class=\"subtitle1\" colspan=\"4\">Cisatracurium</td> </tr> <tr> <td class=\"subtitle2\">Infant</td> <td class=\"subtitle2\">Child</td> <td class=\"subtitle2\">Adult</td> <td class=\"subtitle2\">Elderly</td> <td class=\"subtitle2\">Infant</td> <td class=\"subtitle2\">Child</td> <td class=\"subtitle2\">Adult</td> <td class=\"subtitle2\">Elderly</td> </tr> <tr> <td><strong>ED<sub>95</sub> (mg/kg)</strong></td> <td class=\"centered\">0.16 to 0.20</td> <td class=\"centered\">0.25</td> <td class=\"centered\">0.25</td> <td class=\"centered\">0.25</td> <td class=\"centered\">0.04</td> <td class=\"centered\">0.05</td> <td class=\"centered\">0.05</td> <td class=\"centered\">0.05</td> </tr> <tr> <td><strong>V<sub>D</sub> (L/kg)</strong></td> <td class=\"centered\">0.21</td> <td class=\"centered\">0.13</td> <td class=\"centered\">0.14</td> <td class=\"centered\">0.18</td> <td class=\"centered\">NA</td> <td class=\"centered\">0.21 to 0.35</td> <td class=\"centered\">0.12 to 0.26</td> <td class=\"centered\">0.14 to 0.26</td> </tr> <tr> <td><strong>t<sub>&#189;-Beta</sub> (minutes)</strong></td> <td class=\"centered\">14 to 20</td> <td class=\"centered\">14 to 20</td> <td class=\"centered\">21</td> <td class=\"centered\">22</td> <td class=\"centered\">NA</td> <td class=\"centered\">21 to 23</td> <td class=\"centered\">23 to 30</td> <td class=\"centered\">21 to 29</td> </tr> <tr> <td><strong>Onset time (minutes)</strong></td> <td class=\"centered\">2 to 3</td> <td class=\"centered\">2 to 3</td> <td class=\"centered\">3 to 5</td> <td class=\"centered\">3 to 5</td> <td class=\"centered\">2.5</td> <td class=\"centered\">2.5</td> <td class=\"centered\">4 to 7</td> <td class=\"centered\">5 to 7</td> </tr> <tr> <td><strong>Dosing interval (minutes)</strong></td> <td class=\"centered\">22 to 29</td> <td class=\"centered\">28</td> <td class=\"centered\">30 to 45</td> <td class=\"centered\">30 to 45</td> <td class=\"centered\">42</td> <td class=\"centered\">36</td> <td class=\"centered\">35 to 50</td> <td class=\"centered\">35 to 50</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Onset times and dosing intervals are averages for a 2 &times; ED<sub>95</sub> dose. Infant: 0 to 1 year; Child: 1 to 18 years; Adult: 18 to 65 years; Elderly: &gt;65 years.</div><div class=\"graphic_footnotes\">ED<sub>95</sub>: effective dose required to achieve 95% depression in evoked twitch response; V<sub>D</sub>: volume of distribution; t<sub>&frac12;-Beta</sub>: elimination half-life; NA: data not available.<br />* The data are averages obtained from published literature and do not account for other influences such as volatile anesthetics, organ dysfunction, etc.</div><div class=\"graphic_reference\">Adapted from: Brull SJ. Neuromuscular blocking agents. In: Clinical Anesthesia, 8th ed, Barash PG, Cullen BF, Stoelting RK, et al (Eds), Wolters Kluwer 2017. p.527.</div><div id=\"graphicVersion\">Graphic 114210 Version 1.0</div></div></div>"},"114212":{"type":"graphic_figure","displayName":"Noninvasive imaging modalities vs invasive coronary angiography","title":"Diagnostic performance of noninvasive imaging modalities during evaluation for renal transplant compared with invasive coronary angiography<sup>[1]</sup>","html":"<div class=\"graphic\"><div style=\"width: 696px\" class=\"figure\"><div class=\"ttl\">Diagnostic performance of noninvasive imaging modalities during evaluation for renal transplant compared with invasive coronary angiography<sup>[1]</sup></div><div class=\"cntnt\"><img style=\"width:676px; height:440px;\" src=\"images/NEPH/114212_Comp_img_mod_rnl_trnpt_eval.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CACS: coronary artery calcium score; CTA: computed tomography angiography; SPECT: single-photon emission computed tomography; PPV: positive predictive value; NPV: negative predictive value.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Shroff GR, Herzog CA. Coronary revascularization in patients with CKD stage 5D: Pragmatic considerations. J Am Soc Nephrol 2016; 27:3521.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced from: Winther S, Svensson M, J&oslash;rgensen HS, et al. Diagnostic Performance of Coronary CT Angiography and Myocardial Perfusion Imaging in Kidney Transplantation Candidates. JACC Cardiovasc Imaging 2015; 8:553. Illustration used with the permission of Elsevier, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 114212 Version 1.0</div></div></div>"},"114224":{"type":"graphic_table","displayName":"NCI CTCAE v5 injection site reactions","title":"NCI CTCAE v5.0 injection site reactions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 injection site reactions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Injection site reaction</td> <td>Tenderness with or without associated symptoms (eg, warmth, erythema, itching)</td> <td>Pain; lipodystrophy; edema; phlebitis</td> <td>Ulceration or necrosis; severe tissue damage; operative intervention indicated</td> <td>Life-threatening consequences; urgent intervention indicated</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">An injection site reaction is a disorder characterized by an intense adverse reaction (usually immunologic) developing at the site of an injection.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 114224 Version 5.0</div></div></div>"},"114250":{"type":"graphic_figure","displayName":"Gene correction in S-phase-injected human embryos","title":"Gene correction in S-phase-injected human embryos","html":"<div class=\"graphic\"><div style=\"width: 682px\" class=\"figure\"><div class=\"ttl\">Gene correction in S-phase-injected human embryos</div><div class=\"cntnt\"><img style=\"width:662px; height:565px;\" src=\"images/OBGYN/114250_Gn_cct_S_phs_injct_hn_embry.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic of <em>MYBPC3</em><sup>∆GAGT</sup> gene targeting by injection of CRISPR-Cas9 into human zygotes at the S-phase of the cell cycle. MII oocytes were fertilized by sperm from a heterozygous patient with equal numbers of mutant and wild-type spermatozoa. CRISPR-Cas9 was then injected into one-cell zygotes. Embryos at the 4- to 8-cell stage were collected for genetic analysis. Injection during S-phase resulted in mosaic embryos consisting of non-targeted mutant, targeted NHEJ-repaired and targeted HDR-repaired blastomeres.</div><div class=\"graphic_footnotes\">Mut: mutation; MII: metaphase II; NHEJ: non-homologous end joining; HDR: homology detected repair; WT: wild type.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Nature. Ma H, Marti-Gutierrez N, Park SW, et al. Correction of a pathogenic gene mutation in human embryos. Nature 2017; 548:413. Copyright © 2017. <A href=\"http://www.nature.com/nature\" target=_blank>www.nature.com/nature</A>.</div><div id=\"graphicVersion\">Graphic 114250 Version 1.0</div></div></div>"},"114251":{"type":"graphic_table","displayName":"NCI CTCAE v5 cytokine release syndrome","title":"NCI CTCAE v5.0 cytokine release syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 cytokine release syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Cytokine release syndrome</td> <td>Fever with or without constitutional symptoms</td> <td>Hypotension responding to fluids; hypoxia responding to &#60;40% O<sub>2</sub></td> <td>Hypotension managed with one pressor; hypoxia requiring &#8805;40% O<sub>2</sub></td> <td>Life-threatening consequences; urgent intervention indicated</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Cytokine release syndrome is a disorder characterized by fever, tachypnea, headache, tachycardia, hypotension, rash, and/or hypoxia; it is caused by the release of cytokines from the cells.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; O<sub>2</sub>: oxygen.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 114251 Version 5.0</div></div></div>"},"114255":{"type":"graphic_table","displayName":"Targets for management of pediatric septic shock","title":"Therapeutic endpoints for the ongoing management of septic shock in children*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Therapeutic endpoints for the ongoing management of septic shock in children*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Capillary refill &#8804;2 seconds</li> </ul> </td> </tr> <tr> <td> <ul> <li>Within threshold heart rate for age (beats/minute):</li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Newborn to &#60;2 years: 110 to 160</li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Infant to preschool (2 to 6 years): 90 to 160</li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Child (7 to 12 years): 70 to 150</li> </ul> </ul> </td> </tr> <tr> <td> <ul> <li>Normal pulses (central and peripheral pulses equal)</li> </ul> </td> </tr> <tr> <td> <ul> <li>Warm extremities</li> </ul> </td> </tr> <tr> <td> <ul> <li>Urine output &#62;1 mL/kg/hour</li> </ul> </td> </tr> <tr> <td> <ul> <li>Normal mental status</li> </ul> </td> </tr> <tr> <td> <ul> <li>Normalization of laboratory studies including lactate and anion gap</li> </ul> </td> </tr> <tr> <td> <ul> <li>For patients without invasive monitoring: Normal blood pressure for age</li> </ul> </td> </tr> <tr> <td> <ul> <li>For patients with invasive monitoring (CVP and intraarterial pressure monitors):</li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Cardiac index 3.3 to 6.0 L/minute/m<sup>2</sup> (if monitoring available)</li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>ScVO<sub>2</sub> &#62;70%<sup>&#182;</sup></li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Perfusion pressure (MAP to CVP [mmHg]) &#8805;55 + (age &times; 1.5)<sup>&#916;</sup></li> </ul> </ul> </td> </tr> <tr> <td> <ul> <li>Normalization of glucose and calcium</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ScVO<sub>2</sub>: central venous oxygen saturation; MAP: mean arterial pressure; CVP: central venous pressure.<br />* Septic shock is being adequately treated when all therapeutic endpoints are achieved.<br />&para; Not applicable to patients with congenital heart disease with mixing lesions.<br />&Delta; The MAP goal is based upon the estimated formula for 50th percentile MAP for a child with 50th percentile height in the healthy population with an expected CVP = 0 mmHg. When the CVP is greater than zero, then the goal MAP should be adjusted accordingly to achieve adequate perfusion pressure. Although suggested by many experts as a therapeutic endpoint, evidence is lacking to guide the optimal target perfusion pressure.</div><div class=\"graphic_reference\">Data from: Davis AL, Carcillo JA, Aneja RK, et al. American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock. Crit Care Med 2017; 45:1061.</div><div id=\"graphicVersion\">Graphic 114255 Version 1.0</div></div></div>"},"114258":{"type":"graphic_algorithm","displayName":"Fibrinogen disorders algorithm","title":"Evaluation for a suspected fibrinogen disorder","html":"<div class=\"graphic\"><div style=\"width: 652px\" class=\"figure\"><div class=\"ttl\">Evaluation for a suspected fibrinogen disorder</div><div class=\"cntnt\"><img style=\"width:632px; height:517px;\" src=\"images/HEME/114258_Fibrinogen_disorder_eval.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm does not substitute for the judgment of the treating clinician. Refer to UpToDate for discussions of the typical findings in fibrinogen disorders and our approach to patient evaluation and management.</div><div class=\"graphic_footnotes\">PT: prothrombin time; aPTT: activated partial thromboplastin time; TT: thrombin time; RT: reptilase time; HTC: hemophilia treatment center; DIC: disseminated intravascular coagulation.<br />* A fibrinogen disorder may be suspected in an individual with unexplained bleeding and/or thrombosis after elimination of the more common causes of these findings such as anticoagulation, thrombocytopenia, or DIC or in an individual with a known family history of a congenital fibrinogen disorder.<br />&#182; Specialized testing for congenital afibrinogenemia may include genetic testing or analysis in a specialized laboratory. Additional testing for hypofibrinogenemia or dysfibrinogenemia depends on the clinical presentation and may include genetic testing or specialized laboratory testing for congenital disorders and/or testing for acquired conditions. Rarely, hypodysfibrinogenemia may be present. A coagulation specialist or HTC can assist with the evaluation, urgent management, and development of a comprehensive treatment plan.</div><div id=\"graphicVersion\">Graphic 114258 Version 1.0</div></div></div>"},"114271":{"type":"graphic_table","displayName":"Properties of NMBAs","title":"Properties of neuromuscular blocking agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Properties of neuromuscular blocking agents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent*</td> <td class=\"subtitle1\">Vecuronium</td> <td class=\"subtitle1\">Rocuronium</td> <td class=\"subtitle1\">Pancuronium</td> <td class=\"subtitle1\">Mivacurium</td> <td class=\"subtitle1\">Atracurium</td> <td class=\"subtitle1\">Cisatracurium</td> <td class=\"subtitle1\">Succinylcholine</td> </tr> <tr class=\"divider_bottom\"> <td>Type (structure)</td> <td>Non-depolarizing</td> <td>Non-depolarizing</td> <td>Non-depolarizing</td> <td>Non-depolarizing</td> <td>Non-depolarizing&nbsp;</td> <td>Non-depolarizing</td> <td>Depolarizing</td> </tr> <tr class=\"divider_bottom\"> <td>Type (duration)</td> <td>Intermediate</td> <td>Intermediate</td> <td>Long</td> <td>Short</td> <td>Intermediate</td> <td>Intermediate</td> <td>Ultrashort</td> </tr> <tr class=\"divider_bottom\"> <td>Potency - ED<sub>95</sub> (mg/kg)</td> <td>0.04</td> <td>0.30</td> <td>0.07</td> <td>0.08</td> <td>0.21</td> <td>0.04 to 0.05</td> <td>0.25 to 0.30</td> </tr> <tr class=\"divider_bottom\"> <td>Intubating dose (mg/kg)</td> <td>0.10 to 0.20</td> <td>0.60 to 1.00 (1.20 with RSII dose)</td> <td>0.08 to 0.12</td> <td>0.20</td> <td>0.50 to 0.60</td> <td>0.15 to 0.20</td> <td>0.60 to 1.50</td> </tr> <tr class=\"divider_bottom\"> <td>Onset time (min)</td> <td>3 to 4</td> <td>1 to 2</td> <td>2 to 3</td> <td>3 to 4</td> <td>3 to 5</td> <td>4 to 6</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>Time to 25% recovery (min)</td> <td>20 to 35</td> <td>30 to 50 (60 to 80 with RSII dose)</td> <td>60 to 120</td> <td>15 to 20</td> <td>20 to 35</td> <td>30 to 60</td> <td>5 to 10</td> </tr> <tr> <td colspan=\"8\">Elimination half-life (min)</td> </tr> <tr> <td class=\"indent1\">Normal organ function</td> <td>50 to 60</td> <td>60 to 100</td> <td>100 to 130</td> <td>2 to 2.5</td> <td>21</td> <td>23 to 30</td> <td>&#60;1</td> </tr> <tr> <td class=\"indent1\">Renal impairment</td> <td>Mild increase</td> <td>100 to 300</td> <td>Increased x2</td> <td>3 to 4</td> <td>21</td> <td>Mild increase</td> <td>&#60;1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hepatic impairment</td> <td>Significant increase</td> <td>120 to 400</td> <td>Increased x2</td> <td>3 to 6</td> <td>21</td> <td>23 to 30</td> <td>&#60;1</td> </tr> <tr class=\"divider_bottom\"> <td>Maintenance dose (mg/kg)</td> <td>0.01</td> <td>0.10</td> <td>0.02</td> <td>0.10</td> <td>0.10</td> <td>0.01</td> <td>N/A</td> </tr> <tr class=\"divider_bottom\"> <td>Infusion dose (mcg/kg/min)</td> <td>1 to 2</td> <td>5 to 12</td> <td>20 to 40 (not recommended)</td> <td>5 to 8</td> <td>10 to 20</td> <td>1 to 3</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Elimination route/metabolism</td> <td>Renal 10 to 50%;<br /> hepatic 30 to 50%</td> <td>Renal 30%;<br /> hepatic 70%</td> <td>Renal 40 to 70%;<br /> hepatic 20%</td> <td>Plasma cholinesterase (70% of succinylcholine rate)</td> <td>Renal 10%;<br /> Hoffman 30%;<br /> ester hydrolysis 60%</td> <td>Hoffman 30%;<br /> ester hydrolysis 60%</td> <td>Butyrylcholinesterase (plasma cholinesterase, pseudocholinesterase)</td> </tr> <tr class=\"divider_bottom\"> <td>Active metabolites</td> <td>3-desacetyl-vecuronium</td> <td>17-desacetyl-rocuronium (minimal)</td> <td>3-OH-pancuronium; 17-OH-pancuronium</td> <td>No active metabolites</td> <td>No active metabolites</td> <td>No active metabolites</td> <td>No active metabolites</td> </tr> <tr class=\"divider_bottom\"> <td>Side effects</td> <td>Vagal blockade with large doses</td> <td>Minimal</td> <td>Vagal block (tachycardia), catecholamine release</td> <td>Histamine release</td> <td>Histamine release; laudanosine and acrylates production</td> <td>None; histamine release at high doses</td> <td>Myalgia; bradycardia/ asystole in children or with repeated dosing; dual (phase II, competitive) block; anaphylaxis</td> </tr> <tr class=\"divider_bottom\"> <td>Contraindications (other than specific allergy)</td> <td>None</td> <td>None</td> <td>Short surgical procedures (&#60;60 min); not recommended for continuous infusion</td> <td>Pseudocholinesterase deficiency</td> <td>Hemodynamically unstable patients due to histamine release</td> <td>None</td> <td>High K<sup>+</sup>; MH; muscular dystrophy; children; receptor up-regulation settings; pseudocholinesterase deficiency</td> </tr> <tr> <td>Comments</td> <td>Not for prolonged ICU administration (myopathy); reversible by sugammadex; elimination half-life halved in late pregnancy; 3-desacetyl metabolite has 60% of the parent compound potency</td> <td>Pain on injection; easily reversible by sugammadex; elimination half-life prolonged in ICU patient; 17-desacetyl metabolite has 20% activity</td> <td>Significant accumulation, prone to residual block (3-OH metabolite has 50% activity of pancuronium)</td> <td>Reversal by cholinesterase inhibitors; mixture of 3 isomers (cis-cis minimal); edrophonium for antagonism more effective during deep block</td> <td>Organ-independent elimination</td> <td>Trivial histamine release; minimal plasma laudanosine and acrylate levels</td> <td>Fastest onset, most reliable NMBA for rapid tracheal intubation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NA: data not available; ED<SUB>95</SUB>: effective dose to achieve 95% depression of baseline muscle contraction; NMBA: neuromuscular blocking agents; RSII: rapid sequence induction and intubation; K<SUP>+</SUP>: potassium; MH: malignant hyperthermia; ST: single twitch; ICU: intensive care unit.<br />* The data are averages obtained from published literature and do not account for other influences such as volatile anesthetics, muscle temperature, etc.</div><div class=\"graphic_reference\">Adapted from: Brull SJ. Neuromuscular blocking agents. In: Clinical Anesthesia, 8th ed, Barash PG, Cullen BF, Stoelting RK, et al (Eds), Wolters Kluwer, Philadelphia 2017.</div><div id=\"graphicVersion\">Graphic 114271 Version 2.0</div></div></div>"},"114275":{"type":"graphic_picture","displayName":"Phytophotodermatitis severe","title":"Severe phytophotodermatitis","html":"<div class=\"graphic\"><div style=\"width: 738px\" class=\"figure\"><div class=\"ttl\">Severe phytophotodermatitis</div><div class=\"cntnt\"><img style=\"width:718px; height:477px;\" src=\"images/DERM/114275_Phytophotodermatitissevere.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema and erosions on the left thigh in a 10-year-old girl with severe phytophotodermatitis caused by exposure to lime juice and sunlight.</div><div class=\"graphic_reference\">From: Darracq MA, Heppner J, Lee H, Armenian P. Backyard Pool Party: Not Your Typical Sunburn. Pediatr Emerg Care 2017; 33:440. DOI: <a href=\"http://journals.lww.com/pec-online/Citation/2017/06000/Backyard_Pool_Party__Not_Your_Typical_Sunburn.16.aspx\" target=\"_blank\">10.1097/PEC.0000000000001204</a>. Copyright &copy; 2017 Wolters Kluwer Health. Reproduced with permission. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 114275 Version 1.0</div></div></div>"},"114279":{"type":"graphic_table","displayName":"mAb naming","title":"Therapeutic monoclonal antibody nomenclature","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Therapeutic monoclonal antibody nomenclature</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Prefix</td> <td class=\"subtitle1\" colspan=\"2\">Substem A&nbsp;= Target*</td> <td class=\"subtitle1\" colspan=\"2\">Substem B&nbsp;= Source<sup>&#182;</sup></td> <td class=\"subtitle1\" rowspan=\"2\">Suffix</td> </tr> <tr> <td class=\"subtitle2\">Substem</td> <td class=\"subtitle2\">Definition</td> <td class=\"subtitle2\">Substem</td> <td class=\"subtitle2\">Definition</td> </tr> <tr> <td rowspan=\"12\"> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>Random and distinctive</p> </td> <td>-ami</td> <td>Amyloid protein</td> <td>-a</td> <td>Rat</td> <td rowspan=\"12\"> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>-mab</p> </td> </tr> <tr> <td>-ba</td> <td>Bacterial protein</td> <td>-axo</td> <td>Rat-mouse</td> </tr> <tr> <td>-ci</td> <td>Cardiovascular</td> <td>-e</td> <td>Hamster</td> </tr> <tr> <td>-fung</td> <td>Fungal protein</td> <td>-i</td> <td>Primate</td> </tr> <tr> <td>-gros</td> <td>Skeletal muscle</td> <td>-o</td> <td>Mouse</td> </tr> <tr> <td>-ki</td> <td>Interleukin</td> <td>-u</td> <td>Human</td> </tr> <tr> <td>-li</td> <td>Immuno-modulating</td> <td>-xi</td> <td>Chimeric</td> </tr> <tr> <td>-ne</td> <td>Neural</td> <td>-xizu</td> <td>Chimeric-humanized</td> </tr> <tr> <td>-os</td> <td>Bone</td> <td>-zu</td> <td>Humanized</td> </tr> <tr> <td>-toxa</td> <td>Toxin</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>-ta</td> <td>Tumor antigen</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>-vi</td> <td>Viral antigen</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate and Lexicomp for general information about therapeutic mAbs and specific dosing for individual products.</div><div class=\"graphic_footnotes\">mAb: monoclonal antibody.<br />* The final letter may be omitted if it interferes with pronunciation; this is expected not to be an issue with substems created after mid-2017 since substem B will no longer be used.<br />¶ The use of substem B was eliminated in mid-2017. mAbs created before this time use substems A and B; mAbs created after this time only use substem A.</div><div id=\"graphicVersion\">Graphic 114279 Version 1.0</div></div></div>"},"114283":{"type":"graphic_picture","displayName":"Simple aphthosis","title":"Recurrent aphthous stomatitis","html":"<div class=\"graphic\"><div style=\"width: 692px\" class=\"figure\"><div class=\"ttl\">Recurrent aphthous stomatitis</div><div class=\"cntnt\"><img style=\"width:672px; height:746px;\" src=\"images/DERM/114283_Simple_aphthosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A round ulceration is visible on the oral mucosa of this patient with recurrent aphthous stomatitis.&#xD;&#xA;​</div><div id=\"graphicVersion\">Graphic 114283 Version 1.0</div></div></div>"},"114284":{"type":"graphic_picture","displayName":"Simple aphthosis 2","title":"Recurrent aphthous stomatitis","html":"<div class=\"graphic\"><div style=\"width: 772px\" class=\"figure\"><div class=\"ttl\">Recurrent aphthous stomatitis</div><div class=\"cntnt\"><img style=\"width:752px; height:564px;\" src=\"images/DERM/114284_Simpl_aphthosis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A small, oval ulceration is present on the gingival mucosa of a patient with recurrent aphthous stomatitis.</div><div id=\"graphicVersion\">Graphic 114284 Version 1.0</div></div></div>"},"114287":{"type":"graphic_diagnosticimage","displayName":"Peliosis hepatis CT image","title":"Peliosis hepatis on computed tomographic (CT) scan","html":"<div class=\"graphic\"><div style=\"width: 711px\" class=\"figure\"><div class=\"ttl\">Peliosis hepatis on computed tomographic (CT) scan</div><div class=\"cntnt\"><img style=\"width:691px; height:507px;\" src=\"images/GAST/114287_PeliosishepatisCTimage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This contrast-enhanced computed tomography (CT) scan of the liver from a patient with peliosis hepatis shows an enhancing solid mass in the central portion of the right lobe. The mass has an appearance that is similar to other solid vascular masses such as hepatic adenoma or hepatocellular carcinoma. Peliosis hepatis does not have typical contrast-enhancement features such as those seen in patients with hepatic hemangioma or focal nodular hyperplasia.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Michael P Curry, MD, and Jonathan B Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 114287 Version 1.0</div></div></div>"},"114290":{"type":"graphic_table","displayName":"ICSD-3 diagnostic criteria for nightmare disorder","title":"Diagnostic criteria for nightmare disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for nightmare disorder</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"90%\"></colgroup> <tbody> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Diagnostic criteria A-C must be met:</td> </tr> <tr> <td class=\"centered\">A</td> <td>Repeated occurrences of extended, extremely dysphoric, and well-remembered dreams that usually involve threats to survival, security, or physical integrity</td> </tr> <tr> <td class=\"centered\">B</td> <td>On awakening from the dysphoric dreams, the person rapidly becomes oriented and alert</td> </tr> <tr> <td class=\"centered\">C</td> <td>The dream experience, or sleep disturbance produced by awakening from it, causes clinically significant distress or impairment in social, occupational, or other important areas of functioning as indicated by the report of at least one of the following: <ol> <li>Mood disturbance (eg, persistence of nightmare affect, anxiety, dysphoria) </li> <li>Sleep resistance (eg, bedtime anxiety, fear of sleep or subsequent nightmares) </li> <li>Cognitive impairments (eg, intrusive nightmare imagery, impaired concentration or memory) </li> <li>Negative impact on caregiver or family functioning (eg, nighttime disruption) </li> <li>Behavioral problems (eg, bedtime avoidance, fear of the dark) </li> <li>Daytime sleepiness </li> <li>Fatigue or low energy </li> <li>Impaired occupational or educational function </li> <li>Impaired interpersonal/social function </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: International Classification of Sleep Disorders, 3rd ed, American Academy of Sleep Medicine 2014. Copyright &copy; 2014 American Academy of Sleep Medicine. All rights reserved.</div><div id=\"graphicVersion\">Graphic 114290 Version 1.0</div></div></div>"},"114309":{"type":"graphic_table","displayName":"Revised criteria for the clinical diagnosis of DLB","title":"Revised criteria for the clinical diagnosis of dementia with Lewy bodies (DLB)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Revised criteria for the clinical diagnosis of dementia with Lewy bodies (DLB)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td><strong>Probable</strong> DLB</td> <td> <ul> <li>Two or more core clinical features of DLB are present, with or without indicative biomarkers; <strong>OR</strong> </li> <li>Only one core clinical feature is present, but with one or more indicative biomarkers </li> <li>Probable DLB should not be diagnosed on the basis of biomarkers alone </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Possible</strong> DLB</td> <td> <ul> <li>Only one core clinical feature of DLB is present, with no indicative biomarker evidence; <strong>OR</strong> </li> <li>One or more indicative biomarkers&nbsp;are present, but there are no core clinical features </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>DLB is <strong>less likely</strong></td> <td> <ul> <li>In the presence of any other physical illness or brain disorder including cerebrovascular disease, sufficient to account in part or in total for the clinical picture* </li> <li>If parkinsonian features are the only core clinical feature and appear for the first time at a stage of severe dementia<sup>&#182;</sup> </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\">Essential features</td> <td class=\"subtitle1_left\">Dementia<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Core clinical features</strong> (the first three typically occur early and may persist throughout the course)</td> <td> <ul> <li>Fluctuating cognition with pronounced variations in attention and alertness </li> <li>Recurrent visual hallucinations that are typically well formed and detailed </li> <li>REM sleep behavior disorder, which may precede cognitive decline </li> <li>One or more spontaneous cardinal features of parkinsonism (bradykinesia, rest tremor, rigidity) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Supportive clinical features</strong></td> <td> <ul> <li>Severe sensitivity to antipsychotic agents </li> <li>Postural instability </li> <li>Repeated falls </li> <li>Syncope or other transient episodes of unresponsiveness </li> <li>Severe autonomic dysfunction (eg, constipation, orthostatic hypotension, urinary incontinence) </li> <li>Hypersomnia </li> <li>Hyposmia </li> <li>Hallucinations in other modalities </li> <li>Systematized delusions </li> <li>Apathy, anxiety, and depression </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Indicative biomarkers</strong></td> <td> <ul> <li>Reduced dopamine transporter uptake in basal ganglia by SPECT or PET </li> <li>Abnormal (low-uptake) <sup>123</sup>iodine-MIBG myocardial scintigraphy </li> <li>Polysomnographic confirmation of REM sleep without atonia </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Supportive biomarkers</strong></td> <td> <ul> <li>Relative preservation of medial temporal lobe structures on CT/MRI scan </li> <li>Generalized low uptake on SPECT/PET perfusion/metabolism scan with reduced occipital activity &#177; cingulate island sign on FDG-PET imaging </li> <li>Prominent posterior slow-wave activity on EEG with periodic fluctuations in the pre-alpha/theta range </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DLB: dementia with Lewy bodies; REM: rapid eye movement; SPECT: single-photon emission computed tomography; PET: positron emission tomography; MIBG: metaiodobenzylguanidine; CT: computed tomography; MRI: magnetic resonance imaging; FDG: fluorodeoxyglucose; EEG: electroencephalography.<br />* These do not exclude a DLB diagnosis and may serve to indicate mixed or multiple pathologies contributing to the clinical presentation.<br />¶ DLB should be diagnosed when dementia occurs before or concurrently with parkinsonism. The term \"Parkinson disease dementia\" (PDD) should be used to describe dementia that occurs in the context of well-established Parkinson disease.<br />Δ Dementia is defined as a progressive cognitive decline of sufficient magnitude to interfere with normal social or occupational functions, or with usual daily activities. Prominent or persistent memory impairment may not necessarily occur early in the early stages but is usually evident with progression. Deficits on tests of attention, executive function, and visuoperceptual ability may be especially prominent and occur early.</div><div class=\"graphic_reference\">Modified from: McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 2017; 89:88. DOI: <A href=\"http://www.neurology.org/content/89/1/88.abstract\" target=_blank>10.1212/WNL.0000000000004058</A>. Copyright © 2017 American Academy of Neurology. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 114309 Version 3.0</div></div></div>"},"114310":{"type":"graphic_table","displayName":"Risk factors for MDR in UTI","title":"Risk factors for multidrug-resistant urinary tract infections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for multidrug-resistant urinary tract infections</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> </tbody></table><div class=\"graphic\"><div class=\"figure\"><table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\"><strong>Suspect</strong> <strong>multidrug-resistant&nbsp;urinary tract infection&nbsp;in patients with a history of&nbsp;any of the following in the prior three months:</strong></td> </tr> <tr> <td> <ul> <li>A multidrug-resistant urinary isolate </li> </ul> </td> </tr> <tr> <td> <ul> <li>Inpatient stay at a health care facility (eg, hospital, nursing home, long-term acute&nbsp;care facility)&nbsp; &nbsp; </li> </ul> </td> </tr> <tr> <td> <ul> <li>Use of a broad-spectrum antibiotic* (eg, fluoroquinolone, trimethoprim-sulfamethoxazole, third or later generation cephalosporin)&nbsp; </li> </ul> </td> </tr> <tr> <td> <ul> <li>Travel to parts of the world with high rates of&nbsp;multidrug-resistant organisms<sup>&#182;</sup> </li> </ul> </td> </tr> <tr> <td>NOTE: The predictive value of these risk factors for multidrug-resistant urinary tract infections has not been&nbsp;systematically evaluated. In particular, the&nbsp;time interval since these exposures is not well&nbsp;validated. The threshold for empirically covering a multidrug-resistant infection varies with the severity of infection, with a lower threshold warranted for more severe disease. </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Multidrug resistance refers to nonsusceptibility to at least one agent in three or more antibiotic classes. This includes isolates that produce an extended-spectrum beta-lactamase (ESBL). </div><div class=\"graphic_footnotes\">* This includes a single antibiotic dose given for prophylaxis prior to prostate procedures.<br />¶ The prevalence of multidrug resistance is not well documented in all parts of the world. Some countries where the prevalence is particularly high include&nbsp;India, Israel, Spain, and Mexico.</div><div id=\"graphicVersion\">Graphic 114310 Version 1.0</div></div></div>"},"114315":{"type":"graphic_algorithm","displayName":"Management of NSGCT following radical orchiectomy","title":"Management of NSGCT following radical orchiectomy*","html":"<div class=\"graphic\"><div style=\"width: 814px\" class=\"figure\"><div class=\"ttl\">Management of NSGCT following radical orchiectomy*</div><div class=\"cntnt\"><img style=\"width:794px; height:455px;\" src=\"images/ONC/114315_Mgmt_NSGCT_radcl_orchctmy.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NSGCT: nonseminomatous germ cell tumor; AFP: alpha-fetoprotein; hCG: human chorionic gonadotropin; CT: computed tomography; LVI: lymphovascular invasion; LDH: lactate dehydrogenase; ULN: upper limit of normal; BEP: bleomycin, etoposide, and cisplatin; RPLND: retroperitoneal lymph node dissection; VIP: etoposide, ifosfamide, and cisplatin; EP: etoposide and cisplatin; MRI: magnetic resonance imaging.<br />* Patients with pure seminoma on pathology but with an elevated AFP are considered to have NSGCT.<br />¶ Inguinal or pelvic lymph nodes are classified as distant metastases and constitute stage III disease.<br />Δ Treatment for systemic disease is discussed in the topic on risk stratification and treatment of advanced disease.<br /><FONT class=lozenge>◊</FONT> Involved lymph nodes are those with a short axis ≥10 mm.<br />§ All options are associated with a very high probability of cure. Choice is based upon a consideration of patient preference and available expertise.<br />¥ If RPLND is negative or reveals only teratoma, no further therapy is indicated. For men with tumors containing elements of embryonal carcinoma, seminoma, yolk sac tumor, and/or choriocarcinoma, options include either adjuvant chemotherapy or careful surveillance. Refer to discussion in the topic on stage II NSGCT.<br />‡ RPLND should be limited to centers with adequate surgical expertise.<br />† Further evaluation should include MRI of the brain to rule out brain metastases.</div><div id=\"graphicVersion\">Graphic 114315 Version 1.0</div></div></div>"},"114327":{"type":"graphic_table","displayName":"Atypical antidepressant poisoning - Rapid overview","title":"Atypical antidepressant poisoning: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Atypical antidepressant poisoning: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td style=\"color: red;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">1-800-222-1222<a href=\"#\" title=\"Call: 1-800-222-1222\"><img alt=\"\" title=\"Call: 1-800-222-1222\" style=\"overflow: hidden; cursor: hand; height: 16px; width: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span>, or access the World Health Organization's list of international poison centers (<a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a>).</td> </tr> <tr> <td class=\"subtitle1_left\">Clinical and laboratory features</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Toxicity varies by drug. Bupropion and venlafaxine most toxic in overdose: may cause seizures or cardiac conduction abnormalities. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Additional potential complications include serotonin syndrome and arrhythmias. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Potential signs and symptoms include: </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>CNS - Sedation, coma, tremor; agitation (bupropion) </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Cardiopulmonary - Tachycardia, hypertension </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Gastrointestinal - Abdominal tenderness, vomiting, diarrhea </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Neuromuscular - Clonus (ankle), hyperreflexia </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>ECG may reveal prolonged&nbsp;QTc interval or evidence of sodium channel blockade. Signs of severe sodium channel blockade include: </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Prolongation of the QRS complex &#8805;120 milliseconds </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Terminal R wave of 3 mm or more in lead aVR </li> </ul> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <ul> <li>Ratio of terminal R wave to S wave of 0.7 or more in lead aVR </li> </ul> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\">Management</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Most atypical antidepressant ingestions cause minimal toxicity; supportive care is generally sufficient.&nbsp;Determine drug and amount ingested, formulation, timing, and coingestants.&nbsp; </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Secure airway, breathing, and circulation; intubate as clinically indicated. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>To awake patients protecting their airway, may give one dose of activated charcoal (1 g/kg; standard adult dose is 50 g). </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Avoid giving additional serotonergic agents. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Treat seizures with benzodiazepines (eg, diazepam, lorazepam). Initial diazepam dose for adults is 5 to 10 mg IV, given every 5 to 10 minutes (children &#62;5 years: 1 to 2 mg; children &#60;5 years: 0.2 to 0.5 mg). </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Treat prolonged QRS interval with sodium bicarbonate: 1 to 2 mEq/kg IV push (typically, 50 to 100 mEq for an adult). Doses may be repeated as needed until the QRS interval narrows or the blood pH reaches 7.55. If QRS narrows with bicarbonate bolus, infuse bicarbonate (refer to dosing details in topic). </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Observe patients with prolonged QTc for development of torsades de pointes. Treat torsades de pointes with magnesium sulfate (Mg): initial dose 2 g IV over 2 minutes; may repeat after 10 minutes; infusion may be needed. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>For management of serotonin syndrome, refer to separate UpToDate topic. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system; ECG: electrocardiogram.</div><div id=\"graphicVersion\">Graphic 114327 Version 3.0</div></div></div>"},"114332":{"type":"graphic_picture","displayName":"Ecthyma gangrenosum from systemic infection","title":"Ecthyma gangrenosum caused by <EM>Pseudomonas aeruginosa</EM> bacteremia","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Ecthyma gangrenosum caused by <EM>Pseudomonas aeruginosa</EM> bacteremia</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/EM/114332_Ecthymagngrnssystmcinfct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ecthyma gangrenosum arises from <EM>Pseudomonas aeruginosa </EM>bacteremia and sepsis&nbsp;in immunocompromised patients, such as those with hematologic malignancy, immunodeficiency syndromes, neutropenia, pancytopenia, immunosuppression&nbsp;from chemotherapy or transplant rejection drugs, or severe malnutrition. The lesion shown above started as a painless erythematous macule, that within 24 hours developed into a painful, hemorrhagic bulla. Over time, this lesion will rupture leaving an ulcer with a central black eschar. </div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"https://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 114332 Version 2.0</div></div></div>"},"114333":{"type":"graphic_figure","displayName":"Oxygen and hemoglobin values where central cyanosis occurs","title":"Oxygen and hemoglobin values at which central cyanosis occurs","html":"<div class=\"graphic\"><div style=\"width: 749px\" class=\"figure\"><div class=\"ttl\">Oxygen and hemoglobin values at which central cyanosis occurs</div><div class=\"cntnt\"><img style=\"width:729px; height:569px;\" src=\"images/ANEST/114333_O2hmglbnvlcntlcynsoccr.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The threshold for central cyanosis is a capillary reduced hemoglobin content of 5 g/dL, which can occur at varying values of the two parameters that are measured most commonly, arterial oxygen saturation (SaO<sub>2</sub>) and arterial hemoglobin content. The vertical axis shows values for venous, capillary, and arterial reduced hemoglobin (RHB, g/dL blood), and the horizontal axis shows a percent saturation of hemoglobin in arterial blood (SaO<sub>2</sub>) along with corresponding PaO<sub>2</sub> (mmHg). Each diagonal line represents a different hemoglobin content (g/dL). For example, central cyanosis can manifest when SaO<sub>2</sub> is 79% in a patient with a hemoglobin of 15 g/dL.</div><div class=\"graphic_reference\">Original figure modified for this publication. Reproduced from: Martin L, Khalil H. How much reduced hemoglobin is necessary to generate central cyanosis? Chest 1990; 97:182. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 114333 Version 1.0</div></div></div>"},"114345":{"type":"graphic_algorithm","displayName":"Management of ventral hernias","title":"Management of ventral hernias","html":"<div class=\"graphic\"><div style=\"width: 650px\" class=\"figure\"><div class=\"ttl\">Management of ventral hernias</div><div class=\"cntnt\"><img style=\"width:630px; height:615px;\" src=\"images/SURG/114345_Managementventralhernias.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Ventral hernias are hernias of the anterior abdominal wall. They include primary ventral hernias (eg, epigastric, umbilical, Spigelian hernias) and incisional ventral hernias.<br />&para; Loss of domain is commonly defined as having &gt;50% of viscera outside of the boundaries of the abdomen.</div><div id=\"graphicVersion\">Graphic 114345 Version 2.0</div></div></div>"},"114346":{"type":"graphic_table","displayName":"Patient history for airway assessment","title":"Patient history for airway assessment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient history for airway assessment</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ol class=\"numbers_no_heading\" style=\"font-weight: bold;\"> <li>Previous airway management documentation </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Check anesthesia records for previous difficulties and ask patients whether they are aware of any anesthetic problems </li> </ul> </td> </tr> <tr> <td> <ol class=\"numbers_no_heading\" style=\"font-weight: bold;\" start=\"2\"> <li>Conditions associated with airway difficulties </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>History of difficult airway </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>History of aspiration pneumonia after intubation </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>History of dental or oral trauma following intubation </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Head and neck irradiation </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Head and neck surgery </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Cervical spine disease </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Cervical spine surgery </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Obstructive sleep apnea </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Acromegaly </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Rheumatoid arthritis </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Ankylosing spondylitis </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Marfan's syndrome </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Pierre-Robin syndrome </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Klippel-Feil abnormalities of the cervical spine </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Significant sore throat after anesthesia </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Previous airway injury during anesthesia </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Patient reporting need for a \"small tube\" </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Head, neck, and oropharyngeal </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <ul> <li>Tumors </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <ul> <li>Infections </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <ul> <li>Hematomas </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <ul> <li>Trauma </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <ul> <li>Cystic hygroma </li> </ul> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 114346 Version 1.0</div></div></div>"},"114348":{"type":"graphic_picture","displayName":"Large occipital encephalocele","title":"Large occipital encephalocele","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Large occipital encephalocele</div><div class=\"cntnt\"><img style=\"width:756px; height:622px;\" src=\"images/PEDS/114348_Lrg_occipital_encephalocele.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Newborn infant with large skin-covered occipital encephalocele.</div><div id=\"graphicVersion\">Graphic 114348 Version 1.0</div></div></div>"},"114358":{"type":"graphic_table","displayName":"Adrenal neuroendocrine tumors TNM 2017","title":"Adrenal neuroendocrine tumors TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adrenal neuroendocrine tumors TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">PH &#60;5 cm in greatest dimension, no extra-adrenal invasion</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">PH &#8805;5 cm or PG-sympathetic of any size, no extra-adrenal invasion</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor of any size with invasion into surrounding tissues (eg, liver, pancreas, spleen, kidneys)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\"><em>NOTE:</em> Parasympathetic paragaglioma are not staged because they are largely benign.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No lymph node metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N1</td> <td colspan=\"3\">Regional lymph node metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr> <td class=\"indent2\">M1a</td> <td colspan=\"3\">Distant metastasis to only bone</td> </tr> <tr> <td class=\"indent2\">M1b</td> <td colspan=\"3\">Distant metastasis to only distant lymph nodes/liver or lung</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">M1c</td> <td colspan=\"3\">Distant metastasis to bone plus multiple other sites</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Pheochromocytoma/sympathetic paraganglioma</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1 highlight_gray_text\"><strong>When T is...</strong></td> <td class=\"highlight_gray_text\"><strong>And N is...</strong></td> <td class=\"highlight_gray_text\"><strong>And M is...</strong></td> <td class=\"highlight_gray_text\"><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>Any N</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent2\">Any T</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">PH: pheochromocytoma; PG: paraganglioma.</div><div class=\"graphic_footnotes\">PH: within adrenal gland; PG-sympathetic: functional; PG-parasympathetic: nonfunctional, usually in the head and neck region.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 114358 Version 2.0</div></div></div>"},"114360":{"type":"graphic_algorithm","displayName":"Acute FPIES at home","title":"Management of acute FPIES episode at home","html":"<div class=\"graphic\"><div style=\"width: 589px\" class=\"figure\"><div class=\"ttl\">Management of acute FPIES episode at home</div><div class=\"cntnt\"><img style=\"width:569px; height:375px;\" src=\"images/ALLRG/114360_Acute_FPIES_home.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">FPIES: food protein-induced enterocolitis syndrome.</div><div class=\"graphic_reference\">Current Treatment Options in Allergy, Management of Food Protein-Induced Enterocolitis Syndrome (FPIES): Current Approach and Future Needs, 2017, p. 1, Jarock-Cyrta E, Valverde-Monge M, Nowak-Wegrzyn A, © Springer International Publishing AG 2017. Adapted with permission of Springer.</div><div id=\"graphicVersion\">Graphic 114360 Version 1.0</div></div></div>"},"114361":{"type":"graphic_algorithm","displayName":"Acute FPIES at a medical facility","title":"Management of acute FPIES episode at a medical facility*","html":"<div class=\"graphic\"><div style=\"width: 811px\" class=\"figure\"><div class=\"ttl\">Management of acute FPIES episode at a medical facility*</div><div class=\"cntnt\"><img style=\"width:791px; height:563px;\" src=\"images/ALLRG/114361_Acute_FPIES_medical_fclty.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">FPIES: food protein-induced enterocolitis syndrome; IM: intramuscular; IV: intravenous; ECG: electrocardiogram.<br />* Medical facilities include outpatient clinics/medical offices, emergency departments, and inpatient units (regular and intensive care).<br />¶ ECG changes, including dose-dependent QT interval prolongation, have been observed with ondansetron use. Thus, a baseline and post-dose ECG is suggested in at-risk patients (eg, those with underlying heart disease and/or uncorrected electrolyte abnormalities).</div><div class=\"graphic_reference\">Current Treatment Options in Allergy, Management of Food Protein-Induced Enterocolitis Syndrome (FPIES): Current Approach and Future Needs, 2017, p. 1, Jarock-Cyrta E, Valverde-Monge M, Nowak-Wegrzyn A, © Springer International Publishing AG 2017. Adapted with permission of Springer.</div><div id=\"graphicVersion\">Graphic 114361 Version 2.0</div></div></div>"},"114362":{"type":"graphic_table","displayName":"Dental care/prophylaxis for dry mouth","title":"Routine dental care and caries prophylaxis in patients with salivary hypofunction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Routine dental care and caries prophylaxis in patients with salivary hypofunction</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Mild caries risk*</td> <td class=\"subtitle1\">Moderate caries risk<sup>&#182;</sup></td> <td class=\"subtitle1\">High caries risk<sup>&#916;</sup></td> </tr> <tr> <td> <ul> <li>Brush two times per day</li> <li>Floss at least once a day</li> <li>Daily over-the-counter fluoride rinse (ACT, Fluorigard, etc)</li> <li>Dental visits every six months</li> </ul> </td> <td> <ul> <li>Brush two times per day</li> <li>Floss at least once a day</li> <li>Daily use of 1.1% sodium fluoride gel (or an equivalent supplemental fluoride preparation prescribed by a dentist)</li> <li>Dental visits every four to six months</li> <li>Annual bite-wing radiographs</li> </ul> </td> <td> <ul> <li>Brush two times per day</li> <li>Floss at least once a day</li> <li>Use of 1.1% sodium fluoride gel each day and professionally administered fluoride varnishes every three to six months</li> <li>Dental visits every three to four months</li> <li>Bite-wing radiographs every six months</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* A patient with symptomatic dry mouth but without clinical signs of dry mouth and without recent active or recurrent decay.<br />¶ A patient with clinical signs of dry mouth but no new carious lesions and no other risk factors.<br />Δ A patient with clinical signs of dry mouth and/or salivary hypofunction (eg, whole unstimulated saliva flow &lt;0.1 mL/minute) who has developed any new carious lesions.</div><div id=\"graphicVersion\">Graphic 114362 Version 1.0</div></div></div>"},"114364":{"type":"graphic_table","displayName":"Severity assessment in pediatric PH","title":"Severity assessment of pulmonary hypertension in pediatric patients<SUP>*</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Severity assessment of pulmonary hypertension in pediatric patients<SUP>*</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical variable</td> <td class=\"subtitle1\">Low risk</td> <td class=\"subtitle1\">High risk</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Standard criteria (assessed in all patients)</td> </tr> <tr> <td class=\"indent1\">Clinical evidence of RV failure </td> <td>No</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">WHO functional class</td> <td>I to II</td> <td>III to IV</td> </tr> <tr> <td class=\"indent1\">Syncope</td> <td>None</td> <td>Recurrent</td> </tr> <tr> <td class=\"indent1\">Echocardiography</td> <td>Minimal RV enlargement and/or dysfunction</td> <td> <p>Considerable&nbsp;RV enlargement and/or dysfunction</p> Pericardial effusion</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hemodynamics measured by cardiac catheterization</td> <td> <p>PVRI &#60;10 WU &times; m<sup>2</sup></p> <p>CI &#62;3.0 L/min/m<sup>2</sup></p> PVR/SVR &#60;0.5</td> <td> <p>PVRI &#62;20 WU &times; m<sup>2</sup></p> <p>CI &#60;2.0 L/min/m<sup>2</sup></p> PVR/SVR &#62;1.0</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Additional markers</td> </tr> <tr> <td class=\"indent1\">BNP/NTproBNP</td> <td>Minimally elevated</td> <td>Markedly elevated</td> </tr> <tr> <td class=\"indent1\">6MWD</td> <td>&#62;500 meters</td> <td>&#60;300 meters</td> </tr> <tr> <td class=\"indent1\">CPET</td> <td>Peak VO<sub>2</sub> &#62;25 mL/kg/min</td> <td>Peak VO<sub>2</sub> &#60;15 mL/kg/min</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table is intended for use in conjunction with additional UpToDate content on PH in children. Refer to UpToDate topics on the evaluation and management of PH in children for additional details.</div><div class=\"graphic_footnotes\">RV: right ventricle; WHO: World Health Organization; PVRI: pulmonary vascular resistance indexed to body surface area; WU: Wood unit; CI: cardiac index; PVR: pulmonary vascular resistance; SVR: systemic vascular resistance; BNP: brain natriuretic peptide; NTproBNP: N-terminal pro-BNP; 6MWD: six-minute walk distance; CPET: cardiopulmonary exercise testing; VO<SUB>2</SUB>: volume of oxygen; PH: pulmonary hypertension.<br /><br />* The severity of PH is assessed using the clinical criteria listed above. Categorization as low- or high-risk is not precise and is based in part on the clinical judgment of the treating clinician. For the low-risk category, all standard criteria should generally be met; for the high-risk category, patients typically meet multiple criteria, though all criteria need not be met. As a general principle, echocardiography and cardiac catheterization should be performed in patients prior to starting PH therapy. Additional data (eg, BNP level, 6MWD, CPET) may also be taken into account in assessing the severity of disease. Some&nbsp; patients have intermediate findings and do not fall clearly into a low- or high-risk category; consensus regarding management of such patients is lacking and practice varies considerably.</div><div class=\"graphic_reference\">Adapted from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006; 114:1417.</LI>&#xD;&#xA;<LI>Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30:2493.</LI>&#xD;&#xA;<LI>Abman SH, Hansmann G, Archer SL, et al. Pediatric Pulmonary Hypertension: Guidelines from the American Heart Association and American Thoracic Society. Circulation 2015; 132:2037.</LI></OL></div><div id=\"graphicVersion\">Graphic 114364 Version 1.0</div></div></div>"},"114366":{"type":"graphic_algorithm","displayName":"Targeted PH therapy algorithm","title":"Overview of targeted therapy in pediatric pulmonary arterial hypertension","html":"<div class=\"graphic\"><div style=\"width: 967px\" class=\"figure\"><div class=\"ttl\">Overview of targeted therapy in pediatric pulmonary arterial hypertension</div><div class=\"cntnt\"><img style=\"width:947px; height:746px;\" src=\"images/PEDS/114366_Targeted_PH_therapy_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm is intended for use in conjunction with additional UpToDate content on PH in children. Refer to UpToDate topics on the evaluation and management of PH in children for additional details of our approach to treatment and the overall efficacy of these treatments. This algorithm applies specifically to patients with pulmonary arterial hypertension (PAH). In pediatrics, the most common etiologies within this category are familial, idiopathic, and PAH associated with congenital cardiac shunting defects. For pediatric patients with other types of PH (eg, with lung disease), established treatment guidelines are lacking.</div><div class=\"graphic_footnotes\">CCB: calcium channel blocker; RV: right ventricle; ERA: endothelin receptor antagonist; PDE-5i: phosphodiesterase type 5 inhibitor; IV: intravenous; PAP: pulmonary artery pressure; WHO: World Health Organization; PVRI: pulmonary vascular resistance indexed to body surface area; WU: Wood unit; CI: cardiac index; PVR: pulmonary vascular resistance; SVR: systemic vascular resistance; BNP: brain natriuretic peptide; NTproBNP: N-terminal pro-brain natriuretic peptide; 6MWD: six-minute walk distance; CPET: cardiopulmonary exercise testing; VO<SUB>2</SUB>: volume of oxygen; PH: pulmonary hypertension.<br />* Acute vasoreactivity testing is performed via cardiac catheterization and involves the administration of a short-acting vasodilator (typically inhaled nitric oxide) followed by measurement of the hemodynamic response. The criteria used to identify \"reactivity\" on AVT in pediatric patients differ somewhat between centers and among published studies. A response to AVT is generally determined by a ≥20% decrease in mean PAP, an increase or lack of decrease in cardiac output, and no change or a decrease in PVR/SVR ratio. For additional details, refer to UpToDate content on PH in children.<br />¶ The severity of PH is assessed using the clinical criteria outlined in the table. Categorization as low- or high-risk is not precise and is based in part on the clinical judgement of the treating clinician. For the low-risk category, all standard criteria should generally be met; for the high-risk category, patients typically meet multiple criteria, though all criteria need not be met. As a general principle, echocardiography and cardiac catheterization should be performed prior to starting PH therapy. Additional data (eg, BNP level, 6MWD, CPET) may also be taken into account in assessing the severity of disease. Some patients have intermediate findings and do not fall clearly into a low- or high-risk category; consensus regarding management of such patients is lacking and practice varies considerably.<br />Δ CCBs should <STRONG>not</STRONG> be used in patients with depressed RV function. Patients with depressed RV function are often classified as high-risk and are managed accordingly. Refer to UpToDate topic on management of PH in children for additional details.<br /><FONT class=lozenge>◊</FONT> Oral ERAs that have been used in children include bosentan and ambrisentan; PDE5 inhibitors that are used for treatment of PH include sildenafil and tadalafil; inhaled prostenoids include iloprost and treprosinil. The choice between these agents is based largely on patient and provider preference. For additional details, refer to UpToDate content on PH in children.<br />§ In pediatric patients, epoprostenol is primarily used acutely in critically ill or unstable patients due the short half-life of the drug and ease of titration. By contrast, treprostinil is used more commonly for long-term management of more stable patients.</div><div class=\"graphic_reference\">Adapted from: Abman SH, Hansmann G, Archer SL, et al. Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. Circulation 2015; 132:2037.</div><div id=\"graphicVersion\">Graphic 114366 Version 1.0</div></div></div>"},"114371":{"type":"graphic_waveform","displayName":"Atrial versus sinus tachycardia on ECG","title":"Atrial versus sinus tachycardia on electocardiogram","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Atrial versus sinus tachycardia on electocardiogram</div><div class=\"cntnt\"><img style=\"width:756px; height:452px;\" src=\"images/CARD/114371_AtrlvssinustchycrdiaECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An ECG demonstrating an intra-atrial reentrant tachycardia/atrial flutter in a congenital heart disease patient. Viewing lead V1, only a single p-wave is visible (arrows) and it is slightly positive with a negative terminal component, consistent with sinus rhythm/sinus tachycardia and potentially misleading. Lead II, however, reveals notching of the T-wave (a second p-wave, dashed arrows), and the third p-wave is entirely hidden within the QRS complex (not shown) in a 3:1 atrioventricular ratio.</div><div class=\"graphic_footnotes\">ECG: electrocardiogram.</div><div id=\"graphicVersion\">Graphic 114371 Version 1.0</div></div></div>"},"114372":{"type":"graphic_picture","displayName":"Lip freckling","title":"Lip freckling","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lip freckling</div><div class=\"cntnt\"><img style=\"width:179px; height:268px;\" src=\"images/PEDS/114372_Lip_freckling.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scattered freckles on the lower lip of a child with facial freckles.</div><div class=\"graphic_reference\">Courtesy of Martha Ann Keels, DDS, PhD.</div><div id=\"graphicVersion\">Graphic 114372 Version 3.0</div></div></div>"},"114374":{"type":"graphic_picture","displayName":"Infiltrative gingival enlargement","title":"Infiltrative gingival enlargement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infiltrative gingival enlargement</div><div class=\"cntnt\"><img style=\"width:420px; height:618px;\" src=\"images/PEDS/114374_Infiltrtve_gingival_enlgmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Infiltrative gingival enlargement in a child with acute lymphoblastic leukemia (ALL).<br />(B) Infiltrative gingival enlargement in a child with acute myeloid leukemia. Note that the gingiva is more hemorrhagic than that in the child with ALL.</div><div class=\"graphic_reference\">Courtesy of Martha Ann Keels, DDS, PhD.</div><div id=\"graphicVersion\">Graphic 114374 Version 3.0</div></div></div>"},"114375":{"type":"graphic_figure","displayName":"Trajectories vasomotor symptoms over menopause transition","title":"Trajectories of vasomotor symptoms over the menopause transition","html":"<div class=\"graphic\"><div style=\"width: 781px\" class=\"figure\"><div class=\"ttl\">Trajectories of vasomotor symptoms over the menopause transition</div><div class=\"cntnt\"><img style=\"width:761px; height:497px;\" src=\"images/ENDO/114375_Trjctvsmtrsyptmmnpstrns.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Probability of VMS represents the average observed probability of VMS at each time point within each trajectory subgroup. No factors were included in the model.</div><div class=\"graphic_footnotes\">VMS: vasomotor symptoms.</div><div class=\"graphic_reference\">From: Tepper PG, Brooks MM, Randolph JF, et al. Characterizing the trajectories of vasomotor symptoms across the menopausal transition. Menopause 2016 23:1067. DOI: <A href=\"http://journals.lww.com/menopausejournal/Abstract/2016/10000/Characterizing_the_trajectories_of_vasomotor.5.aspx\" target=_blank>10.1097/GME.0000000000000676</A>. Copyright © 2016 The North American Menopause Society. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 114375 Version 1.0</div></div></div>"},"114376":{"type":"graphic_table","displayName":"Stress fracture return to sport by radiographic finding","title":"Time to return to sport by stress fracture radiographic findings","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Time to return to sport by stress fracture radiographic findings</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stress fracture type</td> <td class=\"subtitle1\">Recovery time</td> </tr> <tr> <td>Metatarsals (not proximal second/fourth/fifth)</td> <td>3 to 12 weeks</td> </tr> <tr> <td>Tibia (posteromedial)</td> <td>2 to 7 weeks (average 3.5)</td> </tr> <tr> <td>Fibula</td> <td>10 to 13 weeks</td> </tr> <tr> <td>Femoral neck (compression-side, non-surgical treatment)</td> <td>4 to 32 weeks (average 7.4 weeks if MRI grade 1; average 15 weeks if MRI grade 2 to 4)</td> </tr> <tr> <td>Low-risk site* and low-grade severity<sup>&#182;</sup> on MRI/bone scan</td> <td>8.7 weeks</td> </tr> <tr> <td>High-risk site<sup>&#916;</sup> and low-grade severity on MRI/bone scan</td> <td>19.3 weeks</td> </tr> <tr> <td>Low-risk site and high-grade severity<sup>&#9674;</sup> on MRI/bone scan</td> <td>21.8 weeks</td> </tr> <tr> <td>High-risk site and high-grade severity on MRI/bone scan</td> <td>18.7 days</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.<br />* Low-risk sites: Metatarsal shafts 2,3,4; posterior tibial cortex, fibula, tarsals other than talus or navicular, pelvis, femoral shaft.<br />&para; Low-grade severity: Grades 1 or 2 on MRI or bone scan.<br />&Delta; High-risk sites: Base of second metatarsal, fifth metatarsal, tarsal navicular, talus, femoral neck, patella, medial malleolus, great toe sesamoids.<br /><span class=\"lozenge\">&loz;</span> High-grade severity: Grades 3 or 4 on MRI or bone scan.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Beck BR, Matheson GO, Bergman G, et al. Do capacitively coupled electric fields accelerate tibial stress fracture healing? A randomized controlled trial. Am J Sports Med 2008; 36:545.</li>&#xD;&#xA;    <li>Henningsen A, Hinz P, L&uuml;dde R, et al. [Retrospective analysis of march fractures in the german armed forces in the years 1998 to 2000]. Z Orthop Ihre Grenzgeb 2006; 144:502.</li>&#xD;&#xA;    <li>Heaslet MW, Kanda-Mehtani SL. Return-to-activity levels in 96 athletes with stress fractures of the foot, ankle, and leg: a retrospective analysis. J Am Podiatr Med Assoc 2007; 97:81.</li>&#xD;&#xA;    <li>Dobrindt O, Hoffmeyer B, Seidensticker M et al. Estimation of return-to-sports-time for athletes with stress fractures - an approach combining risk level of fracture site with severity based on imaging. BMC Musculoskeletal Disorders 2012; 13:139.</li>&#xD;&#xA;    <li>Ramey LN, McInnis KC, Palmer WE. Femoral neck stress fracture: can MRI grade help predict return-to-running time? Am J Sports Med 2016; 44:2122.</li>&#xD;&#xA;</ol>&#xD;&#xA;Courtesy of Kevin deWeber, MD.</div><div id=\"graphicVersion\">Graphic 114376 Version 1.0</div></div></div>"},"114377":{"type":"graphic_diagnosticimage","displayName":"Ultrasound findings in a child with intussusception","title":"Ultrasound findings in a child with intussusception","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Ultrasound findings in a child with intussusception</div><div class=\"cntnt\"><img style=\"width:586px; height:874px;\" src=\"images/PEDS/114377_USchildintussusception.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">10-month-old girl who presented to emergency department with clinical suspicion for intussusception.<br />(Image A) Grayscale ultrasound image demonstrates a classic \"bullseye\" mass lesion (arrow) in the mid-upper abdomen where the transverse colon is typically located.<br />(Image B) Color Doppler demonstrates persistent flow (arrow) within the ileocolic bowel involved with the intussusception.</div><div class=\"graphic_reference\">Courtesy of Kevin Boyd, DO, and Nghia-Jack Vo, MD.</div><div id=\"graphicVersion\">Graphic 114377 Version 1.0</div></div></div>"},"114378":{"type":"graphic_diagnosticimage","displayName":"Soft tissue meniscus in a child with intussusception","title":"Soft tissue meniscus in a child with intussusception","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Soft tissue meniscus in a child with intussusception</div><div class=\"cntnt\"><img style=\"width:537px; height:756px;\" src=\"images/PEDS/114378_Sfttissmeniscsintssscptn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">10-month-old girl with intussusception. Abdominal radiograph shows a soft tissue meniscus (arrow) within the transverse colon and absence of gas in the cecum and ascending colon. There were no abnormally dilated loops of small bowel at&nbsp;the time that this radiograph was taken, although some patients with intussusception develop this finding.</div><div class=\"graphic_reference\">Courtesy of Kevin Boyd, DO, and Nghia-Jack Vo, MD.</div><div id=\"graphicVersion\">Graphic 114378 Version 1.0</div></div></div>"},"114379":{"type":"graphic_diagnosticimage","displayName":"Ileocolic intussusception in a child with Burkitt lymphoma","title":"Ileocolic intussusception in a child with Burkitt lymphoma","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Ileocolic intussusception in a child with Burkitt lymphoma</div><div class=\"cntnt\"><img style=\"width:756px; height:503px;\" src=\"images/PEDS/114379_IleclcintssBurkittlymphm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">15-year-old male with history of Burkitt lymphoma and non-specific abdominal pain. Computerized tomography (CT) identifies an ileocolic intussusception, with the&nbsp;lymphoma-infiltrated bowel serving as the lead point for the intussusception (arrow).</div><div class=\"graphic_reference\">Courtesy of Kevin Boyd, DO, and Nghia-Jack Vo, MD.</div><div id=\"graphicVersion\">Graphic 114379 Version 1.0</div></div></div>"},"114380":{"type":"graphic_diagnosticimage","displayName":"Successful reduction of intussusception by pneumatic enema","title":"Successful reduction of intussusception by pneumatic enema","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Successful reduction of intussusception by pneumatic enema</div><div class=\"cntnt\"><img style=\"width:766px; height:453px;\" src=\"images/PEDS/114380_Redctintusspneumtcenema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three-year-old girl undergoing pneumatic enema reduction for intussusception.<br />(Image A) Air serves as a negative contrast leaving the intussusception visible as a soft tissue meniscus density in the ascending colon (thin arrow). The tip of the enema nozzle can be seen&nbsp;within the rectum (thick arrow).<br />(Image B) Following successful pneumatic reduction of the intussusception there is resolution of the prior soft tissue density in the ascending colon, and air is now identified within the ileum and distal small bowel.</div><div class=\"graphic_reference\">Courtesy of Kevin Boyd, DO, and Nghia-Jack Vo, MD.</div><div id=\"graphicVersion\">Graphic 114380 Version 1.0</div></div></div>"},"114381":{"type":"graphic_diagnosticimage","displayName":"Unsuccessful reduction of intussusception with bowel perforation","title":"Unsuccessful attempt to reduce intussusception by pneumatic enema, complicated by bowel perforation","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Unsuccessful attempt to reduce intussusception by pneumatic enema, complicated by bowel perforation</div><div class=\"cntnt\"><img style=\"width:766px; height:467px;\" src=\"images/PEDS/114381_Unscsflredctenemacmplctd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Five-month-old boy undergoing pneumatic enema reduction for intussusception.<br />(Image A) The rectum and colon are distended with air and the intussusception is identified as a persistent soft tissue meniscus density in the region of the cecum (asterisk). There is no air in the ileum and distal small bowel, indicating that the intussusception has not been reduced.<br />(Image B) Nonreducible intussusception (asterisk) complicated by bowel perforation during pneumatic enema reduction attempt. There is diffuse pneumoperitoneum/free air, which is best seen&nbsp;as a rim of lucency around the liver surface (arrowheads).</div><div class=\"graphic_reference\">Courtesy of Kevin Boyd, DO, and Nghia-Jack Vo, MD.</div><div id=\"graphicVersion\">Graphic 114381 Version 1.0</div></div></div>"},"114382":{"type":"graphic_diagnosticimage","displayName":"US plantar fascia lateral band","title":"US plantar fascia lateral band","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">US plantar fascia lateral band</div><div class=\"cntnt\"><img style=\"width:754px; height:380px;\" src=\"images/SM/114382_US_plntr_fsc_ltrl_bnd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image above shows the lateral band of the plantar fascia near its origin.</div><div class=\"graphic_footnotes\">PFL: lateral band of the plantar fascia; PFC: central band of the plantar fascia; Med: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 114382 Version 1.0</div></div></div>"},"114383":{"type":"graphic_diagnosticimage","displayName":"US inferior calcaneal nerve short-axis view","title":"US inferior calcaneal nerve short-axis view","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">US inferior calcaneal nerve short-axis view</div><div class=\"cntnt\"><img style=\"width:754px; height:398px;\" src=\"images/SM/114383_US_inf_calcaneal_nrv_sht-ax.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Short-axis image of inferior calcaneal nerve (arrow).</div><div class=\"graphic_footnotes\">AH: abductor hallucis muscle; QP: quadratus plantae muscle.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 114383 Version 1.0</div></div></div>"},"114388":{"type":"graphic_table","displayName":"Interstitial pneumonia with autoimmune features","title":"Classification criteria for \"interstitial pneumonia with autoimmune features (IPAF)\"","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification criteria for \"interstitial pneumonia with autoimmune features (IPAF)\"</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_to_nine\"> <li>Presence of an interstitial pneumonia (by HRCT or surgical lung biopsy) <strong>and</strong>, </li> <li>Exclusion of alternative etiologies <strong>and</strong>, </li> <li>Does not meet criteria of a defined connective tissue disease <strong>and</strong>, </li> <li>At least one feature from at least two of these domains: <ol style=\"list-style-type: lower-alpha;\"> <li>Clinical domain </li> <li>Serologic domain </li> <li>Morphologic domain </li> </ol> </li> </ol> </td> </tr> <tr> <td><strong>A. Clinical domain</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ol> <li>Distal digital fissuring (<strong>ie</strong>, \"mechanic hands\") </li> <li>Distal digital tip ulceration </li> <li>Inflammatory arthritis <strong>or</strong> polyarticular morning joint stiffness &#8805;60 minutes </li> <li>Palmar telangiectasia </li> <li>Raynaud phenomenon </li> <li>Unexplained digital edema </li> <li>Unexplained fixed rash on the digital extensor surfaces (Gottron's sign) </li> </ol> </td> </tr> <tr> <td><strong>B. Serologic domain</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ol> <li>ANA &#8805;1:320 titer, diffuse, speckled, homogeneous patterns <strong>or</strong> <ol style=\"list-style-type: lower-alpha;\"> <li>ANA nucleolar pattern (any titer) <strong>or</strong> </li> <li>ANA centromere pattern (any titer) </li> </ol> </li> <li>Rheumatoid factor &#8805;2&times; upper limit of normal </li> <li>Anti-CCP </li> <li>Anti-dsDNA </li> <li>Anti-Ro (SS-A) </li> <li>Anti-La (SS-B) </li> <li>Anti-ribonucleoprotein </li> <li>Anti-Smith </li> <li>Anti-topoisomerase (Scl-70) </li> <li>Anti-tRNA synthetase (<strong>eg</strong>, Jo-1, PL-7, PL-12; others are: EJ, OJ, KS, Zo, tRS) </li> <li>Anti-PM-Scl </li> <li>Anti-MDA-5 </li> </ol> </td> </tr> <tr> <td><strong>C. Morphologic domain</strong></td> </tr> <tr> <td class=\"indent1\"> <ol> <li>Suggestive radiology patterns by HRCT (please refer to UpToDate topic text for additional details): <ol style=\"list-style-type: lower-alpha;\"> <li>NSIP </li> <li>OP </li> <li>NSIP with OP overlap </li> <li>LIP </li> </ol> </li> <li>Histopathology patterns or features by surgical lung biopsy: <ol style=\"list-style-type: lower-alpha;\"> <li>NSIP </li> <li>OP </li> <li>NSIP with OP overlap </li> <li>LIP </li> <li>Interstitial lymphoid aggregates with germinal centers </li> <li>Diffuse lymphoplasmacytic infiltration (with or without lymphoid follicles) </li> </ol> </li> <li>Multi-compartment involvement (in addition to interstitial pneumonia): <ol style=\"list-style-type: lower-alpha;\"> <li>Unexplained pleural effusion or thickening </li> <li>Unexplained pericardial effusion or thickening </li> <li>Unexplained intrinsic airways disease* (by PFT, imaging or pathology) </li> <li>Unexplained pulmonary vasculopathy </li> </ol> </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HRCT: high resolution computed tomography; ANA: antinuclear antibody; anti-CCP: anti-cyclic citrullinated peptide antibodies; anti-dsDNA: anti-double-stranded DNA antibodies; anti-tRNA synthetase: anti-aminoacyl-transfer RNA antibodies (antisynthetase antibodies); anti-MDA-5: antimelanoma differentiation-associated gene 5; NSIP: nonspecific interstitial pneumonia; OP: organizing pneumonia; LIP: lymphoid interstitial pneumonia; PFT: pulmonary function testing.<br />* Includes airflow obstruction, bronchiolitis, or bronchiectasis.</div><div class=\"graphic_reference\">Reproduced with permission from the European Respiratory Society &copy;. European Respiratory Journal Oct 2015, 46 (4) 976-987; DOI: 10.1183/13993003.00150-2015.</div><div id=\"graphicVersion\">Graphic 114388 Version 1.0</div></div></div>"},"114389":{"type":"graphic_algorithm","displayName":"Antiviral treatment for chronic HEV in nonpregnant adults","title":"Antiviral treatment for chronic hepatitis E virus in treatment-naïve nonpregnant adults","html":"<div class=\"graphic\"><div style=\"width: 823px\" class=\"figure\"><div class=\"ttl\">Antiviral treatment for chronic hepatitis E virus in treatment-naïve nonpregnant adults</div><div class=\"cntnt\"><img style=\"width:803px; height:898px;\" src=\"images/ID/114389_Antvrl_trt_chrn_HEV_nprg_ad.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HEV: hepatitis E virus.<br />* In solid organ transplant recipients, we typically reduce tacrolimus first if possible. In addition, for such patients, we administer antiviral therapy in conjunction with reducing immunosuppressive therapy.<br />¶ HEV RNA assay should be performed in both stool and serum.<br />Δ HEV RNA should not detected in both stool and serum.<br /><FONT class=lozenge>◊</FONT> HEV RNA detected in either stool or serum.</div><div id=\"graphicVersion\">Graphic 114389 Version 1.0</div></div></div>"},"114391":{"type":"graphic_table","displayName":"Mosaic RASopathies","title":"Mosaic RASopathies: Genotype analysis of mosaic nevoid proliferations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mosaic RASopathies: Genotype analysis of mosaic nevoid proliferations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup span=\"7\" width=\"7%\"></colgroup><colgroup width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"4\"><em>HRAS</em></td> <td class=\"subtitle1\" colspan=\"2\"><em>KRAS</em></td> <td class=\"subtitle1\"><em>NRAS</em></td> <td class=\"subtitle1\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2\">Nevus type</td> <td class=\"subtitle2\">Mutation analyses*</td> <td class=\"subtitle2\">G13R</td> <td class=\"subtitle2\">G12D</td> <td class=\"subtitle2\">G12C</td> <td class=\"subtitle2\">Other<sup>&#182;</sup></td> <td class=\"subtitle2\">G12D</td> <td class=\"subtitle2\">G12V</td> <td class=\"subtitle2\">Other<sup>&#182;</sup></td> <td class=\"subtitle2\">Other<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Keratinocytic</td> </tr> <tr> <td class=\"indent1\">KEN plus urothelial carcinomas<sup>&#916;</sup><sup>[1]</sup></td> <td>Sanger sequencing</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">G12S</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"indent1\">KEN<sup>[2]</sup></td> <td>SNaPshot assay, Sanger sequencing</td> <td class=\"centered\">21/72</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">1/72</td> <td class=\"centered\">G12V, Q61L</td> <td class=\"centered\">1/72</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">G12D, P34L, Q61R</td> <td><em>FGFR3</em> (16/72), <em>PIK3CA</em> (6/72)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">KEN plus rhabdomyosarcoma<sup>&#916;</sup><sup>[3]</sup></td> <td>WGA-aCGH</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">1/1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Sebaceous</td> </tr> <tr> <td class=\"indent1\">Schimmelpenning syndrome, NS<sup>[4]</sup></td> <td>RAS SNaPshot assay, Sanger sequencing</td> <td class=\"centered\">1/2<br /> 59/65</td> <td class=\"centered\">1/65</td> <td class=\"centered\">1/65</td> <td class=\"centered\">G12S (3/65), A11S</td> <td class=\"centered\">1/2<br /> 2/65</td> <td class=\"centered\">1/65</td> <td class=\"centered\">&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">NS<sup>&#9674;</sup><sup>[5]</sup></td> <td>WES of index cases, Sanger sequencing</td> <td class=\"centered\">25/27</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">1/27</td> <td class=\"centered\">1/27</td> <td class=\"centered\">&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Schimmelpenning syndrome (index), NS<sup>[6]</sup></td> <td>WES of index case, Sanger sequencing</td> <td class=\"centered\">1/1<br /> 24/31</td> <td class=\"centered\">1/31</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">2/31</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">PPK</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Nevus spilus plus NS<sup>[7]</sup></td> <td>RAS SNaPshot assay, Sanger sequencing</td> <td class=\"centered\">4/6</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">G61R<br /> (2/6)</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Melanocytic</td> </tr> <tr> <td class=\"indent1\">Agminated segmental nevi<sup>&#916;</sup><sup>[8]</sup></td> <td>Sanger sequencing</td> <td class=\"centered\">1/1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td><em>BRAF</em> V600E</td> </tr> <tr> <td class=\"indent1\">Nevus spilus plus overlying agminated Spitz nevi<sup>&#916;[9]</sup></td> <td>WES-aCGH</td> <td class=\"centered\">1/1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>Copy number increase in chromosome 11p in overlying Spitz nevi</td> </tr> <tr> <td class=\"indent1\">Nevus spilus<sup>[10]</sup></td> <td>Sanger sequencing</td> <td class=\"centered\">8/8</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent1\">Nevus spilus-type CMN<sup>[11]</sup></td> <td>WES</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">G13R, Q61H (2/3)</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">KEN: keratinocytic epidermal nevi; WGA-aCGH: whole genome amplification-array comparative genomic hybridization; NS: nevus sebaceous; WES: whole exome sequencing; PPK: phakomatosis pigmentokeratotica; CMN: congenital melanocytic nevus.<br />* Analyses techniques are summarized but may not reflect the breakdown of additional methods used. Refer to original study for details. En dash (–) indicates genes not screened.<br />¶ Mutations listed under other are present in one sample of the total tested only unless otherwise indicated.<br />Δ Case report.<br /><FONT class=lozenge>◊</FONT> Merged data. Breakdown: 3/5 <EM>HRAS</EM> G13R (two additional separate sets were 11/11 and 11/11 for this mutation), 1/5 <EM>KRAS</EM> G12D, and 1/5 <EM>KRAS</EM> G12V.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Hafner C, Toll A, Real FX. HRAS mutation mosaicism causing urothelial cancer and epidermal nevus. N Engl J Med 2011; 365:1940.</li>&#xD;&#xA;    <li>Hafner C, Toll A, Gantner S, et al. Keratinocytic epidermal nevi are associated with mosaic RAS mutations. J Med Genet 2012; 49:249.</li>&#xD;&#xA;    <li>Bourdeaut F, H&eacute;rault A, Gentien D, et al. Mosaicism for oncogenic G12D KRAS mutation associated with epidermal nevus, polycystic kidneys and rhabdomyosarcoma. J Med Genet 2010; 47:859.</li>&#xD;&#xA;    <li>Groesser L, Herschberger E, Ruetten A, et al. Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. Nat Genet 2012; 44:783.</li>&#xD;&#xA;    <li>Levinsohn JL, Tian LC, Boyden LM, et al. Whole-exome sequencing reveals somatic mutations in HRAS and KRAS, which cause nevus sebaceous. J Invest Dermatol 2013; 133:827.</li>&#xD;&#xA;    <li>Sun BK, Saggini A, Sarin KY, et al. Mosaic activating RAS mutations in nevus sebaceus and nevus sebaceus syndrome. J Invest Dermatol 2013; 133:824.</li>&#xD;&#xA;    <li>Groesser L, Herschlberger E, Sagrera A, et al. Phacomatosis pigmentokeratotica is caused by a postzygotic HRAS mutation in a multipotent progenitor cell. J Invest Dermatol 2013; 133:1998.</li>&#xD;&#xA;    <li>Luo S, Chaplin AC, Langley RG, et al. Agminated segmental nevi demonstrating intranevic concordance of BRAF status. J Invest Dermatol 2011; 131:788.</li>&#xD;&#xA;    <li>Sarin KY, Sun BK, Bangs CD, et al. Activating HRAS mutation in agminated Spitz nevi arising in a nevus spilus. JAMA Dermatol 2013; 149:1077.</li>&#xD;&#xA;    <li>Sarin KY, McNiff JM, Kwok S, et al. Activating HRAS mutation in nevus spilus. J Invest Dermatol 2014; 134:1766.</li>&#xD;&#xA;    <li>Kinsler VA, Krengel S, Riviere JB, et al. Next-generation sequencing of nevus spilus-type congenital melanocytic nevus: exquisite genotype-phenotype correlation in mosaic RASopathies. J Invest Dermatol 2014; 134:2658.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced from: Luo S, Tsao H. Epidermal, sebaceous, and melanocytic nevoid proliferations are spectrums of mosaic RASopathies. J Invest Dermatol 2014; 134:2493. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 114391 Version 1.0</div></div></div>"},"114394":{"type":"graphic_figure","displayName":"Variable clinical course in IPF","title":"Schematic representation of potential clinical courses of idiopathic pulmonary fibrosis (IPF)","html":"<div class=\"graphic\"><div style=\"width: 761px\" class=\"figure\"><div class=\"ttl\">Schematic representation of potential clinical courses of idiopathic pulmonary fibrosis (IPF)</div><div class=\"cntnt\"><img style=\"width:741px; height:486px;\" src=\"images/PULM/114394_VariablclinicalcourseIPF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">As IPF progresses, there is a subclinical period in which only radiographic findings of disease may be present, followed by a symptomatic period consisting of both pre-diagnosis and post-diagnosis clinical phases. The rate of decline and progression to death may be rapid (line A), slow (lines C and D), or mixed (curve B), with periods of relative stability interposed with periods of acute decline (asterisk).</div><div class=\"graphic_reference\">Reprinted with permission of the American Thoracic Society. Copyright &copy; 2017 American Thoracic Society. From: Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183:431. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 114394 Version 1.0</div></div></div>"},"114395":{"type":"graphic_table","displayName":"Predictors of survival in IPF","title":"Predictors of shorter survival in patient with idiopathic pulmonary fibrosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Predictors of shorter survival in patient with idiopathic pulmonary fibrosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical</td> <td class=\"subtitle1\">Morphologic</td> <td class=\"subtitle1\">Physiologic</td> <td class=\"subtitle1\">Molecular*</td> </tr> <tr> <td><strong>Demographic</strong> <ul class=\"decimal_heading\"> <li>Older age </li> <li>Male sex </li> </ul> <br /> <strong>Symptoms</strong> <ul class=\"decimal_heading\"> <li>Worse dyspnea </li> <li>Cough </li> </ul> <br /> <strong>Physical exam</strong> <ul class=\"decimal_heading\"> <li>Lower body mass index </li> </ul> <br /> <strong>Comorbidities</strong> <ul class=\"decimal_heading\"> <li>Lung cancer </li> <li>Cardiac disease </li> <li>Pulmonary hypertension </li> </ul> <br /> <strong>Acute respiratory worsening</strong> <ul class=\"decimal_heading\"> <li>Acute exacerbation </li> <li>Respiratory hospitalization </li> </ul> <br /> </td> <td><strong>High-resolution CT</strong> <ul class=\"decimal_heading\"> <li>Greater extent of fibrotic findings, ie, reticulation, traction bronchiectasis, and honeycombing (quantified by visual or automated methods) </li> </ul> <br /> <strong>Surgical lung biopsy</strong> <ul class=\"decimal_heading\"> <li>Greater profusion of fibroblast foci </li> </ul> <br /> </td> <td><strong>Pulmonary function tests</strong> <ul class=\"decimal_heading\"> <li>Lower FVC (especially &#60;50%) </li> <li>Lower DLCO (especially &#60;35%) </li> <li>10% or greater decline in FVC over 3 to 12 months </li> <li>15% or greater decline in DLCO over 3 to 12 months </li> <li>Composite physiologic index (composite score of FEV<sub>1</sub>, FVC, and DLCO) </li> </ul> <br /> <strong>Six-minute walk test</strong> <ul class=\"decimal_heading\"> <li>Shorter distance (especially &#60;250 meters) </li> <li>50 meter or greater decline over six months </li> <li>Desaturation </li> </ul> <br /> </td> <td><strong>Genomic</strong> <ul class=\"decimal_heading\"> <li>Shorter peripheral blood telomere length (especially &#60;10th percentile for age) </li> <li>Homozygous wild-type for MUC5B promotor polymorphism rs35705950 </li> <li>Hetero- or homozygous for TOLLIP minor allele rs5743890 </li> <li>Peripheral blood mononuclear cell gene expression profile </li> </ul> <br /> <strong>Blood proteins</strong> <ul class=\"decimal_heading\"> <li>Elevated levels of SPA or D, KL6, CCL18, MMP7, YKL40, Anti-HSP70 IgG, CXCL13, periostin, fibulin-1, collagen degradation products </li> </ul> <br /> <strong>Blood cells</strong> <ul class=\"decimal_heading\"> <li>Increased circulating fibrocytes </li> </ul> <br /> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed cosmography; FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide; FEV<SUB>1</SUB>: forced expiratory volume in one second; MUC5B: mucin 5B; TOLLIP: toll interacting protein; SP: surfactant proteins; KL6: Krebs von den Lungen 6 (also called mucin 1); CCL18: CC chemokine ligand 18; MMP7: matrix metalloproteinase 7; YKL40: chitinase-3-like protein 1; HSP: heat shock protein; IgG: immunoglobulin g; CXCL13: C-X-C motif chemokine 13G.<br />* These molecular biomarkers are predictive of shorter survival in research studies, but are not ready for routine clinical use.</div><div id=\"graphicVersion\">Graphic 114395 Version 2.0</div></div></div>"},"114397":{"type":"graphic_table","displayName":"GAP index and staging","title":"The GAP index and staging system","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The GAP index and staging system</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Predictor</td> <td class=\"subtitle1\">Points</td> </tr> <tr> <td class=\"divider_bottom centered\" style=\"vertical-align: middle;\" rowspan=\"3\"><strong>G</strong></td> <td colspan=\"3\">Gender</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ul> <li>Female </li> </ul> </td> <td class=\"centered\">0</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <ul> <li>Male </li> </ul> </td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"divider_bottom centered\" style=\"vertical-align: middle;\" rowspan=\"4\"><strong>A</strong></td> <td colspan=\"3\">Age (years)</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ul> <li>&#8804;60 </li> </ul> </td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ul> <li>61 to 65 </li> </ul> </td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <ul> <li>&#62;65 </li> </ul> </td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"divider_bottom centered\" style=\"vertical-align: middle;\" rowspan=\"10\"><strong>P</strong></td> <td colspan=\"3\">Physiology</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\"> <ul> <li>FVC (% predicted) </li> </ul> </td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ul> <ul> <li>&#62;75 </li> </ul> </ul> </td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ul> <ul> <li>50 to 75 </li> </ul> </ul> </td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ul> <ul> <li>&#60;50 </li> </ul> </ul> </td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\"> <ul> <li>DLCO (% predicted) </li> </ul> </td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ul> <ul> <li>&#62;55 </li> </ul> </ul> </td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ul> <ul> <li>36 to 55 </li> </ul> </ul> </td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ul> <ul> <li>&#8804;35 </li> </ul> </ul> </td> <td class=\"centered\">2</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <ul> <ul> <li>Cannot perform </li> </ul> </ul> </td> <td class=\"centered\">3</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td colspan=\"3\"><strong>Total possible points</strong></td> <td class=\"centered\"><strong>8</strong></td> </tr> <tr class=\"divider_top divider_bottom\"> <td><strong>Stage</strong></td> <td class=\"centered\">I</td> <td class=\"centered\">II</td> <td class=\"centered\">III</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Points</strong></td> <td class=\"centered\">0 to 3</td> <td class=\"centered\">4 to 5</td> <td class=\"centered\">6 to 8</td> </tr> <tr> <td colspan=\"4\"><strong>Mortality</strong></td> </tr> <tr> <td class=\"indent1\">1-year</td> <td class=\"centered\">5.6</td> <td class=\"centered\">16.2</td> <td class=\"centered\">39.2</td> </tr> <tr> <td class=\"indent1\">2-years</td> <td class=\"centered\">10.9</td> <td class=\"centered\">29.9</td> <td class=\"centered\">62.1</td> </tr> <tr> <td class=\"indent1\">3-years</td> <td class=\"centered\">16.3</td> <td class=\"centered\">42.1</td> <td class=\"centered\">76.8</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Points are assigned for each variable of the scoring system to obtain a total point score (range 0 to 8). Patients should be scored in the \"cannot perform\" category for DLCO if their symptoms or lung function prohibited performance of the DLCO maneuver. If DLCO is unavailable because it was not ordered or not completed because of nonrespiratory limitations, then the model cannot be applied. The total point score is used to classify patients as stage I (0 to 3 points), stage II (4 to 5 points), or stage III (6 to 8 points). Model-predicted one-, two-, and three-year mortality is shown by stage.</div><div class=\"graphic_footnotes\">GAP: gender, age, and two lung physiology variables (FVC and DLCO); FVC: forced vital capacity; DLCO: diffusing capacity for carbon monoxide.</div><div class=\"graphic_reference\">From Annals of Internal Medicine, Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156(10):684-91. Copyright &copy; 2012 American College of Physicians. All Rights Reserved. Reprinted with the permission of American College of Physicians, Inc.</div><div id=\"graphicVersion\">Graphic 114397 Version 1.0</div></div></div>"},"114440":{"type":"graphic_diagnosticimage","displayName":"MRI of GBS","title":"Magnetic resonance imaging of 51-year-old woman with Guillain-Barré syndrome","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance imaging of 51-year-old woman with Guillain-Barr&eacute; syndrome</div><div class=\"cntnt\"><img style=\"width:726px; height:303px;\" src=\"images/NEURO/114440_MRIGBS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Coronal brain T1 MRI with Gd images showing bilateral facial nerve enhancement (arrows).<br />(B) Sagittal lumbar spine T1 MRI with Gd showing enhancement in the medullary cone (arrow).<br />(C) Axial lumbar-spine T2 MRI showing increased signal intensity in the spinal ganglia bilaterally (arrowheads).<br />(D) Axial lumbar-spine T1 MRI (fast scanning) with Gd showing enhancement of the spinal ganglia (arrowheads) and cauda equina roots (dashed arrows).</div><div class=\"graphic_footnotes\">Gd: gadolinium contrast; MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">From: Neuroradiology, Magnetic resonance imaging findings in Guillain-Barr&eacute; syndrome caused by Zika virus infection, Vol. 58, 2016, p. 837, Fontes CA, Dos Santos AA, Marchiori E, &copy; Springer-Verlag Berlin Heidelberg 2016. With permission of Springer.</div><div id=\"graphicVersion\">Graphic 114440 Version 1.0</div></div></div>"},"114443":{"type":"graphic_figure","displayName":"Current use of e-cigarettes among US youth","title":"Trends in current e-cigarette use among US middle and high school students; National Youth Tobacco Survey (NYTS) 2011 to 2016","html":"<div class=\"graphic\"><div style=\"width: 687px\" class=\"figure\"><div class=\"ttl\">Trends in current e-cigarette use among US middle and high school students; National Youth Tobacco Survey (NYTS) 2011 to 2016</div><div class=\"cntnt\"><img style=\"width:667px; height:338px;\" src=\"images/PEDS/114443_Cur_use_e_cigarettes_US_yth.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li>These data reflect students who selected \"1 or more\" for the following question: \"During the last 30 days, on how many days did you use electronic cigarettes or e-cigarettes?\"</li>&#xD;&#xA;    <li>In 2014, modifications were made to the e-cigarette measure to enhance its accuracy, which may limit the comparability of this estimate to those collected in previous years. The dotted lines from 2013 to 2016 represent these differences. </li>&#xD;&#xA;</ul></div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Jamal A, Gentzke A, Hu SS, et al. Tobacco Use Among Middle and High School Students - United States, 2011-2016. MMWR Morb Mortal Wkly Rep 2017; 66:597.</li>&#xD;&#xA;</ol>&#xD;&#xA;Adapted from: US Department of Health and Human Services. E-Cigarette Use Among Youth and Young Adults: A Report of the Surgeon General&mdash;Executive Summary. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2016.</div><div id=\"graphicVersion\">Graphic 114443 Version 1.0</div></div></div>"},"114447":{"type":"graphic_algorithm","displayName":"Overview of imaging and assessment of stress fracture","title":"Overview of imaging and assessment of stress fracture","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Overview of imaging and assessment of stress fracture</div><div class=\"cntnt\"><img style=\"width:533px; height:710px;\" src=\"images/SM/114447_Ovrvw_img_asmnt_strss_frctr.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 114447 Version 1.0</div></div></div>"},"114453":{"type":"graphic_algorithm","displayName":"Management of an IUD in a woman diagnosed with PID","title":"Management of an IUD in a woman diagnosed with PID","html":"<div class=\"graphic\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Management of an IUD in a woman diagnosed with PID</div><div class=\"cntnt\"><img style=\"width:704px; height:577px;\" src=\"images/OBGYN/114453_Mgmt_IUD_womn_diagnosed_PID.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IUD: intrauterine device; PID: pelvic inflammatory disease​; TOA: tubo-ovarian abscess.<br />* Refer to UpToDate content for more information on the diagnosis of PID, oral and parenteral treatment options, and indications for in-hospital treatment.<br />¶ Most women do not require IUD removal for treatment of PID. One exception is women who have actinomyces on cervical culture; these women are advised to have the IUD removed after initiation of antibiotics for PID.<br />Δ While the optimal time to remove the IUD after initiation of antibiotics is not known, it is common to wait 30 to 60 minutes, or until enough time has passed to establish an antibiotic serum level.<br /><FONT class=lozenge>◊</FONT> Refer to UpToDate content on selecting contraception.<br />§ Clinical improvement includes reduction in pain and/or resolution of fever.<br />¥ Refer to UpToDate content on management of tubo-ovarian abscess.<br />‡ The optimal time for IUD insertion, if desired, following documented intrauterine infection is not known, although 12 weeks has historically been advised. Minimum criteria for IUD insertion include that the procedure be delayed until the treatment course is complete, the symptoms are resolved, and the cervical exam is normal. For more information, refer to the UpToDate topic on management of IUD complications and side effects.</div><div id=\"graphicVersion\">Graphic 114453 Version 1.0</div></div></div>"},"114456":{"type":"graphic_table","displayName":"Clinical findings in inherited disorders of fibrinogen","title":"Clinical findings in inherited fibrinogen disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical findings in inherited fibrinogen disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Bleeding complications</td> <td class=\"subtitle1\">Thromboembolic complications</td> <td class=\"subtitle1\">Complications of pregnancy</td> <td class=\"subtitle1\">Other findings (rare)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Afibrinogenemia</strong></td> <td> <ul> <li>Common </li> <li>Can be severe </li> <li>Can occur during neonatal period (eg, umbilical cord bleeding) </li> <li>Sites may include gastrointestinal, urinary, central nervous system, spleen (with splenic rupture) </li> </ul> </td> <td> <ul> <li>Possible </li> <li>May be venous or arterial </li> </ul> </td> <td> <ul> <li>Spontaneous abortion, early fetal loss, and/or placental abruption may occur </li> <li>Can have bleeding antepartum or postpartum </li> </ul> </td> <td> <ul> <li>Bone cysts </li> <li>Abnormal wound healing </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Hypofibrinogenemia</strong></td> <td> <ul> <li>Variable frequency </li> <li>Variable severity </li> </ul> </td> <td> <ul> <li>Rare but possible </li> <li>May be venous or arterial </li> </ul> </td> <td> <ul> <li>Spontaneous abortion may occur; the likelihood of successful pregnancy appears to correlate with the fibrinogen level </li> <li>Can have bleeding antepartum or postpartum </li> </ul> </td> <td> <ul> <li>Hepatic storage disease </li> </ul> </td> </tr> <tr> <td><strong>Dysfibrinogenemia and hypodysfibrinogenemia</strong></td> <td> <ul> <li>Variable frequency; affects less than half of individuals </li> <li>Most bleeding is mild, but severe bleeding can occur </li> <li>Common sites include menorrhagia and skin bleeding </li> </ul> </td> <td> <ul> <li>More common than bleeding; may affect up to 30% of individuals </li> <li>May occur in the setting of fibrinogen replacement therapy </li> </ul> </td> <td> <ul> <li>Spontaneous abortion and postpartum hemorrhage may occur </li> </ul> </td> <td> <ul> <li>Renal amyloidosis secondary to mutant fibrinogen (alpha-chain) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate for additional details regarding the clinical manifestations and evaluation of fibrinogen disorders.</div><div id=\"graphicVersion\">Graphic 114456 Version 1.0</div></div></div>"},"114458":{"type":"graphic_picture","displayName":"Colon pseudopolyps in inflammatory bowel disease","title":"Endoscopic view of colon pseudopolyps in inflammatory bowel disease","html":"<div class=\"graphic\"><div style=\"width: 773px\" class=\"figure\"><div class=\"ttl\">Endoscopic view of colon pseudopolyps in inflammatory bowel disease</div><div class=\"cntnt\"><img style=\"width:753px; height:592px;\" src=\"images/GAST/114458_Colon_psdplyps_inflm_bwl_ds.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This endoscopic image from a patient with ulcerative colitis demonstrates multiple pseudopolyps. Pseudopolyps may also be seen in patients with Crohn colitis.</div><div id=\"graphicVersion\">Graphic 114458 Version 1.0</div></div></div>"},"114459":{"type":"graphic_figure","displayName":"Arterial pressure waveform","title":"Arterial pressure waveform","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Arterial pressure waveform</div><div class=\"cntnt\"><img style=\"width:501px; height:315px;\" src=\"images/ANEST/114459_Arterial_pressure_waveform.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 114459 Version 1.0</div></div></div>"},"114470":{"type":"graphic_algorithm","displayName":"LDL-C lowering with drugs in CVD (secondary prevention)","title":"Low density lipoprotein cholesterol (LDL-C) lowering with drugs in adults with cardiovascular disease (secondary prevention)*","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Low density lipoprotein cholesterol (LDL-C) lowering with drugs in adults with cardiovascular disease (secondary prevention)*</div><div class=\"cntnt\"><img style=\"width:356px; height:557px;\" src=\"images/CARD/114470_LDLClwdrgCVDscndprvtn.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Secondary prevention adults include those with coronary artery, carotid, aorta, or peripheral artery disease.<br />¶ In some cases, it may be appropriate to start at a lower dose and uptitrate.<br />Δ The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary. \"Significant\" will vary from patient to patient and depends on many factors such as overall cardiovascular risk, likely compliance with a recommendation for additional therapy, or comorbidities. Refer to relevant topic reviews.<br /><FONT class=lozenge>◊</FONT> High-risk second prevention adults include those with acute coronary syndrome in the past year, familial hypercholesterolemia, diabetes, chronic kidney disease (stage 3 or 4), repeat atherosclerotic cardiovascular disease event, or the need for revascularization while on statin.<br />§ Refer to relevant topic reviews.</div><div id=\"graphicVersion\">Graphic 114470 Version 1.0</div></div></div>"},"114475":{"type":"graphic_picture","displayName":"Aplasia cutis congenita scalp scar","title":"Aplasia cutis congenita","html":"<div class=\"graphic\"><div style=\"width: 770px\" class=\"figure\"><div class=\"ttl\">Aplasia cutis congenita</div><div class=\"cntnt\"><img style=\"width:750px; height:562px;\" src=\"images/DERM/114475_Aplasiactscngntasclpscr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small, scar-like, hairless area on the vertex of an infant with aplasia cutis congenita.</div><div id=\"graphicVersion\">Graphic 114475 Version 1.0</div></div></div>"},"114476":{"type":"graphic_picture","displayName":"Aplasia cutis congenita scalp scar 2","title":"Aplasia cutis congenita","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Aplasia cutis congenita</div><div class=\"cntnt\"><img style=\"width:754px; height:564px;\" src=\"images/DERM/114476_Aplsiactscngntsclpscr2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two small, circular, scar-like defects on the scalp vertex of an infant with aplasia cutis congenita.</div><div id=\"graphicVersion\">Graphic 114476 Version 1.0</div></div></div>"},"114478":{"type":"graphic_table","displayName":"Indications for chromosome analysis to diagnose Turner syndrome","title":"Indications for chromosome analysis to diagnose Turner syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for chromosome analysis to diagnose Turner syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>As the only clinical feature:</strong></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Fetal cystic hygroma, or hydrops, especially when severe </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Idiopathic short stature </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Obstructive left-sided congenital heart defect* </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Unexplained delayed puberty/menarche </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Couple with infertility </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Characteristic facial features in a female<sup>&#182;</sup> </li> </ul> </td> </tr> <tr> <td><strong>At least two of the following:</strong></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Renal anomaly (horseshoe, absence, or hypoplasia) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Madelung deformity </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Neuropsychologic problems, and/or psychiatric issues </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Multiple typical or melanocytic nevi </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Dysplastic or hyperconvex nails </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Other congenital heart defects<sup>&#916;</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Hearing impairment &#60;40 years of age together with short stature </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Typically bicuspid aortic valve, coarctation, aortic stenosis (with/without bicuspid aortic valve), mitral valve anomalies, and hypoplastic left heart syndrome.<br />&para; Down-slanted palpebral fissures, epicanthal folds, low-set anomalous pinnae, micrognathia, narrow palate, short broad neck, and webbing.<br />&Delta; Partial anomalous pulmonary venous return; atrial septal defect, secundum type; and ventricular septal defects, muscular or membranous.</div><div class=\"graphic_reference\">Reproduced with permission from: Gravholt CH, Andersen NH, Conway GS, etc. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol 2017; 177:G1. Copyright &copy; 2017 BioScientifica Ltd. All rights reserved.</div><div id=\"graphicVersion\">Graphic 114478 Version 1.0</div></div></div>"},"114479":{"type":"graphic_picture","displayName":"Aplasia cutis congenita scalp scar 3","title":"Aplasia cutis congenita","html":"<div class=\"graphic\"><div style=\"width: 509px\" class=\"figure\"><div class=\"ttl\">Aplasia cutis congenita</div><div class=\"cntnt\"><img style=\"width:489px; height:536px;\" src=\"images/DERM/114479_Aplsiactscngntsclpscr3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large, irregular, scar-like lesion with residual, peripheral erosion and crust on the scalp of an infant with aplasia cutis congenita.</div><div id=\"graphicVersion\">Graphic 114479 Version 1.0</div></div></div>"},"114480":{"type":"graphic_algorithm","displayName":"Evaluation of iron deficiency anemia in children","title":"Algorithm for evaluation of iron deficiency anemia in children 6 months to 12 years old","html":"<div class=\"graphic\"><div style=\"width: 723px\" class=\"figure\"><div class=\"ttl\">Algorithm for evaluation of iron deficiency anemia in children 6 months to 12 years old</div><div class=\"cntnt\"><img style=\"width:703px; height:853px;\" src=\"images/PEDS/114480_Evalirndfcncyanemiachld.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IDA: iron deficiency anemia; GI; gastrointestinal; CBC: complete blood count; MCV: mean corpuscular volume; Hgb: hemoglobin; IV: intravenous; TIBC: total iron-binding capacity.<br />* CBC findings typical for IDA are low hemoglobin (Hgb &lt;11 g/dL) and low MCV (microcytic anemia). These findings do not exclude some other causes of anemia, including anemia of chronic disease/inflammation, or thalassemia. A low serum ferritin&nbsp;level is always consistent with iron deficiency, but normal or elevated ferritin does not exclude iron deficiency.<br />¶ Evaluation may include iron panel (serum iron, ferritin, TIBC), peripheral blood smear, hemoglobin electrophoresis, and evaluation for gastrointestinal blood loss, assessment for inflammatory disease (eg, C-reactive protein [CRP]), and review of newborn screening results to assess for alpha thalassemia trait (which cannot be diagnosed by hemoglobin electrophoresis). For details, refer to UpToDate content on approach to anemia in children. Depending on the type of concern, referral to a pediatric hematologist or gastroenterologist may be appropriate.<br />Δ Dietary counseling includes measures to improve iron intake, and also to avoid excessive cow's milk. Infants should not consume unmodified (non-formula) cow's milk. For children 12 months of age and older, cow's milk consumption should be limited to less than 20 oz (600 mL) daily. If occult blood is present in the stool, all milk products should be stopped, and the patient should be evaluated to determine the cause of the GI blood loss.<br /><FONT class=lozenge>◊</FONT> In children with IDA, the Hgb rise (&gt;1 g/dL) is expected within four weeks for those with mild or moderate anemia (baseline Hgb 7 to 11 g/dL), and within two weeks for those with severe anemia (baseline Hgb &lt;7 g/dL).</div><div id=\"graphicVersion\">Graphic 114480 Version 1.0</div></div></div>"},"114481":{"type":"graphic_picture","displayName":"Aplasia cutis congenita membranous","title":"Aplasia cutis congenita","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Aplasia cutis congenita</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/114481_Aplasiacutiscongntmmbrns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two lesions of membranous aplasia cutis congenita are present on the scalp of an infant. The lesions are surrounded by a circle of long, coarse hairs (\"hair collar sign\"), a marker of neural tube defect.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 114481 Version 1.0</div></div></div>"},"114482":{"type":"graphic_picture","displayName":"Aplasia cutis congenita nonmembranous","title":"Aplasia cutis congenita","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Aplasia cutis congenita</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/114482_Aplasiacutscngntnnmmbrns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large, irregular defect of the scalp midline in an infant with nonmembranous aplasia cutis congenita.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 114482 Version 1.0</div></div></div>"},"114484":{"type":"graphic_picture","displayName":"Aplasia cutis congenita feet","title":"Aplasia cutis congenita","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Aplasia cutis congenita</div><div class=\"cntnt\"><img style=\"width:700px; height:524px;\" src=\"images/DERM/114484_Aplasiacutiscongenitfeet.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large skin defects involving the medial and dorsal surface of the feet in an infant with aplasia cutis congenita.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 114484 Version 1.0</div></div></div>"},"114485":{"type":"graphic_table","displayName":"Risk factors for iron deficiency anemia in children","title":"Risk factors for iron deficiency anemia in infants and young children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for iron deficiency anemia in infants and young children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Period</td> <td class=\"subtitle1\">Risk factors</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Perinatal</td> <td>Maternal iron deficiency</td> </tr> <tr> <td>Prematurity</td> </tr> <tr> <td>Administration of erythropoietin for anemia of prematurity</td> </tr> <tr> <td class=\"divider_bottom\">Perinatal hemorrhagic events (eg, twin-twin transfusion or fetal-maternal hemorrhage)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Infancy</td> <td>Dietary risk factors: <ul class=\"decimal_heading\"> <li>Lack of iron supplements for breastfed infants* </li> <li>Use of low-iron infant formula </li> <li>Feeding of unmodified (non-formula) cow's milk, goat's milk, or soy milk<sup>&#182;</sup> </li> <li>Insufficient iron-rich complementary foods<sup>&#916;</sup> </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\">Other risk factors: <ul class=\"decimal_heading\"> <li>Disorders with GI blood loss (eg, milk protein-induced proctocolitis) </li> <li>Malabsorptive disease </li> </ul> </td> </tr> <tr> <td rowspan=\"2\">1 to &#60;12 years</td> <td>Dietary risk factors: <ul class=\"decimal_heading\"> <li>Excessive intake of cow's milk<sup>&#9674;</sup> </li> <li>Insufficient iron in foods<sup>&#167;</sup> </li> </ul> </td> </tr> <tr> <td>Other risk factors: <ul class=\"decimal_heading\"> <li>Disorders with GI blood loss (eg, inflammatory bowel disease, or chronic gastritis) </li> <li>Malabsorptive disease (eg, celiac disease, or chronic intestinal infections)</li> <li>Obesity</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GI: gastrointestinal.<br />* For all breastfed infants, iron supplements should be introduced by two weeks for premature infants, and by four months for term infants, and should be continued until sufficient iron is supplied by complementary foods.<br />¶ Unmodified cow's milk (non-formula cow's milk) increases intestinal blood loss in infants as compared with formula feeding or breast feeding.<br />Δ Iron-rich complementary foods include infant cereals and pureed meats, and should be introduced by six months. Refer to UpToDate content on prevention of iron deficiency in infants and young children.<br /><FONT class=lozenge>◊</FONT> In children one to five years old, cow's milk should be limited to no more than 20 oz (600 mL) daily.<br />§ Preschool-aged children should have at least 3 servings/day of iron-rich foods (eg, fortified breakfast cereal or meats).</div><div id=\"graphicVersion\">Graphic 114485 Version 2.0</div></div></div>"},"114486":{"type":"graphic_table","displayName":"Dietary recommendations to reduce iron deficiency in children","title":"Dietary recommendations to reduce the risk of iron deficiency anemia in children 6 months to 12 years","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dietary recommendations to reduce the risk of iron deficiency anemia in children 6 months to 12 years</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"45%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age group</td> <td class=\"subtitle1\">Dietary recommendations</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Infants</td> <td>Encourage exclusive breastfeeding for four to six months.</td> <td> <ul> <li>Breastmilk has low levels of iron (0.3 to 1 mg/L), but with high bioavailability </li> </ul> </td> </tr> <tr> <td> <p>For breastfed infants, introduce an iron supplement by four months for term infants, or by two weeks for premature infants.</p> Continue supplements until sufficient iron is provided through complementary foods.</td> <td> <ul> <li>Term infants: Elemental iron 1 mg/kg/day (maximum 15 mg) </li> <li>Premature infants: Elemental iron 2 to 4 mg/kg/day (maximum 15 mg) </li> </ul> </td> </tr> <tr> <td>Infant formula (if used) should be iron-fortified (&#62;6.7 mg/L of iron).</td> <td> <ul> <li>Low-iron formulas should not be used </li> </ul> </td> </tr> <tr> <td>Introduce iron-rich complementary foods between four and six months.</td> <td> <ul> <li>Iron sufficient for needs is provided by two servings/day iron-fortified infant cereal </li> <li>Pureed meats are also good sources of iron </li> <li>Encourage one serving/day of foods rich in vitamin C (such as citrus fruits, cantaloupe, strawberries, tomatoes and dark green vegetables), to enhance iron absorption </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Avoid unmodified (non-formula) cow's milk until 12 months of age.</td> <td> <ul> <li>Unmodified cow's milk increases intestinal blood loss in infants as compared with formula feeding or breast feeding </li> </ul> </td> </tr> <tr> <td rowspan=\"2\">1 to 5 years</td> <td>Limit cow's milk to no more than 20 oz (600 mL) daily.</td> <td> <ul> <li>The risk of iron deficiency increases in young children drinking more than 24 oz of milk per day </li> </ul> </td> </tr> <tr> <td>Encourage at least three servings/day of iron-rich foods.</td> <td> <ul> <li>Examples include fortified breakfast cereal, 3 oz of meat, or 4 oz of tofu </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 114486 Version 1.0</div></div></div>"},"114487":{"type":"graphic_picture","displayName":"Aplasia cutis congenita stellate","title":"Aplasia cutis congenita","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Aplasia cutis congenita</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/114487_Aplasiacutiscngntstellat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large, angulated (\"stellate\") defect of the scalp, with extensive hemorrhagic areas in a newborn with aplasia cutis congenita.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 114487 Version 1.0</div></div></div>"},"114495":{"type":"graphic_table","displayName":"Diagnostic criteria cancer-induced bone pain","title":"Core diagnostic criteria for cancer-induced bone pain from the ACTTION-APS collaboration","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Core diagnostic criteria for cancer-induced bone pain from the ACTTION-APS collaboration</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Criteria</td> </tr> <tr> <td>1</td> <td>History of primary or metastatic bone cancer diagnosed using imaging and physical examination</td> </tr> <tr> <td>2</td> <td>Presence of continuous, background pain (usually described as annoying, dull, gnawing, aching, and/or nagging) in 1 or more locations generally consistent with known distribution of bone lesions</td> </tr> <tr> <td>3</td> <td>Presence of evoked or spontaneous pain (often described as electric or shock-like) in 1 or more locations generally consistent with known distribution of bone lesions, associated with weight bearing or movement or can occur spontaneously</td> </tr> <tr> <td>4</td> <td>Clinical examination over the site of pain reveals: <ul class=\"decimal_heading\"> <li>Hyperalgesia to blunt, non-noxious pressure or pin-prick stimuli </li> <li>Hypoesthesia to non-noxious thermal stimuli </li> <li>Hypoesthesia to light touch stimuli </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACTTION: Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks; APS: American Pain Society.</div><div class=\"graphic_reference\">Reproduced from: Paice JA, Mulvey M, Bennett M, et al. AAPT Diagnostic Criteria for Chronic Cancer Pain Conditions. J Pain 2017; 18:233. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 114495 Version 1.0</div></div></div>"},"114496":{"type":"graphic_table","displayName":"Diagnostic criteria for pancreatic cancer pain","title":"Core diagnostic criteria for pancreatic cancer pain from the ACTTION-APS collaboration","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Core diagnostic criteria for pancreatic cancer pain from the ACTTION-APS collaboration</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Criteria</td> </tr> <tr> <td>1</td> <td>History of pancreatic cancer diagnosed using imaging, physical examination, and in some cases, biopsy and laboratory analysis of blood or tissues for tumor markers</td> </tr> <tr> <td>2</td> <td>Presence of pain in the&nbsp;upper abdominal region (typically referred to the epigastric region or upper abdominal quadrants) spreading posteriorly and/or radiating to the back</td> </tr> <tr> <td>3</td> <td>On clinical examination, the patient displays tenderness on upper abdominal palpation</td> </tr> <tr> <td>4</td> <td>No other condition (eg, constipation) could plausibly account for persisting pain in the upper abdomen</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACTTION: Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks; APS: American Pain Society.</div><div class=\"graphic_reference\">Reproduced from: Paice JA, Mulvey M, Bennett M, et al. AAPT Diagnostic Criteria for Chronic Cancer Pain Conditions. J Pain 2017; 18:233. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 114496 Version 1.0</div></div></div>"},"114497":{"type":"graphic_table","displayName":"Diagnostic criteria for pain: Chemotherapy-induced neuropathy","title":"Core diagnostic criteria for chronic pain related to chemotherapy-induced peripheral neuropathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Core diagnostic criteria for chronic pain related to chemotherapy-induced peripheral neuropathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Criteria</td> </tr> <tr> <td>1</td> <td>Onset of pain after exposure to chemotherapeutic agent known to be neurotoxic</td> </tr> <tr> <td>2</td> <td>Presence of painful symptoms in a symmetrical stocking and glove distribution beginning in lower extremities, which may progress to the upper extremities, although finding in the feet and not in the hands is common</td> </tr> <tr> <td>3</td> <td>Painful symptoms are accompanied by nonpainful symptoms (eg, \"pins and needles\" or numbness) in a similar distribution</td> </tr> <tr> <td>4</td> <td>Clinical examination reveals sensory loss to 1 or more sensory modalities and/or evoked pain in a stocking and glove distribution, as reflected in at least 1 of the following: <ul class=\"decimal_heading\"> <li>Hypoesthesia: bilateral increase in detection thresholds to tactile, vibration, or non-noxious warm or cool stimuli </li> <li>Hypoalgesia: bilateral increase in pain detection thresholds to blunt pressure or pinprick stimuli </li> <li>Hyperalgesia: bilateral decrease in pain detection threshold to noxious heat or cold stimuli </li> </ul> </td> </tr> <tr> <td>5</td> <td>Magnitude of the sensory abnormalities is disproportionately greater than the magnitude of any motor abnormalities in the affected region (except in the case of neuropathy after vinca alkaloids)</td> </tr> <tr> <td>6</td> <td>No other condition (eg, polyneuropathy of other origin) could plausibly account for painful symptoms</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Paice JA, Mulvey M, Bennett M, et al. AAPT Diagnostic Criteria for Chronic Cancer Pain Conditions. J Pain 2017; 18:233. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 114497 Version 1.0</div></div></div>"},"114503":{"type":"graphic_table","displayName":"MRSA oral antibiotics - Septic arthritis","title":"Oral antimicrobial agents for completing treatment of septic arthritis due to methicillin-resistant <EM>Staphylococcus aureus </EM>(MRSA) in adults*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral antimicrobial agents for completing treatment of septic arthritis due to methicillin-resistant <EM>Staphylococcus aureus </EM>(MRSA) in adults*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Treatment</td> <td class=\"subtitle1\">Adult dose</td> </tr> <tr> <td>Clindamycin</td> <td>600 mg orally three times daily</td> </tr> <tr> <td>Trimethoprim-sulfamethoxazole (cotrimoxazole)</td> <td>2&nbsp;DS tablets orally twice daily (alternatively: 4 mg/kg per dose [trimethoprim component] orally twice daily [maximum&nbsp;2 DS tablets twice daily]) </td> </tr> <tr> <td>Doxycycline</td> <td>100 mg orally twice daily</td> </tr> <tr> <td>Minocycline</td> <td>200 mg orally once, then 100 mg orally twice daily</td> </tr> <tr> <td>Linezolid</td> <td>600 mg orally twice daily</td> </tr> <tr> <td>Tedizolid<sup>&#182;</sup></td> <td>200 mg orally once daily</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The doses above are intended for patients with normal renal function; dosing may require adjustment in patients with renal insufficiency.</div><div class=\"graphic_footnotes\">DS: double strength (ie, 160 mg trimethoprim with 800 mg sulfamethoxazole per tablet).<br />*&nbsp;Following joint drainage, the typical duration of antibiotic therapy for treatment of septic arthritis is three to four weeks; we typically administer parenteral antibiotics for at least 14 days followed by oral therapy for an additional 14 days.&nbsp;<br />¶ The mechanism of tedizolid is comparable with that of linezolid; however, thus far there are no data/experience regarding use of tedizolid for treatment of septic arthritis.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014; 59:e10.</li>&#xD;&#xA;    <li>Liu C, Bayer A, Cosgrove SE, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children. Clin Infect Dis 2011; 52:e18.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 114503 Version 1.0</div></div></div>"},"114504":{"type":"graphic_figure","displayName":"Kobayashi score for IVIG resistance in KD","title":"Kobayashi score for IVIG resistance in Kawasaki disease","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Kobayashi score for IVIG resistance in Kawasaki disease</div><div class=\"cntnt\"><img style=\"width:766px; height:525px;\" src=\"images/ALLRG/114504_KobayashiscrIVIGrstncKD.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IVIG: intravenous immune globulin; AST: aspartate aminotransferase; CRP: C-reactive protein.</div><div class=\"graphic_reference\">From: Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006; 113:2606. DOI: <a href=\"http://circ.ahajournals.org/content/113/22/2606\" target=\"_blank\">10.1161/CIRCULATIONAHA.105.592865</a>. Copyright &copy; 2006 American Heart Association. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 114504 Version 1.0</div></div></div>"},"114505":{"type":"graphic_picture","displayName":"Squamous cell carcinoma dermoscopy","title":"Dermoscopic image of cutaneous squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of cutaneous squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:387px; height:578px;\" src=\"images/DERM/114505_SCCdermoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nonpigmented cutaneous squamous cell carcinoma. Dermoscopy demonstrates focal areas of glomerular and dotted vessels, white-yellowish scale, and hyperkeratosis.</div><div class=\"graphic_reference\">Reproduced with permission from Ashfaq Marghoob, MD, and Natalia Jaimes, MD.</div><div id=\"graphicVersion\">Graphic 114505 Version 1.0</div></div></div>"},"114507":{"type":"graphic_table","displayName":"Targeted PH drugs in children","title":"Medications used for targeted therapy in pediatric patients with pulmonary hypertension*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications used for targeted therapy in pediatric patients with pulmonary hypertension*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"12.5%\"></colgroup><colgroup span=\"3\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">US brand name</td> <td class=\"subtitle1\">Dose/route</td> <td class=\"subtitle1\">Side effects</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">PDE5 inhibitors</td> </tr> <tr> <td class=\"indent1\">Sildenafil</td> <td>Revatio</td> <td>Age &#60;1 year: <ul class=\"decimal_heading\"> <li>0.5 to 1 mg/kg/day orally three times per day </li> </ul> Age &#8805;1 year: <ul class=\"decimal_heading\"> <li>&#60;20 kg: 10 mg orally three times per day</li> <li>&#8805;20 kg: 20 mg orally three times per day </li> </ul> Maximum dose: <ul class=\"decimal_heading\"> <li>20 mg&nbsp;orally three times per day</li> </ul> </td> <td>Headache, flushing, nasal congestion, epistaxis, dizziness, hypotension, peripheral edema, dyspepsia, diarrhea, priapism</td> <td> <ul> <li>Co-administration of nitrates is contraindicated </li> <li>Sensorineural hearing loss and ischemic optic neuropathy have been reported </li> <li>In extremely preterm infants, use should be delayed until retinal vascularization established </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tadalafil</td> <td>Adcirca</td> <td> <p>Initial dose:&nbsp;</p> <ul> <li>1 mg/kg/dose&nbsp;orally once daily </li> </ul> Maximum dose: <ul class=\"decimal_heading\"> <li>40 mg/day </li> </ul> </td> <td>Similar to sildenafil</td> <td> <ul> <li>Co-administration of nitrates is contraindicated </li> <li>Sensorineural hearing loss has been reported </li> <li>Ischemic optic neuropathy has been reported </li> <li>Very limited information in children regarding dosing, safety, and efficacy </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Calcium channel blockers</td> </tr> <tr> <td class=\"indent1\">Nifedipine</td> <td>&nbsp;</td> <td>Initial&nbsp;dose: <ul class=\"decimal_heading\"> <li>0.1 to 0.2 mg/kg orally three times per day; increase to 2 to 3 mg/kg/day total oral dose </li> </ul> Maximum dose: <ul class=\"decimal_heading\"> <li>180 mg/day </li> </ul> Extended release tablets preferred </td> <td>Hypotension, bradycardia, flushing, headache, peripheral edema, dizziness, rash, gingival hyperplasia</td> <td> <ul> <li>Contraindicated with RV dysfunction </li> <li>Used in patients who demonstrate a response to acute vasoreactivity testing<sup>&#182;</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Amlodipine</td> <td>&nbsp;</td> <td>Initial&nbsp;dose: <ul class=\"decimal_heading\"> <li>0.1 to 0.3 mg/kg orally once daily; increase to 2.5 to 10 mg orally once daily </li> </ul> Maximum dose: <ul class=\"decimal_heading\"> <li>10 mg/day </li> </ul> </td> <td>Similar to nifedipine</td> <td> <ul> <li>Contraindicated with RV dysfunction </li> <li>Used in patients who demonstrate a response to acute vasoreactivity testing<sup>&#182;</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Diltiazem</td> <td>&nbsp;</td> <td>Initial&nbsp;dose: <ul class=\"decimal_heading\"> <li>0.5 mg/kg/dose orally three times per day; increase to 2 to 5 mg/kg/day total oral dose </li> </ul> Maximum dose: <ul class=\"decimal_heading\"> <li>360 mg/day </li> </ul> Extended release tablets preferable </td> <td>Similar to nifedipine</td> <td> <ul> <li>Contraindicated with RV dysfunction </li> <li>Used in patients who demonstrate a response to acute vasoreactivity testing<sup>&#182;</sup> </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Endothelin receptor antagonists</td> </tr> <tr> <td class=\"indent1\">Bosentan</td> <td>Tracleer</td> <td>Maintenance dose: <ul class=\"decimal_heading\"> <li>&#60;10 kg: 2 mg/kg/dose orally twice per day </li> <li>10 to 20 kg: 31.25 mg orally twice per day </li> <li>20 to 40 kg: 62.5 mg orally twice per day </li> <li>&#62;40 kg: 125 mg orally twice per day </li> </ul> Maximum dose: <ul class=\"decimal_heading\"> <li>125 mg orally twice per day </li> </ul> </td> <td> <p>Abdominal pain, vomiting, extremity pain, fatigue, flushing, headache, edema, nasal congestion, anemia, decreased sperm count</p> Potential risk of dose-dependent increases in aminotransaminase levels</td> <td> <ul> <li>Starting dose is one-half maintenance dose; increase to full maintenance after 2 to 4 weeks if LFTs and Hgb are stable </li> <li>Monitor LFTs and Hgb and adjust dose per manufacturer's recommendations </li> <li>Not recommended in patients with moderate or severe hepatic impairment </li> <li>Caution with concomitant use of CYP3A4 inducers and inhibitors </li> <li>Is a teratogen; pregnancy test required prior to use and for 1 month afterwards; 2 forms of contraception required </li> <li>Concurrent use of bosentan and sildenafil increases bosentan serum levels and decreases sildenafil levels </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Ambrisentan</td> <td>Letairis</td> <td> <p>Maintenance dose: </p> <ul> <ul> <li>&#60;20 kg: 2.5 to 5 mg orally once daily </li> <li>&#62;20 kg: 5 to 10 mg orally once daily </li> </ul> </ul> <p>Maximum dose:</p> <ul> <ul> <li>10 mg/day </li> </ul> </ul> </td> <td> <p>Peripheral edema, nasal congestion, headache, flushing, anemia, nausea, and decreased sperm count</p> The incidence of serum aminotransferase elevation is low</td> <td> <ul> <li>Obtain baseline LFTs and Hgb, monitor after 1 month, then every 6 months or as clinically indicated </li> <li>Teratogenicity concerns as for bosentan </li> <li>Little efficacy and safety data for children </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Macitentan</td> <td>Opsumit</td> <td> <p>Pediatric dosing is not established</p> Adult dosing: <ul class=\"decimal_heading\"> <li>10 mg orally daily </li> </ul> </td> <td> <p>Nasal congestion, headache, flushing, anemia, decreased sperm count</p> The incidence of serum aminotransferase elevation is low</td> <td> <ul> <li>Obtain baseline LFTs and Hgb and monitor as clinically indicated </li> <li>Teratogenicity as for other ERAs </li> <li>No data in pediatric patients </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Prostacyclin analogues</td> </tr> <tr> <td class=\"indent1\">Epoprostenol (IV)</td> <td> <p>Flolan</p> Veletri</td> <td>Initial infusion rate: <ul class=\"decimal_heading\"> <li>1 to 3 nanograms/kg/min; slowly increase infusion rate over weeks </li> </ul> Maintenance infusion rate: <ul class=\"decimal_heading\"> <li>50 to 80 nanograms/kg/min, titrated to effect </li> </ul> No clear maximum </td> <td>Flushing, headache, nausea, diarrhea, jaw discomfort, rash, hypotension, thrombocytopenia</td> <td> <ul> <li>Potential risk of hypotension and bleeding in children receiving concomitant drugs such as anticoagulants, platelet inhibitors, or other vasodilators </li> <li>Short elimination half-life (3 to 5 min) </li> <li>Cooling is needed for Flolan but not Veletri </li> <li>Dose increases needed due to tachyphylaxis </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Iloprost (inhaled)</td> <td>Ventavis</td> <td>Initial dose: <ul class=\"decimal_heading\"> <li>2.5 micrograms per inhalation 6 times a day </li> </ul> Maintenance dose: <ul class=\"decimal_heading\"> <li>5 micrograms per inhalation 6 to 9 times per day </li> </ul> </td> <td>Cough, wheeze, headache, flushing, jaw pain, diarrhea, rash, hypotension (at higher doses)</td> <td> <ul> <li>Elimination half-life 20 to 30 min </li> <li>Potential risk of exacerbating reactive airway disease </li> <li>Patient must be old enough to initiate breath from nebulizer </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Treprostinil (IV/SC)</td> <td>Remodulin</td> <td>As for epoprostanol, but maintenance infusion rate may need to be higher</td> <td> <p>As for epoprostanol</p> Pain and redness at subcutaneous infusion site</td> <td> <ul> <li>Stable at room temperature </li> <li>Elimination half-life 4 hours </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Treprostinil (inhaled)</td> <td>Tyvaso</td> <td>Initial dose: <ul class=\"decimal_heading\"> <li>3 breaths (18 micrograms) 4 times a day </li> </ul> Maintenance dose: <ul class=\"decimal_heading\"> <li>9 breaths (54 micrograms) 4 times a day </li> </ul> </td> <td>Cough, headache, nausea, dizziness, flushing, throat irritation</td> <td> <ul> <li>As for iloprost </li> <li>Elimination half-life 4 hours </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Treprostinil diolamine (oral)</td> <td>Orenitram</td> <td>Initial dose: <ul class=\"decimal_heading\"> <li>0.25 mg&nbsp;orally&nbsp;twice per day&nbsp;</li> </ul> Maintenance dose: <ul class=\"decimal_heading\"> <li>Determined by tolerability </li> </ul> </td> <td>Headache, nausea, diarrhea, jaw pain, extremity pain, hypokalemia, abdominal discomfort, flushing</td> <td> <ul> <li>Must be taken with food </li> <li>Limited experience in pediatric patients </li> <li>Unlikely to be sufficient substitute for parenteral prostacyclin for patients requiring high-dose prostacyclin </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">US: United States; PDE5: phosphodiesterase type 5; RV: right ventricle;&nbsp;ERA: endothelin receptor antagonist; LFTs: liver function tests; Hgb: hemoglobin; CYP3A4: cytochrome P450 3A4; IV: intravenous; SC: subcutaneous.<br />* Data related to efficacy, dosing, and safety of these medications is very limited for children. No targeted PH medication is approved by the US Food and Drug Administration for pediatric use.<br />¶ Refer to UpToDate topics on pulmonary hypertension in children for details.</div><div class=\"graphic_reference\">Adapted from: Abman SH, Hansmann G, Archer SL, et al. Pediatric Pulmonary Hypertension: Guidelines from the American Heart Association and American Thoracic Society. Circulation 2015; 132:2037.</div><div id=\"graphicVersion\">Graphic 114507 Version 1.0</div></div></div>"},"114521":{"type":"graphic_table","displayName":"Common oral health conditions that occur during pregnancy","title":"Common oral health conditions that occur during pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common oral health conditions that occur during pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td><strong>Pregnancy gingivitis</strong></td> <td>An increased inflammatory response to dental plaque during pregnancy causes the gingivae to swell and bleed more easily in most women. Rinsing with saltwater (ie, 1 teaspoon of salt in 1 cup of warm water) may help with the irritation. Pregnancy gingivitis typically peaks during the third trimester. Women who have gingivitis before pregnancy are more prone to exacerbation during pregnancy.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Benign oral gingival lesions</strong><br /> (known as pyogenic granuloma, granuloma gravidarum or epulis of pregnancy)</td> <td>In approximately 5% of pregnancies, a highly vascularized, hyperplastic, and often pedunculated lesion up to 2 cm in diameter may appear, usually on the anterior gingiva. These lesions may result from a heightened inflammatory response to oral pathogens and usually regress after pregnancy. Excision is rarely necessary but may be needed if there is severe pain, bleeding, or interference with mastication.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Tooth mobility</strong></td> <td>Ligaments and bone that support the teeth may temporarily loosen during pregnancy, which results in increased tooth mobility. There is normally not any tooth loss unless other complications are present.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Tooth erosion</strong></td> <td>Erosion of tooth enamel may be more common because of increased exposure to gastric acid from vomiting secondary to morning sickness, hyperemesis gravidarum, or gastric reflux during late pregnancy. Rinsing with a baking soda solution (ie, a teaspoon of baking soda dissolved in a cup of water) may help neutralize the associated acid.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Dental caries</strong></td> <td>Pregnancy may result in dental caries due to the increased acidity in the mouth, greater intake of sugary snacks and drinks secondary to pregnancy cravings, and decreased attention to prenatal oral health maintenance.</td> </tr> <tr> <td><strong>Periodontitis</strong></td> <td>Untreated gingivitis can progress to periodontitis, an inflammatory response in which a film of bacteria, known as plaque, adheres to teeth and releases bacterial toxins that create pockets of destructive infection in the gums and bones. The teeth may loosen, bone may be lost, and a bacteremia may result.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted with permission from Oral health care during pregnancy and through the lifespan. ACOG Committee Opinion No. 569. American College of Obstetricians and Gynecologists. Obstet Gynecol 2013; 122:417-22. Copyright &copy; 2013.</div><div id=\"graphicVersion\">Graphic 114521 Version 1.0</div></div></div>"},"114522":{"type":"graphic_figure","displayName":"Histopathology of critical illness myopathy","title":"Histopathology of critical illness myopathy","html":"<div class=\"graphic\"><div style=\"width: 773px\" class=\"figure\"><div class=\"ttl\">Histopathology of critical illness myopathy</div><div class=\"cntnt\"><img style=\"width:753px; height:516px;\" src=\"images/NEURO/114522_Histocritillnssmyopathy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A myosin ATPase (pH 9.4)-reacted frozen muscle section reveals atrophic, type 2 (dark) fibers, patchy regions of reduced reactivity (arrows) in some type 1 (light) and type 2 fibers, and absent staining (asterisks) in other fibers. Normal muscle is seen in the inset.</div><div class=\"graphic_footnotes\">ATPase: adenosine triphosphatase.</div><div class=\"graphic_reference\">Courtesy of David Lacomis, MD.</div><div id=\"graphicVersion\">Graphic 114522 Version 1.0</div></div></div>"},"114523":{"type":"graphic_table","displayName":"Medications associated with nightmares","title":"Medications associated with nightmares","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications associated with nightmares</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication category</td> <td class=\"subtitle1\">Examples</td> <td class=\"subtitle1\">Mechanism</td> </tr> <tr> <td> <p>Acetylcholinesterase inhibitors</p> </td> <td> <p>Donepezil, galantamine,&nbsp;rivastigmine</p> </td> <td> <p>Increase in REM intensity</p> </td> </tr> <tr> <td>Antidepressants*</td> <td>Bupropion, MAOIs, mirtazapine, SNRIs, SSRIs, TCAs</td> <td> <p>Increase in REM intensity with REM delay and cholinergic rebound</p> <p>REM rebound (during withdrawal)</p> </td> </tr> <tr> <td> <p>Antihistamines</p> </td> <td> <p>Chlorpheniramine</p> </td> <td> <p>Unclear</p> </td> </tr> <tr> <td>Antimicrobials&nbsp;</td> <td>Ciprofloxacin, efavirenz, erythromycin, ganciclovir, mefloquine&nbsp;</td> <td>Unclear;&nbsp;possibly related to cytokine modulation&nbsp;</td> </tr> <tr> <td>Atypical antipsychotic medications</td> <td>Clozapine, olanzapine, risperidone</td> <td>Associated with dopamine</td> </tr> <tr> <td>Beta blockers</td> <td>Labetalol, metoprolol, propranolol</td> <td>Unclear; may suppress REM</td> </tr> <tr> <td>Calcium channel blockers</td> <td>Verapamil</td> <td>Unclear</td> </tr> <tr> <td>Dopaminergic drugs</td> <td>Amantadine, amphetamine, levodopa, methylphenidate, pramipexole, ropinirole, selegiline</td> <td>Associated with dopamine</td> </tr> <tr> <td>Sedative-hypnotics*&nbsp;</td> <td>Alcohol, barbiturates, temazepam, triazolam</td> <td>REM rebound</td> </tr> <tr> <td>Statins</td> <td>Atorvastatin</td> <td>Unclear</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">REM: rapid eye movement sleep; SSRIs: selective serotonin reuptake inhibitors; SNRIs: serotonin-norepinephrine reuptake inhibitors; TCAs: tricyclic antidepressants; MAOIs: monoamine oxidase inhibitors.<br />* When administered and during withdrawal.</div><div id=\"graphicVersion\">Graphic 114523 Version 1.0</div></div></div>"},"114524":{"type":"graphic_picture","displayName":"Sarcoptes scabiei 2","title":"<EM>Sarcoptes scabiei</EM>","html":"<div class=\"graphic\"><div style=\"width: 779px\" class=\"figure\"><div class=\"ttl\"><EM>Sarcoptes scabiei</EM></div><div class=\"cntnt\"><img style=\"width:759px; height:569px;\" src=\"images/DERM/114524_Sarcoptesscabiei2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 114524 Version 1.0</div></div></div>"},"114525":{"type":"graphic_picture","displayName":"Scabies mite and eggs","title":"<EM>Sarcoptes scabiei</EM> and eggs","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\"><EM>Sarcoptes scabiei</EM> and eggs</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/114525_Scabiesmiteeggs.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 114525 Version 1.0</div></div></div>"},"114526":{"type":"graphic_table","displayName":"Disorders mimicking or confused with nightmares","title":"Disorders mimicking or confused with nightmares","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disorders mimicking or confused with nightmares</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle2\">Nightmare</td> <td class=\"subtitle2\">Sleep terror</td> <td class=\"subtitle2\">REM sleep behavior<br> disorder</td> <td class=\"subtitle2\">Nocturnal panic<br> disorder</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Peak time of occurrence</strong></td> <td>Last third of the night</td> <td>First third of the night</td> <td>Last third of the night</td> <td>Anytime</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Behavior</strong></td> <td>Awakening from a disturbing dream; no associated motor behavior</td> <td>Screaming, agitation, facial flushing, sweating, mydriasis, tachycardia, tachypnea</td> <td>Vocalizations, flailing limbs, sometimes specific motor behavior related to the dream</td> <td>Frightened awakening&nbsp;with a sense of impending doom or sense of heart attack or dying; tachycardia, tachypnea, nausea; similar to daytime panic events</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Associated dream</strong></td> <td>Yes</td> <td>No</td> <td>Yes</td> <td>Sometimes, but often related to gasping or choking</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Recall</strong></td> <td>Yes; vivid recall with details</td> <td>No; occasional faint recollection of a vague scary event but unable to provide details</td> <td>Yes</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Autonomic activation</strong></td> <td>Sometimes</td> <td>Yes</td> <td>No</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Motor behavior</strong></td> <td>No</td> <td>Sometimes</td> <td>Yes</td> <td>No</td> </tr> <tr> <td><strong>Age</strong></td> <td>All ages, although frequency decreases with age</td> <td>Most common in preschool-age children, decreasing in prevalence with adolescence and rare in older adults</td> <td>Older adults, generally over age 50 years</td> <td>Common in children and in adults with stress or anxiety disorder</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">REM: rapid eye movement.</div><div id=\"graphicVersion\">Graphic 114526 Version 1.0</div></div></div>"},"114527":{"type":"graphic_picture","displayName":"Scabies - interdigital","title":"Scabies","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Scabies</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/114527_Scabiesinterdigital.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple interdigital papules.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 114527 Version 1.0</div></div></div>"},"114528":{"type":"graphic_picture","displayName":"Scabies on wrist","title":"Scabies","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Scabies</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/114528_Scabieswrist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small papules on the ventral wrist.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 114528 Version 1.0</div></div></div>"},"114529":{"type":"graphic_picture","displayName":"Scabies on the wrist","title":"Scabies","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Scabies</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/114529_Scabiesonwrist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous papules on the ventral wrist.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 114529 Version 1.0</div></div></div>"},"114530":{"type":"graphic_picture","displayName":"Scabies on foot","title":"Scabies","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Scabies</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/114530_Scabiesfoot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple papules on the foot.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 114530 Version 1.0</div></div></div>"},"114531":{"type":"graphic_picture","displayName":"Scabies on breast","title":"Scabies","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Scabies</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/114531_Scabiesonbreast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple excoriated papules on the breast.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 114531 Version 1.0</div></div></div>"},"114532":{"type":"graphic_picture","displayName":"Scabies extensive","title":"Scabies","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Scabies</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/114532_Scabiesextensive.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous erythematous papules and excoriations on the arms and chest&nbsp;in a patient with extensive skin involvement.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 114532 Version 2.0</div></div></div>"},"114534":{"type":"graphic_picture","displayName":"Scabies on penis","title":"Scabies","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Scabies</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/114534_Scabiepenis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous papules on the distal penis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 114534 Version 1.0</div></div></div>"},"114535":{"type":"graphic_table","displayName":"PS severity in children","title":"Pulmonic stenosis (PS) severity in children as determined by the pressure gradient","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pulmonic stenosis (PS) severity in children as determined by the pressure gradient</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Severity</td> <td class=\"subtitle1\">Maximum instantaneous<br /> gradient (MIG)*</td> </tr> <tr> <td class=\"centered\">Mild</td> <td class=\"centered\">&#60;40 mmHg</td> </tr> <tr> <td class=\"centered\">Moderate</td> <td class=\"centered\">40 to 60 mmHg</td> </tr> <tr> <td class=\"centered\">Severe</td> <td class=\"centered\">&#62;60 mmHg</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Severity of PS is determined by the pressure gradient across the pulmonary valve, which is estimated noninvasively with echocardiography. The definitions provided here are based on the maximum instantaneous gradient (MIG) measured via Doppler echocardiography. PS severity can also be determined by cardiac catheterization, measuring the peak-to-peak gradient. However, in the modern era, cardiac catheterization is primarily used for therapeutic intervention and is rarely performed solely for diagnostic purposes in children with PS. There is generally good correlation between the Doppler-derived gradient and that obtained by direct catheterization measurements. However, because cardiac catheterization is typically performed with the patient sedated, catheter measurements are typically lower than corresponding echocardiographic estimates (eg, a catheterization measurement of 40 mmHg in a sedated patient corresponds roughly to a Doppler-derived gradient of 60 mmHg in an awake patient).</div><div id=\"graphicVersion\">Graphic 114535 Version 1.0</div></div></div>"},"114536":{"type":"graphic_picture","displayName":"Nodular scabies on penis","title":"Scabies","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Scabies</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/114536_Nodularscabiespenis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nodular scabies on the penis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 114536 Version 1.0</div></div></div>"},"114537":{"type":"graphic_picture","displayName":"Scabies on scrotum","title":"Scabies","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Scabies</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/114537_Scabiesonscrotum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Papules and small nodules on the scrotum.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 114537 Version 1.0</div></div></div>"},"114538":{"type":"graphic_picture","displayName":"Crusted scabies on hand","title":"Crusted scabies","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Crusted scabies</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/114538_Crustedscabieshand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperkeratotic, fissured plaque on the hand.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 114538 Version 1.0</div></div></div>"},"114539":{"type":"graphic_picture","displayName":"Crusted scabies on extremity","title":"Crusted scabies","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Crusted scabies</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/114539_Crustedscabiesextremity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperkeratotic, fissured plaque on the extremity.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 114539 Version 1.0</div></div></div>"},"114540":{"type":"graphic_picture","displayName":"Crusted scabies on the scalp","title":"Crusted scabies","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Crusted scabies</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/114540_Crustedscabiesscalp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperkeratotic plaque on the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 114540 Version 1.0</div></div></div>"},"114541":{"type":"graphic_picture","displayName":"Crusted scabies on the foot","title":"Crusted scabies","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Crusted scabies</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/114541_Crustedscabiesfoot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Marked hyperkeratosis on the foot.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 114541 Version 1.0</div></div></div>"},"114544":{"type":"graphic_algorithm","displayName":"Algorithm for cardiovascular disease risk assessment in adults","title":"CVD risk assessment in adults ages 20 to 79 years without a history of atherosclerotic CVD*<sup>¶</sup>","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">CVD risk assessment in adults ages 20 to 79 years without a history of atherosclerotic CVD*<sup>&para;</sup></div><div class=\"cntnt\"><img style=\"width:469px; height:795px;\" src=\"images/CARD/114544_Alg_crdvsclr_ds_rsk_as_adlt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CVD: cardiovascular disease; LDL-C: low-density lipoprotein-cholesterol.<br />* Patients with known CVD should receive appropriate treatment for secondary prevention; refer to UpToDate topics on secondary prevention of CVD.<br />&para; Patients &gt;79 years of age may wish to undergo CVD risk assessment following a discussion of the risks and benefits of treatment and shared decision making.<br />&Delta; Refer to UpToDate topics on familial hyperlipidemia and secondary prevention of CVD.<br /><span class=\"lozenge\">&loz;</span> Validated risk calculators have not included patients &lt;40 years of age. If desired, a more formal risk estimate can be calculated using an imputed age of 40 years in this population.<br />&sect; Refer to UpToDate content on CVD risk assessment in primary prevention for available risk calculators to estimate 10-year and lifetime CVD risks.</div><div id=\"graphicVersion\">Graphic 114544 Version 2.0</div></div></div>"},"114546":{"type":"graphic_table","displayName":"Overview of imagery rehearsal plus CBT for insomnia","title":"Overview of imagery rehearsal plus components of cognitive behavioral therapy for insomnia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Overview of imagery rehearsal plus components of cognitive behavioral therapy for insomnia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td><strong>Session 1</strong></td> <td>Session 1 focuses on creating a comfortable psychotherapeutic environment, and the therapist gets to know the client's particular difficulties with sleep and nightmares. The therapist presents an overview of the six-session treatment and provides psychoeducation about PTSD, sleep, and nightmares. In addition, the client will be taught de-arousal/grounding strategies to use when awakened by a nightmare.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Session 2</strong></td> <td>Session 2 is focused on helping the client to choose and write out the target nightmare. Because this task is often associated with an increase in anxiety, progressive muscle relaxation is also taught in this session.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Session 3</strong></td> <td>Session 3 covers psychoeducation about sleep hygiene and sleep habits, and encourages problem solving about possible changes in the client's sleep habits. The therapist also provides the client with specific examples and suggestions for changing the nightmare to make the dream less distressing and more like a normal dream.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Session 4</strong></td> <td>Session 4 introduces stimulus control procedures. Stimulus control seeks to reestablish a conditioned association between the bed/bedroom and sleep by reducing time spent tossing and turning in bed. Next, the therapist continues to brainstorm with the client about ways of \"rescripting\" the target nightmare and then helps him/her to write out the new dream script.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Session 5</strong></td> <td>Session 5 reviews previously discussed sleep management strategies and obstacles to change, and discusses the effects of daily stressors and the put the day to rest exercise. The therapist reviews the client's experience with rehearsing the rescripted dream during the previous week and suggests ways of removing obstacles to rehearsal and, possibly, revisions to the changed script.</td> </tr> <tr> <td><strong>Session 6</strong></td> <td>Session 6, the final session, reviews progress made in treatment. If needed, the new script is further \"fine-tuned.\" Any changes in sleep and nightmares experienced by the client during the treatment are reviewed and summarized and the client is encouraged to examine likely stressors and obstacles to consistent practice in the months ahead.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PTSD: posttraumatic stress disorder.</div><div class=\"graphic_reference\">Courtesy of: Harb, GC, Forbes, D, Phelps, A, Gehrman, PR, Cook, JM, Gamble, G &amp; Ross, RJ (2010). Treatment Manual for Imagery Rehearsal + cCBT for Insomnia.</div><div id=\"graphicVersion\">Graphic 114546 Version 1.0</div></div></div>"},"114552":{"type":"graphic_algorithm","displayName":"Approach to diagnosis of babesiosis infection","title":"Suggested approach to diagnosis in the setting of suspected babesiosis infection","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Suggested approach to diagnosis in the setting of suspected babesiosis infection</div><div class=\"cntnt\"><img style=\"width:488px; height:451px;\" src=\"images/ID/114552_Apr_dx_babesiosis_infection.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PCR: polymerase chain reaction.<br />* The diagnosis of babesiosis should be suspected in patients with typical clinical manifestations (fever, fatigue, chills, sweats, headache, myalgia, arthralgia, and/or anorexia) and laboratory features (hemolytic anemia, thrombocytopenia, and/or elevation of aminotransferases) in the setting of relevant epidemiologic exposure (eg, residents of endemic areas, travelers returning from endemic areas, or blood transfusion in the previous six months). The diagnosis should also be suspected in patients with Lyme disease, human granulocytic anaplasmosis, or other <em>Ixodes</em> tickborne infections (since the causative agents of these infections are transmitted by the same vector as babesiosis). Refer to the UpToDate topic on diagnosis of babesiosis for further discussion.<br />&para; The level of parasitemia may be low initially and rise subsequently during the course of illness; therefore, it is reasonable to repeat smears every 12 to 24 hours for a total of at least three smears.</div><div id=\"graphicVersion\">Graphic 114552 Version 1.0</div></div></div>"},"114553":{"type":"graphic_figure","displayName":"Neutral cervical spine positioning in the infant or young child","title":"Neutral cervical spine positioning in the infant or young child","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Neutral cervical spine positioning in&nbsp;the infant or young child</div><div class=\"cntnt\"><img style=\"width:539px; height:445px;\" src=\"images/EM/114553_Neutralcervicalspinepositioninginaninfant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In young children and infants, backboard modifications that maintain safe cervical spine positioning include: recess in the board for the occiput (A) or padding under the shoulders, trunk and legs (B). </div><div class=\"graphic_reference\">Modified from:<br /><OL>&#xD;&#xA;<LI>Herzenberg JE, Hensinger RN, Dedrick DK, Phillips WA. Emergency transport and positioning of young children who have an injury of the cervical spine. The standard backboard may be hazardous. J Bone Joint Surg Am 1989; 71:15.</LI>&#xD;&#xA;<LI>Leonard JC, Leonard JR. Cervical spine injury. In: Strange and Schafermeyer's Pediatric Emergency Medicine, 4th ed, Schafermeyer R, Tenenbein M, Macias CG, et al (Eds), McGraw-Hill Education, New York 2015.</LI></OL></div><div id=\"graphicVersion\">Graphic 114553 Version 2.0</div></div></div>"},"114556":{"type":"graphic_figure","displayName":"Blood glucose trends by type of exercise","title":"Blood glucose trends caused by different types of exercise in individuals with type 1 diabetes","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Blood glucose trends caused by different types of exercise in individuals with type 1 diabetes</div><div class=\"cntnt\"><img style=\"width:567px; height:578px;\" src=\"images/PEDS/114556_Blood_glucose_trends_by_type_of_exercise.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In general, aerobic exercise decreases blood glucose, anaerobic exercise increases blood glucose, and mixed activities are associated with glucose stability. Individual responses are dependent on various additional factors, including the duration and intensity of the activity, initial blood glucose concentrations, individual fitness, concentrations of insulin, glucagon, and other counterregulatory hormones in the circulation, and the nutritional status of the individual.</div><div class=\"graphic_reference\">Modified from: Riddell MC, Gallen IW, Smart CE, et al. Exercise management in type 1 diabetes: a consensus statement. Lancet Diabetes Endocrinol 2017; 5:377.</div><div id=\"graphicVersion\">Graphic 114556 Version 2.0</div></div></div>"},"114557":{"type":"graphic_form","displayName":"Patient education: Swelling caused by ACE inhibitor medications","title":"Patient education: Swelling (angioedema) caused by ACE inhibitor medications","html":"<div class=\"graphic\"><div style=\"width: 576px\" class=\"figure\"><div class=\"ttl\">Patient education: Swelling (angioedema) caused by ACE inhibitor medications</div><div class=\"cntnt\"><img style=\"width:556px; height:754px;\" src=\"images/ALLRG/114557_PE_Swll_cause_ACE_inhbtr_md.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 114557 Version 1.0</div></div></div>"},"114562":{"type":"graphic_picture","displayName":"GIST histology spindle cell and epithelioid types","title":"Histology of gastrointestinal stromal tumor (GIST) with spindle cell and epithelioid morphology","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Histology of gastrointestinal stromal tumor (GIST) with spindle cell and epithelioid morphology</div><div class=\"cntnt\"><img style=\"width:513px; height:766px;\" src=\"images/ONC/114562_GISThistspndlecllepthld.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spindle cell and epithelioid histologic patters of GIST.<br />(A) Biopsy specimen (20x) of a spindle cell GIST stained with hematoxylin and eosin (H&amp;E). Histologically, the tumor is composed of fairly uniform spindle cells with elongated nuclei and eosinophilic cytoplasm, growing in fascicles.<br />(B) Biopsy specimen (20x) of an H&amp;E-stained section of an epithelioid GIST with rounded cells, round central nuclei, and eosinophilic or clear cytoplasm. Note the nested morphology.</div><div id=\"graphicVersion\">Graphic 114562 Version 1.0</div></div></div>"},"114563":{"type":"graphic_picture","displayName":"GIST histology mixed spindle cell and epithelioid type","title":"Histology of gastrointestinal stromal tumor (GIST) of mixed spindle cell and epithelioid type","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Histology of gastrointestinal stromal tumor (GIST) of mixed spindle cell and epithelioid type</div><div class=\"cntnt\"><img style=\"width:513px; height:766px;\" src=\"images/ONC/114563_GISThstmxdspdlcllepthl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Biopsy specimen of a mixed-type GIST stained with hematoxylin and eosin (H&amp;E).<br />(A) At low power (4x), note the abrupt transition between spindle and epithelioid areas, as indicated by the arrows.<br />(B) As shown with higher magnification (20x), the tumor is composed of elongated spindle cells as well as rounded epithelioid cells.</div><div id=\"graphicVersion\">Graphic 114563 Version 1.0</div></div></div>"},"114564":{"type":"graphic_picture","displayName":"GIST immunohistochemical staining for KIT","title":"Positive immunohistochemical staining for KIT (CD117) in a spindle cell type gastrointestinal stromal tumor (GIST)","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Positive immunohistochemical staining for KIT (CD117) in a spindle cell type gastrointestinal stromal tumor (GIST)</div><div class=\"cntnt\"><img style=\"width:513px; height:766px;\" src=\"images/ONC/114564_GISTimmnhistochemstngKIT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Low magnification (10x) image of a section of a spindle type GIST stained for KIT expression by immunohistochemistry. The positive tumor cells are brown, and the surrounding tissue is negative. Note the KIT-positive mast cells (arrows) in a lymphoid aggregate.<br />(B) High magnification (20x) image shows typical membrane and cytoplasmic KIT staining with dot-like enhanced staining of the Golgi apparatus. The tumor vasculature does not stain for KIT.</div><div id=\"graphicVersion\">Graphic 114564 Version 1.0</div></div></div>"},"114565":{"type":"graphic_figure","displayName":"Natural history of Chagas disease","title":"Natural history of Chagas disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Natural history of Chagas disease</div><div class=\"cntnt\"><img style=\"width:342px; height:543px;\" src=\"images/ID/114565_Natural_history_Chagas_dx.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PCR: polymerase chain reaction; ECG: electrocardiogram.</div><div class=\"graphic_reference\">Adapted from: Bern C. Chagas' Disease. N Engl J Med 2015; 373:456.</div><div id=\"graphicVersion\">Graphic 114565 Version 1.0</div></div></div>"},"114571":{"type":"graphic_algorithm","displayName":"Ectopic pregnancy choosing tx","title":"Algorithm: Choosing a treatment for ectopic pregnancy","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Algorithm: Choosing a treatment for ectopic pregnancy</div><div class=\"cntnt\"><img style=\"width:511px; height:735px;\" src=\"images/OBGYN/114571_Ectopic_pregnancy_chsg_tx.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">hCG: human chorionic gonadotropin; TVUS: transvaginal ultrasound.<br />* Severe or persistent lower abdominal pain and/or evidence of hematoperitoneum.<br />¶ Serum quantitative beta-hCG.<br />Δ Some clinicians treat with MTX for patients with hCG &gt;5000 to ≤10,000 mIU/mL if the following criteria are met: no free fluid in the pelvic cul-de-sac or abdomen, pelvic ultrasound meets criteria for methotrexate, and the patient has minimal pelvic or abdominal pain.<br /><FONT class=lozenge>◊</FONT> Ectopic mass diameter &lt;3 to 4 cm is also commonly used as a patient selection criterion; however, this has not been confirmed as a predictor of successful treatment.</div><div id=\"graphicVersion\">Graphic 114571 Version 2.0</div></div></div>"},"114572":{"type":"graphic_algorithm","displayName":"Management of unfavorable early stage HL","title":"Management of unfavorable prognosis early stage classical Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 964px\" class=\"figure\"><div class=\"ttl\">Management of unfavorable prognosis early stage classical Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:944px; height:559px;\" src=\"images/HEME/114572_Mgmt_unfvrbl_erly_stg_HL.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm describes our approach to the management of classical Hodgkin lymphoma with: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Early stage &#xD;&#xA;<UL>&#xD;&#xA;<LI>Stage I: Involvement of a single lymph node region or of a single extralymphatic organ or site, or</LI>&#xD;&#xA;<LI>Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm alone or with involvement of limited contiguous extralymphatic organ or tissue,</LI></UL></LI>&#xD;&#xA;<LI>And at least one of the following unfavorable prognostic features: &#xD;&#xA;<OL class=numbers_to_nine style=\"LIST-STYLE-TYPE: upper-alpha\">&#xD;&#xA;<LI>Age &gt;50 years,</LI>&#xD;&#xA;<LI>Large mediastinal adenopathy,</LI>&#xD;&#xA;<LI>Elevated ESR, or</LI>&#xD;&#xA;<LI>At least four regions of involvement.*</LI></OL></LI></OL>Further details are presented in UpToDate content on the treatment of unfavorable prognosis early stage classical Hodgkin lymphoma.</div><div class=\"graphic_footnotes\">ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine; PET: positron emission tomography; CT: computed tomography; CR: complete response; PR: partial response; PD: progressive disease; ESR: erythrocyte sedimentation rate; cHL: classical Hodgkin lymphoma; BEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone.<br />* Large mediastinal adenopathy (at least 10 cm or one-third of the cardiothoracic diameter); ESR at least 50 mm/hour with no B symptoms, or ESR at least 30 mm/hour with B symptoms.<br />¶ For select patients with large mediastinal adenopathy in whom radiation therapy is felt to pose an excessive risk, treatment with six to eight cycles of ABVD is an option; further details are presented in UpToDate content on management of unfavorable prognosis early stage cHL.<br />Δ The most common initial chemotherapy option is ABVD; some experts suggest alternative regimens (refer to UpToDate content on the treatment of unfavorable prognosis early stage cHL).<br /><FONT class=lozenge>◊</FONT> Perform PET/CT just before next scheduled chemotherapy cycle; CR (Deauville 1 to 3), PR (Deauville 4 to 5), PD (radiologic or clinical progression).<br />§ Some experts recommend changing to BEACOPP if PR after two cycles of ABVD; further details are presented in UpToDate content on management of unfavorable prognosis early stage cHL.<br />¥ Total of six cycles of ABVD is preferred for patients with unfavorable prognosis cHL.<br />‡ If PR after ABVD cycle 4, a decision to proceed with two additional cycles of ABVD versus salvage systemic chemotherapy depends on the clinician's judgment regarding chemotherapy responsiveness of cHL.<br />† Further details are presented in UpToDate content on the treatment of relapsed or refractory cHL.<br />** Routine PET/CT surveillance is not recommended after achievement of CR; further details are presented in UpToDate content on monitoring the patient with cHL during and after treatment.</div><div id=\"graphicVersion\">Graphic 114572 Version 2.0</div></div></div>"},"114573":{"type":"graphic_table","displayName":"Echo frequency asymptomatic pts with VHD and normal LVF","title":"Frequency of echocardiograms in asymptomatic patients with VHD and normal left ventricular function","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of echocardiograms in asymptomatic patients with VHD and normal left ventricular function</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"12%\"></colgroup><colgroup span=\"4\" width=\"22%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Stage</td> <td class=\"subtitle1\" colspan=\"4\">Valve lesion</td> </tr> <tr> <td class=\"subtitle2\">Aortic stenosis*</td> <td class=\"subtitle2\">Aortic regurgitation</td> <td class=\"subtitle2\">Mitral stenosis</td> <td class=\"subtitle2\">Mitral regurgitation</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Progressive (stage B)</td> <td>Every 3 to 5 years (mild severity V<sub>max</sub> 2.0 to 2.9 m/second)</td> <td>Every 3 to 5 years (mild severity)</td> <td class=\"divider_bottom\" rowspan=\"2\">Every 3 to 5 years (MVA &#62;1.5 cm<sup>2</sup>)</td> <td>Every 3 to 5 years (mild severity)</td> </tr> <tr class=\"divider_bottom\"> <td>Every 1 to 2 years (moderate severity V<sub>max</sub> 3.0 to 3.9 m/second)</td> <td>Every 1 to 2 years (moderate severity)</td> <td>Every 1 to 2 years (moderate severity)</td> </tr> <tr> <td rowspan=\"2\">Severe (stage C)</td> <td rowspan=\"2\">Every 6 to 12 months (V<sub>max</sub> &#8805;4 m/second)</td> <td>Every 6 to 12 months</td> <td>Every 1 to 2 years (MVA 1.0 to 1.5 cm<sup>2</sup>)</td> <td>Every 6 to 12 months</td> </tr> <tr> <td>Dilating LV: more frequently</td> <td>Once every year (MVA &#60;1.0 cm<sup>2</sup>)</td> <td>Dilating LV: more frequently</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Patients with mixed valve disease may require serial evaluations at intervals earlier than recommended for single valve lesions.</div><div class=\"graphic_footnotes\">VHD: valvular heart disease; LV: left ventricle; MVA: mitral valve area; V<sub>max</sub>: maximum velocity.<br />* With normal stroke volume.</div><div class=\"graphic_reference\">Reproduced from: Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:e57. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 114573 Version 1.0</div></div></div>"},"114574":{"type":"graphic_table","displayName":"2017 AAP updated definitions for pediatric BP","title":"2017 American Academy of Pediatrics updated definitions for pediatric blood pressure categories","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">2017 American Academy of Pediatrics updated definitions for pediatric blood pressure categories</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">For children aged 1 to 13 years</td> <td class=\"subtitle1\">For children aged &#8805;13 years</td> </tr> <tr> <td><strong>Normal BP</strong></td> <td>Systolic and diastolic BP &#60;90<sup>th</sup> percentile</td> <td>Systolic BP &#60;120 and diastolic BP &#60;80 mmHg</td> </tr> <tr> <td><strong>Elevated BP</strong></td> <td>Systolic and diastolic BP &#8805;90<sup>th</sup> percentile to &#60;95<sup>th</sup> percentile, or 120/80 mmHg to &#60;95<sup>th</sup> percentile (whichever is lower)</td> <td>Systolic BP 120 to&nbsp;129 and diastolic BP &#60;80 mmHg</td> </tr> <tr> <td><strong>Stage 1 HTN</strong></td> <td>Systolic and diastolic BP &#8805;95<sup>th</sup> percentile to &#60;95<sup>th</sup> percentile + 12 mmHg, or<br /> 130/80 to 139/89 mmHg (whichever is lower)</td> <td>130/80 to 139/89 mmHg</td> </tr> <tr> <td><strong>Stage 2 HTN</strong></td> <td>Systolic and diastolic BP &#8805;95<sup>th</sup> percentile + 12 mmHg, or<br /> &#8805;140/90 mmHg (whichever is lower)</td> <td>&#8805;140/90 mmHg</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BP: blood pressure; HTN: hypertension.</div><div class=\"graphic_reference\">Reproduced with permission from: Pediatrics, Vol. 140, doi: 10.1542/peds.2017-1904. Copyright © 2017 by the AAP.</div><div id=\"graphicVersion\">Graphic 114574 Version 1.0</div></div></div>"},"114575":{"type":"graphic_table","displayName":"2017 AAP guidelines for follow up of high BP","title":"2017 American Academy of Pediatrics guidelines for follow-up of high blood pressure levels in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">2017 American Academy of Pediatrics guidelines for follow-up of high blood pressure levels in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"6\" width=\"12.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">BP screening schedule</td> <td class=\"subtitle1\">Lifestyle counseling (weight and nutrition)</td> <td class=\"subtitle1\">Check upper and lower extremity BP</td> <td class=\"subtitle1\">ABPM*</td> <td class=\"subtitle1\">Diagnostic evaluation<sup>&#182;</sup></td> <td class=\"subtitle1\">Initiate treatment</td> <td class=\"subtitle1\">Consider subspecialty referral</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Normal BP</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Annual</td> <td class=\"centered\">X</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Elevated BP</td> </tr> <tr> <td class=\"indent1\">Initial measurement</td> <td class=\"centered\">X</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"indent1\">Second measurement (repeat in six months)</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Third measurement (repeat in six months)</td> <td class=\"centered\">X</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Stage 1 HTN</td> </tr> <tr> <td class=\"indent1\">Initial measurement</td> <td class=\"centered\">X</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"indent1\">Second measurement (repeat in one to two weeks)</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Third measurement (repeat in three months)</td> <td class=\"centered\">X</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Stage 2 HTN<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Initial measurement</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"indent1\">Second measurement (repeat, refer to specialty care within one week)</td> <td class=\"centered\">X</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BP: blood pressure; ABPM: ambulatory blood pressure monitoring; HTN: hypertension; ED: emergency department.<br />* ABPM is done to confirm HTN before initiating a diagnostic evaluation.<br />¶ Treatment may be initiated by a primary care provider or subspecialist.<br />Δ If the patient is symptomatic or BP is &gt;30 mmHg above the 95<SUP>th</SUP> percentile (or &gt;180/120 mmHg in an adolescent), send to an ED.</div><div class=\"graphic_reference\">Reproduced with permission from: Pediatrics, Vol. 140, doi: 10.1542/peds.2017-1904. Copyright © 2017 by the AAP.</div><div id=\"graphicVersion\">Graphic 114575 Version 2.0</div></div></div>"},"114576":{"type":"graphic_table","displayName":"Pruritus clinical syndromes in palliative care","title":"Common clinical syndromes associated with pruritus in palliative care populations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common clinical syndromes associated with pruritus in palliative care populations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical condition</td> <td class=\"subtitle1\">Clinical manifestations</td> <td class=\"subtitle1\">Postulated mechanism</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Systemic conditions</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Uremic pruritus</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Chronic renal failure </li> <li>Not seen with acute renal failure </li> </ul> </td> <td> <ul> <li>Pruritus usually generalized; may be intermittent or continuous </li> </ul> </td> <td> <ul> <li>Skin atrophy and dryness </li> <li>Secondary hyperparathyroidism </li> <li>Accumulation of pruritogenic metabolites </li> <li>Abnormal mast-cell proliferation in skin </li> </ul> </td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Cholestatic pruritus</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Primary or secondary liver disease/malignancy </li> </ul> </td> <td> <ul> <li>Pruritus may be generalized, but is typically worse on the palms and soles </li> </ul> </td> <td> <ul> <li>Altered opioidergic transmission </li> <li>Increased serotonin release </li> <li>Increased expression of autotaxin and lysophosphatidic acid </li> <li>No correlation between bile acid levels and degree of pruritus </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Malignancy related</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Paraneoplastic <ul> <li>Hematological disorders </li> <li>Solid tumors </li> </ul> </li> </ul> </td> <td> <ul> <li>Aquagenic pruritus in lymphoproliferative disorders </li> </ul> </td> <td> <ul> <li>Cytokine imbalance in response to tumor-specific antigens </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">HIV/AIDs</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>&nbsp;</p> </td> <td> <ul> <li>Pruritus may be generalized or localized, with or without cutaneous lesions </li> <li>Localized pruritus with peripheral neuropathy </li> </ul> </td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Drugs</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Opioids </li> </ul> </td> <td> <ul> <li>With spinal opioids, pruritus usually starts in the upper aspect of the face and nose </li> <li>With systemic opioids, pruritus is generalized and may be accompanied with wheal/flare response </li> </ul> </td> <td> <ul> <li>Centrally mediated by mu-opioid receptor activation of serotonin pathways </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Neurological conditions</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Brachioradial pruritus </li> <li>Postherpetic neuralgia </li> </ul> </td> <td> <ul> <li>Pruritus follows dermatome pattern </li> </ul> </td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Dermatological conditions</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Dry skin </li> </ul> </td> <td> <ul> <li>Present in the majority of elderly patients </li> </ul> </td> <td>&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 114576 Version 1.0</div></div></div>"},"114577":{"type":"graphic_table","displayName":"Risk factors for revised cardiac risk index","title":"Risk factors for revised cardiac risk index","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for revised cardiac risk index</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>High risk surgery (intraperitoneal, intrathoracic, or suprainguinal vascular procedures)</li> </ul> </td> </tr> <tr> <td> <ul> <li>Ischemic heart disease (by any diagnostic criteria) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Heart failure </li> </ul> </td> </tr> <tr> <td> <ul> <li>Cerebrovascular disease </li> </ul> </td> </tr> <tr> <td> <ul> <li>Diabetes mellitus requiring insulin </li> </ul> </td> </tr> <tr> <td> <ul> <li>Creatinine &#8805;2.0 mg/dL </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999; 100:1043.</div><div id=\"graphicVersion\">Graphic 114577 Version 1.0</div></div></div>"},"114580":{"type":"graphic_table","displayName":"Antipruritic therapies for use in palliative care populations","title":"Systemic antipruritic therapies commonly used in palliative care populations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Systemic antipruritic therapies commonly used in palliative care populations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"30%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug category and proposed<br /> antipruritic mechanism</td> <td class=\"subtitle1\">Drug name</td> <td class=\"subtitle1\">Pruritus indication<br /> and comments</td> </tr> <tr> <td><strong>H<sub>1</sub> receptor antagonist</strong> </td> <td> <ul> <li>Diphenhydramine </li> <li>Hydroxyzine </li> </ul> </td> <td> <ul> <li>Opioid-induced pruritus when a histamine may play a role, such as with systemic morphine </li> <li>Sedating effect may be beneficial for nocturnal pruritus </li> <li>Not effective for the majority of patients </li> </ul> </td> </tr> <tr> <td><strong>Mu-opioid antagonists</strong></td> <td> <ul> <li>Naloxone </li> <li>Naltrexone </li> </ul> </td> <td> <ul> <li>Cholestasis </li> <li>Uremia </li> <li>Opioid-induced pruritus </li> <li>Particularly for patients with cancer pain, there are concerns about reversing peripheral opioid receptor stimulation</li> </ul> </td> </tr> <tr> <td><strong>Mixed mu-opioid receptor agonist/antagonist</strong></td> <td> <ul> <li>Nalbuphine </li> </ul> </td> <td> <ul> <li>Opioid-induced pruritus </li> <li>Compared to pure antagonists, there may be fewer concerns about reversing peripheral opioid receptor stimulation</li> </ul> </td> </tr> <tr> <td><strong>5-HT<sub>3</sub> receptor antagonists</strong></td> <td> <ul> <li>Ondansetron </li> <li>Dolasetron </li> </ul> </td> <td> <ul> <li>Cholestasis </li> <li>Uremia </li> <li>Opioid-induced pruritus </li> </ul> </td> </tr> <tr> <td><strong>Glucocorticoids</strong>&nbsp;</td> <td> <ul> <li>Dexamethasone </li> <li>Prednisone </li> </ul> </td> <td> <ul> <li>Conditions associated with skin inflammation </li> <li>Lymphoma </li> </ul> </td> </tr> <tr> <td><strong>Antidepressants</strong><br /> 5-HT<sub>3</sub> reuptake inhibition </td> <td> <ul> <li>Paroxetine </li> <li>Sertraline </li> </ul> </td> <td> <ul> <li>Cholestasis </li> <li>Uremia </li> <li>Opioid-induced pruritus </li> <li>Malignancy </li> <li>General palliative care patients, if no other established cause </li> </ul> </td> </tr> <tr> <td><strong>Adrenergic, 5-HT<sub>2</sub>, 5-HT<sub>3</sub>, and H<sub>1</sub> receptor antagonists</strong></td> <td> <ul> <li>Mirtazapine </li> </ul> </td> <td> <ul> <li>Cholestasis </li> <li>Uremia </li> <li>Opioid-induced pruritus </li> <li>Malignancy </li> </ul> </td> </tr> <tr> <td><strong>Anticonvulsants</strong></td> <td> <ul> <li>Gabapentin </li> </ul> </td> <td> <ul> <li>Neuropathic pruritus </li> <li>Pruritus of unknown cause </li> </ul> </td> </tr> <tr> <td><strong>NK1 receptor antagonist</strong></td> <td> <ul> <li>Aprepitant </li> </ul> </td> <td> <ul> <li>Lymphoproliferative disorders </li> <li>Biological anticancer therapies </li> </ul> </td> </tr> <tr> <td><strong>Pregnane X receptor antagonist</strong></td> <td> <ul> <li>Rifampin </li> </ul> </td> <td> <ul> <li>Cholestasis </li> </ul> </td> </tr> <tr> <td><strong>Bile</strong> <strong>acid sequestrants</strong></td> <td> <ul> <li>Cholestyramine </li> <li>Colestipol </li> </ul> </td> <td> <ul> <li>Cholestasis </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NK1: neurokinin 1.</div><div id=\"graphicVersion\">Graphic 114580 Version 2.0</div></div></div>"},"114581":{"type":"graphic_table","displayName":"Advantages of LMWH in children","title":"Advantages and disadvantages of different anticoagulants for treatment of venous thromboembolism in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Advantages and disadvantages of different anticoagulants for treatment of venous thromboembolism in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">LMWH</td> <td class=\"subtitle1\">Unfractionated heparin</td> <td class=\"subtitle1\">Vitamin K antagonists (eg, warfarin)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Predictability of anticoagulant response</strong></td> <td>Response is highly predictable</td> <td>Response is less predictable (compared with LMWH)</td> <td>Response is unpredictable</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Need for laboratory monitoring and dose adjustment</strong></td> <td>Requires only periodic monitoring</td> <td>Requires frequent monitoring and dose adjustment</td> <td>Requires frequent monitoring and dose adjustment</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Impact of diet on drug's effect</strong></td> <td>Little impact</td> <td>Little impact</td> <td>Effectiveness is impacted by vitamin K intake, which can have considerable variation in children's diets</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Ease of administration</strong></td> <td>Does not require IV access, but subcutaneous administration may be bothersome to patients</td> <td>Requires IV access</td> <td>Orally administered</td> </tr> <tr> <td colspan=\"4\"><strong>Special considerations:</strong></td> </tr> <tr> <td class=\"indent1\">Renal failure</td> <td>For patients with mild renal insufficiency, dose adjustment and close monitoring may be necessary; for those with severe renal failure, LMWH should be avoided</td> <td>Dose adjustment is not necessary</td> <td>Dose adjustment is not necessary</td> </tr> <tr> <td class=\"indent1\">Hepatic failure</td> <td>Dose adjustment is not necessary</td> <td>Dose adjustment is not necessary</td> <td>For patients with mild liver dysfunction and/or elevated baseline prothrombin time, dose adjustment and close monitoring are necessary; for those with severe liver failure, warfarin should be avoided</td> </tr> <tr> <td class=\"indent1\">Pregnancy</td> <td>Does not cross the placenta and does not result in fetal anticoagulation</td> <td>Does not cross the placenta and does not result in fetal anticoagulation</td> <td>Crosses the placenta, is a teratogen, and causes fetal anticoagulation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LMWH: low molecular weight heparin; IV: intravenous.</div><div id=\"graphicVersion\">Graphic 114581 Version 1.0</div></div></div>"},"114582":{"type":"graphic_table","displayName":"Inherited platelet disorders genes","title":"Genes implicated in inherited platelet disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genes implicated in inherited platelet disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Platelet disorders</td> <td class=\"subtitle1\">Genes</td> <td class=\"subtitle1\">Inheritance pattern</td> </tr> <tr> <td>Adenosine diphosphate (ADP) receptor defect</td> <td><em>P2RY12</em></td> <td>Autosomal recessive (AR)</td> </tr> <tr> <td>Amegakaryocytic thrombocytopenia with radioulnar synostosis</td> <td><em>HOXA11</em></td> <td>Autosomal dominant (AD)</td> </tr> <tr> <td>Autosomal dominant thrombocytopenia</td> <td><em>ANKRD26</em>; <em>CYCS</em>; <em>TUBB1</em></td> <td>All AD</td> </tr> <tr> <td>Bernard-Soulier syndrome (BSS)</td> <td><em>GP1BA</em>; <em>GP1BB</em>; <em>GP9</em></td> <td>All AR</td> </tr> <tr> <td>Bleeding diathesis due to glycoprotein VI deficiency</td> <td><em>GP6</em></td> <td>AR</td> </tr> <tr> <td>Chediak-Higashi syndrome</td> <td><em>LYST</em></td> <td>AR</td> </tr> <tr> <td>Congenital amegakaryocytic thrombocytopenia (CAMT)</td> <td><em>MPL</em></td> <td>AR</td> </tr> <tr> <td>Cyclic thrombocytopenia and thrombocythemia 1</td> <td><em>THPO</em></td> <td>AD</td> </tr> <tr> <td>Deficiency of phospholipase A2, group IVA</td> <td><em>PLA2G4A</em></td> <td>AR</td> </tr> <tr> <td>Dense granule abnormalities</td> <td><em>NBEA</em></td> <td>AD</td> </tr> <tr> <td>Familial platelet disorder with predisposition to acute myeloid leukemia (AML)</td> <td><em>RUNX1</em></td> <td>AD</td> </tr> <tr> <td>Filamin A-related disorders</td> <td><em>FLNA</em></td> <td>X-linked</td> </tr> <tr> <td>Ghosal syndrome</td> <td><em>TBXAS1</em></td> <td>AR</td> </tr> <tr> <td>Glanzmann thrombasthenia (GT)</td> <td><em>ITGA2B</em>; <em>ITGB3</em></td> <td>AR</td> </tr> <tr> <td>Gray platelet syndrome</td> <td><em>NBEAL2</em></td> <td>AR</td> </tr> <tr> <td>Hermansky-Pudlak syndrome</td> <td><em>HPS1</em>; <em>AP3B1</em>; <em>HPS3</em>; <em>HPS4</em>; <em>HPS5</em>; <em>HPS6</em>; <em>DTNBP1</em>; <em>BLOC1S3</em></td> <td>All AR</td> </tr> <tr> <td>May-Hegglin and other <em>MYH9</em>-related disorders</td> <td><em>MYH9</em></td> <td>AD</td> </tr> <tr> <td>Paris-Trousseau thrombocytopenia and Jacobsen syndrome</td> <td><em>FLI1</em></td> <td>AD</td> </tr> <tr> <td>Platelet-type von Willebrand disease (VWD)</td> <td><em>GP1BA</em></td> <td>AD</td> </tr> <tr> <td>Qu&#233;bec platelet disorder</td> <td><em>PLAU</em></td> <td>AD</td> </tr> <tr> <td>Thrombocytopenia absent radius (TAR) syndrome</td> <td><em>RBM8A</em></td> <td>AR</td> </tr> <tr> <td>Thromboxane A2 receptor defect</td> <td><em>TBXA2R</em></td> <td>AR</td> </tr> <tr> <td>Wiskott-Aldrich syndrome (WAS)</td> <td><em>WAS</em></td> <td>X-linked</td> </tr> <tr> <td>X-linked thrombocytopenia with dyserythropoiesis</td> <td><em>GATA1</em></td> <td>X-linked</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on thrombocytopenia and inherited platelet disorders for the approach to patient evaluation and management.</div><div class=\"graphic_reference\">Adapted with permission of the American Society of Hematology, from: Simeoni I, Stephens JC, Fengyuan H, et al. A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. Blood 2016; 127:2791; permission conveyed through Copyright Clearance Center, Inc. Copyright &copy; 2016.</div><div id=\"graphicVersion\">Graphic 114582 Version 1.0</div></div></div>"},"114584":{"type":"graphic_table","displayName":"Causes of acquired hypocholesteremia","title":"Causes of acquired hypocholesteremia<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of acquired hypocholesteremia<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Examples</td> </tr> <tr> <td>Malignancy</td> <td> <ul> <li>Colorectal and prostatic carcinoma, leukemias, reticuloses </li> <li>Myeloma and other monoclonal gammopathies </li> </ul> </td> </tr> <tr> <td>Malabsorption</td> <td> <ul> <li>Short-bowel syndrome, blind loop syndrome, celiac disease, pancreatic exocrine insufficiency, giardiasis </li> </ul> </td> </tr> <tr> <td>Anaemia</td> <td> <ul> <li>Thalassemia, pernicious anaemia </li> </ul> </td> </tr> <tr> <td>Chronic infection and infestations</td> <td> <ul> <li>Pulmonary tuberculosis, schistosomiasis </li> </ul> </td> </tr> <tr> <td>Severe illness in hospitalised patients</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Durrington P. Dyslipidaemia. Lancet 2003; 362:717.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 114584 Version 1.0</div></div></div>"},"114592":{"type":"graphic_table","displayName":"Potential maternal and neonatal complications of OP position","title":"Potential maternal and neonatal complications of occiput posterior position","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential maternal and neonatal complications of occiput posterior position</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Maternal complications</td> <td class=\"subtitle1\">Neonatal complications</td> </tr> <tr> <td> <ul> <li>Protracted first stage of labor </li> </ul> </td> <td> <ul> <li>Five-minute Apgar score less than 7 </li> </ul> </td> </tr> <tr> <td> <ul> <li>Protracted/arrested second stage of labor </li> </ul> </td> <td> <ul> <li>Umbilical artery acidemia </li> </ul> </td> </tr> <tr> <td> <ul> <li>Increased rate of labor augmentation </li> </ul> </td> <td> <ul> <li>Meconium-stained amniotic fluid </li> </ul> </td> </tr> <tr> <td> <ul> <li>Operative vaginal delivery </li> </ul> </td> <td> <ul> <li>Admission to neonatal intensive care unit </li> </ul> </td> </tr> <tr> <td> <ul> <li>Anal sphincter injury </li> </ul> </td> <td>&nbsp;</td> </tr> <tr> <td> <ul> <li>Failure of operative vaginal delivery </li> </ul> </td> <td>&nbsp;</td> </tr> <tr> <td> <ul> <li>Cesarean delivery </li> </ul> </td> <td>&nbsp;</td> </tr> <tr> <td> <ul> <li>Inadvertent extension of hysterotomy at cesarean delivery </li> </ul> </td> <td>&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 114592 Version 1.0</div></div></div>"},"114593":{"type":"graphic_diagnosticimage","displayName":"Ultrasound image of OP position","title":"Ultrasound image of occiput posterior position","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound image of occiput posterior position</div><div class=\"cntnt\"><img style=\"width:373px; height:279px;\" src=\"images/OBGYN/114593_US_image_OP_position.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Occiput posterior position is diagnosed when the fetal orbits face towards the transducer held in the transverse position just above the symphysis pubis.&nbsp; </div><div id=\"graphicVersion\">Graphic 114593 Version 1.0</div></div></div>"},"114594":{"type":"graphic_diagnosticimage","displayName":"Standard foot plain radiographs","title":"Standard plain radiographs of the foot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Standard plain radiographs of the foot</div><div class=\"cntnt\"><img style=\"width:439px; height:757px;\" src=\"images/SM/114594_Standard_foot_radiographs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Standard AP radiograph of the foot: The AP radiograph provides a better view of the proximal fifth metatarsal. The long arrow points to the base of the fifth metatarsal. The short arrow points to the cuboid. The arrowhead points to the navicular. The \"x\" lies just medial to the first MTP joint.<br />(B) Standard oblique radiograph of the foot: The oblique angle provides a better view of the Lisfranc joint, indicated by the thick arrow. The two standard arrows indicate the&nbsp;oval projection of two sesamoids, just proximal to the first MTP joint. The superimposed line crosses the Lisfranc joint and&nbsp;divides the midfoot from the forefoot. The&nbsp;arrowhead points to&nbsp;the body of the navicular.&nbsp;<br />(C)&nbsp;Standard lateral radiograph of the foot: The&nbsp;arrowhead points to navicular. The&nbsp;dashed arrow points to the tarsometatarsal joint. The standard arrow&nbsp;points to&nbsp;the cuboid. The&nbsp;asterisk&nbsp;lies on&nbsp;the calcaneus. </div><div class=\"graphic_footnotes\">AP: anterior-posterior; MTP: metatarsophalangeal.</div><div id=\"graphicVersion\">Graphic 114594 Version 1.0</div></div></div>"},"114596":{"type":"graphic_table","displayName":"Opioids for acute pain PI","title":"Opioid medicines commonly used to treat short-term pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Opioid medicines commonly used to treat short-term pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Generic name</td> <td class=\"subtitle1\">Sample brand names</td> <td class=\"subtitle1\">Forms</td> </tr> <tr> <td>Oxycodone (alone, with acetaminophen, or with ibuprofen)</td> <td> <ul> <li>Roxicodone</li> <li>Percocet (with acetaminophen)</li> </ul> </td> <td> <ul> <li>Pills </li> <li>Liquids </li> </ul> </td> </tr> <tr> <td>Hydrocodone (with acetaminophen or ibuprofen)</td> <td> <ul> <li>Lorcet, Lortab, Norco, Vicodin (with acetaminophen) </li> <li>Vicoprofen (with ibuprofen)</li> </ul> </td> <td> <ul> <li>Pills </li> <li>Liquids </li> </ul> </td> </tr> <tr> <td>Hydromorphone</td> <td> <ul> <li>Dilaudid </li> </ul> </td> <td> <ul> <li>Pills </li> <li>Liquids </li> <li>Shots </li> <li>Suppositories (small amounts of medicine that go into the rectum)</li> </ul> </td> </tr> <tr> <td>Tramadol (alone or with acetaminophen)</td> <td> <ul> <li>Ultram</li> <li>Ultracet (with acetaminophen)</li> </ul> </td> <td> <ul> <li>Pills </li> </ul> </td> </tr> <tr> <td>Codeine (alone or with acetaminophen)</td> <td> <ul> <li>Tylenol with codeine no. 3 (with acetaminophen) </li> </ul> </td> <td> <ul> <li>Pills </li> <li>Liquids </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>These are some of the opioid medicines doctors prescribe to treat acute pain. \"Acute\" means pain that needs treatment for a few days, such as after surgery or an injury. There are other opioids, too, as well as other forms. But those are used more often for treating pain in people with long-term conditions like cancer.</LI>&#xD;&#xA;<LI>When opioid pills are prescribed for short-term pain, they come in the form of \"immediate-release\" pills. This type of pill works fast to relieve pain. Some opioids also come as \"extended-release\" pills. These release medicine into the body more slowly over time. Extended-release pills are not usually prescribed to treat short-term pain.</LI>&#xD;&#xA;<LI>For more detailed information about your medicines, ask your doctor or nurse for the patient hand-out from Lexicomp available through UpToDate. It explains how to use each medicine, describes its possible side effects, and lists other medicines or foods that can affect how it works.</LI></UL></div><div id=\"graphicVersion\">Graphic 114596 Version 1.0</div></div></div>"},"114597":{"type":"graphic_table","displayName":"Sleep hygiene advice for shift workers","title":"Sleep hygiene advice for shift workers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sleep hygiene advice&nbsp;for shift workers</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">When possible, maximize regularity in activity and sleep schedule</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Regularity in the timing of sleep, food intake, and social activity helps to&nbsp;stabilize the biological clock. Minimizing discrepancies in sleep timing between on-shift and off-shift periods may help you adapt to a fixed-shift schedule and may also help&nbsp;you adapt&nbsp;to each shift type in a rotating-shift schedule (depending on rotation speed and direction).</td> </tr> <tr> <td class=\"subtitle2_left\">Create a sleep-friendly bedroom environment</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Make sure that your bed is comfortable and that your bedroom is dark, quiet, and cool (around 65&#176;F or 18&#176;C). Blackout shades may be particularly important to block sunlight during daytime sleep. Creating constant background noise in the sleep environment with a fan or&nbsp;humidifier, for example, will eliminate unexpected sounds that would otherwise wake you up.</td> </tr> <tr> <td class=\"subtitle2_left\">Limit exposure to bright light before daytime sleep</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Exposure to bright light (eg, sunlight during the morning commute home following a night shift) can be alerting and may also set your biological clock to a time that interferes with daytime sleep.</td> </tr> <tr> <td class=\"subtitle2_left\">Make the last hour before bed a \"wind-down\" time</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Engage in relaxing and pleasant activities, dim or block light in the room, and have a light snack.</td> </tr> <tr> <td class=\"subtitle2_left\">Do not use alcohol to help you sleep&nbsp;and do not&nbsp;consume alcohol too close to bedtime</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Although alcohol may help you to fall asleep more easily, it disrupts your sleep during the night by causing frequent awakenings. One drink of alcohol should not be consumed within three hours of bedtime.</td> </tr> <tr> <td class=\"subtitle2_left\">Smoking and other drugs will disrupt your sleep</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">If you smoke, do not smoke too close to bedtime or if&nbsp;you wake up&nbsp;during the intended sleep period. Most drugs of abuse can disrupt sleep.</td> </tr> <tr> <td class=\"subtitle2_left\">Avoid caffeinated products within six hours of bedtime</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">In addition to coffee, these may include tea, chocolate, and&nbsp;many sodas.</td> </tr> <tr> <td class=\"subtitle2_left\">Exercise regularly, but avoid activities that raise body temperature close to bedtime</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Regular exercise can improve sleep quality, but exercising or having a warm bath too close to bedtime can disrupt your ability to fall asleep. Warm baths should be avoided within 1.5 hours of bedtime.</td> </tr> <tr> <td class=\"subtitle2_left\">Avoid consuming more than 8 to 10 ounces of liquids close to bedtime</td> </tr> <tr> <td class=\"indent1\">A full or semi-full bladder can contribute to awakenings. Restrict liquids close to bedtime and empty your bladder just before going to&nbsp;bed.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 114597 Version 1.0</div></div></div>"},"114598":{"type":"graphic_table","displayName":"Common medications with sedating or alerting side effects","title":"Common medications with sedating or alerting side effects","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common medications with sedating or alerting side effects</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Common medications that have sedating side effects</td> <td class=\"subtitle1\">Common medications that have alerting side effects and can disrupt sleep</td> </tr> <tr> <td> <ul> <li>First-generation antihistamines (eg, diphenhydramine) </li> </ul> </td> <td> <ul> <li>Alerting antidepressants (eg, selective serotonin reuptake inhibitors) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Sedating antidepressants (eg, amitriptyline, mirtazapine, trazodone) </li> </ul> </td> <td> <ul> <li>Glucocorticoids (eg, methylprednisolone, prednisone) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Anxiolytics (eg, diazepam, lorazepam) </li> </ul> </td> <td> <ul> <li>Smoking cessation medications (eg, nicotine patch) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Pain medications (eg, opioids) </li> </ul> </td> <td> <ul> <li>Angiotensin-converting enzyme inhibitors </li> </ul> </td> </tr> <tr> <td> <ul> <li>Sedating antiseizure drugs&nbsp;(eg, carbamazepine,&nbsp;gabapentin) </li> </ul> </td> <td> <ul> <li>Diuretics </li> </ul> </td> </tr> <tr> <td> <ul> <li>Antipsychotics (eg, olanzapine, quetiapine, risperidone) </li> </ul> </td> <td> <ul> <li>Nasal decongestants (eg, ephedrine, pseudoephedrine) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Hypnotics (eg, benzodiazepines, melatonin agonists,&nbsp;nonbenzodiazepine benzodiazepine receptor agonists) </li> </ul> </td> <td> <ul> <li>Some immunosuppressants (eg, cyclosporine, tacrolimus) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Dopamine agonists (eg, pramipexole, ropinirole) </li> </ul> </td> <td> <ul> <li>Stimulants (eg, amphetamine, methylphenidate) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Some muscle relaxants (eg, cyclobenzaprine) </li> </ul> </td> <td> <ul> <li>Bronchodilators (eg, aminophylline) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Cheng P, Drake C. Occupational Sleep Medicine. Sleep Med Clin 2016; 11:65. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 114598 Version 1.0</div></div></div>"},"114599":{"type":"graphic_picture","displayName":"Sachet of ready-to-use therapeutic food","title":"Sachet of ready-to-use therapeutic food (RUTF)","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Sachet of ready-to-use therapeutic food (RUTF)</div><div class=\"cntnt\"><img style=\"width:754px; height:502px;\" src=\"images/PEDS/114599_Sachetrdytousethrptcfd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A sachet of locally-produced ready-to-use therapeutic food (RUTF).</div><div class=\"graphic_reference\">Reproduced with permission from Project Peanut Butter.</div><div id=\"graphicVersion\">Graphic 114599 Version 1.0</div></div></div>"},"114601":{"type":"graphic_table","displayName":"Effect of primary tumor location on survival, metastatic CRC","title":"Effect of primary tumor location on survival times of<EM> RAS</EM> wild-type metastatic colorectal cancer with and without first-line cetuximab","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Effect of primary tumor location on survival times of<EM> RAS</EM> wild-type metastatic colorectal cancer with and without first-line cetuximab</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Study</td> <td class=\"subtitle1\" rowspan=\"2\">Treatment</td> <td class=\"subtitle1\" colspan=\"2\">Median PFS (months)</td> <td class=\"subtitle1\" colspan=\"2\">Median OS (months)</td> </tr> <tr> <td class=\"subtitle2\">Left</td> <td class=\"subtitle2\">Right</td> <td class=\"subtitle2\">Left</td> <td class=\"subtitle2\">Right</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">FIRE-3<sup>[1]</sup></td> <td>FOLFIRI + cetuximab</td> <td class=\"centered\">10.7</td> <td class=\"centered\">7.6</td> <td class=\"centered\">38.3</td> <td class=\"centered\">18.3</td> </tr> <tr class=\"divider_bottom\"> <td>FOLFIRI + bevacizumab</td> <td class=\"centered\">10.7</td> <td class=\"centered\">9</td> <td class=\"centered\">28</td> <td class=\"centered\">23</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">CRYSTAL<sup>[1]</sup></td> <td>FOLFIRI + cetuximab</td> <td class=\"centered\">12.0</td> <td class=\"centered\">8.1</td> <td class=\"centered\">28.7</td> <td class=\"centered\">18.5</td> </tr> <tr class=\"divider_bottom\"> <td>FOLFIRI</td> <td class=\"centered\">8.9</td> <td class=\"centered\">7.1</td> <td class=\"centered\">21.7</td> <td class=\"centered\">15.0</td> </tr> <tr> <td rowspan=\"2\">CALGB 80405<sup>[2]</sup></td> <td>FOLFOX/FOLFIRI + cetuximab</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">39.3</td> <td class=\"centered\">13.6</td> </tr> <tr> <td>FOLFOX/FOLFIRI + bevacizumab</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">32.6</td> <td class=\"centered\">29.2</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PFS: progression-free survival; OS: overall survival; FOLFIRI: irinotecan plus leucovorin and short-term infusional fluorouracil; CALGB: Cancer and Leukemia Group B; FOLFOX: oxaliplatin plus leucovorin and short-term infusional fluorouracil.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Tejpar S, Stintzing S, Ciardiello F, et al. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol 2016.</LI>&#xD;&#xA;<LI>Venook AP, Niedzwiecki D, Innocenti F, et al. Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol 2016; 34:(suppl; abstr 3504).</LI></OL></div><div id=\"graphicVersion\">Graphic 114601 Version 1.0</div></div></div>"},"114602":{"type":"graphic_table","displayName":"International anesthesia organizations' standards of monitoring","title":"International anesthesia organizations' standards of monitoring during anesthesia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">International anesthesia organizations' standards of monitoring during anesthesia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"15%\"></colgroup><colgroup width=\"55%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Organization</td> <td class=\"subtitle1\">Continuous presence of</td> <td class=\"subtitle1\">Descriptor</td> <td class=\"subtitle1\">Patient monitors</td> </tr> <tr class=\"divider_bottom\"> <td>ASA</td> <td>Qualified anesthesia personnel</td> <td>Minimum</td> <td> <ul> <li>Inspired O<sub>2</sub> with low O<sub>2</sub> limit alarm </li> <li>Pulse oximeter, with audible pulse tone and low threshold alarm </li> <li>Expired CO<sub>2</sub> continuous, with audible alarm, during general anesthesia or moderate/deep sedation </li> <li>Disconnect alarm during mechanical ventilation </li> <li>Continuous ECG </li> <li>Blood pressure and heart rate at least every five minutes </li> <li>During GA, pulse plethysmography or oximetry, or continuous palpation of pulse, or auscultation of heart sounds, or monitored intraarterial pressure trace, or ultrasound peripheral pulse </li> <li>Temperature when clinically significant changes in body temperature are anticipated or suspected </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">AAGBI</td> <td class=\"divider_bottom\" rowspan=\"4\">Anaesthetist of appropriate experience, or fully trained Physician Assistant (Anaesthesia) under the supervision of a Consultant Anesthetist</td> <td>Minimum</td> <td> <ul> <li>Pulse oximeter </li> <li>NIBP </li> <li>ECG </li> <li>Inspired and expired O<sub>2</sub>, CO<sub>2</sub>, N<sub>2</sub>O, volatile anesthetic agent if used </li> <li>Airway pressure </li> <li>Peripheral nerve stimulator if NMBAs used </li> <li>Temperature for procedures &#62;30 minutes duration </li> </ul> </td> </tr> <tr> <td>Available</td> <td> <ul> <li>Stethoscope </li> </ul> </td> </tr> <tr> <td>Additional</td> <td> <ul> <li>Invasive blood pressure, cardiac output at discretion of anaesthetist </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Recommended</td> <td> <ul> <li>EEG-based depth of anesthesia when neuromuscular blockade is used in combination with TIVA </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">EBA</td> <td class=\"divider_bottom\" rowspan=\"2\">Appropriately trained and experienced anaesthesiologist</td> <td>Essential</td> <td> <ul> <li>Pulse oximeter </li> <li>NIBP </li> <li>ECG </li> <li>Airway gases: O<sub>2</sub> with audible alarm, CO<sub>2</sub>, vapour when volatile anesthetics used </li> <li>Airway pressure </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Available</td> <td> <ul> <li>Peripheral nerve stimulator with NMBAs </li> <li>Temperature </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">WFSA</td> <td class=\"divider_bottom\" rowspan=\"3\">Vigilant anesthesia professional</td> <td>Highly recommended (mandatory)</td> <td> <ul> <li>Pulse oximeter </li> <li>HR from the pulse oximeter </li> <li>NIBP </li> <li>Intermittent temperature where clinically indicated </li> </ul> </td> </tr> <tr> <td>Recommended</td> <td> <ul> <li>Continuous monitoring with stethoscope (precordial, pretracheal, or oesophageal) </li> <li>Capnography </li> <li>ECG </li> <li>Availability of a defibrillator </li> <li>Continual temperature when change is anticipated, intended, or suspected </li> <li>Peripheral nerve stimulator with muscle relaxants </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Suggested</td> <td> <ul> <li>Inspiratory and/or expired gas volumes, and concentration of volatile agents </li> <li>Invasive blood pressure in appropriate cases </li> <li>Depth of anesthesia: inspired/expired concentrations of gases and volatile agents; electronic devices when high risk of awareness </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">CAS</td> <td class=\"divider_bottom\" rowspan=\"3\">Physician or an anesthesia assistant (with appropriate training and experience) under the immediate supervision of an anesthesiologist</td> <td>Required</td> <td> <ul> <li>Pulse oximeter </li> <li>BP (either invasive or non-invasive) </li> <li>ECG </li> <li>Capnography for GA and sedation </li> <li>Agent-specific anesthetic gas analyser with inhalation agents </li> </ul> </td> </tr> <tr> <td>Exclusively available for each patient</td> <td> <ul> <li>Temperature </li> <li>Peripheral nerve stimulator when NMBAs used </li> <li>Stethoscope (precordial, esophageal, or paratracheal) </li> <li>Lighting appropriate to visualize an exposed portion of the patient </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Immediately available</td> <td> <ul> <li>Spirometer </li> <li>Manometer to measure ETT cuff pressure </li> </ul> </td> </tr> <tr> <td rowspan=\"2\">ANZCA</td> <td rowspan=\"2\">Vigilant anaesthetist, practitioner, medical practitioner</td> <td>Mandatory</td> <td> <ul> <li>Pulse oximeter </li> <li>CO<sub>2</sub> monitor during GA </li> <li>ECG </li> <li>NIBP </li> <li>Inspired and end tidal concentration of inhaled anesthetics when used </li> <li>Temperature when warming devices used </li> <li>Neuromuscular function monitor (quantitative preferred) when considering extubation after use of nondepolarizing NMBAs </li> </ul> </td> </tr> <tr> <td>Available</td> <td> <ul> <li>CO<sub>2</sub> monitor during sedation </li> <li>Continuous invasive blood pressure </li> <li>Temperature </li> <li>Neuromuscular function monitor when NMBAs used </li> <li>Temperature </li> <li>Other (EEG, CVP, CO, TEE, respiratory mechanics) when clinically indicated </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li>ASA: American Society of Anesthesiologists Standards for Basic Anesthetic Monitoring. Committee of Origin: Standards and Practice Parameters (Approved by the ASA House of Delegates on October 21, 1986, last amended on October 20, 2010, and last affirmed on October 28, 2016). Available at <a href=\"https://www.asahq.org/~/media/Sites/ASAHQ/Files/Public/Resources/standards-guidelines/standards-for-basic-anesthetic-monitoring.pdf\" target=\"_blank\">https://www.asahq.org/~/media/Sites/ASAHQ/Files/Public/Resources/standards-guidelines/standards-for-basic-anesthetic-monitoring.pdf</a>.</li>&#xD;&#xA;    <li>AAGBI: Association of Anaesthetists of Great Britain and Ireland. Available at <a href=\"http://www.aagbi.org/sites/default/files/Standards_of_monitoring_2015_0.pdf\" target=\"_blank\">http://www.aagbi.org/sites/default/files/Standards_of_monitoring_2015_0.pdf</a>.</li>&#xD;&#xA;    <li>EBA: European Board of Anaesthesiology. Available at <a href=\"http://www.eba-uems.eu/resources/PDFS/safety-guidelines/EBA-Minimal-monitor.pdf\" target=\"_blank\">http://www.eba-uems.eu/resources/PDFS/safety-guidelines/EBA-Minimal-monitor.pdf</a>.</li>&#xD;&#xA;    <li>WFSA: World Federation of Societies of Anaesthesiologists.</li>&#xD;&#xA;    <li>CAS: Canadian Anesthesiologists' Society. Available at <a href=\"http://www.cas.ca/English/Page/Files/97_Guidelines-2017.pdf\" target=\"_blank\">http://www.cas.ca/English/Page/Files/97_Guidelines-2017.pdf</a>.</li>&#xD;&#xA;    <li>ANZCA: Australian and New Zealand College of Anaesthetists. Available at <a href=\"http://www.anzca.edu.au/documents/ps18-2015-guidelines-on-monitoring-during-anaesthe.pdf\" target=\"_blank\">http://www.anzca.edu.au/documents/ps18-2015-guidelines-on-monitoring-during-anaesthe.pdf</a>.</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">O<SUB>2</SUB>: oxygen; CO<SUB>2</SUB>: carbon dioxide; ECG: electrocardiogram; GA: general anesthesia; NIBP: non-invasive blood pressure; N<SUB>2</SUB>O: nitrous oxide; NMBAs: neuromuscular blocking agents; EEG: electroencephalogram; TIVA: total intravenous anesthesia; HR: heart rate; ETT: endotracheal tube; CVP: central venous pressure; CO: cardiac output; TEE: transesophageal echocardiography.</div><div id=\"graphicVersion\">Graphic 114602 Version 1.0</div></div></div>"},"114603":{"type":"graphic_waveform","displayName":"Hemodynamic tracings during weaning from CPB","title":"Hemodynamic tracings during weaning from cardiopulmonary bypass","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Hemodynamic tracings&nbsp;during weaning from cardiopulmonary bypass</div><div class=\"cntnt\"><img style=\"width:764px; height:842px;\" src=\"images/ANEST/114603_Hmdynmc_trcng_weanng_bypass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During weaning from cardiopulmonary bypass, venous drainage to the pump is reduced, the heart gradually fills, and the arterial blood pressure (ABP) tracing becomes pulsatile.<br />(A) The tracing shows the beginning of the weaning process, with the patient requiring atrial pacing at a rate of 86 for bradycardia, an ABP of 80/71, and central venous pressure (CVP) of 11.<br />(B) With further reduction of venous drainage to the pump, the ABP tracing becomes more pulsatile as additional cardiac filling generates a larger stroke volume and pulse pressure. The tracing shows this phase of weaning from bypass, with ABP 103/62 and CVP 12. Note that atrial pacing is no longer required, because the patient is in normal sinus rhythm at a rate of 77.</div><div class=\"graphic_footnotes\">CPB: cardiopulmonary bypass.</div><div class=\"graphic_reference\">Reproduced with permission from Jonathan B Mark, MD.</div><div id=\"graphicVersion\">Graphic 114603 Version 1.0</div></div></div>"},"114609":{"type":"graphic_picture","displayName":"Hidradenitis suppurativa comedones","title":"Hidradenitis suppurativa","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Hidradenitis suppurativa</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/114609_Hidradentssppurativacmdns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Open comedones and inflammatory papules&nbsp;in the axilla.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 114609 Version 1.0</div></div></div>"},"114620":{"type":"graphic_diagnosticimage","displayName":"Segmental renal injury","title":"Segmental renal injury","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Segmental renal injury</div><div class=\"cntnt\"><img style=\"width:484px; height:338px;\" src=\"images/SURG/114620_GrdIIIparenchymalinjury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Delayed imaging of the renal collecting system on abdominal CT scanning&nbsp;shows an upper pole renal injury&nbsp;(arrow) due to blunt abdominal trauma. This may represent a segmental vascular injury leading to infarction.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 114620 Version 1.0</div></div></div>"},"114621":{"type":"graphic_diagnosticimage","displayName":"Grade IV renal laceration with urine extravasation","title":"Grade IV renal laceration with urine extravasation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Grade IV renal laceration with urine extravasation</div><div class=\"cntnt\"><img style=\"width:418px; height:305px;\" src=\"images/SURG/114621_GrdIVrnlcrtnurnxtrvstn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The delayed image of a CT IVP shows a grade IV renal laceration due to blunt abdominal injury with extravasation of contrast from the collecting system (arrow). </div><div class=\"graphic_footnotes\">CT: computed tomography; IVP: intravenous pyelogram. </div><div id=\"graphicVersion\">Graphic 114621 Version 1.0</div></div></div>"},"114622":{"type":"graphic_diagnosticimage","displayName":"Grade V renal laceration","title":"Grade V renal laceration","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Grade V renal laceration</div><div class=\"cntnt\"><img style=\"width:764px; height:705px;\" src=\"images/SURG/114622_GrdVrenallaceration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse abdominal CT (A,B) shows a large left perirenal hematoma due to shattered renal parenchyma from blunt abdominal injury. Nephrectomy was required due to ongoing blood loss. The picture (C) shows the shattered kidney.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 114622 Version 1.0</div></div></div>"},"114623":{"type":"graphic_diagnosticimage","displayName":"Grade V renal avulsion injury","title":"Grade V renal avulsion injury","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Grade V renal avulsion injury</div><div class=\"cntnt\"><img style=\"width:554px; height:392px;\" src=\"images/SURG/114623_GradeVrenalavulsioninjry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Absent uptake of parenchymal contrast to the left renal parenchyma (arrow) compared to normal renal parenchymal contrast uptake in the right kidney. </div><div id=\"graphicVersion\">Graphic 114623 Version 1.0</div></div></div>"},"114625":{"type":"graphic_diagnosticimage","displayName":"Bladder neck injury","title":"Bladder neck injury","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Bladder neck injury</div><div class=\"cntnt\"><img style=\"width:455px; height:765px;\" src=\"images/SURG/114625_Bladderneckinjury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pelvic CT scan shows a bladder neck injury (arrows) in the coronal (A) and sagittal (B) views.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 114625 Version 1.0</div></div></div>"},"114626":{"type":"graphic_picture","displayName":"Straddle injury with pulsatile bleeding from urethral meatus","title":"Straddle injury with pulsatile bleeding from urethral meatus","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Straddle injury with pulsatile bleeding from urethral meatus</div><div class=\"cntnt\"><img style=\"width:519px; height:756px;\" src=\"images/SURG/114626_Strddlinjrplstlbldngmts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient presented with pulsatile bleeding from the urethral meatus (finger compression of penis was used to reduce active bleeding) following a&nbsp;straddle injury. Rapid swelling of the scrotum required open exploration to achieve hemostasis and to evaluate clot evacuation. Acute urethral reconstruction was not performed to avoid overdebridement of the distracted urethral segments. Delayed reconstruction was successfully performed three months later.</div><div id=\"graphicVersion\">Graphic 114626 Version 1.0</div></div></div>"},"114627":{"type":"graphic_picture","displayName":"Low-velocity penile gunshot wound","title":"Low-velocity penile gunshot wound","html":"<div class=\"graphic\"><div style=\"width: 785px\" class=\"figure\"><div class=\"ttl\">Low-velocity penile gunshot wound</div><div class=\"cntnt\"><img style=\"width:765px; height:765px;\" src=\"images/SURG/114627_Lwvelocitypenilgnshtwnd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The picture show the ventral entry (A) and dorsal exit (B) wounds near the meatus from a low-velocity gunshot wound causing urethral injury and associated tissue injury to the fossa navicularis. A mid-penile urethrostomy was created for urinary diversion proximal to the injured segment (surgical instrument projecting through the wound at time of exploration; urethral catheter within the uninjured penile urethra; C).<br />Delayed urethral reconstruction was performed by advancing the urethra to the glans penis.</div><div id=\"graphicVersion\">Graphic 114627 Version 1.0</div></div></div>"},"114629":{"type":"graphic_diagnosticimage","displayName":"Pseudoaneurysm following blunt renal injury","title":"Pseudoaneurysm following blunt renal injury","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Pseudoaneurysm following blunt renal injury</div><div class=\"cntnt\"><img style=\"width:764px; height:392px;\" src=\"images/SURG/114629_Pseudanrysmblntrenalinjr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The digital subtraction angiogram (A) shows a renal pseudoaneurysm (arrow) following a blunt grade III renal injury. Selective angioembolization (B) was performed using coils&nbsp;to&nbsp;treat&nbsp;the pseudoaneurysm, which no longer has flow (arrow).</div><div id=\"graphicVersion\">Graphic 114629 Version 1.0</div></div></div>"},"114630":{"type":"graphic_diagnosticimage","displayName":"Urinoma following grade IV renal trauma","title":"Urinoma following grade IV renal trauma","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Urinoma following grade IV renal trauma</div><div class=\"cntnt\"><img style=\"width:471px; height:626px;\" src=\"images/SURG/114630_UrinomagrdIVrenaltrauma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The delayed phase of a CT scan shows a grade IV blunt renal trauma involving the left kidney (arrow, A) with progression to a urinoma (arrow, B).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 114630 Version 1.0</div></div></div>"},"114631":{"type":"graphic_diagnosticimage","displayName":"Aortic infection","title":"Aortic infection","html":"<div class=\"graphic\"><div style=\"width: 785px\" class=\"figure\"><div class=\"ttl\">Aortic infection</div><div class=\"cntnt\"><img style=\"width:765px; height:651px;\" src=\"images/SURG/114631_Aorticinfection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The images are from a woman in her late sixties who presented with about a two-month history of fever, night sweats, and unintentional weight loss. A noncontrast CT scan of the chest (sagittal images; A,B) demonstrated air in the aortic wall (white and black arrows) consistent with an aortic infection.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 114631 Version 1.0</div></div></div>"},"114633":{"type":"graphic_picture","displayName":"Seborrheic dermatitis dark skin","title":"Seborrheic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Seborrheic dermatitis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/114633_Seborrheicdermattsdrkskn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Faint pinkish, scaly plaques with annular configuration in this patient with seborrheic dermatitis of the face.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 114633 Version 1.0</div></div></div>"},"114634":{"type":"graphic_picture","displayName":"Seborrheic dermatitis dark skin 2","title":"Seborrheic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Seborrheic dermatitis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/114634_Seborrheicdrmattsdrkskn2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thin plaque at nasolabial fold and oral commissure&nbsp;and fine papules over lower face.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 114634 Version 3.0</div></div></div>"},"114635":{"type":"graphic_picture","displayName":"Seborrheic dermatitis dark skin 3","title":"Seborrheic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Seborrheic dermatitis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/114635_Seborrheicdrmattsdrkskn3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scaly, pigmented plaques at nasolabial folds and perioral area.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 114635 Version 3.0</div></div></div>"},"114636":{"type":"graphic_picture","displayName":"Seborrheic dermatitis dark skin 4","title":"Seborrheic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Seborrheic dermatitis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/114636_Seborrheicdrmattsdrkskn4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Annular, hypopigmented plaques&nbsp;typically located at the nasolabial folds.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 114636 Version 3.0</div></div></div>"},"114637":{"type":"graphic_table","displayName":"Risk factors for hypertension in children <3 years","title":"Risk factors for hypertension in children <3 years","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for hypertension in children &lt;3 years</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Check BP at health supervision visits for children with the following:*</td> </tr> <tr> <td class=\"indent1\">Perinatal risk factors: <ul class=\"decimal_heading\"> <li>Born at &#60;32 weeks gestation</li> <li>Small for gestational age</li> <li>Birth weight &#60;1500 g</li> <li>Neonatal complications that required intensive care or umbilical artery catheterization</li> </ul> </td> </tr> <tr> <td class=\"indent1\">Recurrent urinary tract infection, hematuria, or proteinuria</td> </tr> <tr> <td class=\"indent1\">Renal disease or urologic malformation</td> </tr> <tr> <td class=\"indent1\">Family history of congenital renal disease</td> </tr> <tr> <td class=\"indent1\">Solid organ or hematopoietic cell transplant</td> </tr> <tr> <td class=\"indent1\">Malignancy or other systemic illness associated with hypertension (eg, neurofibromatosis, tuberous sclerosis complex, sickle cell disease)</td> </tr> <tr> <td class=\"indent1\">Treatment with drugs known to raise blood pressure (eg, caffeine, nonsteroidal anti-inflammatory drugs, glucocorticoids)</td> </tr> <tr> <td class=\"indent1\">Evidence of elevated intracranial pressure</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BP: blood pressure.<br />* For children without risk factors, BP should be measured annually at health supervision visits beginning at age 3 years.</div><div class=\"graphic_reference\">Reproduced with permission from: Pediatrics, Vol. 140, doi: 10.1542/peds.2017-1904. Copyright © 2017 by the AAP.</div><div id=\"graphicVersion\">Graphic 114637 Version 1.0</div></div></div>"},"114638":{"type":"graphic_table","displayName":"Screening BP requiring further evaluation","title":"Screening blood pressure requiring further evaluation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Screening blood pressure requiring further evaluation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">Age (years)</td> <td class=\"subtitle1\" colspan=\"4\">BP (mmHg)</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">Boys</td> <td class=\"subtitle2\" colspan=\"2\">Girls</td> </tr> <tr> <td class=\"subtitle3\">Systolic BP</td> <td class=\"subtitle3\">Diastolic BP</td> <td class=\"subtitle3\">Systolic BP</td> <td class=\"subtitle3\">Diastolic BP</td> </tr> <tr> <td class=\"centered\">1</td> <td class=\"centered\">98</td> <td class=\"centered\">52</td> <td class=\"centered\">98</td> <td class=\"centered\">54</td> </tr> <tr> <td class=\"centered\">2</td> <td class=\"centered\">100</td> <td class=\"centered\">55</td> <td class=\"centered\">101</td> <td class=\"centered\">58</td> </tr> <tr> <td class=\"centered\">3</td> <td class=\"centered\">101</td> <td class=\"centered\">58</td> <td class=\"centered\">102</td> <td class=\"centered\">60</td> </tr> <tr> <td class=\"centered\">4</td> <td class=\"centered\">102</td> <td class=\"centered\">60</td> <td class=\"centered\">103</td> <td class=\"centered\">62</td> </tr> <tr> <td class=\"centered\">5</td> <td class=\"centered\">103</td> <td class=\"centered\">63</td> <td class=\"centered\">104</td> <td class=\"centered\">64</td> </tr> <tr> <td class=\"centered\">6</td> <td class=\"centered\">105</td> <td class=\"centered\">66</td> <td class=\"centered\">105</td> <td class=\"centered\">67</td> </tr> <tr> <td class=\"centered\">7</td> <td class=\"centered\">106</td> <td class=\"centered\">68</td> <td class=\"centered\">106</td> <td class=\"centered\">68</td> </tr> <tr> <td class=\"centered\">8</td> <td class=\"centered\">107</td> <td class=\"centered\">69</td> <td class=\"centered\">107</td> <td class=\"centered\">69</td> </tr> <tr> <td class=\"centered\">9</td> <td class=\"centered\">107</td> <td class=\"centered\">70</td> <td class=\"centered\">108</td> <td class=\"centered\">71</td> </tr> <tr> <td class=\"centered\">10</td> <td class=\"centered\">108</td> <td class=\"centered\">72</td> <td class=\"centered\">109</td> <td class=\"centered\">72</td> </tr> <tr> <td class=\"centered\">11</td> <td class=\"centered\">110</td> <td class=\"centered\">74</td> <td class=\"centered\">111</td> <td class=\"centered\">74</td> </tr> <tr> <td class=\"centered\">12</td> <td class=\"centered\">113</td> <td class=\"centered\">75</td> <td class=\"centered\">114</td> <td class=\"centered\">75</td> </tr> <tr> <td class=\"centered\">&#8805;13</td> <td class=\"centered\">120</td> <td class=\"centered\">80</td> <td class=\"centered\">120</td> <td class=\"centered\">80</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table is designed as a screening tool only for the identification of children and adolescents who need further evaluation of their BP, starting with repeat BP measurements. The table should not be used by itself to diagnose elevated BP or hypertension. Refer to UpToDate content on hypertension in children for additional details.</div><div class=\"graphic_footnotes\">BP: blood pressure.</div><div class=\"graphic_reference\">Reproduced with permission from: Pediatrics, Vol. 140, doi: 10.1542/peds.2017-1904. Copyright © 2017 by the AAP.</div><div id=\"graphicVersion\">Graphic 114638 Version 1.0</div></div></div>"},"114639":{"type":"graphic_figure","displayName":"PLA2R staining versus anti-PLA2R versus proteinuria schematic","title":"PLA2R staining versus anti-PLA2R versus proteinuria schematic","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">PLA2R staining versus anti-PLA2R versus proteinuria schematic</div><div class=\"cntnt\"><img style=\"width:710px; height:464px;\" src=\"images/NEPH/114639_PLA2RstnaPLA2Rprtrschm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the temporal association of serological tests for anti-PLA2R, tissue staining for PLA2R, and clinical activity represented by proteinuria. Note that tissue staining for PLA2R may precede the appearance of circulating anti-PLA2R and persist after the antibodies disappear from circulation. Resolution of proteinuria lags behind immunological remission.</div><div class=\"graphic_footnotes\">PLA2R: phospholipase A2 receptor.</div><div class=\"graphic_reference\">Reproduced from: Francis JM, Beck LH Jr, Salant DJ. Membranous nephropathy: A journey from bench to bedside. Am J Kidney Dis 2016; 68:138. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 114639 Version 1.0</div></div></div>"},"114640":{"type":"graphic_diagnosticimage","displayName":"Glomerulus of a patient with primary MN stained for PLA2R","title":"Immunofluorescence micrograph of a glomerulus in a biopsy of a patient with primary MN stained for PLA2R","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Immunofluorescence micrograph of a glomerulus in a biopsy of a patient with primary MN stained for PLA2R</div><div class=\"cntnt\"><img style=\"width:309px; height:345px;\" src=\"images/NEPH/114640_GlmsptntprmyMNstdPLA2R.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MN: membranous nephropathy; PLA2R: phospholipase A2 receptor.</div><div class=\"graphic_reference\">Reproduced from: Francis JM, Beck LH Jr, Salant DJ. Membranous nephropathy: A journey from bench to bedside. Am J Kidney Dis 2016; 68:138. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 114640 Version 1.0</div></div></div>"},"114641":{"type":"graphic_table","displayName":"Summary vaccine administration for children","title":"Summary of schedule, dose, route, and preferred site for routinely recommended immunizations for children <18 years of age in the United States","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of schedule, dose, route, and preferred site for routinely recommended immunizations for children &lt;18 years of age in the United States</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Vaccine</td> <td class=\"subtitle1\">Recommended ages for routine administration</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Route</td> <td class=\"subtitle1\">Preferred site</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Inactivated vaccines and/or toxoids</td> </tr> <tr> <td class=\"indent1\">Diphtheria, tetanus, acellular pertussis</td> <td> <ul> <li>2 months </li> <li>4 months </li> <li>6 months </li> <li>15 through 18 months </li> <li>4 through 6 years </li> </ul> </td> <td> <ul> <li>0.5 mL </li> </ul> </td> <td>IM</td> <td> <ul> <li>&#60;3 years: Anterolateral thigh (vastus lateralis) </li> <li>&#8805;3 years: Deltoid </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><em>Haemophilus influenzae</em> type b</td> <td> <ul> <li>2 months </li> <li>4 months </li> <li>6 months* </li> <li>12 through 15 months </li> </ul> </td> <td> <ul> <li>0.5 mL </li> </ul> </td> <td>IM</td> <td> <ul> <li>Anterolateral thigh </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Hepatitis A</td> <td> <ul> <li>Two doses, at least 6 months apart, between 12 and 24 months </li> </ul> </td> <td> <ul> <li>0.5 mL </li> </ul> </td> <td>IM</td> <td> <ul> <li>Anterolateral thigh </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Hepatitis B<sup>&#182;</sup></td> <td> <ul> <li>Within 24 hours of birth </li> <li>1 to 2 months </li> <li>6 to 12 months </li> </ul> </td> <td> <ul> <li>0.5 mL </li> </ul> </td> <td>IM</td> <td> <ul> <li>Anterolateral thigh </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Human papillomavirus<sup>&#916;</sup></td> <td> <ul> <li>11 through 12 years: Two doses separated by at least six months </li> </ul> </td> <td> <ul> <li>0.5 mL </li> </ul> </td> <td>IM</td> <td> <ul> <li>Deltoid </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Influenza, inactivated</td> <td> <ul> <li>One or two doses annually<sup>&#9674;</sup> </li> </ul> </td> <td> <ul> <li>&#60;36 months: 0.25 (Fluzone)&nbsp;or 0.5 mL (FluLaval) </li> <li>&#8805;36 months: 0.5 mL </li> </ul> </td> <td>IM</td> <td> <ul> <li>&#60;3 years: Anterolateral thigh </li> <li>&#8805;3 years: Deltoid </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Meningococcal conjugate vaccine, quadrivalent</td> <td> <ul> <li>11 through 12 years </li> <li>16 years </li> </ul> </td> <td> <ul> <li>0.5 mL </li> </ul> </td> <td>IM</td> <td> <ul> <li>Deltoid </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Meningococcal serogroup B<sup>&#167;</sup></td> <td> <ul> <li>16 to 18 years </li> </ul> </td> <td> <ul> <li>0.5 mL </li> </ul> </td> <td>IM</td> <td> <ul> <li>Deltoid </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Pneumococcal conjugate vaccine</td> <td> <ul> <li>2 months </li> <li>4 months </li> <li>6 months </li> <li>12 through 15 months </li> </ul> </td> <td> <ul> <li>0.5 mL </li> </ul> </td> <td>IM</td> <td> <ul> <li>Anterolateral thigh </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Poliovirus, inactivated</td> <td> <ul> <li>2 months </li> <li>4 months </li> <li>6 through 18 months </li> <li>4 through 6 years </li> </ul> </td> <td> <ul> <li>0.5 mL </li> </ul> </td> <td>IM or subcutaneous</td> <td> <ul> <li>IM: <ul> <li>&#60;3 years: Anterolateral thigh (vastus lateralis) </li> <li>&#8805;3 years: Deltoid </li> </ul> </li> <li>Subcutaneous: <ul> <li>&#60;12 months: Fatty tissue over anterolateral thigh </li> <li>&#8805;12 months: Fatty tissue over upper-outer triceps<sup>&#165;</sup>&nbsp; </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis</td> <td> <ul> <li>11 through 12 years </li> </ul> </td> <td> <ul> <li>0.5 mL </li> </ul> </td> <td>IM</td> <td> <ul> <li>Deltoid </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Inactivated combination vaccines</td> </tr> <tr> <td class=\"indent1\">DTaP-HepB-IPV vaccine (Pediarix)</td> <td> <ul> <li>2 months </li> <li>4 months </li> <li>6 months </li> </ul> </td> <td> <ul> <li>0.5 mL </li> </ul> </td> <td>IM</td> <td> <ul> <li>Anterolateral thigh </li> </ul> </td> </tr> <tr> <td class=\"indent1\">DTaP-IPV/Hib vaccine (Pentacel)</td> <td> <ul> <li>2 months </li> <li>4 months </li> <li>6 months </li> <li>15 through 18 months </li> </ul> </td> <td> <ul> <li>0.5 mL </li> </ul> </td> <td>IM</td> <td> <ul> <li>Anterolateral thigh </li> </ul> </td> </tr> <tr> <td class=\"indent1\">DTaP-IPV vaccine (Kinrix, Quadricel)</td> <td> <ul> <li>4 through 6 years </li> </ul> </td> <td> <ul> <li>0.5 mL </li> </ul> </td> <td>IM</td> <td> <ul> <li>Deltoid </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Live attenuated vaccines</td> </tr> <tr> <td class=\"indent1\">Influenza, live attenuated</td> <td> <ul> <li><strong>Live attenuated influenza vaccine is not recommended for the 2017-2018 influenza season in the United States</strong> </li> </ul> </td> <td> <ul> <li>0.2 mL (0.1 mL in each nostril) </li> </ul> </td> <td>Intranasal</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"indent1\">Measles, mumps, and rubella</td> <td> <ul> <li>12 through 15 months </li> <li>4 through 6 years </li> </ul> </td> <td> <ul> <li>0.5 mL </li> </ul> </td> <td>Subcutaneous</td> <td> <ul> <li>Fatty tissue over upper-outer triceps<sup>&#165; </sup></li> </ul> </td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Rotavirus</td> <td> <ul> <li>RV1: <ul> <li>2 months </li> <li>4 months </li> </ul> </li> </ul> </td> <td> <ul> <li>1 mL </li> </ul> </td> <td>Orally</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td> <ul> <li>RV5: <ul> <li>2 months </li> <li>4 months </li> <li>6 months </li> </ul> </li> </ul> </td> <td> <ul> <li>2 mL </li> </ul> </td> <td>Orally</td> <td class=\"centered\">&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Varicella</td> <td> <ul> <li>12 through 15 months </li> <li>4 through 6 years </li> </ul> </td> <td> <ul> <li>0.5 mL </li> </ul> </td> <td>Subcutaneous</td> <td> <ul> <li>Fatty tissue over upper-outer triceps<sup>&#165;</sup> </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Live attenuated combination vaccines</td> </tr> <tr> <td class=\"indent1\"> <p>MMRV vaccine (ProQuad)</p> Available only for children &#8804;12 years</td> <td> <ul> <li>12 through 15 months<sup>&#135;</sup> </li> <li>4 through 6 years </li> </ul> </td> <td> <ul> <li>0.5 mL </li> </ul> </td> <td>Subcutaneous</td> <td> <ul> <li>Fatty tissue over upper-outer triceps<sup>&#165;</sup> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IM: intramuscular; DTaP: diphtheria, tetanus, acellular pertussis; HepB: hepatitis B; IPV: inactivated poliovirus; Hib: <EM>H. influenzae</EM> type b; Hib-MenCY: Hib-meningococcal serogroups CY combination vaccine;&nbsp;RV1: attenuated human rotavirus vaccine; RV5: pentavalent human-bovine rotavirus reassortant vaccine; MMRV: measles, mumps, rubella, and varicella; MMR: measles, mumps, and rubella.<br />* The 6 month dose may not be necessary, depending upon vaccine formulation.<br />¶ The recommended schedule varies with birth weight and hepatitis B surface antigen status of the mother. Refer to UpToDate content on hepatitis B vaccines for infants for details.<br />Δ If the human papillomavirus series is initiated at age ≥15 years, three doses should be administered: The second dose is recommended one to two months after the first dose, and the third dose is recommended six months after the first dose.<br /><FONT class=lozenge>◊</FONT> Refer to UpToDate content on seasonal influenza vaccines for children for additional information.<br />§ Meningococcal serogroup B vaccines are not routinely recommended for adolescents who are not at increased risk for meningococcal disease. However, they may be given to adolescents and young adults age 16 through 23 years.<br />¥ The fatty tissue over the upper outer triceps is the preferred site. The fatty tissue over the anterolateral thigh is an acceptable alternative.<br />‡ Administration MMRV as the first dose of measles-containing vaccine at age 12 through 15 months has been associated with an increased risk of febrile seizures. The <A href=\"https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5903a1.htm\" target=_open>Centers for Disease Control and Prevention</A> and American Academy of Pediatrics suggest that MMR and varicella vaccine be administered as separate injections at age 12 through 15 months unless the parents/caregivers have a preference for MMRV. Refer to UpToDate content on MMR and varicella vaccination for children for additional details.</div><div id=\"graphicVersion\">Graphic 114641 Version 5.0</div></div></div>"},"114642":{"type":"graphic_table","displayName":"Renal pathology in nephrotic syndrome","title":"Renal pathology in nephrotic syndrome associated with genetic and systemic disorders (secondary nephrotic syndrome)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Renal pathology in nephrotic syndrome associated with genetic and systemic disorders (secondary nephrotic syndrome)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">Podocytopathies: Minimal change or FSGS pattern</td> </tr> <tr> <td class=\"indent1\">Infections: HIV, macrophage activation syndrome, polyomavirus, cytomegalovirus</td> </tr> <tr> <td class=\"indent1\">Drugs: Interferon, pamidronate, NSAIDs, lithium, vaccines, venoms, stings</td> </tr> <tr> <td class=\"indent1\">Malignancies: Thymoma, Hodgkin lymphoma (formerly called Hodgkin disease)</td> </tr> <tr> <td class=\"indent1\">Genetic disorders of podocyte proteins, eg, nephrin, podocin, Alport syndrome, etc</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Other: Sickle cell, myelodysplastic syndromes, hepatitis C, von Gierke disease, Fabry disease, dysautonomia, obesity</td> </tr> <tr> <td class=\"subtitle2_left\">Membranous nephropathy pattern</td> </tr> <tr> <td class=\"indent1\">Autoimmune disease: Lupus</td> </tr> <tr> <td class=\"indent1\">Infections: Hepatitis B, malaria, syphilis</td> </tr> <tr> <td class=\"indent1\">Malignancies: Solid organ tumors, leukemia</td> </tr> <tr> <td class=\"indent1\">Drugs: Gold, mercury, heavy metals, captopril, penicillamine, NSAIDs</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Other: Sarcoidosis, Sj&#246;gren's syndrome, graft-versus-host disease</td> </tr> <tr> <td class=\"subtitle2_left\">Membranoproliferative pattern*</td> </tr> <tr> <td class=\"indent1\">Autoimmune disease: Connective tissue diseases including lupus</td> </tr> <tr> <td class=\"indent1\">Infection: Chronic bacterial infections (eg, endocarditis, VA shunts), hepatitis C</td> </tr> <tr> <td class=\"indent1\">Chronic thrombotic microangiopathy</td> </tr> <tr> <td class=\"indent1\">Malignancy: Monoclonal gammopathy, cryoglobulinemia</td> </tr> <tr> <td class=\"indent1\">Other: POEMS syndrome</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Transplant glomerulopathy</td> </tr> <tr> <td class=\"subtitle2_left\">Glomerular deposition diseases</td> </tr> <tr> <td class=\"indent1\">Amyloidosis: AL, AA, hereditary amyloidosis, and others</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Other monoclonal deposition diseases*: Immunoglobulin deposition disease, immunotactoid glomerulopathy</td> </tr> <tr> <td class=\"subtitle2_left\">Hereditary disorders</td> </tr> <tr> <td class=\"indent1\">Alport syndrome*</td> </tr> <tr> <td class=\"indent1\">Fabry disease*</td> </tr> <tr> <td class=\"indent1\">Nail-patella syndrome</td> </tr> <tr> <td class=\"indent1\">Partial lipodystrophy*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">APOL1-associated nephropathy</td> </tr> <tr> <td class=\"subtitle2_left\">Other</td> </tr> <tr> <td class=\"indent1\">Diabetes mellitus</td> </tr> <tr> <td class=\"indent1\">Idiopathic nodular glomerulosclerosis</td> </tr> <tr> <td class=\"indent1\">Fibrillary glomerulonephritis*</td> </tr> <tr> <td class=\"indent1\">Pregnancy related (includes preeclampsia)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FSGS: focal segmental glomerulosclerosis; HIV: human immunodeficiency virus; NSAIDs: nonsteroidal antiinflammatory drugs; VA: ventriculoatrial; POEMS: Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes; APOL1: apolipoprotein L1; RBC: red blood cell.<br />* Indicates those disorders that could also present as a nephritic-nephrotic syndrome (RBC, RBC casts with nephrotic-range proteinuria).</div><div class=\"graphic_reference\">Courtesy of Jai Radhakrishnan, MD, MS.</div><div id=\"graphicVersion\">Graphic 114642 Version 1.0</div></div></div>"},"114643":{"type":"graphic_table","displayName":"Renal pathology in primary nephrotic syndrome","title":"Renal pathology in primary nephrotic syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Renal pathology in primary nephrotic syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup></colgroup> <tbody> <tr> <td> <ul> <li>Minimal change disease </li> </ul> </td> </tr> <tr> <td> <ul> <li>Focal segmental glomerulosclerosis </li> </ul> </td> </tr> <tr> <td> <ul> <li>Membranous nephropathy </li> </ul> </td> </tr> <tr> <td> <ul> <li>Membranoproliferative glomerulonephritis: C3 glomerulonephritis, dense deposit disease, and \"idiopathic\" immune complex-mediated membranoproliferative glomerulonephritis* </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RBC: red blood cell.<br />* Indicates those disorders that could also present as a nephritic-nephrotic syndrome (RBC, RBC casts with nephrotic-range proteinuria).</div><div class=\"graphic_reference\">Courtesy of Jai Radhakrishnan, MD, MS.</div><div id=\"graphicVersion\">Graphic 114643 Version 1.0</div></div></div>"},"114644":{"type":"graphic_table","displayName":"Vaccine injection procedure children and adolescents","title":"Vaccine injection procedure for infants, children, and adolescents<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Vaccine injection procedure for infants, children, and adolescents<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Preferred position</td> <td class=\"subtitle1\">Preferred<br /> injection site*</td> <td class=\"subtitle1\">Pain reduction strategies</td> </tr> <tr class=\"divider_bottom\"> <td><strong>&#60;12 months</strong></td> <td>Held by caregiver (skin-to-skin contact for infants &#60;1 month of age)</td> <td>IM: <ul class=\"decimal_heading\"> <li>Anterolateral thigh (vastus lateralis) </li> </ul> Subcutaneous: <ul class=\"decimal_heading\"> <li>Fatty tissue over anterolateral thigh </li> </ul> </td> <td><strong>Before injection:</strong> <ul class=\"decimal_heading\"> <li>Feeding (at breast or with bottle) or nonnutritive sucking (eg, pacifier use) </li> <li>Administration of rotavirus vaccine (for infants who require rotavirus vaccine) </li> <li>Administration of sucrose or glucose<sup>&#182;</sup> (for infants who do not require rotavirus vaccine) </li> <li>Application of topical anesthetic agent </li> </ul> <strong>During injection:</strong> <ul class=\"decimal_heading\"> <li>Feeding (at breast or with bottle) or nonnutritive sucking (eg, pacifier use) </li> <li>If possible, administration of multiple injections simultaneously (by two clinicians) rather than one after the other </li> <li>Administration of PCV13 <strong>after</strong> other injections </li> <li>Administration of MMR vaccine (if needed for travel or outbreak) <strong>after</strong> other injections </li> </ul> <strong>After injection:</strong> <ul class=\"decimal_heading\"> <li>Feeding (at breast or with bottle) or nonnutritive sucking (eg, pacifier use) </li> <li>Swaddling, holding/cuddling, side/stomach position, shushing, and/rocking </li> <li>Administration of acetaminophen or ibuprofen for pain </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>12 months through 2 years</strong></td> <td>Held by caregiver</td> <td>IM: <ul class=\"decimal_heading\"> <li>Anterolateral thigh (vastus lateralis) </li> </ul> Subcutaneous <ul class=\"decimal_heading\"> <li>Fatty tissue over upper outer area of triceps<sup>&#916;</sup> </li> </ul> </td> <td><strong>Before injection:</strong> <ul class=\"decimal_heading\"> <li>Feeding (at breast or with bottle) or nonnutritive sucking (for children who continue to breastfeed, bottle-feed, or use a pacifier) </li> <li>For children &#60;2 years: Administration of sucrose or glucose<sup>&#182;</sup> </li> <li>Application of topical anesthetic agent </li> </ul> <strong>During injection:</strong> <ul class=\"decimal_heading\"> <li>Feeding (at breast or bottle) or nonnutritive sucking (for children who continue to breastfeed, bottle-feed, or use a pacifier) </li> <li>Distraction (eg, with a video or toy) </li> <li>Administration of PCV13 and MMR vaccine <strong>after</strong> other injections </li> </ul> <strong>After injection:</strong> <ul class=\"decimal_heading\"> <li>Feeding (at breast or with bottle) or nonnutritive sucking (for children who continue to breastfeed, bottle-feed, or use a pacifier) </li> <li>Stroking, rocking, or \"blowing the pain away\" </li> <li>Administration of acetaminophen or ibuprofen for pain </li> </ul> </td> </tr> <tr> <td><strong>&#8805;3 years</strong></td> <td>Children 3 through 11 years: <ul class=\"decimal_heading\"> <li>Seated (may be held by caregiver) </li> </ul> Children &#8805;12 years: <ul class=\"decimal_heading\"> <li>Seated or lying down </li> </ul> </td> <td>IM: <ul class=\"decimal_heading\"> <li>Deltoid </li> </ul> Subcutaneous: <ul class=\"decimal_heading\"> <li>Fatty tissue over upper outer area of triceps<sup>&#916;</sup> </li> </ul> </td> <td><strong>Before injection:</strong> <ul class=\"decimal_heading\"> <li>Application of topical anesthetic agent </li> </ul> <strong>During injection:</strong> <ul class=\"decimal_heading\"> <li>Video, music, or verbal distraction for children &#60;12 years</li> <li>Breathing distraction (eg, blowing bubbles or a pinwheel, deep breathing) for children &#60;12 years</li> <li>If PCV13 or MMR vaccine are necessary, administer <strong>after</strong> other injections </li> </ul> <strong>After injection:</strong> <ul class=\"decimal_heading\"> <li>Administration of acetaminophen or ibuprofen for pain </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IM: intramuscular; PCV13: 13-valent pneumococcal conjugate vaccine; MMR: measles, mumps, and rubella.<br />* If multiple injections are required at the same visit, separate limbs should be used if possible. If necessary, two or more injections can be given in the same limb; they should be separated by at least 2.5 cm (1 inch), if possible.<br />¶&nbsp;Sucrose 2 mL of 24% or 50% strength solution administered one to two minutes before injection; glucose 2 mL of a 30% strength solution can be used if sucrose is not available.<br />Δ The fatty tissue over the upper outer area of the triceps is the preferred site for subcutaneous injections in children ≥12 months of age; the fatty tissue over the anterolateral thigh is an alternative. <br /></div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Taddio A, McMurtry CM, Shah V, et al. Reducing pain during vaccine injections: Clinical practice guideline. CMAJ 2015; 187:975.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 114644 Version 3.0</div></div></div>"},"114645":{"type":"graphic_figure","displayName":"Structure of human IgA1 and its O-glycans","title":"Structure of human IgA1 and its O-glycans","html":"<div class=\"graphic\"><div style=\"width: 695px\" class=\"figure\"><div class=\"ttl\">Structure of human IgA1 and its O-glycans</div><div class=\"cntnt\"><img style=\"width:675px; height:825px;\" src=\"images/NEPH/114645_StructurehmnIgA1Oglycns.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) IgA1 has an extended hinge region that contains between three and six O-glycans attached to serine or threonine residue between position 225 to 236. (IgA1 with five O-glycans per hinge region is shown.)<br />(B) Glycosylation of IgA1 is mediated by stepwise co/post-translational modifications. First, N-acetylgalactosamine (GalNAc) is added to serine/threonine residue by activity of N-acetylgalactosaminyl-transferase (GalNAcT2; step 1). Next, a galactose moiety is added to GalNAc by core 1 beta 1,3-galactosyltransferase (C1GalT1) and core 1 beta3GalT-specific molecular chaperone (Cosmc; step 2). Sialic acid may then be added to the galactose moiety by alpha2,3 sialytransferase (ST2,3; step 3) or to the GalNAc moiety by alpha2,6 sialytransferase (ST2,6; step 4). Alternatively, sialic acid may be added to GalNAc by ST2,6 before the addition of galactose (step 2a). Notably, sialylated GalNAc (step 2a) cannot be subsequently galactosylated, whereas galactosylated GalNAc may be sialylated at either the GalNAc or galactose moiety, or both (step 3 and/or 4).<br />(C) These steps produce a combination of different O-glycoforms of varying degrees of galactosylation and sialylation. The relative proportion of poorly galactosylated IgA1 is increased in IgA nephropathy.</div><div class=\"graphic_footnotes\">Fab: fragment, antigen binding; Fc: fragment, crystallizable; Ser/Thr: serine/threonine; IgA: immunoglobulin A.</div><div class=\"graphic_reference\">From: Yeo SC, Cheung CK, Barratt J. New insights into the pathogenesis of IgA nephropathy. Pediatr Nephrol 2017. Copyright © 2017 Yeo SC et al; published by Springer International. Available at: <A href=\"https://link.springer.com/article/10.1007%2Fs00467-017-3699-z\" target=_blank>https://link.springer.com/article/10.1007%2Fs00467-017-3699-z</A> (Accessed October 10, 2017). Reproduced under the terms of the <A href=\"https://creativecommons.org/licenses/by/4.0/\" target=_blank>Creative Commons Attribution License</A>.</div><div id=\"graphicVersion\">Graphic 114645 Version 1.0</div></div></div>"},"114647":{"type":"graphic_figure","displayName":"Anterolateral thigh injection site","title":"Anterolateral thigh (vastus lateralis) injection site","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Anterolateral thigh (vastus lateralis) injection site</div><div class=\"cntnt\"><img style=\"width:540px; height:281px;\" src=\"images/PEDS/114647_Anterolateral_thigh_injection_site.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The hip and knee should be flexed to relax the vastus lateralis. Identify the following landmarks: anterior superior iliac spine (ASIS), pubic tubercle, upper part of the patella. Draw an imaginary line between the ASIS and the pubic tubercle. Draw a second imaginary line between the midpoint of the first line and the upper part of the patella. The correct injection site, depicted by the X above, is lateral to the second imaginary line in the vastus lateralis.</div><div class=\"graphic_reference\">Adapted from: Administration of vaccines. In: The Australian Immunisation Handbook, 10<SUP>th</SUP> ed. Available at: <A spellcheck=true href=\"http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home\"target=_blank>www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home</A> (Accessed on August 16, 2017).</div><div id=\"graphicVersion\">Graphic 114647 Version 4.0</div></div></div>"},"114648":{"type":"graphic_figure","displayName":"Deltoid injection site","title":"Deltoid injection site","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Deltoid injection site</div><div class=\"cntnt\"><img style=\"width:527px; height:551px;\" src=\"images/PEDS/114648_Deltoid_injection_site.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arm should be completely exposed and lifted slightly out to the side (which causes the subdeltoid bursa to slide under the acromion). Identify the shoulder tip (acromion) and the deltoid tuberosity (ie, the site of insertion of the deltoid). Draw an imaginary inverted triangle between the acromion and the deltoid tuberosity. The correct injection site is in the middle one-third of this triangle (ie, in the center of the deltoid muscle, midway between the acromion and the deltoid tuberosity).</div><div class=\"graphic_reference\">Adapted from:<br /><OL>&#xD;&#xA;<LI>Administration of vaccines. In: The Australian Immunisation Handbook, 10<SUP>th</SUP> ed. Available at: <A spellcheck=true href=\"http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home\" target=_blank>www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home</A> (Accessed on August 16, 2017).</LI>&#xD;&#xA;<LI>Wadman M. Vaccines on trial. Science 2017; 356:370.</LI></OL></div><div id=\"graphicVersion\">Graphic 114648 Version 3.0</div></div></div>"},"114649":{"type":"graphic_figure","displayName":"Holding children for vaccines","title":"Suggested positions for holding children for vaccine administration","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Suggested positions for holding children for vaccine administration</div><div class=\"cntnt\"><img style=\"width:538px; height:375px;\" src=\"images/PEDS/114649_Holding_children_for_vaccines.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) The child is seated sideways on the parent/caregiver's lap with the child's legs held between the parent's legs. The arm to be injected is held close to the child's body; the other arm is tucked under the parent's arm and behind the back of the parent/caregiver. This positon permits access to one deltoid and both anterolateral thighs. <br />(Panel B) The child is seated facing the parent/caregiver with the child's legs straddling the parent/caregiver's lap. The parent/caregiver's arms hold the child's arms in a reciprocal hug. This position permits access to both deltoids and both anterolateral thighs.</div><div class=\"graphic_reference\">Adapted from: Administration of vaccines. In: The Australian Immunisation Handbook, 10th ed. Available at: <A spellcheck=true href=\"http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home\"target=_blank>www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home</A> (Accessed on August 16, 2017).</div><div id=\"graphicVersion\">Graphic 114649 Version 5.0</div></div></div>"},"114650":{"type":"graphic_figure","displayName":"Ventrogluteal injection site","title":"Ventrogluteal injection site","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Ventrogluteal injection site</div><div class=\"cntnt\"><img style=\"width:452px; height:557px;\" src=\"images/PEDS/114650_Ventrogluteal_injection_site.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The child should be in the prone position on the parent/caregiver's lap or the clinic table with the arms tucked against their chest and the legs dangling towards the floor. The knee and hip should be turned inward to relax the muscle. The injection site should be completely exposed. Identify the following anatomic markers: anterior superior iliac spine (ASIS), the greater trochanter of the femur, and the iliac crest.<br />(A) For infants and small children: Place the web between the index and middle finger over the greater trochanter, the index finger on the ASIS, and the middle finger on the iliac crest. The injection site is in the center of this triangle. <br />(B) For larger children, adolescents, and adults: Place the palm over the greater trochanter with the thumb pointing towards the umbilicus, the index finger pointing toward the ASIS, and the middle finger pointing toward the iliac crest, forming a \"V\" outlining the ventrogluteal triangle. The injection site is in the center of this triangle.</div><div class=\"graphic_reference\">Adapted from: Administration of vaccines. In: The Australian Immunisation Handbook, 10th ed. Available at: <A spellcheck=true href=\"http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home\"target=_blank>www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home</A> (Accessed on August 16, 2017).</div><div id=\"graphicVersion\">Graphic 114650 Version 2.0</div></div></div>"},"114654":{"type":"graphic_table","displayName":"Characteristic features of anorectal problems","title":"Characteristic features of anorectal problems","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristic features of anorectal&nbsp;problems</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">History</td> <td class=\"subtitle1\">Symptoms</td> <td class=\"subtitle1\">External exam</td> <td class=\"subtitle1\">Digital exam</td> <td class=\"subtitle1\">Anoscopy</td> </tr> <tr> <td><strong>Proctitis</strong></td> <td> <ul> <li>History of receptive anal intercourse </li> <li>Prior sexually transmitted diseases </li> <li>Prior inflammatory bowel disease </li> </ul> </td> <td> <ul> <li>Rectal pain, bleeding, and/or purulent discharge </li> </ul> </td> <td> <ul> <li>Usually normal; discharge may be visible </li> </ul> </td> <td> <ul> <li>Diffuse tenderness </li> </ul> </td> <td> <ul> <li>Inflamed or friable mucosa </li> <li>Presence of ulcers may suggest LGV, HSV infection, or syphilis </li> </ul> </td> </tr> <tr> <td><strong>Perianal abscess/anal fistula</strong></td> <td> <ul> <li>Prior perianal abscess or anal fistula </li> </ul> </td> <td> <ul> <li>Rectal pain, bleeding, and/or purulent discharge </li> <li>May be associated with fever/chills </li> </ul> </td> <td> <ul> <li>Usually normal; discharge or fistula tract may be visible </li> </ul> </td> <td> <ul> <li>Diffuse tenderness </li> <li>Submucosal fullness with perianal abscess </li> </ul> </td> <td> <ul> <li>May show pustule, fistula tract and/or discharge </li> </ul> </td> </tr> <tr> <td><strong>Anal warts/dysplasia</strong></td> <td> <ul> <li>Prior anogenital HPV infection (eg, warts, dysplasia) </li> </ul> </td> <td> <ul> <li>Generally asymptomatic </li> </ul> </td> <td> <ul> <li>May show skin-colored papular lesions (warts) </li> </ul> </td> <td> <ul> <li>Usually normal </li> </ul> </td> <td> <ul> <li>May show mucosal white papular lesions (warts) </li> </ul> </td> </tr> <tr> <td><strong>Anal cancer</strong></td> <td> <ul> <li>Prior anogenital HPV infection (eg, warts, dysplasia) </li> </ul> </td> <td> <ul> <li>Rectal bleeding and/or pain </li> <li>Stool caliber may be reduced </li> </ul> </td> <td> <ul> <li>Normal </li> </ul> </td> <td> <ul> <li>Lack of tenderness </li> <li>Submucosal fullness </li> </ul> </td> <td> <ul> <li>May show mucosal erosion </li> </ul> </td> </tr> <tr> <td><strong>Anal fissure</strong></td> <td> <ul> <li>History of receptive anal intercourse </li> <li>History of chronic constipation </li> <li>Prior anal fissure(s) </li> </ul> </td> <td> <ul> <li>Intense pain, especially with defecation, and intermittent bleeding </li> </ul> </td> <td> <ul> <li>Usually normal; bleeding may be visible </li> </ul> </td> <td> <ul> <li>Localized tenderness </li> </ul> </td> <td> <ul> <li>Fissure may be visible </li> </ul> </td> </tr> <tr> <td><strong>Hemorrhoids</strong></td> <td> <ul> <li>Prior hemorrhoid(s) </li> </ul> </td> <td> <ul> <li>Recurrent rectal bleeding, especially with defecation </li> <li>Pain with thrombosed hemorrhoids </li> </ul> </td> <td> <ul> <li>Dilated vein(s) may be visible </li> <li>Tenderness with thrombosed hemorrhoids </li> </ul> </td> <td> <ul> <li>Localized tenderness </li> </ul> </td> <td> <ul> <li>Dilated vein(s) may be visible </li> </ul> </td> </tr> <tr> <td><strong>Pruritus ani</strong></td> <td> <ul> <li>Prior episodes of pruritus ani </li> </ul> </td> <td> <ul> <li>Itchy anal region </li> </ul> </td> <td> <ul> <li>Inflamed skin </li> <li>May be evidence of cause (eg, pinworm, dermatitis) in small percentage of cases </li> </ul> </td> <td> <ul> <li>Normal </li> </ul> </td> <td> <ul> <li>Normal </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LGV: lymphogranuloma venereum; HSV: herpes simplex virus; HPV: human papillomavirus.</div><div id=\"graphicVersion\">Graphic 114654 Version 3.0</div></div></div>"},"114656":{"type":"graphic_table","displayName":"Risk factors for hypertension in children 3 years and older","title":"Risk factors for hypertension in children ≥3 years","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for hypertension in children ≥3 years</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Check BP at all health encounters for children with the following:*</td> </tr> <tr> <td class=\"indent1\">Obesity</td> </tr> <tr> <td class=\"indent1\">Type 1 or type 2 diabetes</td> </tr> <tr> <td class=\"indent1\">Renal disease</td> </tr> <tr> <td class=\"indent1\">History of aortic arch obstruction or coarctation</td> </tr> <tr> <td class=\"indent1\">Treatment with or taking drugs known to increase blood pressure: <ul class=\"decimal_heading\"> <li>Decongestants </li> <li>Caffeine </li> <li>Nonsteroidal anti-inflammatory drugs </li> <li>Glucocorticoids </li> <li>Stimulants </li> <li>Hormonal contraception </li> <li>Tricyclic antidepressants </li> <li>Amphetamines </li> <li>Cocaine </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BP: blood pressure.<br />* For children without risk factors, BP should be measured annually at health supervision visits beginning at age 3 years.</div><div class=\"graphic_reference\">Adapted from: Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 2017.</div><div id=\"graphicVersion\">Graphic 114656 Version 2.0</div></div></div>"},"114657":{"type":"graphic_figure","displayName":"Orbital fracture with proptosis and dystopia","title":"Orbital fracture with proptosis and dystopia","html":"<div class=\"graphic\"><div style=\"width: 782px\" class=\"figure\"><div class=\"ttl\">Orbital fracture with proptosis and dystopia</div><div class=\"cntnt\"><img style=\"width:762px; height:658px;\" src=\"images/EM/114657_Orbtlfrctrprptsisdystpia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 7-year-old presented to ED with complaints of right eye pain and double vision. The patient had been involved in a sledding accident one week before, in which he crashed into a fence. There was no loss of consciousness. On examination in the ED, the right eye was proptotic and dystopic (image A), although with normal visual acuity and no deficits during visual field testing. The pupils were equal, round, and reactive to light, without evidence of an afferent pupillary defect. Dilated funduscopic examination was normal. Extraocular mobility demonstrated limitation of upward gaze and adduction of the right eye. CT imaging of the head including facial cuts was performed (images B and C).<br />(A) Patient with proptosis and orbital dystopia, with the right eye lower than the left. There is also limitation of upward gaze.<br />(B) Coronal CT image demonstrates a retroorbital hematoma (H) with downward displacement of the globe.<br />(C) Sagittal CT image also shows downward displacement of the globe and an associated epidural hematoma (arrow).</div><div class=\"graphic_footnotes\">ED: emergency department: CT: computed tomographic.</div><div class=\"graphic_reference\">Reproduced from: Neuman MI, Nagler J, Madati PJ. Eye pain and double vision: superior orbital wall fracture with retro-orbital hematoma. Ann Emerg Med 2008; 52:473. Illustrations used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 114657 Version 1.0</div></div></div>"},"114660":{"type":"graphic_picture","displayName":"Seborrheic dermatitis scalp dark skin","title":"Seborrheic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Seborrheic dermatitis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/114660_Seborrhcdrmtssclpdrkskn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scaling along the hairline extending to the forehead and along the eyebrows.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 114660 Version 1.0</div></div></div>"},"114661":{"type":"graphic_picture","displayName":"Pityriasis amiantacea 2","title":"Pityriasis amiantacea","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Pityriasis amiantacea</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/114661_Pityriasisamiantacea2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Seborrheic dermatitis with concretions of scale around hair shafts (pityriasis amiantacea).</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 114661 Version 1.0</div></div></div>"},"114662":{"type":"graphic_table","displayName":"Surgeries amenable to neuraxial anesthesia","title":"Surgeries amenable to neuraxial anesthesia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Surgeries amenable to neuraxial anesthesia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Surgery</td> <td class=\"subtitle1\">Type of neuraxial<br /> anesthetic/analgesic</td> <td class=\"subtitle1\">Need for supplemental<br /> general anesthesia</td> </tr> <tr> <td>Breast</td> <td>Epidural</td> <td>Yes</td> </tr> <tr> <td>Thoracic</td> <td>Epidural</td> <td>Yes</td> </tr> <tr> <td>Major abdominal</td> <td>Epidural</td> <td>Yes</td> </tr> <tr> <td>Hip replacement</td> <td>Spinal/epidural</td> <td>No</td> </tr> <tr> <td>Knee replacement</td> <td>Spinal/epidural</td> <td>No</td> </tr> <tr> <td>Inguinal hernia</td> <td>Spinal</td> <td>No</td> </tr> <tr> <td>Laparoscopy</td> <td>Spinal/epidural</td> <td>Likely</td> </tr> <tr> <td>Anal</td> <td>Spinal</td> <td>No</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 114662 Version 1.0</div></div></div>"},"114663":{"type":"graphic_table","displayName":"Summary of FAO disorders","title":"Summary of fatty acid oxidation disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of&nbsp;fatty acid oxidation&nbsp;disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Enzyme</td> <td class=\"subtitle1\">Gene</td> <td class=\"subtitle1\">Prevalence</td> <td class=\"subtitle1\">Symptoms</td> <td class=\"subtitle1\">Other complications</td> <td class=\"subtitle1\">Plasma acylcarnitines</td> </tr> <tr> <td>VLCADD</td> <td>Very-long-chain acyl-CoA dehydrogenase deficiency</td> <td><em>ACADVL</em></td> <td>1 in 42,500 to 120,000</td> <td>G, L, C, M, R</td> <td>&nbsp;</td> <td>Elevated C14:1-, C14-, C16:1-, C16-</td> </tr> <tr> <td>LCHADD</td> <td>Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency</td> <td><em>HADHA</em></td> <td>1 in 110,000</td> <td>G, L, C, M, R</td> <td>Retinopathy, peripheral neuropathy</td> <td>Elevated C16:1-OH-, C16-OH-, C18:1-OH-, C18-OH-</td> </tr> <tr> <td>TFPD</td> <td>Trifunctional protein deficiency</td> <td><em>HADHA, HADHB</em></td> <td>Rare</td> <td>G, L, C, M, R</td> <td>Retinopathy, peripheral neuropathy</td> <td>Elevated C16:1-OH-, C16-OH-, C18:1-OH-, C18-OH-</td> </tr> <tr> <td>CTD</td> <td>Carnitine transporter deficiency</td> <td><em>SLC22A5</em></td> <td>1 in 20,000 to 120,000</td> <td>G, L, C, M, R</td> <td>NBS maternal CTD</td> <td>Low total and free carnitine levels</td> </tr> <tr> <td>CACTD</td> <td>Carnitine-acylcarnitine translocase deficiency</td> <td><em>SLC25A20</em></td> <td>&nbsp;</td> <td>G, L, C</td> <td>&nbsp;</td> <td>Elevated C16-, C16:1-, C18, C18:1-</td> </tr> <tr> <td>CPT1D</td> <td>Carnitine palmitoyl-transferase 1A deficiency</td> <td><em>CPT1A</em></td> <td>1 in 500,000</td> <td>G, L</td> <td>Renal tubular acidosis, Arctic variant</td> <td>Elevated total and free plasma carnitine levels</td> </tr> <tr> <td>CPT2D</td> <td>Carnitine palmitoyl-transferase 2 deficiency</td> <td><em>CPT2</em></td> <td>&nbsp;</td> <td>G, L, C, M, R</td> <td>Renal cysts, facial dysmorphism</td> <td>Elevated C16-, C16:1-, C18, C18:1-</td> </tr> <tr> <td>MCADD</td> <td>Medium-chain acyl-CoA dehydrogenase deficiency</td> <td><em>ACADM</em></td> <td>1 in 20,000</td> <td>G, L</td> <td>&nbsp;</td> <td>Elevated C6-, C8-, C10-, C10:1-</td> </tr> <tr> <td>MADD</td> <td>Multiple acyl-CoA dehydrogenase deficiency</td> <td><em>ETFA, ETFB, ETFDH</em></td> <td>&nbsp;</td> <td>G, L, C, M</td> <td>Renal cysts, congenital malformations, facial dysmorphism, sweaty foot odor</td> <td>Elevated C4-, C5-, C5DC-, C6-, C8-, C10:1-, C12-, C14-, C14:1-, C16-, C16:1-, C18-, C18:1-, C16-OH-, C16:1-OH-, C18-OH-, C18:1-OH-</td> </tr> <tr> <td>SCADD</td> <td>Short-chain acyl-CoA dehydrogenase deficiency</td> <td><em>ACADS</em></td> <td>1 in 35,000 to 50,000</td> <td>&nbsp;</td> <td>Asymptomatic</td> <td>Elevated C4-</td> </tr> <tr> <td>M/SCHAD</td> <td>Short-chain l-3-hydroxyacyl-CoA dehydrogenase deficiency</td> <td><em>HADH</em></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Hyperinsulinism</td> <td>Elevated C4-OH-</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><em>ACADVL</em>: acyl-CoA dehydrogenase, very long chain gene; G: hypoglycemia; L: liver dysfunction; C: cardiomyopathy; M: skeletal myopathy; R: rhabdomyolysis; <em>HADHA:</em> hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), alpha subunit; <em>HADHB</em>: hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), beta subunit; <em>SLC22A5</em>: solute carrier family 22 member 5 gene; NBS: newborn screening; <em>SLC25A20</em>: solute carrier family 25 member 20 gene; <em>CPT1A</em>: carnitine palmitoyltransferase 1A; <em>CPT2</em>: carnitine palmitoyltransferase 2; <em>ACADM</em>: acyl-CoA dehydrogenase, C-4 to C-12 straight chain; <em>ETFA</em>: electron transfer flavoprotein, alpha subunit; <em>ETFB</em>: electron transfer flavoprotein, beta subunit; <em>ETFDH</em>: electron transfer flavoprotein dehydrogenase; <em>ACADS</em>: acyl-CoA dehydrogenase, C-2 to C-3 short chain; <em>HADH</em>: hydroxyacyl-CoA dehydrogenase.</div><div class=\"graphic_reference\">Adapted from: Sun A, Merritt JW II. Orphan drugs in development for long-chain fatty acid oxidation disorders: Challenges and progress. Orph Drug Res Rev 2015; 5:33.</div><div id=\"graphicVersion\">Graphic 114663 Version 2.0</div></div></div>"},"114666":{"type":"graphic_picture","displayName":"Two-out stretching program for throwers","title":"Two-out stretching program for throwers","html":"<div class=\"graphic\"><div style=\"width: 903px\" class=\"figure\"><div class=\"ttl\">Two-out stretching program for throwers</div><div class=\"cntnt\"><img style=\"width:883px; height:1684px;\" src=\"images/SM/114666_2ot_strtchng_prgrm_throwers.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IR: internal rotation; ER: external rotation.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT.</div><div id=\"graphicVersion\">Graphic 114666 Version 1.0</div></div></div>"},"114668":{"type":"graphic_table","displayName":"Blood chemical constituent changes during pregnancy","title":"Blood chemical constituent changes during pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Blood chemical constituent changes during pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"4\" width=\"17.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Nonpregnant adult</td> <td class=\"subtitle1\">First trimester</td> <td class=\"subtitle1\">Second trimester</td> <td class=\"subtitle1\">Third trimester</td> </tr> <tr> <td><strong>Alanine aminotransferase</strong> (unit/L)</td> <td class=\"centered\">7 to 41</td> <td class=\"centered\">3 to 30</td> <td class=\"centered\">2 to 33</td> <td class=\"centered\">2 to 25</td> </tr> <tr> <td><strong>Albumin</strong> (g/dL)</td> <td class=\"centered\">4.1 to 5.3</td> <td class=\"centered\">3.1 to 5.1</td> <td class=\"centered\">2.6 to 4.5</td> <td class=\"centered\">2.3 to 4.2</td> </tr> <tr> <td><strong>Alkaline phosphatase</strong> (unit/L)</td> <td class=\"centered\">33 to 96</td> <td class=\"centered\">17 to 88</td> <td class=\"centered\">25 to 126</td> <td class=\"centered\">38 to 229</td> </tr> <tr> <td><strong>Alpha-1 antitrypsin</strong> (mg/dL)</td> <td class=\"centered\">100 to 200</td> <td class=\"centered\">225 to 323</td> <td class=\"centered\">273 to 391</td> <td class=\"centered\">327 to 487</td> </tr> <tr> <td><strong>Alpha-fetoprotein</strong> (ng/mL)</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">Approximately 130 to 400</td> <td class=\"centered\">Approximately 130 to 590</td> </tr> <tr> <td><strong>Ammonia</strong> (micrometer)</td> <td class=\"centered\">31.0&#177;3.2</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">27.3&#177;1.6</td> </tr> <tr> <td><strong>Amylase</strong> (unit/L)</td> <td class=\"centered\">20 to 96</td> <td class=\"centered\">24 to 83</td> <td class=\"centered\">16 to 73</td> <td class=\"centered\">15 to 81</td> </tr> <tr> <td><strong>Anion gap</strong> (mmol/L)</td> <td class=\"centered\">7 to 16</td> <td class=\"centered\">13 to 17</td> <td class=\"centered\">12 to 16</td> <td class=\"centered\">12 to 16</td> </tr> <tr> <td><strong>Aspartate aminotransferase</strong> (unit/L)</td> <td class=\"centered\">12 to 38</td> <td class=\"centered\">3 to 23</td> <td class=\"centered\">3 to 33</td> <td class=\"centered\">4 to 32</td> </tr> <tr> <td><strong>Bicarbonate</strong> (mmol/L)</td> <td class=\"centered\">22 to 30</td> <td class=\"centered\">20 to 24</td> <td class=\"centered\">20 to 24</td> <td class=\"centered\">20 to 24</td> </tr> <tr> <td><strong>Bilirubin, total</strong> (mg/dL)</td> <td class=\"centered\">0.3 to 1.3</td> <td class=\"centered\">0.1 to 0.4</td> <td class=\"centered\">0.1 to 0.8</td> <td class=\"centered\">0.1 to 1.1</td> </tr> <tr> <td><strong>Bilirubin, unconjugated</strong> (mg/dL)</td> <td class=\"centered\">0.2 to 0.9</td> <td class=\"centered\">0.1 to 0.5</td> <td class=\"centered\">0.1 to 0.4</td> <td class=\"centered\">0.1 to 0.5</td> </tr> <tr> <td><strong>Bilirubin, conjugated</strong> (mg/dL)</td> <td class=\"centered\">0.1 to 0.4</td> <td class=\"centered\">0.0 to 0.1</td> <td class=\"centered\">0.0 to 0.1</td> <td class=\"centered\">0.0 to 0.1</td> </tr> <tr> <td><strong>Bile acids</strong> (micromol/L)</td> <td class=\"centered\">0.3 to 4.8</td> <td class=\"centered\">0.0 to 4.9</td> <td class=\"centered\">0.0 to 9.1</td> <td class=\"centered\">0.0 to 11.3</td> </tr> <tr> <td><strong>CA-125</strong> (microgram/mL)</td> <td class=\"centered\">7.2 to 27.0</td> <td class=\"centered\">2.2 to 268.0</td> <td class=\"centered\">12.0 to 25.1</td> <td class=\"centered\">16.8 to 43.8</td> </tr> <tr> <td><strong>Calcium, ionized</strong> (mg/dL)</td> <td class=\"centered\">4.5 to 5.3</td> <td class=\"centered\">4.5 to 5.1</td> <td class=\"centered\">4.4 to 5.0</td> <td class=\"centered\">4.4 to 5.3</td> </tr> <tr> <td><strong>Calcium, total</strong> (mg/dL)</td> <td class=\"centered\">8.7 to 10.2</td> <td class=\"centered\">8.8 to 10.6</td> <td class=\"centered\">8.2 to 9.0</td> <td class=\"centered\">8.2 to 9.7</td> </tr> <tr> <td><strong>Ceruloplasmin</strong> (mg/dL)</td> <td class=\"centered\">25 to 63</td> <td class=\"centered\">30 to 49</td> <td class=\"centered\">40 to 53</td> <td class=\"centered\">43 to 78</td> </tr> <tr> <td><strong>Chloride</strong> (mEq/L)</td> <td class=\"centered\">102 to 109</td> <td class=\"centered\">101 to 105</td> <td class=\"centered\">97 to 109</td> <td class=\"centered\">97 to 109</td> </tr> <tr> <td><strong>Creatinine</strong> (mg/dL)</td> <td class=\"centered\">0.5 to 0.9</td> <td class=\"centered\">0.4 to 0.7</td> <td class=\"centered\">0.4 to 0.8</td> <td class=\"centered\">0.4 to 0.9</td> </tr> <tr> <td><strong>Gamma-glutamyl transpeptidase</strong> (unit/L)</td> <td class=\"centered\">9 to 58</td> <td class=\"centered\">2 to 23</td> <td class=\"centered\">4 to 22</td> <td class=\"centered\">3 to 26</td> </tr> <tr> <td><strong>Lactate dehydrogenase</strong> (unit/L)</td> <td class=\"centered\">115 to 221</td> <td class=\"centered\">78 to 433</td> <td class=\"centered\">80 to 447</td> <td class=\"centered\">82 to 524</td> </tr> <tr> <td><strong>Lipase</strong> (unit/L)</td> <td class=\"centered\">3 to 43</td> <td class=\"centered\">21 to 76</td> <td class=\"centered\">26 to 100</td> <td class=\"centered\">41 to 112</td> </tr> <tr> <td><strong>Magnesium</strong> (mg/dL)</td> <td class=\"centered\">1.5 to 2.3</td> <td class=\"centered\">1.6 to 2.2</td> <td class=\"centered\">1.5 to 2.2</td> <td class=\"centered\">1.1 to 2.2</td> </tr> <tr> <td><strong>Osmolality</strong> (mOsm/kg H<sub>2</sub>O)</td> <td class=\"centered\">275 to 295</td> <td class=\"centered\">275 to 280</td> <td class=\"centered\">276 to 289</td> <td class=\"centered\">278 to 280</td> </tr> <tr> <td><strong>Phosphate</strong> (mg/dL)</td> <td class=\"centered\">2.5 to 4.3</td> <td class=\"centered\">3.1 to 4.6</td> <td class=\"centered\">2.5 to 4.6</td> <td class=\"centered\">2.8 to 4.6</td> </tr> <tr> <td><strong>Potassium</strong> (mEq/L)</td> <td class=\"centered\">3.5 to 5.0</td> <td class=\"centered\">3.6 to 5.0</td> <td class=\"centered\">3.3 to 5.0</td> <td class=\"centered\">3.3 to 5.1</td> </tr> <tr> <td><strong>Prealbumin</strong> (mg/dL)</td> <td class=\"centered\">17 to 34</td> <td class=\"centered\">15 to 27</td> <td class=\"centered\">20 to 27</td> <td class=\"centered\">14 to 23</td> </tr> <tr> <td><strong>Protein, total</strong> (g/dL)</td> <td class=\"centered\">6.7 to 8.6</td> <td class=\"centered\">6.2 to 7.6</td> <td class=\"centered\">5.7 to 6.9</td> <td class=\"centered\">5.6 to 6.7</td> </tr> <tr> <td><strong>Sodium</strong> (mEq/L)</td> <td class=\"centered\">136 to 146</td> <td class=\"centered\">133 to 148</td> <td class=\"centered\">129 to 148</td> <td class=\"centered\">130 to 148</td> </tr> <tr> <td><strong>Urea nitrogen</strong> (mg/dL)</td> <td class=\"centered\">7 to 20</td> <td class=\"centered\">7 to 12</td> <td class=\"centered\">3 to 13</td> <td class=\"centered\">3 to 11</td> </tr> <tr> <td><strong>Uric acid</strong> (mg/dL)</td> <td class=\"centered\">2.5 to 5.6</td> <td class=\"centered\">2.0 to 4.2</td> <td class=\"centered\">2.4 to 4.9</td> <td class=\"centered\">3.1 to 6.3</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Cunningham FG, Leveno KJ, Bloom SL, et al. Williams Obstetrics, 24th ed, McGraw-Hill Education, 2014. Copyright &copy; 2014 McGraw-Hill Education. McGraw-Hill Education makes no representations or warranties as to the accuracy of any information contained in the McGraw-Hill Education Material, including any warranties of merchantability or fitness for a particular purpose. In no event shall McGraw-Hill Education have any liability to any party for special, incidental, tort, or consequential damages arising out of or in connection with the McGraw-Hill Education Material, even if McGraw-Hill Education has been advised of the possibility of such damages.</div><div id=\"graphicVersion\">Graphic 114668 Version 1.0</div></div></div>"},"114669":{"type":"graphic_figure","displayName":"Invasive disease-free survival: Anthracyclines early breast ca","title":"Invasive disease-free survival with anthracyclines in early breast cancer","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Invasive disease-free survival with anthracyclines in early breast cancer</div><div class=\"cntnt\"><img style=\"width:598px; height:728px;\" src=\"images/ONC/114669_Invs_d_f_s_Anthrcy_e_brst_c.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Forest plots of (panel A) invasive disease-free survival hazard ratio (HR) according to stratification variables, and (panel B) with test for interaction by combined hormone receptor and nodal status. TaxAC, doxorubicin, and cyclophosphamide regimens with a taxane; TC, docetaxel, and cyclophosphamide.</div><div class=\"graphic_footnotes\">TC: docetaxel/cyclophosphamide; TaxAC: paclitaxel/doxorubicin/cyclophosphamide; HR: hazard ratio.</div><div class=\"graphic_reference\">From: Blum JL, Flynn PJ, Yothers G, et al. Anthracyclines in early breast cancer: The ABC trials&mdash;USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol 2017; Vol. 35(23):2647-2655. Reprinted with permission &copy; 2017 American Society of Clinical Oncology.</div><div id=\"graphicVersion\">Graphic 114669 Version 1.0</div></div></div>"},"114670":{"type":"graphic_table","displayName":"Pretest counseling expanded genetic screening in pregnancy","title":"Pretest counseling before preconception or prenatal expanded genetic screening","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pretest counseling before preconception or prenatal expanded genetic screening</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Explain that testing is optional </li> </ul> </td> </tr> <tr> <td> <ul> <li>Calculate the patient's a priori risk for each condition based on age, family history, maternal health, or environmental exposures </li> </ul> </td> </tr> <tr> <td> <ul> <li>Explain that screening and diagnostic testing options are available to all women </li> </ul> </td> </tr> <tr> <td> <ul> <li>Clarify the difference between the two types of testing </li> </ul> </td> </tr> <tr> <td> <ul> <li>Review clinical features and variability of conditions for which testing may be available </li> </ul> </td> </tr> <tr> <td> <ul> <li>Describe technology of the test </li> </ul> </td> </tr> <tr> <td> <ul> <li>Describe performance of the test: sensitivity/specificity, positive/negative predictive value, risk/benefit </li> </ul> </td> </tr> <tr> <td> <ul> <li>Explain that negative or low-risk screening result does not guarantee a healthy child </li> </ul> </td> </tr> <tr> <td> <ul> <li>Explain that positive or high-risk screening result does not mean fetus is affected </li> </ul> </td> </tr> <tr> <td> <ul> <li>Review the concept of residual risk </li> </ul> </td> </tr> <tr> <td> <ul> <li>Discuss cost of testing </li> </ul> </td> </tr> <tr> <td> <ul> <li>Discuss potential for unanticipated information, variant of uncertain significance, incidental findings </li> </ul> </td> </tr> <tr> <td> <ul> <li>Discuss timing and format of test results disclosure </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 114670 Version 1.0</div></div></div>"},"114677":{"type":"graphic_picture","displayName":"Spine alignment inspection","title":"Spine alignment inspection","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Spine alignment inspection</div><div class=\"cntnt\"><img style=\"width:548px; height:412px;\" src=\"images/SM/114677_Spinealignmentinspection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Assessment of patient function and gait includes inspection of the spine. Normal alignment in the coronal plane (image A) and normal curvature in the sagittal plane (image B) are seen in the photographs above.<br />(A) Frontal plane scoliosis check.<br />(B) Sagittal plane kyphosis lordosis check.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114677 Version 1.0</div></div></div>"},"114678":{"type":"graphic_picture","displayName":"Toe-in and toe-out gait","title":"Toe-in and toe-out gait","html":"<div class=\"graphic\"><div style=\"width: 649px\" class=\"figure\"><div class=\"ttl\">Toe-in and toe-out gait</div><div class=\"cntnt\"><img style=\"width:629px; height:653px;\" src=\"images/SM/114678_Toeintoeoutgait.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Common gait variants include (image A) toe-in (or \"in-toeing\") and (image B and C) toe-out (or \"out-toeing\"), as shown in the photographs above.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114678 Version 1.0</div></div></div>"},"114679":{"type":"graphic_picture","displayName":"Heel varus and valgus","title":"Heel varus and valgus","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Heel varus and valgus</div><div class=\"cntnt\"><img style=\"width:720px; height:497px;\" src=\"images/SM/114679_Heelvarusvalgus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inspection of the hindfoot should include an assessment of heel varus and heel valgus.<br />(A) Heel varus (right foot).<br />(B) Heel valgus (bilateral).</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114679 Version 1.0</div></div></div>"},"114680":{"type":"graphic_picture","displayName":"Hip adduction during mid-stance of gait","title":"Hip adduction during mid-stance of gait","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hip adduction during mid-stance of gait</div><div class=\"cntnt\"><img style=\"width:400px; height:679px;\" src=\"images/SM/114680_Hipaddctnmidstancegait.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During the midstance phase of walking or running gait, the hip of the supporting leg adducts and there is a slight tilt of the pelvis towards the unsupported (swing) leg.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114680 Version 1.0</div></div></div>"},"114681":{"type":"graphic_picture","displayName":"Hip extension and anterior pelvic tilt during running gait","title":"Hip extension and anterior pelvic tilt during running gait","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hip extension and anterior pelvic tilt during running gait</div><div class=\"cntnt\"><img style=\"width:428px; height:523px;\" src=\"images/SM/114681_Hpxtsnantrplvctltrngt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The combination of hip extension (dashed line) and anterior pelvic tilt (solid line) enables runners to maximize foot contact with the ground. However, excessive anterior pelvic tilt can lead to injury.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114681 Version 1.0</div></div></div>"},"114682":{"type":"graphic_table","displayName":"Surgical options for male posterior urethral injuries","title":"Surgical options for male posterior urethral injuries","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Surgical options for male posterior urethral injuries</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"5\" width=\"22.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Realignment</td> <td class=\"subtitle1\" colspan=\"2\">Repair</td> </tr> <tr> <td class=\"subtitle2\">Endoscopic</td> <td class=\"subtitle2\">Open</td> <td class=\"subtitle2\">Endoscopic</td> <td class=\"subtitle2\">Open</td> </tr> <tr class=\"divider_bottom\"> <td>Immediate</td> <td> <ul> <li>Performed within 24 to 72 hours post-injury. </li> <li>May be attempted in hemodynamically stable patients. </li> <li>Should be accomplished with minimal manipulation; avoid prolonged attempts or excessive irrigation. </li> <li>May be associated with restricturing, incontinence, erectile dysfunction, or injury to the rectum. </li> </ul> </td> <td> <ul> <li>Performed within 24 to 72 hours post-injury. </li> <li>May reduce stricture length or severity in some patients. </li> <li>May be associated with stricture recurrence. </li> <li>Generally <strong>not recommended</strong> due to the risk of significant bleeding from a retropubic hematoma with the open approach. </li> </ul> </td> <td>&nbsp;</td> <td> <ul> <li>Only appropriate when there is concomitant bladder neck or rectal injury, or another indication for open laparotomy. </li> <li>Otherwise <strong>not recommended</strong> due to high rates of blood loss, impotence, incontinence, and stricture recurrence. </li> </ul> </td> </tr> <tr> <td>Delayed</td> <td> <ul> <li>Performed 5 to 7 days post-injury, typically in conjunction with another procedure (eg, orthopedics). </li> <li>May reduce the stricture length or severity in some patients. </li> <li>Avoid prolonged attempts or excessive irrigation. </li> </ul> </td> <td>&nbsp;</td> <td> <ul> <li>Used to be performed 3 to 6 months post-injury for very short distraction defects. </li> <li>Associated with a high risk of stricture recurrence or injury to the rectum. </li> <li>Generally <strong>not recommended</strong>. </li> </ul> </td> <td> <ul> <li>Performed 3 to 6 months post-injury. </li> <li>Our <strong>preferred approach</strong> to the majority of patients with a traumatic posterior urethral injury. </li> <li>Typically accomplished with a one-stage perineal anastomotic urethroplasty. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For the majority of patients with a posterior urethral injury related to pelvic fracture, treatment options include immediate endoscopic realignment versus early suprapubic tube drainage/delayed open reconstruction with a perineal anastomotic urethroplasty. We prefer delayed reconstruction to immediate realignment; refer to UpToDate topic for an explanation.<br />Immediate open repair and delayed endoscopic realignment are performed occasionally in patients who require operative intervention for an unrelated reason (eg, trauma or orthopedic). <br />Immediate open realignment and delayed endoscopic repair are&nbsp;generally no&nbsp;longer&nbsp;performed due to high risks of complications and better alternatives.</div><div id=\"graphicVersion\">Graphic 114682 Version 1.0</div></div></div>"},"114683":{"type":"graphic_algorithm","displayName":"Ectopic pregnancy expect mng","title":"Algorithm: Expectant management of ectopic pregnancy","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Algorithm: Expectant management of ectopic pregnancy</div><div class=\"cntnt\"><img style=\"width:541px; height:683px;\" src=\"images/OBGYN/114683_Ectopicpregnancyexpectmg.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">hCG: human chorionic gonadotropin; TVUS: transvaginal ultrasound.<br />* Severe or persistent lower abdominal pain and/or evidence of hematoperitoneum.<br />¶ Serum quantitative beta-hCG.<br />Δ We define a decreasing hCG as a &gt;10% decrease across two consecutive measurements.<br /><FONT class=lozenge>◊</FONT> If no mass is visualized sonographically, there is a high likelihood that a tubal pregnancy will not be visualized or palpated at surgery, and the surgery may be unnecessary or unsuccessful.</div><div id=\"graphicVersion\">Graphic 114683 Version 1.0</div></div></div>"},"114685":{"type":"graphic_picture","displayName":"Midfoot and forefoot strike patterns during gait","title":"Midfoot and forefoot strike patterns during gait","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Midfoot and forefoot strike patterns during gait</div><div class=\"cntnt\"><img style=\"width:720px; height:447px;\" src=\"images/SM/114685_Midftforeftstrkpatgait.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Midfoot strike.<br />(B) Forefoot strike.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114685 Version 1.0</div></div></div>"},"114686":{"type":"graphic_picture","displayName":"Excessive pronation with arch collapse during gait","title":"Excessive pronation with arch collapse during gait","html":"<div class=\"graphic\"><div style=\"width: 788px\" class=\"figure\"><div class=\"ttl\">Excessive pronation with arch collapse during gait</div><div class=\"cntnt\"><img style=\"width:768px; height:392px;\" src=\"images/SM/114686_Excsprntnarchcollpsgait.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photographs above show a runner in the mid-stance phase of gait who demonstrates excessive foot pronation associated with collapse of the arch (ie, marked navicular drop).</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114686 Version 1.0</div></div></div>"},"114688":{"type":"graphic_table","displayName":"Treatment of babesioisis in immunocompetent patients","title":"Antibiotic regimens for treatment of <em>Babesia microti</em> infection in immunocompetent patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antibiotic regimens for treatment of <em>Babesia microti</em> infection in immunocompetent patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease severity</td> <td class=\"subtitle1\">Adult dosing</td> <td class=\"subtitle1\">Pediatric dosing</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Mild to moderate disease*</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"3\">Preferred regimen</td> <td>Azithromycin <ul class=\"decimal_heading\"> <li>500 mg/day orally on day 1; </li> <li>250 mg/day orally from day 2 on </li> </ul> </td> <td>Azithromycin <ul class=\"decimal_heading\"> <li>10 mg/kg/day orally on day 1 (maximum 500 mg/dose); </li> <li>5 mg/kg/day orally from day 2 on (maximum 250 mg/dose) </li> </ul> </td> </tr> <tr> <td><strong>PLUS</strong></td> <td><strong>PLUS</strong></td> </tr> <tr class=\"divider_bottom\"> <td>Atovaquone <ul class=\"decimal_heading\"> <li>750 mg orally every 12 hours </li> </ul> </td> <td>Atovaquone <ul class=\"decimal_heading\"> <li>20 mg/kg orally every 12 hours (maximum 750 mg/dose) </li> </ul> </td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"3\">Alternative regimen</td> <td>Clindamycin <ul class=\"decimal_heading\"> <li>600 mg orally every 8 hours </li> </ul> </td> <td>Clindamycin <ul class=\"decimal_heading\"> <li>7 to 10 mg/kg orally every 6 to 8 hours (maximum 600 mg/dose) </li> </ul> </td> </tr> <tr> <td><strong>PLUS</strong></td> <td><strong>PLUS</strong></td> </tr> <tr class=\"divider_bottom\"> <td>Quinine <ul class=\"decimal_heading\"> <li>650 mg orally every 6 to 8 hours </li> </ul> </td> <td>Quinine <ul class=\"decimal_heading\"> <li>8 mg/kg orally every 8 hours (maximum 650 mg/dose) </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Severe disease<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"3\">Preferred regimen</td> <td>Azithromycin <ul class=\"decimal_heading\"> <li>500 mg/day IV </li> </ul> </td> <td>Azithromycin<sup>&#916;</sup> <ul class=\"decimal_heading\"> <li>10 mg/kg/day IV (maximum 500 mg/dose) </li> </ul> </td> </tr> <tr> <td><strong>PLUS</strong></td> <td><strong>PLUS</strong></td> </tr> <tr class=\"divider_bottom\"> <td>Atovaquone <ul class=\"decimal_heading\"> <li>750 mg orally every 12 hours </li> </ul> </td> <td>Atovaquone <ul class=\"decimal_heading\"> <li>20 mg/kg orally every 12 hours (maximum 750 mg/dose) </li> </ul> </td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Alternative regimen</td> <td>Clindamycin <ul class=\"decimal_heading\"> <li>300 to 600 mg IV every 6 hours </li> </ul> </td> <td>Clindamycin <ul class=\"decimal_heading\"> <li>7 to 10 mg/kg IV every 6 to 8 hours (maximum 600 mg/dose) </li> </ul> </td> </tr> <tr> <td><strong>PLUS</strong></td> <td><strong>PLUS</strong></td> </tr> <tr> <td>Quinine <ul class=\"decimal_heading\"> <li>650 mg orally every 6 to 8 hours </li> </ul> </td> <td>Quinine <ul class=\"decimal_heading\"> <li>8 mg/kg orally every 8 hours (maximum 650 mg/dose) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenously.<br />* The duration of therapy is 7 to 10 days.<br />¶ The duration of therapy is 7 to 10 days, although a more extended course of therapy may be needed. Intravenous azithromycin (or clindamycin) can be replaced with oral therapy once symptoms have abated and parasitemia has been reduced. <br />Δ There have been no studies of pediatric IV azithromycin dosing for babesiosis.</div><div id=\"graphicVersion\">Graphic 114688 Version 1.0</div></div></div>"},"114689":{"type":"graphic_algorithm","displayName":"Approach to diagnosis of congenital Chagas disease","title":"Approach to diagnosis of congenital Chagas disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Approach to diagnosis of congenital Chagas disease</div><div class=\"cntnt\"><img style=\"width:447px; height:557px;\" src=\"images/ID/114689_Appr_dx_congentl_Chagas_dss.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PCR: polymerase chain reaction. <br />* Pregnant women who warrant screening include those who have lived or spent significant periods of time in areas of Latin America with vector-borne transmission, especially those who lived in houses with adobe walls and/or thatched roofs. (Refer to the UpToDate topic on epidemiology of Chagas disease for further discussion.)<br />&para; Further follow-up should be arranged for maternal evaluation and treatment for Chagas disease after completion of lactation. In addition, testing for Chagas disease should be pursued for the mother's other children (if any). (Refer to UpToDate topic on diagnosis of Chagas disease for further discussion.)<br />&Delta; Positive microscopy in fresh blood or buffy coat is sufficient to make the diagnosis; however, the sensitivity is &lt;30% in a single specimen. The sensitivity of PCR in a single specimen is 65 to 75%. Thus, PCR is often positive despite negative microscopy.<br /><span class=\"lozenge\">&loz;</span> Interpretation of PCR results and threshold for positivity depends on the assay used and the local laboratory threshold. In general, positive PCR results with high parasite load (eg, &gt;100 parasite equivalents per mL, where estimated detection threshold is &lt;1 parasite equivalent per mL) in an experienced laboratory is sufficient to establish the diagnosis. The diagnosis may also be established by two positive PCR results in two separate specimens, regardless of parasite load. Occasionally transiently positive PCR results with low parasite load (usually &lt;50 parasite equivalents per mL) occur in uninfected infants, especially soon after birth. In such cases, a repeat specimen should be tested for microscopy and PCR in 1 to 3 weeks.</div><div id=\"graphicVersion\">Graphic 114689 Version 1.0</div></div></div>"},"114699":{"type":"graphic_diagnosticimage","displayName":"Radiograph of pubic symphysis separation","title":"Radiograph of pubic symphysis separation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiograph of pubic symphysis separation</div><div class=\"cntnt\"><img style=\"width:409px; height:430px;\" src=\"images/OBGYN/114699_Rdiogrphpbcsymphysssprtn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Conventional radiograph of the pelvis demonstrating a symphysis widening of 14.5 mm, consistent with pubic symphysis separation.</div><div class=\"graphic_reference\">Reproduced from: Herren C, Sobottke R, Dadgar A, et al. Peripartum pubic synphysis separation&mdash;current strategies in disagnosis and therapy and presentation of two cases. Injury 2015; 46:1074. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 114699 Version 1.0</div></div></div>"},"114700":{"type":"graphic_algorithm","displayName":"Management of retropharyngeal abscess in children","title":"Management of retropharyngeal abscess in children","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Management of retropharyngeal abscess in children</div><div class=\"cntnt\"><img style=\"width:520px; height:900px;\" src=\"images/EM/114700_Mgmtretrphrynglabscschld.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">OR: operating room; CT: computed tomography; IV: intravenous.<br />* The differential diagnosis of retropharyngeal infection includes other conditions that cause upper airway obstruction, sore throat, and/or neck stiffness. The diagnosis of retropharyngeal cellulitis or abscess is made by a combination of physical findings and confirmatory imaging. For further discussion, refer to UpToDate topics on retropharyngeal infections in children.<br />&para; CT of the neck with intravenous contrast is the best tool to identify abscesses in the retropharyngeal area. Anesthesiology and otolaryngology should be consulted and present for CT if significant airway compromise is anticipated from positioning or sedation during the procedure.<br />&Delta; For specific antibiotic recommendations, refer to UpToDate topics on retropharyngeal infections. Empiric therapy should include coverage for Group A Streptococcus, <em>Staphylococcus aureus</em> and respiratory anaerobes. The choice of initial antibiotics should take into account the severity of disease and the local prevalence of methicillin-resistant <em>S. aureus</em>. Empiric therapy can be amended as necessary based upon culture results if drainage is performed or clinical response to treatment. When tailoring therapy based upon culture results, it is important to bear in mind that retropharyngeal infections are frequently polymicrobial and not all microbes are consistently cultured.</div><div id=\"graphicVersion\">Graphic 114700 Version 2.0</div></div></div>"},"114701":{"type":"graphic_picture","displayName":"Image of support brace for pubis symphysis and pelvis","title":"Image of support brace for pubis symphysis and pelvis","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Image of support brace for pubis symphysis and pelvis</div><div class=\"cntnt\"><img style=\"width:510px; height:762px;\" src=\"images/OBGYN/114701_Imsprtbrcpbssyphysplvs.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Example of a symphysis/pelvic belt brace.</div><div class=\"graphic_reference\">Reproduced from: Herren C, Sobottke R, Dadgar A, et al. Peripartum pubic synphysis separation&mdash;current strategies in disagnosis and therapy and presentation of two cases. Injury 2015; 46:1074. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 114701 Version 1.0</div></div></div>"},"114703":{"type":"graphic_table","displayName":"Pelvic pain provocation tests","title":"Pelvic pain provocation tests","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pelvic pain provocation tests</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ol class=\"numbers_to_nine\"> <li><strong>Posterior pain pelvic provocation test (P4 test):</strong> The patient lies supine and the hip is flexed to 90 degrees. Downward pressure is applied to the knee along the axis of the femur. A positive test will elicit pain in the gluteal region. The reported sensitivity and specificity are&nbsp;approximately 80% for each.&nbsp; </li> </ol> </td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"2\"> <li><strong>Patrick FABER test (Flexion, Abduction and External Rotation test):</strong> The patient lies supine with the hips flexed; the leg is externally rotated and abducted with the ipsilateral heel resting on the opposite knee. This test is positive if it elicits pain in the ipsilateral joints of the pelvis. The sensitivity and specificity reported by Albert et al were 0.40 to 0.70 and 0.99, respectively. </li> </ol> </td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"3\"> <li><strong>Long dorsal sacroiliac ligament palpation:</strong> If the pain lasts for &#62;5 seconds after the examiner removes his/her hand, it is recorded as pain; if the pain lasts for &#60;5 seconds, it is recorded as tenderness. The reported sensitivity and specificity are 0.35 and 0.98, respectively. </li> </ol> </td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"4\"> <li><strong>Active straight leg raise test:</strong> With the patient lying supine, she is asked to raise one leg at a time approximately 20 cm off the table, with the knee straight. The degree of difficulty in performing this test is an indicator of the severity of the condition. The sensitivity and specificity are 0.87 and 0.94, respectively. </li> </ol> </td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"5\"> <li><strong>Pain at palpation of the pubic symphysis:</strong> After the examiner removes the palpating hand, pain lasting for &#62;5 seconds is considered positive. The reported sensitivity and specificity are 0.60 to 0.81 and 0.99, respectively. </li> </ol> </td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"6\"> <li><strong>Modified Trendelenburg test:</strong> The patient stands on one leg and flexes the hip and knee at 90 degrees. Pain experienced in the symphysis is considered positive. </li> </ol> </td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"7\"> <li><strong>Menell's test:</strong> With the patient supine, one leg is moved into 30 degrees&nbsp;abduction and 10 degrees&nbsp;flexion in the hip joint and is pushed and pulled out from the pelvis thereby resulting in sagittal movement. The sensitivity and specificity are 0.54 to 0.70 and 1.00. </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Bhardwaj A, Nagandla K. Musculoskeletal symptoms and orthopaedic complications in pregnancy: Pathophysiology, diagnostic approaches and modern management. Postgrad Med J 2014; 90:450-60. Copyright &copy; 2014 BMJ Publishing Group Ltd.</div><div id=\"graphicVersion\">Graphic 114703 Version 1.0</div></div></div>"},"114713":{"type":"graphic_algorithm","displayName":"Emergency vascular access for infants and children","title":"Emergency vascular access during resuscitation of infants and children","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Emergency vascular access during resuscitation of infants and children</div><div class=\"cntnt\"><img style=\"width:289px; height:331px;\" src=\"images/EM/114713_Vasclracsrsscttninfchld.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For further information on how to perform vascular (venous) access in infants in children, refer to UpToDate topics on vascular (venous) access for pediatric resuscitation and intraosseous infusion.</div><div class=\"graphic_footnotes\">* If peripheral veins can be reliably seen or palpated, insert two of the largest IV catheters that can be reliably placed (typically, 22 to 24 gauge IV in infants and 18 to 20 gauge in children). Potential sites include the upper and lower extremities, the scalp, and the external jugular vein. Refer to UpToDate topics on vascular (venous) access for pediatric resuscitation and other pediatric emergencies.<br />&para; Intraosseous access using a battery-powered device is recommended. The proximal tibia site is preferred unless otherwise contraindicated (eg, fractured bone or vascular interruption of the extremity).<br />&Delta; Whenever possible, central lines should be placed under ultrasound guidance. In infants and children undergoing cardiopulmonary resuscitation, the femoral vein site is the preferred. <br /><span class=\"lozenge\">&loz;</span> Typical site is the saphenous vein.</div><div id=\"graphicVersion\">Graphic 114713 Version 1.0</div></div></div>"},"114721":{"type":"graphic_figure","displayName":"Incision for carpel tunnel release","title":"Incision for carpel tunnel release","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Incision for carpel tunnel release</div><div class=\"cntnt\"><img style=\"width:446px; height:512px;\" src=\"images/SURG/114721_Upperfasciotomy16.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Landmarks for the incision for carpel tunnel release. </div><div class=\"graphic_reference\">Modified from: Chetta MD, Chung KC. Compartment syndrome. In: Essentials of Hand Surgery, Chung KC (Ed), JP Medical Ltd, London 2015.</div><div id=\"graphicVersion\">Graphic 114721 Version 1.0</div></div></div>"},"114726":{"type":"graphic_algorithm","displayName":"Management of primary tumor in penile carcinoma","title":"Management of primary tumor in penile carcinoma","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Management of primary tumor in penile carcinoma</div><div class=\"cntnt\"><img style=\"width:531px; height:327px;\" src=\"images/ONC/114726_Mgmt_prmry_tumor_penile_CA.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Enrollment in a formal clinical trial whenever possible.<br />¶ Definitive surgery following neoadjuvant chemotherapy when feasible, otherwise palliative care.<br />Δ Tis involving shaft skin and glans penis, Ta lesion involving shaft skin or glans only, or T1a/T1b lesion involving the shaft skin glans alone.<br /><FONT class=lozenge>◊</FONT> Bulky primary T2-T4 involving glans, corpora, or adjacent structures.<br />§ Limited excision is preferred and requires excision to negative margins. Other organ-preserving alternatives include topical therapy, laser ablation, total glans resurfacing, Mohs micrographic surgery, and radiation therapy.<br />¥ Careful surveillance is required because of the risk of local or regional recurrence.<br />‡ Penile amputation may require either partial or total removal of the penis, depending upon the location and extent of the primary tumor. Some patients with smaller lesions can be treated with more limited excision, as long as a tumor-free margin can be achieved.</div><div id=\"graphicVersion\">Graphic 114726 Version 1.0</div></div></div>"},"114727":{"type":"graphic_algorithm","displayName":"Management of nonpalpable regional lymph nodes in penile SCC","title":"Management of nonpalpable regional lymph nodes in penile squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Management of nonpalpable regional lymph nodes in penile squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:539px; height:299px;\" src=\"images/PALC/114727_Nplp_rgnl_lymph_nds_pnl_SCC.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">LND: lymph node dissection; DNSB: dynamic sentinel node biopsy.<br />* DSNB is limited to centers with appropriate expertise.<br />¶ Management with surveillance requires adequate compliance. DNSB or inguinal LND is an alternative if the patient is unable or unwilling to comply.<br />Δ If not completed as a component of initial lymph node evaluation.<br /><FONT class=lozenge>◊</FONT> Ipsilateral pelvic LND based upon ipsilateral findings at inguinal LND.</div><div id=\"graphicVersion\">Graphic 114727 Version 1.0</div></div></div>"},"114728":{"type":"graphic_algorithm","displayName":"Management of solitary lymph node <4 cm in penile SCC","title":"Management of solitary lymph node <4 cm in penile squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Management of solitary lymph node &lt;4 cm in penile squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:392px; height:351px;\" src=\"images/ONC/114728_Sltry_lph_nd_lt_4cm_pnl_SCC.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">LND: lymph node dissection; DSNB: dynamic sentinel node biopsy.</div><div id=\"graphicVersion\">Graphic 114728 Version 1.0</div></div></div>"},"114729":{"type":"graphic_algorithm","displayName":"Management of multiple or bilateral inguinal nodes in penile SCC","title":"Management of multiple or bilateral inguinal nodes in penile squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Management of multiple or bilateral inguinal nodes in penile squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:421px; height:237px;\" src=\"images/ONC/114729_Mltp_bilt_ingnl_nds_pnl_SCC.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">LND: lymph node dissection.<br />​* Pelvic LND performed based on multiple positive inguinal nodes or extranodal extension.<br />¶ Consider postoperative adjuvant therapy if ≥3 positive inguinal nodes, bilateral positive nodes, or pelvic nodes.</div><div id=\"graphicVersion\">Graphic 114729 Version 1.0</div></div></div>"},"114730":{"type":"graphic_picture","displayName":"Nitrocefin beta-lactamase test","title":"Nitrocefin beta-lactamase test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nitrocefin beta-lactamase test</div><div class=\"cntnt\"><img style=\"width:267px; height:187px;\" src=\"images/ID/114730_Nitrocefin_beta-lactams_tst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The organism of interest is placed onto a commercially available nitrocefin disk. Nitrocefin is a chromogenic cephalosporin; in the presence of a bacterial beta-lactamase that hydrolyzes the beta-lactam ring, the disk changes color from yellow to pink.</div><div id=\"graphicVersion\">Graphic 114730 Version 1.0</div></div></div>"},"114731":{"type":"graphic_picture","displayName":"Penicillin zone edge or \"beach and cliff\" test","title":"Penicillin zone edge or \"beach and cliff\" test","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Penicillin zone edge or \"beach and cliff\" test</div><div class=\"cntnt\"><img style=\"width:764px; height:380px;\" src=\"images/ID/114731_Penicillin_zone_edge_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A standard inoculum of the organism of interest is inoculated onto a Mueller-Hinton agar plate and incubated in the presence of a penicillin disk. After incubation, the zone edge of inhibition of growth around the penicillin disk is examined.<br />(A) A fuzzy zone edge, or \"beach,\" indicates the absence of a beta-lactamase.<br />(B) A sharp zone edge, or \"cliff,\" indicates the presence of a beta-lactamase.</div><div id=\"graphicVersion\">Graphic 114731 Version 1.0</div></div></div>"},"114732":{"type":"graphic_picture","displayName":"Detection of inducible clindamycin resistance using the D test","title":"Detection of inducible clindamycin resistance using the D test","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Detection of inducible clindamycin resistance using the D test</div><div class=\"cntnt\"><img style=\"width:764px; height:460px;\" src=\"images/ID/114732_Indcbl_clndmycn_rsstnc_Dtst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Commercially available erythromycin and clindamycin disks are placed in a standardized fashion on an agar plate inoculated with a standardized inoculum of the test organism. The plates are incubated for 16 to 24 hours and then visually inspected.<br />Panel A demonstrates flattening of the clindamycin zone of inhibition (D-zone) adjacent to the erythromycin disk, indicating inducible clindamycin resistance.<br />Panel B shows an isolate that is erythromycin-resistant but clindamycin-susceptible.<br />Panel C shows an isolate that is susceptible to both clindamycin and erythromycin.<br />Panel D shows an isolate with constitutive resistance to both clindamycin and erythromycin.</div><div class=\"graphic_footnotes\">C: clindamycin disk; E: erythromycin disk.</div><div id=\"graphicVersion\">Graphic 114732 Version 3.0</div></div></div>"},"114733":{"type":"graphic_table","displayName":"Methods to determine antimicrobial susceptibility for bacteria","title":"Methods to determine antimicrobial susceptibility for infrequently isolated or fastidious bacteria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Methods to determine antimicrobial susceptibility for infrequently isolated or fastidious bacteria</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> </tbody> <colgroup width=\"75%\"></colgroup><colgroup width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Organism</td> <td class=\"subtitle1\">Method</td> </tr> <tr> <td><em>Abiotrophia</em> species and <em>Granulicatella</em> species (formerly known as nutritionally deficient or nutritionally variant streptococci)</td> <td>Broth microdilution</td> </tr> <tr> <td><em>Aerococcus</em> species</td> <td>Broth microdilution</td> </tr> <tr> <td><em>Aeromonas</em> species (includes members of the <em>Aeromonas caviae</em> complex, <em>Aeromonas hydrophilia</em> complex, and <em>Aeromonas veronii</em> complex)</td> <td> <p>Broth microdilution</p> Disk diffusion</td> </tr> <tr> <td><em>Bacillus</em> species (not <em>Bacillus anthracis</em>) and related genera</td> <td>Broth microdilution</td> </tr> <tr> <td><em>Campylobacter jejuni</em>/<em>coli</em></td> <td> <p>Broth microdilution</p> Disk diffusion</td> </tr> <tr> <td><em>Corynebacterium</em> species (including <em>Corynebacterium diphtheriae</em>) and related coryneform genera</td> <td>Broth microdilution</td> </tr> <tr> <td><em>Erysipelothrix rhusiopathiae</em></td> <td>Broth microdilution</td> </tr> <tr> <td><em>Gemella</em> species</td> <td>Broth microdilution</td> </tr> <tr> <td>HACEK group: <em>Aggregatibacter</em> species, <em>Cardiobacterium</em> species, <em>Eikenella corrodens</em>, <em>Kingella</em> species</td> <td>Broth microdilution</td> </tr> <tr> <td><em>Helicobacter pylori</em></td> <td>Agar dilution</td> </tr> <tr> <td><em>Lactobacillus</em> species</td> <td>Broth microdilution</td> </tr> <tr> <td><em>Lactococcus</em> species</td> <td>Broth microdilution</td> </tr> <tr> <td><em>Leuconostoc</em> species</td> <td>Broth microdilution</td> </tr> <tr> <td><em>Listeria monocytogenes</em></td> <td>Broth microdilution</td> </tr> <tr> <td><em>Micrococcus</em> species</td> <td>Broth microdilution</td> </tr> <tr> <td><em>Moraxella catarrhalis</em></td> <td> <p>Broth microdilution</p> Disk diffusion</td> </tr> <tr> <td><em>Pasteurella</em> species</td> <td> <p>Broth microdilution</p> Disk diffusion</td> </tr> <tr> <td><em>Pediococcus</em> species</td> <td>Broth microdilution</td> </tr> <tr> <td><em>Rothia mucilaginosa</em></td> <td>Broth microdilution</td> </tr> <tr> <td><em>Vibrio</em> species (including <em>Vibrio cholerae</em>)</td> <td> <p>Broth microdilution</p> Disk diffusion</td> </tr> <tr> <td>Potential agents of bioterrorism: <em>Bacillus anthracis</em>, <em>Yersinia pestis</em>, <em>Burkholderia mallei</em>, <em>Burkholderia pseudomallei</em>, <em>Francisella tularensis</em>, <em>Brucella</em> species</td> <td>Broth microdilution</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Clinical and Laboratory Standards Institute (CLSI). Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria, 3rd ed. CLSI Guideline M45, Clinical and Laboratory Standards Institute, Wayne, Pennsylvania 2015.</div><div id=\"graphicVersion\">Graphic 114733 Version 2.0</div></div></div>"},"114734":{"type":"graphic_figure","displayName":"Description of endoscopically visible lesions","title":"Description of endoscopically visible lesions","html":"<div class=\"graphic\"><div style=\"width: 661px\" class=\"figure\"><div class=\"ttl\">Description of endoscopically visible lesions</div><div class=\"cntnt\"><img style=\"width:641px; height:390px;\" src=\"images/GAST/114734_RoleendoscopyIBD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Description of endoscopically visible lesions (Paris classification).<SUP>[1,2]</SUP></div><div class=\"graphic_footnotes\">* Also include location (within or outside an area of known colitis), borders (distinct or indistinct), and presence of ulceration and/or other features of submucosal invasion.<br />¶ Morphological combinations of lesions can occur.<br />Δ 2.5 mm = size of closed cup of biopsy forceps.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc 2003; 58(6 Suppl):S3.</LI>&#xD;&#xA;<LI>Laine L, Kaltenbach T, Barkun A, et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastrointest Endosc 2015; 81:489.</LI></OL>Reproduced from: Shergill AK, Lightdale JR, Bruining DH, et al. The role of endoscopy in inflammatory bowel disease. Gastrointestinal endoscopy 2015; 81:1101. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 114734 Version 1.0</div></div></div>"},"114737":{"type":"graphic_table","displayName":"Treatment-specific RRs for grade 3 to 5 cardiac events","title":"Treatment-specific RRs for grade 3 to 5 cardiac events according to the number of reported cardiovascular risk factors and by individual risk factor","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment-specific RRs for grade 3 to 5 cardiac events according to the number of reported cardiovascular risk factors and by individual risk factor</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"16\" width=\"6.25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">Variable</td> <td class=\"subtitle1\" colspan=\"12\">Chest-directed radiotherapy</td> <td class=\"subtitle1\" rowspan=\"2\" colspan=\"3\">Anthracycline chemotherapy for heart failure</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"3\">Coronary artery disease</td> <td class=\"subtitle2\" colspan=\"3\">Heart failure</td> <td class=\"subtitle2\" colspan=\"3\">Valvular disease</td> <td class=\"subtitle2\" colspan=\"3\">Arrhythmia</td> </tr> <tr> <td class=\"subtitle3\">RR</td> <td class=\"subtitle3\">95% Cl</td> <td class=\"subtitle3\"><em>P</em></td> <td class=\"subtitle3\">RR</td> <td class=\"subtitle3\">95% Cl</td> <td class=\"subtitle3\"><em>P</em></td> <td class=\"subtitle3\">RR</td> <td class=\"subtitle3\">95% Cl</td> <td class=\"subtitle3\"><em>P</em></td> <td class=\"subtitle3\">RR</td> <td class=\"subtitle3\">95% Cl</td> <td class=\"subtitle3\"><em>P</em></td> <td class=\"subtitle3\">RR</td> <td class=\"subtitle3\">95% Cl</td> <td class=\"subtitle3\"><em>P</em></td> </tr> <tr> <td><strong>Number of risk factors*</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#60;0.001<sup>&#182;</sup></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#60;0.001<sup>&#182;</sup></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#60;0.001<sup>&#182;</sup></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#60;0.001<sup>&#182;</sup></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#60;0.001<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">4</td> <td class=\"centered\">17.6</td> <td class=\"centered\">5.3 to 58.3</td> <td class=\"centered\">&#60;0.001</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">0.0 to 20.1</td> <td class=\"centered\">1.0</td> <td class=\"centered\">25.4</td> <td class=\"centered\">5.3 to 121.3</td> <td class=\"centered\">&#60;0.001</td> <td class=\"centered\">39.5</td> <td class=\"centered\">7.5 to 207.4</td> <td class=\"centered\">&#60;0.001</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">0.0 to 19.9</td> <td class=\"centered\">1.0</td> </tr> <tr> <td class=\"indent1\">Any 3</td> <td class=\"centered\">13.7</td> <td class=\"centered\">6.7 to 27.8</td> <td class=\"centered\">&#60;0.001</td> <td class=\"centered\">16.9</td> <td class=\"centered\">7.2 to 40.1</td> <td class=\"centered\">&#60;0.001</td> <td class=\"centered\">8.6</td> <td class=\"centered\">2.3 to 32.6</td> <td class=\"centered\">0.002</td> <td class=\"centered\">10.5</td> <td class=\"centered\">2.0 to 53.7</td> <td class=\"centered\">0.005</td> <td class=\"centered\">9.3</td> <td class=\"centered\">3.2 to 26.8</td> <td class=\"centered\">&#60;0.001</td> </tr> <tr> <td class=\"indent1\">Any 2</td> <td class=\"centered\">10.4</td> <td class=\"centered\">6.1 to 17.7</td> <td class=\"centered\">&#60;0.001</td> <td class=\"centered\">10.4</td> <td class=\"centered\">5.6 to 19.3</td> <td class=\"centered\">&#60;0.001</td> <td class=\"centered\">12.2</td> <td class=\"centered\">5.0 to 29.8</td> <td class=\"centered\">&#60;0.001</td> <td class=\"centered\">5.9</td> <td class=\"centered\">1.6 to 21.4</td> <td class=\"centered\">0.007</td> <td class=\"centered\">6.2</td> <td class=\"centered\">3.3 to 11.6</td> <td class=\"centered\">&#60;0.001</td> </tr> <tr> <td class=\"indent1\">Any 1</td> <td class=\"centered\">4.0</td> <td class=\"centered\">2.5 to 6.4</td> <td class=\"centered\">&#60;0.001</td> <td class=\"centered\">6.0</td> <td class=\"centered\">3.6 to 10.0</td> <td class=\"centered\">&#60;0.001</td> <td class=\"centered\">6.5</td> <td class=\"centered\">2.9 to 14.4</td> <td class=\"centered\">&#60;0.001</td> <td class=\"centered\">4.1</td> <td class=\"centered\">1.4 to 12.0</td> <td class=\"centered\">0.009</td> <td class=\"centered\">4.3</td> <td class=\"centered\">2.8 to 6.7</td> <td class=\"centered\">&#60;0.001</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">None</td> <td class=\"centered\">1.0</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">1.0</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">1.0</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">1.0</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">1.0</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td colspan=\"16\"><strong>Individual and combinations of risk factors</strong><sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Hypertension alone</td> <td class=\"centered\">6.1</td> <td class=\"centered\">3.4 to 11.2</td> <td class=\"centered\">&#60;0.001</td> <td class=\"centered\">19.4</td> <td class=\"centered\">11.4 to 33.1</td> <td class=\"centered\">&#60;0.001</td> <td class=\"centered\">13.6</td> <td class=\"centered\">5.7 to 32.4</td> <td class=\"centered\">&#60;0.001</td> <td class=\"centered\">6.0</td> <td class=\"centered\">1.7 to 21.8</td> <td class=\"centered\">0.006</td> <td class=\"centered\">12.4</td> <td class=\"centered\">7.6 to 20.1</td> <td class=\"centered\">&#60;0.001</td> </tr> <tr> <td class=\"indent1\">Dyslipidemia alone</td> <td class=\"centered\">4.7</td> <td class=\"centered\">2.0 to 10.7</td> <td class=\"centered\">&#60;0.001</td> <td class=\"centered\">1.1</td> <td class=\"centered\">0.2 to 8.5</td> <td class=\"centered\">0.90</td> <td class=\"centered\">5.4</td> <td class=\"centered\">1.4 to 20.7</td> <td class=\"centered\">0.01</td> <td class=\"centered\">2.9</td> <td class=\"centered\">0.3 to 24.6</td> <td class=\"centered\">0.33</td> <td class=\"centered\">1.1</td> <td class=\"centered\">0.1 to 8.0</td> <td class=\"centered\">0.93</td> </tr> <tr> <td class=\"indent1\">Diabetes alone</td> <td class=\"centered\">2.7</td> <td class=\"centered\">0.4 to 20.0</td> <td class=\"centered\">0.32</td> <td class=\"centered\">5.7</td> <td class=\"centered\">1.3 to 24.3</td> <td class=\"centered\">0.02</td> <td class=\"centered\">0.0</td> <td class=\"centered\">0.0 to 21.8</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">14.2</td> <td class=\"centered\">1.7 to 118.9</td> <td class=\"centered\">0.01</td> <td class=\"centered\">4.3</td> <td class=\"centered\">1.0 to 17.8</td> <td class=\"centered\">0.05</td> </tr> <tr> <td class=\"indent1\">Obesity alone</td> <td class=\"centered\">2.8</td> <td class=\"centered\">1.5 to 5.3</td> <td class=\"centered\">0.001</td> <td class=\"centered\">0.9</td> <td class=\"centered\">0.3 to 2.9</td> <td class=\"centered\">0.85</td> <td class=\"centered\">2.4</td> <td class=\"centered\">0.6 to 8.9</td> <td class=\"centered\">0.19</td> <td class=\"centered\">2.5</td> <td class=\"centered\">0.5 to 12.5</td> <td class=\"centered\">0.26</td> <td class=\"centered\">1.6</td> <td class=\"centered\">0.8 to 3.3</td> <td class=\"centered\">0.21</td> </tr> <tr> <td class=\"indent1\">Hypertension and dyslipidemia only</td> <td class=\"centered\">20.9</td> <td class=\"centered\">11.1 to 39.4</td> <td class=\"centered\">&#60;0.001</td> <td class=\"centered\">7.8</td> <td class=\"centered\">2.6 to 23.1</td> <td class=\"centered\">&#60;0.001</td> <td class=\"centered\">11.9</td> <td class=\"centered\">3.8 to 37.8</td> <td class=\"centered\">&#60;0.001</td> <td class=\"centered\">10.1</td> <td class=\"centered\">2.4 to 43.3</td> <td class=\"centered\">0.002</td> <td class=\"centered\">11.3</td> <td class=\"centered\">4.6 to 27.5</td> <td class=\"centered\">&#60;0.001</td> </tr> <tr> <td class=\"indent1\">Hypertension and diabetes</td> <td class=\"centered\">23.5</td> <td class=\"centered\">7.1 to 77.8</td> <td class=\"centered\">&#60;0.001</td> <td class=\"centered\">35.3</td> <td class=\"centered\">12.1 to 103</td> <td class=\"centered\">&#60;0.001</td> <td class=\"centered\">18.1</td> <td class=\"centered\">2.2 to 146.1</td> <td class=\"centered\">0.007</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">16.9</td> <td class=\"centered\">5.1 to 55.7</td> <td class=\"centered\">&#60;0.001</td> </tr> <tr> <td class=\"indent1\">Hypertension and obesity</td> <td class=\"centered\">5.8</td> <td class=\"centered\">2.2 to 14.9</td> <td class=\"centered\">&#60;0.001</td> <td class=\"centered\">18.4</td> <td class=\"centered\">8.8 to 38.6</td> <td class=\"centered\">&#60;0.001</td> <td class=\"centered\">20.6</td> <td class=\"centered\">7.2 to 58.7</td> <td class=\"centered\">&#60;0.001</td> <td class=\"centered\">5.8</td> <td class=\"centered\">0.7 to 48.2</td> <td class=\"centered\">0.11</td> <td class=\"centered\">6.5</td> <td class=\"centered\">2.5 to 16.5</td> <td class=\"centered\">&#60;0.001</td> </tr> <tr> <td class=\"indent1\">No risk factors</td> <td class=\"centered\">1.0</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">1.0</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">1.0</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">1.0</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">1.0</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: All models included age, household income, and education as time-dependent variables and sex, race, smoking, chest-directed radiotherapy, and anthracycline exposure. Grade was determined according to CTCAE version 4.03<SUP>[1]</SUP>.</div><div class=\"graphic_footnotes\">RR: rate ratio; CTCAE: Common Terminology Criteria for Adverse Events.<br />* The results were based on a single model that included the entire study population.<br />¶ <EM>P</EM> value for trend.<br />Δ The results were based on one model of the entire study population in which survivors with only one risk factor were separated into four groups (hypertension alone, dyslipidemia alone, diabetes alone, obesity alone). Survivors with all other combinations or with no risk factors were included in the model but only selected risk estimates are displayed.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Cancer therapy evaluation program. <a href=\"https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf\" target=\"_blank\">https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf</a> (Accessed on September 11, 2017).</li>&#xD;&#xA;</ol>&#xD;&#xA;From: Armstrong GT, Oeffinger KC, Chen Y, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 2013; Vol. 31(29):3673-3680. Reprinted with permission &copy; 2013 American Society of Clinical Oncology.</div><div id=\"graphicVersion\">Graphic 114737 Version 2.0</div></div></div>"},"114740":{"type":"graphic_table","displayName":"Acute pediatric shoulder injuries by location of pain","title":"Location of pain and potential etiology for acute traumatic shoulder injury in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Location of pain and potential etiology for acute traumatic shoulder injury in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">Anterior</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Sternoclavicular dislocation* </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Clavicular injury (fracture, osteolysis, distal clavicular contusion [shoulder pointer]) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Biceps tendonitis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Acromioclavicular injury (separated shoulder) </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Posterior</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Scapula fracture </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Poorly localized pain</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Proximal humerus fracture </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Glenohumeral dislocation or subluxation </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Referred pain</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Brachial plexus injury (\"burner\", \"stinger\" or \"pinched nerve\") </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Cervical spine injury* </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Myocardial injury* </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Abdominal injury* </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Spontaneous axillary or subclavian vein thrombosis (Paget Shroetter disease)* </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Thoracic outlet syndrome </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Potentially life-threatening conditions.</div><div id=\"graphicVersion\">Graphic 114740 Version 3.0</div></div></div>"},"114741":{"type":"graphic_figure","displayName":"All-cause mortality in cancer survivors by CVD status","title":"All-cause mortality in cancer survivors and noncancer comparison cohort by CVD status","html":"<div class=\"graphic\"><div style=\"width: 751px\" class=\"figure\"><div class=\"ttl\">All-cause mortality in cancer survivors and noncancer comparison cohort by CVD status</div><div class=\"cntnt\"><img style=\"width:731px; height:404px;\" src=\"images/ONC/114741_All-cs_mrt_cncr_svr_CVD_sts.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CVD: cardiovascular disease.</div><div class=\"graphic_reference\">From: Armenian SH, Xu L, Ky B, et al. Cardiovascular disease among survivors of adult-onset cancer: A community-based retrospective cohort study. J Clin Oncol 2016; Vol. 34(10):1122-1130. Reprinted with permission &copy; 2016 American Society of Clinical Oncology.</div><div id=\"graphicVersion\">Graphic 114741 Version 1.0</div></div></div>"},"114742":{"type":"graphic_algorithm","displayName":"Diagnostic approach pediatric shoulder injury","title":"Diagnostic approach to the child or adolescent with an isolated shoulder injury*","html":"<div class=\"graphic\"><div style=\"width: 723px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to the child or adolescent with an isolated shoulder injury*</div><div class=\"cntnt\"><img style=\"width:703px; height:804px;\" src=\"images/EM/114742_Diagapprchpedshldrinjry.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* This algorithm is meant for the diagnosis of isolated shoulder pain in verbal pediatric patients who can reliably describe their pain. Shoulder pain may be referred from significant injury to the cervical spine, myocardium, or abdomen. Ensure no abnormal findings in these regions before proceeding with evaluation for an isolated shoulder injury. Refer to UpToDate topics on referred shoulder pain.<br />&para; For a description of the apprehension test, refer to UpToDate graphics and topics on shoulder dislocation.<br />&Delta; More than one fracture or dislocation may be demonstrated. Shoulder dislocation is rare in children younger than 12 years of age. The humerus is frequently a site for pathologic fractures in patients with benign and malignant bone lesions. Refer to UpToDate topics on osteosarcoma, Ewing sarcoma, and benign bone tumors in children and adolescents.<br /><span class=\"lozenge\">&loz;</span> Emergency computed tomography may be necessary to demonstrate a posterior sternoclavicular dislocation.<br />&sect; D-dimer testing and ultrasonography help confirm the diagnosis. Refer to UpToDate topics on primary (spontaneous) upper extremity deep vein thrombosis.<br />&yen; A positive Roos test refers to reproduction of pain, numbness, and/or paresthesias when the patient holds the arms overhead with elbows flexed and rapidly opens and closes the hands for three minutes.</div><div id=\"graphicVersion\">Graphic 114742 Version 1.0</div></div></div>"},"114754":{"type":"graphic_table","displayName":"Checklist for evaluation, care, follow-up of living donors","title":"Checklist items for the evaluation, care, and follow-up of living kidney donors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Checklist items for the evaluation, care, and follow-up of living kidney donors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td> <ul> <li>Provide the donor candidate with individualized estimates of short- and long-term risks</li> </ul> </td> </tr> <tr> <td> <ul> <li>Evaluate risks with respect to predetermined transplant program acceptance thresholds</li> </ul> </td> </tr> <tr> <td> <ul> <li>Obtain consent from the donor candidate for evaluation and donation</li> </ul> </td> </tr> <tr> <td> <ul> <li>Determine ABO blood type and human leukocyte antigen compatibility</li> </ul> </td> </tr> <tr> <td> <ul> <li>Inform incompatible donors about exchange programs and incompatible living donor transplantation options</li> </ul> </td> </tr> <tr> <td> <ul> <li>Conduct a preoperative assessment as per local guidelines to minimize risk</li> </ul> </td> </tr> <tr> <td> <ul> <li>Estimate GFR using serum creatinine-based estimating equations and confirm with one or more of the following according to availability: Measured GFR using an exogenous filtration marker, measured creatinine clearance, estimated GFR from the combination of serum creatinine and cystatin C, or repeat estimated GFR using serum creatinine</li> </ul> </td> </tr> <tr> <td> <ul> <li>Assess albuminuria using albumin-to-creatinine ratio in an untimed urine specimen, and confirm albuminuria with AER in a timed urine specimen or by repeating albumin-to-creatinine ratio if AER cannot be obtained</li> </ul> </td> </tr> <tr> <td> <ul> <li>Perform testing to identify cause of microscopic hematuria that is not reversible</li> </ul> </td> </tr> <tr> <td> <ul> <li>Assess history and renal imaging for nephrolithiasis</li> </ul> </td> </tr> <tr> <td> <ul> <li>Assess history of gout</li> </ul> </td> </tr> <tr> <td> <ul> <li>Measure blood pressure before donation on at least two occasions</li> </ul> </td> </tr> <tr> <td> <ul> <li>Assess metabolic and lifestyle risk factors for CKD and/or CVD before donation by obtaining: <ul> <li>BMI measurement</li> <li>History of diabetes mellitus, gestational diabetes, and family history of diabetes</li> <li>Fasting blood glucose and/or glycated hemoglobin (HbA<sub>1c</sub>)</li> <li>Fasting lipid profile including total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol, and triglycerides</li> <li>Present and past use of tobacco products</li> </ul> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Screen for the following infections before donation: <ul> <li>Human immunodeficiency virus</li> <li>Hepatitis B virus</li> <li>Hepatitis C virus</li> <li>Cytomegalovirus</li> <li>Epstein-Barr virus</li> <li><em>Treponema pallidum</em> (syphilis)</li> <li>Urinary tract infection</li> <li>Other potential infections based on geography and environmental exposures</li> </ul> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Perform cancer screening as per local guidelines</li> </ul> </td> </tr> <tr> <td> <ul> <li>Assess family history of kidney disease</li> </ul> </td> </tr> <tr> <td> <ul> <li>Confirm a negative quantitative beta-hCG pregnancy test immediately before donation in women with childbearing potential</li> </ul> </td> </tr> <tr> <td> <ul> <li>Perform face-to-face psychosocial evaluation, education, and planning session with one or more trained, experienced health professionals</li> </ul> </td> </tr> <tr> <td> <ul> <li>Select optimal surgical approach by an experienced surgeon</li> </ul> </td> </tr> <tr> <td> <ul> <li>Respect donor autonomy during all phases of evaluation and donation</li> </ul> </td> </tr> <tr> <td> <ul> <li>Perform annual postdonation follow-up care including: <ul> <li>Blood pressure measurement</li> <li>BMI measurement</li> <li>Serum creatinine measurement with GFR estimation</li> <li>Albuminuria measurement</li> <li>Review and promotion of healthy lifestyle practices including exercise, diet, and abstinence from tobacco</li> <li>Review and support of psychosocial health and well-being</li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GFR: glomerular filtration rate; AER: albumin excretion rate; CKD: chronic kidney disease; CVD: cardiovascular disease; BMI: body mass index; beta-hCG: human chorionic gonadotropin.</div><div class=\"graphic_reference\">From: Lentine KL, Kasiske BL, Levey AS, et al. Summary of Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline on the evaluation and care of living kidney donors. Transplantation 2017; 101:1783. DOI: <A href=\"http://journals.lww.com/transplantjournal/fulltext/2017/08000/Summary_of_Kidney_Disease___Improving_Global.14.aspx\" target=_blank>10.1097/TP.0000000000001770</A>. Copyright © 2017 Kidney Disease: Improving Global Outcomes (KDIGO). Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 114754 Version 1.0</div></div></div>"},"114756":{"type":"graphic_table","displayName":"Roles in donor identification, evaluation, care, follow-up","title":"Roles and responsibilities of participants in donor candidate identification, evaluation, care, and follow-up","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Roles and responsibilities of participants in donor candidate identification, evaluation, care, and follow-up</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">General nephrologist/dialysis unit/advanced chronic kidney disease clinic</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Educate recipient candidates regarding early referral, preemptive and living donor transplantation options, and resources for identifying donor candidates</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Transplant program</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Educate recipient candidates regarding early referral, preemptive and living donor transplantation options</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Educate donor candidates regarding all phases of the donation process including evaluation, surgery, postdonation follow-up, expected risks and outcomes, and existing uncertainties</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Recipient candidate health insurance carrier</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Provide coverage for costs related to recipient candidate evaluation and transplantation, including coverage of donor candidate evaluation and treatment costs</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Donor/donor candidate health insurance carrier</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Educate donor candidates regarding any anticipated out-of-pocket expenses related to evaluation and donation processes</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Educate donor candidates regarding coverage for postdonation complications, both short-term and long-term after donation</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Donor/donor candidate primary care clinician</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Support donor candidates in their desire for information to make informed decisions</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Participate in predonation and early postdonation care as needed</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Participate in long-term care after donation</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Donor/donor candidate clinician/nephrologist</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Evaluate donor candidates without influence from recipient considerations</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Oversee evaluation testing</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Provide education regarding all phases of the donation process including postdonation follow-up</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Participate in donor candidate selection</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>As needed, participate in care during the surgical hospitalization, in the early postdonation period, and long-term after donation, including serving as resource for primary providers</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Donor surgeon</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Evaluate donor candidates for surgical risks and plan surgical approach</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Provide education on the surgical procedure, risks, and expected recovery</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Participate in donor candidate selection</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Provide care during surgery and perioperative period, and as needed postdonation</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Nurse coordinator</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Educate donor candidates on recipient candidate treatment options and phases of the donation process</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Facilitate and oversee completion of the evaluation</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Assist with arranging surgery and inpatient care</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Arrange and oversee postoperative care, and coordinate a plan for postdonation follow-up</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Dietitian</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Review dietary habits and metabolic status including measures of obesity when needed</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Provide guidance for nutritional treatment if indicated, including recommendations to address obesity</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Social worker/psychologist/psychiatrist</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Perform donor candidate psychosocial evaluation including assessment of motivation</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Educate donor candidates on recipient candidate treatment options</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Provide donor candidates with information and support services related to donation, including information on resources that may be available to assist with donation-related expenses</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Discuss potential adverse outcomes including loss of income because of donation, donation-related complications, or failure of the transplant</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Assess the ability of donor candidates to cope with adverse outcomes</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Support informed donation decisions</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Assist donors with planning support around the time of donation and creation of a long-term follow-up plan</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Independent living donor advocate*</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Verify that donor candidates have information needed to make a voluntary and informed decision on whether or not to donate</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Verify consent for donation</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Function independently from the recipient candidate's team</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Advocate for the rights of donor candidates and donors</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Regulatory and oversight agencies</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Create policies for minimum standards of donor candidate informed consent, evaluation, care, and donor follow-up</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Donor/donor candidate</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Agree to required psychosocial and medical evaluation</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Agree to disclosure of required personal health information to intended recipient with regard to risk of disease transmission when necessary, or to withdraw from donation</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Agree to required lifestyle modifications to reduce risks of donation and promote long-term good health</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Agree to participate in postdonation follow-up</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The role of the independent donor advocate may be served by another team member as long as criteria for independence and advocacy functions are satisfied.</div><div class=\"graphic_reference\">From: Lentine KL, Kasiske BL, Levey AS, et al. KDIGO clinical practice guidelines on the evaluation and care of living kidney donors. Transplantation 2017; 101:S1. DOI: <A href=\"http://journals.lww.com/transplantjournal/fulltext/2017/08001/KDIGO_Clinical_Practice_Guideline_on_the.6.aspx\" target=_blank>10.1097/TP.0000000000001769</A>. Copyright © 2017 Kidney Disease: Improving Global Outcomes (KDIGO). Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 114756 Version 1.0</div></div></div>"},"114758":{"type":"graphic_figure","displayName":"Framework to accept-decline donor candidates","title":"Framework to accept or decline donor candidates","html":"<div class=\"graphic\"><div style=\"width: 581px\" class=\"figure\"><div class=\"ttl\">Framework to accept or decline donor candidates</div><div class=\"cntnt\"><img style=\"width:561px; height:372px;\" src=\"images/NEPH/114758_Frmwk_acpt_dcln_donr_cnddts.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Framework to accept or decline donor candidates based on a transplant program's threshold of acceptable projected lifetime risk of kidney failure, quantified as the aggregate of risk related to demographic and health profile and donation-attributable risks. The decision by the transplant program whether to accept or decline a donor candidate is grounded on the candidate's estimated postdonation lifetime risk, including estimated risk in the absence of donation (risk related to demographic and health characteristics as denoted in the solid blue and diagonally lined red, respectively) and estimated risk attributable to donation (dotted grey).</div><div class=\"graphic_footnotes\">GFR: glomerular filtration rate; BMI: body mass index.</div><div class=\"graphic_reference\">From: Lentine KL, Kasiske BL, Levey AS, et al. KDIGO clinical practice guidelines on the evaluation and care of living kidney donors. Transplantation 2017; 101:S1. DOI: <A href=\"http://journals.lww.com/transplantjournal/fulltext/2017/08001/KDIGO_Clinical_Practice_Guideline_on_the.6.aspx\" target=_blank>10.1097/TP.0000000000001769</A>. Copyright © 2017 Kidney Disease: Improving Global Outcomes (KDIGO). Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 114758 Version 1.0</div></div></div>"},"114760":{"type":"graphic_table","displayName":"Pathology associated with gait abnormalities","title":"Pathology associated with gait abnormalities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pathology associated with gait abnormalities</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"35%\"></colgroup><colgroup width=\"65%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical observation</td> <td class=\"subtitle1\"><em>Possible</em> associated pathology* or abnormality</td> </tr> <tr> <td>Excessive head or shoulder movement or asymmetry</td> <td>Multiple lower extremity pathologies; reduced gait efficiency</td> </tr> <tr> <td>Arm motion asymmetry</td> <td>Shoulder or elbow joint restrictions; abdominal pain; reduced running efficiency; may occur in runner with scoliosis</td> </tr> <tr> <td>Limb length discrepancy</td> <td>Hip pain; knee pain; MTSS; stress fractures; plantar fasciitis</td> </tr> <tr> <td>Lateral pelvic tilt</td> <td>Contralateral hip abductor weakness; hamstring strain</td> </tr> <tr> <td>Excessive hip adduction at midstance</td> <td>Tibial stress fracture; gluteus medius syndrome</td> </tr> <tr> <td>Excessive anterior pelvic tilt</td> <td>Low back pain; hamstring tendinopathy</td> </tr> <tr> <td>Genu valgus</td> <td>MTSS; medial knee joint line pain; PFP; ITBS</td> </tr> <tr> <td>Genu varum</td> <td>ITBS; fibular stress fracture; lateral knee joint line pain</td> </tr> <tr> <td>Heel valgus/low medial longitudinal arch</td> <td>Posterior tibial tendinopathy; plantar fasciitis; calf muscle injury</td> </tr> <tr> <td>Excessive pronation</td> <td>Shin splints; tibial stress fractures; PFP</td> </tr> <tr> <td>Pronation late into toe-off</td> <td>Hallux rigidus; hallux valgus</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MTSS: medial tibial stress syndrome; PFP: patellofemoral pain; ITBS: iliotibial band syndrome.<br />* Evidence supporting the associations between gait abnormalities and specific injuries or conditions is extremely limited. A careful history, examination, and possibly diagnostic imaging are needed to confirm possible associations.</div><div id=\"graphicVersion\">Graphic 114760 Version 1.0</div></div></div>"},"114761":{"type":"graphic_picture","displayName":"Basic limb length measurement","title":"Basic limb length measurement technique","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Basic limb length measurement technique</div><div class=\"cntnt\"><img style=\"width:756px; height:534px;\" src=\"images/SM/114761_Basiclimblengthmeasrmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows a simple technique for measuring limb length. It is important to ensure that the pelvis is level and the lower extremities are positioned symmetrically before taking measurements.</div><div class=\"graphic_footnotes\">ASIS: anterior superior iliac spine.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114761 Version 1.0</div></div></div>"},"114762":{"type":"graphic_picture","displayName":"Inward patellar rotation (patellar squinting)","title":"Inward patellar rotation (patellar squinting)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inward patellar rotation (patellar squinting)</div><div class=\"cntnt\"><img style=\"width:373px; height:585px;\" src=\"images/SM/114762_Inwrdptlrrttnptlrsqntng.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inward rotation or \"tilt\" of the patella, sometimes referred to as \"patellar squinting,\" may be seen during inspection of the lower extremities.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114762 Version 1.0</div></div></div>"},"114763":{"type":"graphic_diagnosticimage","displayName":"Mesiodens","title":"Mesiodens","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mesiodens</div><div class=\"cntnt\"><img style=\"width:217px; height:234px;\" src=\"images/PEDS/114763_Mesiodens.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panoramic radiograph demonstrating a conical shaped mesiodens (dashed arrow) and a left supernumerary central incisor (arrow) that have resulted in marked displacement of the tooth bud of the upper left central incisor (asterisk).</div><div class=\"graphic_reference\">Courtesy of J Tim Wright, DDS, MS.</div><div id=\"graphicVersion\">Graphic 114763 Version 1.0</div></div></div>"},"114764":{"type":"graphic_picture","displayName":"Excessive lateral pelvic tilt and hip adduction during running","title":"Excessive lateral pelvic tilt and hip adduction during running gait","html":"<div class=\"graphic\"><div style=\"width: 667px\" class=\"figure\"><div class=\"ttl\">Excessive lateral pelvic tilt and hip adduction during running gait</div><div class=\"cntnt\"><img style=\"width:647px; height:577px;\" src=\"images/SM/114764_Excsltplvctlthpadctrn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photographs above show a runner at midstance who demonstrates excessive hip adduction and lateral pelvic tilt.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114764 Version 1.0</div></div></div>"},"114765":{"type":"graphic_picture","displayName":"Lack of root resorption","title":"Normal root resorption and lack of root resorption","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Normal root resorption and lack of root resorption</div><div class=\"cntnt\"><img style=\"width:524px; height:638px;\" src=\"images/PEDS/114765_Lack_root_resorption.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Near-complete resorption of the root before exfoliation, which is normal.<br />(B) Lack of root resorption before exfoliation, which occurs in systemic conditions associated with premature shedding of the primary teeth, such as hypophosphatasia.</div><div class=\"graphic_reference\">Courtesy of J Tim Wright, DDS, MS.</div><div id=\"graphicVersion\">Graphic 114765 Version 1.0</div></div></div>"},"114770":{"type":"graphic_table","displayName":"Monitoring patients during administration of PrEP against HIV","title":"Monitoring patients during administration of pre-exposure prophylaxis (PrEP) against HIV","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Monitoring patients during administration of pre-exposure prophylaxis (PrEP) against HIV</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>One month after starting PrEP:</strong></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Evaluate and support PrEP medication adherence* </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Assess risk behaviors and provide risk-reduction counseling and condoms </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Evaluate for side effects </li> </ul> </td> </tr> <tr> <td><strong>Three months after starting PrEP:</strong></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Evaluate and support PrEP medication adherence* </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Perform an HIV test<sup>&#182;</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Assess risk behaviors and provide risk-reduction counseling and condoms </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Check serum creatinine in all patients<sup>&#916;</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Test for STIs among individuals with high-risk sexual behaviors, even if patient is asymptomatic<sup>&#9674;</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Assess pregnancy status for patients who could become pregnant<sup>&#167;</sup> </li> </ul> </td> </tr> <tr> <td><strong>Every three months thereafter:</strong></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Evaluate and support PrEP medication adherence* </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Perform an HIV test<sup>&#182;</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Assess risk behaviors and provide risk-reduction counseling and condoms </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Monitor creatinine in patients at risk for renal disease,<sup>&#916;</sup><sup>&#165;</sup> all others should have creatinine checked every six months </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Test for STIs among individuals with high-risk sexual behaviors, even if patient is asymptomatic<sup>&#9674;</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Assess pregnancy status for patients who could become pregnant<sup>&#167;</sup> </li> </ul> </td> </tr> <tr> <td><strong>On discontinuing PrEP</strong><sup>&#135;</sup> <strong>(at patient request, for safety concerns):</strong></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Perform HIV test(s) to determine whether HIV infection has occurred<sup>&#182;</sup><sup>&#134;</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>If the patient has chronic HBV infection, the decision to switch to an alternative agent or to monitor for HBV flare should be discussed with a provider experienced in the management of HBV </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FTC: emtricitabine; HBV: hepatitis B virus; HIV: human immunodeficiency virus; PrEP: pre-exposure prophylaxis; STI: sexually transmitted infection; TDF: tenofovir disoproxil fumarate.<br />* Adherence should be assessed at each follow-up visit, and more often if inconsistent adherence is identified.<br />¶ Patients should have plasma HIV testing, preferably with a fourth generation antigen/antibody test. Additional testing for HIV RNA may be needed if the patient has&nbsp;signs or symptoms suggestive of acute HIV infection,&nbsp;or has an indeterminate antigen/antibody test. If HIV-positive, order and document results of resistance testing and establish immediate&nbsp;linkage to HIV care. Dual therapy with TDF-FTC should not be continued. Refer to the topics that discuss acute HIV infection more information on the clinical manifestations and diagnosis of acute HIV.<br />Δ Discontinue PrEP if estimated glomerular filtration rate &lt;60 mL/minute/1.73 m<SUP>2</SUP>, or if there is evidence of moderate or severe proximal tubular dysfunction or Fanconi syndrome. Refer to the topic that discusses administration of PrEP for&nbsp;an approach to patients who develop worsening renal function on TDF-FTC.<br /><FONT class=lozenge>◊</FONT> STI screening should include serum testing for syphilis and screening for gonorrhea and chlamydia at mucosal sites with potential exposures (eg, throat, rectum, urogenital). Refer to the topic that discusses screening for STIs within UpToDate.<br />§ PrEP can be used in pregnancy after an informed decision is made. Refer to the topic that discusses how to identify candidates for PrEP for a more detailed discussion of PrEP during pregnancy.<br />¥ Risk factors for renal disease include hypertension, diabetes, proteinuria, and prior history of renal insufficiency. For such patients, we obtain a urinalysis every six months in addition to monitoring the creatinine. More frequent monitoring may be required for those who develop abnormal findings.<br />‡ We generally continue PrEP for one month after the last high-risk exposure, unless PrEP is being discontinued because of toxicity.<br />† If HIV-negative, establish linkage to risk-reduction support services as indicated.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Interim guidance: pre-exposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR 2011; 60:65.</LI>&#xD;&#xA;<LI>Interim Guidance for Clinicians Considering the Use of Preexposure Prophylaxis for the Prevention of HIV Infection in Heterosexually Active Adults. MMWR 2012; 61:586.</LI>&#xD;&#xA;<LI>US Public Health Service. United States Public Health Service Clinical Practice Guideline. Available at: http://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf (Accessed on July 10, 2014).</LI>&#xD;&#xA;<LI>Cohen S, Vittinghoff E, Philip SS. Quarterly STI screening optimizes STI detection among PrEP users in the Demo Project. Presented at the Conference on Retroviruses and Opportunistic Infections, Boston MA, February 22-25, 2016. Abstract #877.</LI></OL></div><div id=\"graphicVersion\">Graphic 114770 Version 1.0</div></div></div>"},"114771":{"type":"graphic_figure","displayName":"Abnormal capnogram waveforms","title":"Abnormal capnogram waveforms","html":"<div class=\"graphic\"><div style=\"width: 727px\" class=\"figure\"><div class=\"ttl\">Abnormal capnogram waveforms</div><div class=\"cntnt\"><img style=\"width:707px; height:297px;\" src=\"images/ANEST/114771_Abnormal_capnogram_waveform.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Prolonged phase II, increased alpha angle, and steeper phase III suggest bronchospasm or airway obstruction.<br />(B) Expiratory valve malfunction resulting in elevation of the baseline, and the angle between the alveolar plateau and the downstroke of inspiration is increased from 90°. This is due to rebreathing of expiratory gases from the expiratory limb during inspiration.<br />(C) Inspiratory valve malfunction resulting in rebreathing of expired gases from inspiratory limb during inspiration (reference 1 for details).<br />(D) Capnogram with normal phase II but with increased slope of phase III. This capnogram is observed in pregnant subjects under general anesthesia (normal physiologic variant and details in reference 2).<br />(E) Curare cleft: Patient is attempting to breathe during partial muscle paralysis. Surgical movements on the chest and abdomen can also result in the curare cleft.<br />(F) Baseline is elevated as a result of carbon dioxide rebreathing.<br />(G) Esophageal intubation resulting in the gastric washout of residual carbon dioxide and subsequent carbon dioxide will be zero.<br />(H) Spontaneously breathing carbon dioxide waveforms where phase III is not well delineated.<br />(I) Dual capnogram in one lung transplantation patient. The first peak in phase III is from the transplanted normal lung, whereas the second peak is from the native disease lung. A variation of dual capnogram (steeple sign capnogram – dotted line) is seen if there is a leak around the sidestream sensor port at the monitor. This is because of the dilution of expired PCO<SUB>2</SUB> with atmospheric air.<br />(J) Malignant hyperpyrexia where carbon dioxide is raising gradually with zero baseline suggesting increased carbon dioxide production with carbon dioxide absorption by the soda lime.<br />(K) Classic ripple effect during the expiratory pause showing cardiogenic oscillations. These occur as a result of to-and-for movement of expired gases at the sensor due to motion of the heartbeat during expiratory pause when respiratory frequency of mechanical ventilation is low. Wave forms with a ripple effect also occur when forward flow of fresh gases from a source during expiratory pause intermingles with expiratory gases at the sensor.<br />(L) Sudden raise of baseline and the end-tidal PCO<SUB>2</SUB> (PETCO<SUB>2</SUB>) due to contamination of the sensor with secretions or water vapor. Gradual rise of baseline and PETCO<SUB>2</SUB> occurs when soda lime is exhausted.<br />(M) Intermittent mechanical ventilation (IMV) breaths in the midst of spontaneously breathing patient. A comparison of the height of spontaneous breaths compared to the mechanical breaths is useful to assess spontaneous ventilation during weaning process.<br />(N) Cardiopulmonary resuscitation: Capnogram showing positive waveforms during each compression suggesting effective cardiac compression generating pulmonary blood.<br />(O) Capnogram showing rebreathing during inspiration. This is normal in rebreathing circuits such as Mapleson D or Bain circuit.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Bhavani-Shankar K, Kumar AY, Moseley HS, Ahyee-Hallsworth R. Terminology and the current limitations of time capnography: A brief review. J Clin Monit 1995; 11:175.</li>&#xD;&#xA;    <li>Fletcher R. The single breath test for carbon dioxide (Thesis). Lund, Sweden, Berlings, 1980.</li>&#xD;&#xA;</ol>&#xD;&#xA;From: Kodali BS. Capnography outside the operating rooms. Anesthesiology 2013; 118:192. DOI: <a href=\"http://anesthesiology.pubs.asahq.org/article.aspx?articleid=2034665\" target=\"_blank\">10.1097/ALN.0b013e318278c8b6</a>. Copyright &copy; 2013 American Society of Anesthesiologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 114771 Version 1.0</div></div></div>"},"114772":{"type":"graphic_picture","displayName":"Negative pressure leak test","title":"Negative pressure leak test","html":"<div class=\"graphic\"><div style=\"width: 583px\" class=\"figure\"><div class=\"ttl\">Negative pressure leak test</div><div class=\"cntnt\"><img style=\"width:563px; height:750px;\" src=\"images/ANEST/114772_Negative_pressure_leak_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A negative pressure leak test is employed to test for leaks in a flowmeter&nbsp;or other internal components of the anesthesia machine. With&nbsp;this test, all compressed gas flows are set to zero, then a suction bulb is attached to the anesthesia machine common gas outlet and repeatedly squeezed until it collapses, as shown in this photo. The bulb will not stay collapsed if there is a leak. (See topics describing the anesthesia machine for further information.)</div><div id=\"graphicVersion\">Graphic 114772 Version 1.0</div></div></div>"},"114773":{"type":"graphic_figure","displayName":"Flowmeter sequence","title":"Flowmeter sequence","html":"<div class=\"graphic\"><div style=\"width: 738px\" class=\"figure\"><div class=\"ttl\">Flowmeter sequence</div><div class=\"cntnt\"><img style=\"width:718px; height:404px;\" src=\"images/ANEST/114773_Flowmeter_sequence.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Oxygen is the last gas to enter the manifold to prevent hypoxic mixtures due to leaks in other flowmeters.</div><div class=\"graphic_footnotes\">O<sub>2</sub>: oxygen; N<sub>2</sub>O: nitrous oxide.</div><div id=\"graphicVersion\">Graphic 114773 Version 1.0</div></div></div>"},"114779":{"type":"graphic_table","displayName":"Definitions of alcohol consumption","title":"Definitions of alcohol consumption","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definitions of alcohol consumption</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Moderate drinking (low risk for alcohol problems)</td> </tr> <tr> <td class=\"indent1\">Women age &#60;65</td> <td>&#60;2 drinks per day</td> </tr> <tr> <td class=\"indent1\">Men age &#60;65</td> <td>&#60;3 drinks per day</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">People age &#8805;65</td> <td>&#60;2 drinks per day</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Heavy drinking (at risk for alcohol problems)</td> </tr> <tr> <td class=\"indent1\">Women</td> <td>&#62;7 drinks per week or three drinks per occasion</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Men</td> <td>&#62;14 drinks per week or four drinks per occasion</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Binge drinking</td> </tr> <tr> <td class=\"indent1\">Women</td> <td>Four or more drinks in one drinking occasion</td> </tr> <tr> <td class=\"indent1\">Men</td> <td>Five or more drinks in one drinking occasion</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The number and size of drinks that define risky amounts varies internationally. In the United States, amounts are based on a “standard drink,” which is defined as 14 to 15 grams of ethanol, 5 ounces of wine, 12&nbsp;ounces of beer, or 1.5 ounces of 80 proof spirits. </div><div id=\"graphicVersion\">Graphic 114779 Version 2.0</div></div></div>"},"114780":{"type":"graphic_figure","displayName":"Adult suicide safety plan","title":"Adult suicide safety plan","html":"<div class=\"graphic\"><div style=\"width: 718px\" class=\"figure\"><div class=\"ttl\">Adult suicide safety plan</div><div class=\"cntnt\"><img style=\"width:698px; height:558px;\" src=\"images/PSYCH/114780_Adultsuicidesafetyplan.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Patient safety plan template. ​Available at:&nbsp;<A href=\"http://www.sprc.org/sites/default/files/Brown_StanleySafetyPlanTemplate.pdf\">http://www.sprc.org/sites/default/files/Brown_StanleySafetyPlanTemplate.pdf</A> (Accessed on January 3, 2018).</LI>&#xD;&#xA;<LI>Samra J, Bilsker D. Coping with suicidal thoughts. Consortium for Organizational Mental Health 2007. Available at: <A href=\"http://www.comh.ca/publications/resources/pub_cwst/cwst.pdf\" target=_blank>http://www.comh.ca/publications/resources/pub_cwst/cwst.pdf</A> (Accessed on November 16, 2016).</LI>&#xD;&#xA;<LI>Stanley B, Brown G, Brent DA, et al. Cognitive-behavioral therapy for suicide prevention (CBT-SP): treatment model, feasibility, and acceptability. J Am Acad Child Adolesc Psychiatry 2009; 48:1005.</LI></OL></div><div id=\"graphicVersion\">Graphic 114780 Version 2.0</div></div></div>"},"114783":{"type":"graphic_figure","displayName":"Closed scavenger system","title":"Closed scavenger system","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Closed scavenger system</div><div class=\"cntnt\"><img style=\"width:430px; height:651px;\" src=\"images/ANEST/114783_Closedscavengersystem.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">APL: Adjustable pressure-limiting.</div><div class=\"graphic_reference\">Reproduced with permission from: Butterworth JF, Mackey DC, Wasnick JD. The anesthesia machine. In: Morgan &amp; Mikhail's Clinical Anesthesiology, 5th ed, McGraw-Hill, 2013. Copyright &copy; 2013 McGraw-Hill Education. McGraw-Hill Education makes no representations or warranties as to the accuracy of any information contained in the McGraw-Hill Education Material, including any warranties of merchantability or fitness for a particular purpose. In no event shall McGraw-Hill Education have any liability to any party for special, incidental, tort, or consequential damages arising out of or in connection with the McGraw-Hill Education Material, even if McGraw-Hill Education has been advised of the possibility of such damages.</div><div id=\"graphicVersion\">Graphic 114783 Version 2.0</div></div></div>"},"114793":{"type":"graphic_waveform","displayName":"Capnogram artifact due to water trap","title":"Capnogram artifact due to water trap","html":"<div class=\"graphic\"><div style=\"width: 748px\" class=\"figure\"><div class=\"ttl\">Capnogram artifact due to water trap</div><div class=\"cntnt\"><img style=\"width:728px; height:230px;\" src=\"images/ANEST/114793_Capnogram_artifact_watr_trp.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Capnograms during mechanical ventilation. The endotracheal tube was partially obstructed and peak pressure in the circuit was 50 cm H<SUB>2</SUB>0. The waveforms indicate a brief expiration during mechanical inspiration.</div><div class=\"graphic_footnotes\">PCO<SUB>2</SUB>: partial pressure of carbon dioxide; H<SUB>2</SUB>O: water.</div><div class=\"graphic_reference\">From: van Genderingen HR, Gravenstein N. Capnogram artifact during high airway pressures caused by water trap. Anesth analg 1987; 66:185. Copyright © 1987 International Anesthesia Research Society. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 114793 Version 1.0</div></div></div>"},"114803":{"type":"graphic_picture","displayName":"Ludwig's angina","title":"Ludwig's angina","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ludwig's angina</div><div class=\"cntnt\"><img style=\"width:429px; height:646px;\" src=\"images/ID/114803_ErlyapprptLudwigsangina.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Early appearance of a patient with Ludwig's angina demonstrating brawny, board-like swelling in the submandibular spaces and protrusion of the tongue.</div><div class=\"graphic_reference\">From: Megran DW, Scheifele DW, Chow AW. Odontogenic infections. Pediatr Infect Dis 1984; 3:257. Copyright &copy; 1984. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 114803 Version 1.0</div></div></div>"},"114804":{"type":"graphic_picture","displayName":"Pus exuding from the orifice of Stensen's duct","title":"Pus exuding from the orifice of Stensen's duct","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Pus exuding from the orifice of Stensen's duct</div><div class=\"cntnt\"><img style=\"width:756px; height:624px;\" src=\"images/ID/114804_PusorificeStensensduct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraoral view of pus exuding from the orifice of the right Stensen's duct opposite to the upper second molar.</div><div class=\"graphic_reference\">Reproduced from: Levine G, Clark M, Mandel L. Obstructive parotitis from extraorally introduced foreign body in the Stensen duct. J Oral Maxillofac Surg 2013; 71:2087. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 114804 Version 1.0</div></div></div>"},"114806":{"type":"graphic_figure","displayName":"Goodsall's rule","title":"Goodsall's rule","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Goodsall's rule</div><div class=\"cntnt\"><img style=\"width:479px; height:442px;\" src=\"images/SURG/114806_Goodsallsrule.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">One of the most commonly cited principles to assist in the surgical management of an anal fistula is Goodsall's rule, which states that all fistula tracks with external openings within 3 cm of the anal verge and posterior to a line drawn through the ischial spines travel in a curvilinear fashion to the posterior midline, and all tracks with external openings anterior to this line enter the anal canal in a radial fashion. The line of demarcation&nbsp;is depicted in this diagram as the \"transverse anal line.\" Although Goodsall's rule is often quoted, it may not always be accurate. In particular, fistula tracks longer than 3 cm from the anal verge do not necessarily follow Goodsall's rule; they often have an internal opening in the posterior midline regardless of the location of the external opening. </div><div class=\"graphic_reference\">Modified from: Nelson H. Anus. In: Sabiston Textbook of Surgery, 19th ed, Townsend CM, Beauchamp RD, Evers BM, et al (Eds), Elsevier, Philadelphia 2012.</div><div id=\"graphicVersion\">Graphic 114806 Version 1.0</div></div></div>"},"114808":{"type":"graphic_picture","displayName":"Fibrolamellar carcinoma histopathology","title":"Fibrolamellar carcinoma histopathology","html":"<div class=\"graphic\"><div style=\"width: 692px\" class=\"figure\"><div class=\"ttl\">Fibrolamellar carcinoma histopathology</div><div class=\"cntnt\"><img style=\"width:672px; height:672px;\" src=\"images/ONC/114808_Fibrolamellarhistopatholgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hematoxylin and eosin (H&amp;E) stain photomicrograph of fibrolamellar carcinoma with characteristic large, polygonal cells filed with eosinophilic cystoplasmic bodies (arrow) and adjacent parallel arrangement of abundant fibrous stroma (arrowheads).</div><div class=\"graphic_reference\">Reprinted with permission from the American Journal of Roentgenology. Ganeshan D, Szklaruk V, Kaseb A, et al. Imaging features of Fibrolamellar Hepatocellular Carcinoma. AJR Am J Roentgenol 2014; 202:544. Copyright &copy; 2014 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 114808 Version 1.0</div></div></div>"},"114809":{"type":"graphic_diagnosticimage","displayName":"Fibrolamellar carcinoma PET","title":"Fibrolamellar carcinoma: Imaging with fluorodeoxyglucose positron emission tomography (FDG-PET)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fibrolamellar carcinoma: Imaging with fluorodeoxyglucose positron emission tomography (FDG-PET)</div><div class=\"cntnt\"><img style=\"width:391px; height:754px;\" src=\"images/ONC/114809_FibrolamellarPET.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">PET scan demonstrates multifocal fibrolamellar carcinoma in the liver with variable uptake of FDG. Some tumors are FDG avid (arrow), and others demonstrate less uptake (arrowhead).</div><div class=\"graphic_reference\">Reprinted with permission from the American Journal of Roentgenology. Ganeshan D, Szklaruk V, Kaseb A, et al. Imaging features of Fibrolamellar Hepatocellular Carcinoma. AJR Am J Roentgenol 2014; 202:544. Copyright &copy; 2014 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 114809 Version 1.0</div></div></div>"},"114811":{"type":"graphic_diagnosticimage","displayName":"Fibrolamellar carcinoma coronal MRI image","title":"Fibrolamellar carcinoma coronal MRI image","html":"<div class=\"graphic\"><div style=\"width: 693px\" class=\"figure\"><div class=\"ttl\">Fibrolamellar carcinoma coronal MRI image</div><div class=\"cntnt\"><img style=\"width:673px; height:672px;\" src=\"images/ONC/114811_FibrolamellarcornlMRIimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T1-weighted coronal image of MRI with gadolinium enhancement demonstrated enhancing mass with characteristic central scar (arrow). Tumor thrombus is also noted in the adjacent portal vein (arrowhead).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reprinted with permission from the American Journal of Roentgenology. Ganeshan D, Szklaruk V, Kaseb A, et al. Imaging features of Fibrolamellar Hepatocellular Carcinoma. AJR Am J Roentgenol 2014; 202:544. Copyright &copy; 2014 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 114811 Version 1.0</div></div></div>"},"114812":{"type":"graphic_picture","displayName":"Small bowel leiomyosarcoma","title":"Small bowel leiomyosarcoma","html":"<div class=\"graphic\"><div style=\"width: 780px\" class=\"figure\"><div class=\"ttl\">Small bowel leiomyosarcoma</div><div class=\"cntnt\"><img style=\"width:760px; height:382px;\" src=\"images/ONC/114812_Smallbowelleiomyosarcoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Low power view of a small bowel leiomyosarcoma. Spindle cells are characteristically elongated and have abundant eosinophilic cytoplasm with well-defined cell borders and prominent perinuclear vacuoles. The tumor cells are immunoreactive for desmin and actin as well as negative for <EM>KIT</EM> and <EM>DOG1</EM> (not shown), distinguishing them from a gastrointestinal stromal tumor (GIST).<br />(B) The high power view reveals pleiomorphic spindle cells with nuclear pleomorphism and atypia.</div><div class=\"graphic_reference\">Courtesy of Uma N. M. Rao, MD.</div><div id=\"graphicVersion\">Graphic 114812 Version 2.0</div></div></div>"},"114815":{"type":"graphic_table","displayName":"Post-bariatric surgery micronutrient supplementation","title":"Post-bariatric surgery micronutrient supplementation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Post-bariatric surgery micronutrient supplementation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Nutrient</td> <td class=\"subtitle1\">Post-bariatric surgery supplementation required to prevent deficiency (oral doses)</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Iron</td> <td>18 mg or 45 to 60 mg</td> <td> <p>After all bariatric procedures</p> Women of childbearing age and individuals with history of iron deficiency: 45 to 60 mg</td> </tr> <tr> <td>Vitamin B12</td> <td>350 to 500 mcg</td> <td>After all bariatric procedures</td> </tr> <tr> <td>Folate</td> <td>400 to 1000 mcg</td> <td>Women of childbearing age: 800 to 1000 mcg</td> </tr> <tr> <td>Thiamin</td> <td>12 to 100 mg</td> <td> <p>After all bariatric procedures</p> Recommend a B-complex vitamin of 50 mg or more in addition to a multivitamin</td> </tr> <tr> <td>Calcium</td> <td>1200 to 2400 mg (all sources)</td> <td>Supplement should include Vitamin D</td> </tr> <tr> <td>Vitamin D</td> <td>3000 IU (titrate to a serum 25(OH)D level of &#62;30 ng/mL)</td> <td>Continue 3000 IU per day total, from all sources (eg, multivitamin, calcium supplement)</td> </tr> <tr> <td>Vitamin A</td> <td>5000 to 10,000 IU</td> <td> <p>5000 to 10,000 IU after gastric bypass or sleeve gastrectomy</p> 10,000 IU after biliopancreatic diversion/duodenal switch</td> </tr> <tr> <td>Vitamins E/K</td> <td>15 mg/90 to 300 mcg</td> <td>&nbsp;</td> </tr> <tr> <td>Zinc/copper</td> <td>8 to 22 mg/1 to 2 mg</td> <td>&nbsp;</td> </tr> <tr> <td>Selenium</td> <td>Quantity contained in a \"high potency\" multivitamin</td> <td>&nbsp;</td> </tr> <tr> <td>Magnesium</td> <td>Quantity contained in a multivitamin that \"contains magnesium\"</td> <td>&nbsp;</td> </tr> <tr> <td>Additional B vitamins</td> <td>100 to 200% of daily value (DV)</td> <td>&nbsp;</td> </tr> <tr> <td>Trace minerals</td> <td>Quantity contained in a multivitamin \"complete in minerals\"</td> <td>Molybdenum, manganese, chromium, etc</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IU: international unit.</div><div id=\"graphicVersion\">Graphic 114815 Version 1.0</div></div></div>"},"114818":{"type":"graphic_algorithm","displayName":"Approach to selecting treatment for PTSD in children","title":"Approach to selecting treatment for PTSD in children and adolescents","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Approach to selecting treatment for PTSD in children and adolescents</div><div class=\"cntnt\"><img style=\"width:449px; height:786px;\" src=\"images/PSYCH/114818_Appr_slct_trtmt_PTSD_chldrn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The treatment choices in this algorithm are suggestions based on relatively weak comparative evidence. Other choices may be reasonable alternatives. As an example, multiple psychotherapies show efficacy in child PTSD, though trauma-focused CBT is supported by more numerous and rigorous trials.</div><div class=\"graphic_footnotes\">PTSD: Posttraumatic stress disorder.<br />* Contraindications to trauma-focused therapies:&#xD;&#xA;<ul>&#xD;&#xA;    <li>Acute clinical states requiring immediate stabilization (eg, suicidality, psychosis, mania, or drug intoxication)</li>&#xD;&#xA;    <li>Severe developmental or cognitive impairment</li>&#xD;&#xA;    <li>For group therapies, behavioral dysfunction interfering with participation</li>&#xD;&#xA;</ul>&#xD;&#xA;&para; A full course of these therapies can range from 12 to 25 sessions. Assessment of progress and associated adjustments to therapy occur over the course of treatment, while changes to modalities generally occur after a full course of treatment is completed.</div><div id=\"graphicVersion\">Graphic 114818 Version 1.0</div></div></div>"},"114821":{"type":"graphic_figure","displayName":"Skin staple removal","title":"Skin staple removal","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Skin staple removal</div><div class=\"cntnt\"><img style=\"width:534px; height:438px;\" src=\"images/EM/114821_Skinstapleremoval.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Place both jaws of the skin staple remover symmetrically under the staple.<br />(B) Depress the handle which unbends the staple and permits removal.</div><div id=\"graphicVersion\">Graphic 114821 Version 1.0</div></div></div>"},"114822":{"type":"graphic_table","displayName":"Acute generalized weakness in the ICU","title":"Acute generalized weakness syndromes in critically ill patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acute generalized weakness syndromes in critically ill patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Bilateral or paramedian brain or brainstem lesions*</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Trauma </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Infarction </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Hemorrhage </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Infectious and noninfectious encephalitides </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Abscess </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Central pontine myelinolysis </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Spinal cord disorders*</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Trauma </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Nontraumatic compressive myelopathies </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Spinal cord infarction </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Immune-mediated myelopathies (transverse myelitis, neuromyelitis optica) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Infective myelopathies (eg, HIV, West Nile virus) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Anterior horn cell disorders</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Motor neuron disease </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Poliomyelitis </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>West Nile virus infection </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Hopkins syndrome (acute postasthmatic amyotrophy) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Polyradiculopathies</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Carcinomatous </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>HIV-associated </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Peripheral nervous disorders</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Guillain-Barr&#233; syndrome<sup>&#182;</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Diphteric neuropathy </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Lymphoma-associated neuropathy </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Vasculitic neuropathy </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Porphyric neuropathy </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Paraneoplastic neuropathy </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Critical illness polyneuropathy </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Neuromuscular junction disorders</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Myasthenia gravis </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Lambert-Eaton myasthenic syndrome </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Neuromuscular-blocking drugs </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Botulism </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Muscle disorders</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Rhabdomyolysis </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Disuse myopathy </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Cachexia </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Infectious and inflammatory myopathies<sup>&#916;</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Mitochondrial myopathies </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Drug-induced and toxic myopathies </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Critical illness myopathy </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Decompensation of congenital myopathies (eg, myotonic dystrophy, Duchenne muscular dystrophy, adult onset acid maltase deficiency) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.<br />* Upper motor neuron signs (increased tone, hyperreflexia) may be absent in the acute setting.<br />¶ Includes acute inflammatory demyelinating polyneuropathy, acute motor axonal neuropathy, acute motor and sensory axonal neuropathy.<br />Δ Includes polymyositis, dermatomyositis, pyomyositis.</div><div class=\"graphic_reference\">From: Stevens RD, Marshall SA, Cornblath DR, et al. A framework for diagnosing and classifying intensive care unit-acquired weakness. Crit Care Med 2009; 37:S299. DOI: <A href=\"http://journals.lww.com/ccmjournal/Abstract/2009/10001/A_framework_for_diagnosing_and_classifying.3.aspx\" target=_blank>10.1097/CCM.0b013e3181b6ef67</A>. Copyright © 2009 Society of Critical Care Medicine. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 114822 Version 1.0</div></div></div>"},"114828":{"type":"graphic_figure","displayName":"Home BP meter PI","title":"Using a home blood pressure meter","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Using a home blood pressure meter</div><div class=\"cntnt\"><img style=\"width:472px; height:517px;\" src=\"images/PI/114828_HomeBPmeterPI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an example of a person using a home blood pressure meter.</div><div id=\"graphicVersion\">Graphic 114828 Version 1.0</div></div></div>"},"114829":{"type":"graphic_waveform","displayName":"Intracardiac electrogram anti-tachycardia pacing monomorphic VT","title":"Implantable cardioverter-defibrillator (ICD) electrogram anti-tachycardia pacing for monomorphic ventricular tachycardia (VT)","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Implantable cardioverter-defibrillator (ICD) electrogram anti-tachycardia pacing for monomorphic ventricular tachycardia (VT)</div><div class=\"cntnt\"><img style=\"width:764px; height:873px;\" src=\"images/CARD/114829_ICDelctgmATPmonomrphcVT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stored intracardiac electrogram from an ICD showing the development of monomorphic ventricular tachycardia, which is successfully terminated by&nbsp;a burst of anti-tachycardia pacing delivered by&nbsp;the ICD. This tachycardia is monomorphic VT, but is labeled VF by the device because it was detected in the VF zone due to the rapid rate.</div><div class=\"graphic_footnotes\">RA: right atrial; RV: right ventricular; VT: ventricular tachycardia; VF: ventricular fibrillation; ATP: anti-tachycardia pacing; AS: atrium sensed; VS: ventricle sensed.</div><div id=\"graphicVersion\">Graphic 114829 Version 2.0</div></div></div>"},"114830":{"type":"graphic_picture","displayName":"Mapleson E (T-piece) circuit","title":"Mapleson E (T-piece) circuit","html":"<div class=\"graphic\"><div style=\"width: 772px\" class=\"figure\"><div class=\"ttl\">Mapleson E (T-piece) circuit</div><div class=\"cntnt\"><img style=\"width:752px; height:564px;\" src=\"images/ANEST/114830_Mapleson_E_T_piece_circuit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Obstructing the outflow through the open limb of the \"T\" could result in airway pressures as high as 50 psig, which equals 3515 cmH<SUB>2</SUB>O.</div><div class=\"graphic_footnotes\">psig: pounds per square inch gauge; cmH<SUB>2</SUB>O: centimeters of water.&nbsp;</div><div id=\"graphicVersion\">Graphic 114830 Version 1.0</div></div></div>"},"114831":{"type":"graphic_waveform","displayName":"Intracardiac electrogram ICD shock for VF","title":"Implantable cardioverter-defibrillator (ICD) electrogram shock for ventricular fibrillation (VF)","html":"<div class=\"graphic\"><div style=\"width: 831px\" class=\"figure\"><div class=\"ttl\">Implantable cardioverter-defibrillator (ICD)&nbsp;electrogram shock for ventricular fibrillation (VF)</div><div class=\"cntnt\"><img style=\"width:811px; height:611px;\" src=\"images/CARD/114831_ICDelectrogramshockVF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stored intracardiac electrogram from an ICD showing the development of ventricular fibrillation, which is successfully terminated by a single shock from the ICD.</div><div class=\"graphic_footnotes\">RA: right atrium; RV: right ventricle; AS: atrium sensed; AP: atrium paced; A pacing: atrial pacing; VF: ventricular fibrillation; PVC: premature ventricular contraction; VPB: ventricular premature beats.</div><div id=\"graphicVersion\">Graphic 114831 Version 1.0</div></div></div>"},"114835":{"type":"graphic_diagnosticimage","displayName":"Fat ring and pseudocapsule in sclerosing mesenteritis","title":"Fat ring and pseudocapsule","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Fat ring and pseudocapsule</div><div class=\"cntnt\"><img style=\"width:512px; height:512px;\" src=\"images/GAST/114835_Fatringpseudocapsule.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial computed tomography image without contrast in a patient with sclerosing mesenteritis shows displacement of small bowel loops by mesenteric fat, which has the appearance of a fat ring/halo sign (arrows) around a small central soft tissue nodule. A surrounding pseudocapsule (arrowheads) is also seen. </div><div id=\"graphicVersion\">Graphic 114835 Version 2.0</div></div></div>"},"114838":{"type":"graphic_diagnosticimage","displayName":"Oral cholecystogram with gallstones","title":"Oral cholecystogram with gallstones","html":"<div class=\"graphic\"><div style=\"width: 657px\" class=\"figure\"><div class=\"ttl\">Oral cholecystogram with gallstones</div><div class=\"cntnt\"><img style=\"width:637px; height:480px;\" src=\"images/GAST/114838_Oralchlcystgrmptntgllstn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An oral cholecystogram in the upright position showing a gallbladder that is outlined by contrast with layers of floating gallstones in its center. </div><div class=\"graphic_reference\">Courtesy of Salam F Zakko, MD, FACP, AGAF.</div><div id=\"graphicVersion\">Graphic 114838 Version 2.0</div></div></div>"},"114839":{"type":"graphic_diagnosticimage","displayName":"Transabdominal ultrasound with gallstones","title":"Transabdominal ultrasound with gallstones","html":"<div class=\"graphic\"><div style=\"width: 771px\" class=\"figure\"><div class=\"ttl\">Transabdominal ultrasound with gallstones</div><div class=\"cntnt\"><img style=\"width:751px; height:495px;\" src=\"images/GAST/114839_Transabdomnlultrsndgllstn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transabdominal ultrasound demonstrating floating cholesterol stones layering in the center of the gallbladder.</div><div class=\"graphic_reference\">Courtesy of Salam F Zakko, MD, FACP, AGAF. </div><div id=\"graphicVersion\">Graphic 114839 Version 2.0</div></div></div>"},"114841":{"type":"graphic_diagnosticimage","displayName":"Abdominal CT scan of gallstones","title":"Abdominal computed tomography scan of gallstones","html":"<div class=\"graphic\"><div style=\"width: 766px\" class=\"figure\"><div class=\"ttl\">Abdominal&nbsp;computed tomography scan&nbsp;of gallstones</div><div class=\"cntnt\"><img style=\"width:746px; height:492px;\" src=\"images/GAST/114841_AbdominalCTdemogllstones.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An abdominal computed tomography scan image&nbsp;with floating cholesterol stones layering in the center of the gallbladder. Note how pure cholesterol stones appear like black holes within gallbladder bile due to the very low computed tomography density of cholesterol.</div><div class=\"graphic_reference\">Courtesy of Salam F Zakko, MD, FACP, AGAF. </div><div id=\"graphicVersion\">Graphic 114841 Version 2.0</div></div></div>"},"114842":{"type":"graphic_picture","displayName":"Gallstones","title":"Gallstones","html":"<div class=\"graphic\"><div style=\"width: 631px\" class=\"figure\"><div class=\"ttl\">Gallstones</div><div class=\"cntnt\"><img style=\"width:611px; height:765px;\" src=\"images/GAST/114842_Gallbladderstones.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gallstones retrieved from six different patients. Note how gallstones are similar in the same patient but differ among patients.</div><div class=\"graphic_reference\">Courtesy of Salam F Zakko, MD, FACP, AGAF. </div><div id=\"graphicVersion\">Graphic 114842 Version 2.0</div></div></div>"},"114844":{"type":"graphic_algorithm","displayName":"Evaluation neuromuscular weakness in critical illness","title":"Evaluation of suspected neuromuscular weakness in a critically ill patient","html":"<div class=\"graphic\"><div style=\"width: 791px\" class=\"figure\"><div class=\"ttl\">Evaluation of suspected neuromuscular weakness in a critically ill patient</div><div class=\"cntnt\"><img style=\"width:771px; height:697px;\" src=\"images/NEURO/114844_Evlnrmsclrwknscritillns.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ICU: intensive care unit; CSF: cerebrospinal fluid; EEG: electroencephalography; EDX: electrodiagnostic studies; NCS: nerve conduction studies; EMG: electromyography; RNS: repetitive nerve stimulation; CIM: critical illness myopathy; CIP: critical illness polyneuropathy; CIM/CIP: combined critical illness myopathy and polyneuropathy; DMS: direct muscle stimulation.</div><div id=\"graphicVersion\">Graphic 114844 Version 1.0</div></div></div>"},"114845":{"type":"graphic_algorithm","displayName":"Initial treatment of acute pericarditis in adults","title":"Initial treatment of acute pericarditis in adults","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Initial treatment of acute pericarditis in adults</div><div class=\"cntnt\"><img style=\"width:345px; height:507px;\" src=\"images/CARD/114845_Intl_trtmt_act_prcrdts_adlt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NSAIDs: nonsteroidal anti-inflammatory drugs.<br />* NSAIDs are the preferred anti-inflammatory for nearly all patients with acute idiopathic or viral pericarditis. Glucocorticoids should be used for initial treatment of acute pericarditis only in patients with contraindications to NSAIDs, or for specific indications (ie, systemic inflammatory diseases, pregnancy, renal failure), and should be used at the lowest effective dose. Refer to the UpToDate topic on treatment of acute pericarditis for glucocorticoid dosing information.<br />¶ Response to treatment includes improvement/resolution of symptoms within one to two weeks of initiation of therapy and normalization of C-reactive protein level (if measured).<br />Δ Refer to UpToDate content on recurrent/refractory pericarditis for therapeutic approach to patients who are not showing clinical improvement.</div><div id=\"graphicVersion\">Graphic 114845 Version 1.0</div></div></div>"},"114861":{"type":"graphic_algorithm","displayName":"Approach to selecting treatment for DDD","title":"Approach to selecting treatment for depersonalization/derealization disorder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Approach to selecting treatment for depersonalization/derealization disorder</div><div class=\"cntnt\"><img style=\"width:328px; height:610px;\" src=\"images/PSYCH/114861_ApprselectingtreatmntDDD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The treatment decisions in this algorithm are suggestions based on relatively weak evidence. Other treatment choices may be reasonable alternatives.</div><div id=\"graphicVersion\">Graphic 114861 Version 1.0</div></div></div>"},"114865":{"type":"graphic_figure","displayName":"Medial collateral ligament bursa","title":"Medial collateral ligament bursa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Medial collateral ligament bursa</div><div class=\"cntnt\"><img style=\"width:390px; height:509px;\" src=\"images/RHEUM/114865_Medialcollateralligamentbursa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Line drawing represents axial section of medial side of knee. Note three distinct layers (I, II, and III). Layer I corresponds to crural fascia, layer II contains superficial portion of the&nbsp;medial collateral ligament (also referred to as the tibial collateral ligament), and layer III contains deep portion of the&nbsp;MCL. The&nbsp;MCL bursa (B) is located between superficial and deep portion of the MCL. Also note split in layer II along anterior margin of superficial&nbsp;MCL (arrowheads). Anteriorly, layer I is fused with layer II (curved arrow), whereas posteriorly, layer II joins layer III (short arrows). Sartorius tendon is embedded in layer I (S).</div><div class=\"graphic_footnotes\">Medial collateral ligament: MCL.</div><div class=\"graphic_reference\">Modified with permission from the American Journal of Roentgenology. De Maeseneer M, Shahabpour M, Van Roy F, et al. MR imaging of the medial collateral ligament bursa: Findings in patients and anatomic data derived from cadavers. AJR Am J Roentgenol 2001; 177:911. Copyright © 2001 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 114865 Version 1.0</div></div></div>"},"114866":{"type":"graphic_figure","displayName":"Semimembranosus-tibial collateral ligament bursa","title":"The semimembranosus-tibial collateral ligament bursa","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">The semimembranosus-tibial collateral ligament bursa</div><div class=\"cntnt\"><img style=\"width:542px; height:557px;\" src=\"images/RHEUM/114866_Semimembranosustibialcollateralligamentbursa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing represents the medial view of the knee and demonstrates the relationships of the oval (superficial) and triangular (deep) pockets of the semimembranosus-tibial collateral ligament bursa, which is saddled on semimembranosus.</div><div class=\"graphic_reference\">From: Hennigan SP, Schneck CD, Mesgarzadeh M, Clancy M. The semimembranosus-tibial collateral ligament bursa. Anatomical study and magnetic resonance imaging. J Bone Joint Surg Am 1994; 76:1322. Copyright ©&nbsp;1994 The Journal of Bone and Joint Surgery, Inc. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 114866 Version 1.0</div></div></div>"},"114867":{"type":"graphic_picture","displayName":"Lateral elbow tissue atrophy from steroid injection","title":"Lateral elbow tissue atrophy from steroid injection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral elbow tissue atrophy from steroid injection</div><div class=\"cntnt\"><img style=\"width:311px; height:568px;\" src=\"images/SM/114867_Ltelbwtssatphystrdinjt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph shows soft tissue atrophy and hypopigmentation in the region of the lateral epicondyle. The patient had received glucocorticoid injections in this region as part of their treatment for lateral epicondylitis (ie, tennis elbow).</div><div class=\"graphic_reference\">Courtesy of Francis O'Connor, MD.</div><div id=\"graphicVersion\">Graphic 114867 Version 1.0</div></div></div>"},"114869":{"type":"graphic_picture","displayName":"Electrocautery endobronchial lesion","title":"Endobronchial lesion pre-and post electrocautery","html":"<div class=\"graphic\"><div style=\"width: 779px\" class=\"figure\"><div class=\"ttl\">Endobronchial lesion pre-and post electrocautery</div><div class=\"cntnt\"><img style=\"width:759px; height:354px;\" src=\"images/PULM/114869_Electrocautryendbrnchllsn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Image A) displays an obstructing tumor of a main stem bronchus. (Image B) shows resolution of the obstruction by treating the tumor locally with electrocautery.</div><div id=\"graphicVersion\">Graphic 114869 Version 1.0</div></div></div>"},"114870":{"type":"graphic_table","displayName":"Categorization of bleeding risk","title":"Categorization of bleeding risk","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Categorization of bleeding risk</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medium risk</td> <td class=\"subtitle1\">High risk</td> </tr> <tr> <td>Pericarditis</td> <td>Bleeding diathesis</td> </tr> <tr> <td>Recent bleeding &#60;48 hours</td> <td>Clotting factor disorder</td> </tr> <tr> <td>Recent placement of tunneled catheter &#60;24 hours</td> <td>Actively bleeding</td> </tr> <tr> <td>Minor surgery &#60;72 hours</td> <td>Eye or major surgery &#60;72 hours</td> </tr> <tr> <td>Eye or major surgery within 3 to 7 days</td> <td>Intracranial hemorrhage &#60;7 days</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Saltissi D. Management of anticoagulation for hemodialysis. In: Dialysis Therapy, 3rd ed, Nissenson AR, Fine RN (Eds), Hanley and Belfus, Philadelphia, 2002. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 114870 Version 1.0</div></div></div>"},"114871":{"type":"graphic_figure","displayName":"Fresh gas decoupled breathing system","title":"Fresh gas decoupled breathing system","html":"<div class=\"graphic\"><div style=\"width: 844px\" class=\"figure\"><div class=\"ttl\">Fresh gas decoupled breathing system</div><div class=\"cntnt\"><img style=\"width:824px; height:573px;\" src=\"images/ANEST/114871_Frshgasdecouplbrthngsys.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">APL: adjustable pressure-limiting (\"pop-off\") valve; PEEP: positive end-expiratory pressure; Pmax: maximum pressure.</div><div class=\"graphic_reference\">From: Loeb RG, Feldman J. Anesthesia Machines. In: Encyclopedia of Medical Devices and Instrumentation, 2nd ed, Webster JG (Ed), Wiley, Hoboken, NJ 2006. <A href=\"http://onlinelibrary.wiley.com/book/10.1002/0471732877\" target=_blank>http://onlinelibrary.wiley.com/book/10.1002/0471732877</A>. Copyright © 2006. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 114871 Version 1.0</div></div></div>"},"114872":{"type":"graphic_figure","displayName":"Anesthesia machine internal piping","title":"Anesthesia machine internal piping","html":"<div class=\"graphic\"><div style=\"width: 888px\" class=\"figure\"><div class=\"ttl\">Anesthesia machine internal piping</div><div class=\"cntnt\"><img style=\"width:868px; height:655px;\" src=\"images/ANEST/114872_Anesthesiamchnintrnlppng.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anesthesia machine internal piping, Draeger Narkomed.</div><div class=\"graphic_footnotes\">N<SUB>2</SUB>O: nitrous oxide; O<SUB>2</SUB>: oxygen.</div><div class=\"graphic_reference\">From: Loeb RG, Feldman J. Anesthesia Machines. In: Encyclopedia of Medical Devices and Instrumentation, 2nd ed, Webster JG (Ed), Wiley, Hoboken, NJ 2006. <A href=\"http://onlinelibrary.wiley.com/book/10.1002/0471732877\" target=_blank>http://onlinelibrary.wiley.com/book/10.1002/0471732877</A>. Copyright © 2006. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 114872 Version 1.0</div></div></div>"},"114873":{"type":"graphic_picture","displayName":"Inspection of lower extremity alignment","title":"Inspection of lower extremity alignment","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Inspection of lower extremity alignment</div><div class=\"cntnt\"><img style=\"width:570px; height:764px;\" src=\"images/SM/114873_Inspectlwrextrmtyalgnmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prior to assessing dynamic gait, the clinician should inspect the patient's lower extremities for alignment and symmetry. The photograph above highlights important areas to evaluate, showing normal joint and lower extremity alignment and appearance.</div><div class=\"graphic_footnotes\">ASIS: anterior superior iliac spine.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114873 Version 1.0</div></div></div>"},"114877":{"type":"graphic_picture","displayName":"Standing increased hip external rotation","title":"Standing increased hip external rotation","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Standing increased hip external rotation</div><div class=\"cntnt\"><img style=\"width:712px; height:560px;\" src=\"images/SM/114877_Standingincrhipextnlrtn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During inspection prior to dynamic gait assessment, the runner above was noted to have increased hip external rotation.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114877 Version 1.0</div></div></div>"},"114878":{"type":"graphic_picture","displayName":"Asymmetric shoulder height","title":"Asymmetric shoulder height during standing inspection","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Asymmetric shoulder height during standing inspection</div><div class=\"cntnt\"><img style=\"width:510px; height:765px;\" src=\"images/SM/114878_Asymmetricshoulderheight.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During standing inspection, the runner pictured above was noted to have an asymmetry in shoulder height.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114878 Version 1.0</div></div></div>"},"114879":{"type":"graphic_table","displayName":"Secondary causes of dyslipidemia","title":"Secondary causes of dyslipidemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Secondary causes of dyslipidemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup></colgroup> <tbody> <tr> <td> <ul> <li>Diabetes mellitus </li> </ul> </td> </tr> <tr> <td> <ul> <li>Cholestatic liver disease </li> </ul> </td> </tr> <tr> <td> <ul> <li>Nephrotic syndrome </li> </ul> </td> </tr> <tr> <td> <ul> <li>Chronic renal disease </li> </ul> </td> </tr> <tr> <td> <ul> <li>Hypothyroidism </li> </ul> </td> </tr> <tr> <td> <ul> <li>Obesity </li> </ul> </td> </tr> <tr> <td> <ul> <li>Cigarette smoking </li> </ul> </td> </tr> <tr> <td> <ul> <li>Excessive alcohol consumption </li> </ul> </td> </tr> <tr> <td> <ul> <li>Medications </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 114879 Version 1.0</div></div></div>"},"114883":{"type":"graphic_diagnosticimage","displayName":"RUG scout","title":"RUG scout","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">RUG scout</div><div class=\"cntnt\"><img style=\"width:756px; height:619px;\" src=\"images/SURG/114883_RUG_Scout_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient must be positioned in a semi-oblique position and rotated 30 degrees, rather than supine, for a retrograde urethrogram to demonstrate the entire urethra. Adequate positioning of the patient is indicated by obliteration of one of the obturator fossa on a scout film. In this scout film, the right obturator fossa cannot be seen because of positioning; the left obturator fossa is outlined. Note the inferior pubic ramus fracture below the left obturator fossa, and orthopedic hardware.</div><div class=\"graphic_footnotes\">RUG: retrograde urethrogram.</div><div id=\"graphicVersion\">Graphic 114883 Version 1.0</div></div></div>"},"114884":{"type":"graphic_diagnosticimage","displayName":"RUG cystogram","title":"RUG cystogram","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">RUG cystogram</div><div class=\"cntnt\"><img style=\"width:754px; height:564px;\" src=\"images/SURG/114884_RUG_with_cystosgram_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A retrograde urethrogram is often combined with an anterograde cystogram, typically performed through a suprapubic tube placed at the time of injury. In this radiograph, the retrograde urethrogram shows an obliterative component in the proximal bulbar/distal membranous urethra. The anterograde cystogram helps delineate the entire length of the obliterated segment of the pelvic fracture urethral distraction defect (outlined by the bracket). Combining these two techniques in an \"up-and-down-o-gram\" helps the surgeon delineate the length of the obliterated segment for surgical planning.</div><div class=\"graphic_footnotes\">RUG: retrograde urethrogram.</div><div id=\"graphicVersion\">Graphic 114884 Version 1.0</div></div></div>"},"114901":{"type":"graphic_picture","displayName":"Greater trochanter height in standing patient","title":"Greater trochanter height in standing patient","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Greater trochanter height in standing patient</div><div class=\"cntnt\"><img style=\"width:281px; height:764px;\" src=\"images/SM/114901_Greatertrchntrhgtstdgpt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inspection of the patient prior to dynamic gait assessment includes evaluation of the height and symmetry of the greater trochanters. Normal height and symmetry are seen in the photograph above. The greater trochanters lie adjacent to each of the superior arrowheads.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114901 Version 1.0</div></div></div>"},"114902":{"type":"graphic_picture","displayName":"Genu varus in runner","title":"Genu varus in runner","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Genu varus in runner</div><div class=\"cntnt\"><img style=\"width:564px; height:754px;\" src=\"images/SM/114902_Genuvarusrunner.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Genu varus (lateral angulation of the knee), as shown in the photograph above, may predispose to medial knee joint problems in runners.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114902 Version 1.0</div></div></div>"},"114903":{"type":"graphic_picture","displayName":"Tibial varus in runner","title":"Tibial varus in runner","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Tibial varus in runner</div><div class=\"cntnt\"><img style=\"width:562px; height:749px;\" src=\"images/SM/114903_Tibialvarusrunner.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above shows mild tibial varus in a standing runner.&nbsp;The&nbsp;solid line shows the angulation of the tibial shaft relative to the dashed line drawn perpendicular to the ground. </div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114903 Version 1.0</div></div></div>"},"114904":{"type":"graphic_table","displayName":"Phenotypic definition of CFLD","title":"Phenotypic definition of cystic fibrosis-related liver disease<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Phenotypic definition of cystic fibrosis-related liver disease<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Cystic fibrosis-related liver disease with cirrhosis, with or without portal hypertension</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Based on any of the following: Clinical exam, imaging, histology, laparoscopy </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Noncirrhotic portal hypertension</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Based on histology and imaging or clinical exam </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">CF-related liver involvement without cirrhosis or portal hypertension</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Patients can have more than one of the following features: </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Persistent (&#62;6 months) elevation of AST, ALT or GGT &#62;2 times upper limit of normal </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Intermittent elevations of the above laboratory values </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Steatosis (histologic determination) </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Fibrosis (histologic or elastography determination) </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Cholangiopathy (based on ultrasound, MRI, CT or ERCP) </li> </ul> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <ul> <li>Ultrasound abnormalities not consistent with cirrhosis </li> </ul> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Preclinical: No evidence of liver involvement</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Based on clinical exam and laboratory values and imaging if available </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGT: gamma glutamyl transferase; MRI: magnetic resonance imaging; CT: computerized tomography; ERCP: endoscopic retrograde cholangiopancreatography.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>van de Peppel IP, Bertolini A, Jonker JW, et al. Diagnosis, follow-up and treatment of cystic fibrosis-related liver disease. Curr Opin Pulm Med 2017.</li>&#xD;&#xA;</ol>&#xD;&#xA;Original figure modified for this publication. From: Flass T, Narkewicz MR. Cirrhosis and other liver disease in cystic fibrosis. J Cyst Fibros 2013; 12:116. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 114904 Version 1.0</div></div></div>"},"114907":{"type":"graphic_table","displayName":"Management of aortic stenosis during cardiac surgery","title":"Key points for anesthetic and hemodynamic management of aortic stenosis during cardiac surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key points for anesthetic and hemodynamic management of aortic stenosis during cardiac surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Hemodynamic goals</td> <td class=\"subtitle1\">Avoid</td> <td class=\"subtitle1\">Monitor</td> <td class=\"subtitle1\">Intervention</td> </tr> <tr> <td>Sinus rhythm</td> <td>Avoid atrial fibrillation or other SVT</td> <td>5-lead ECG</td> <td>Manage new-onset atrial fibrillation or other SVT: <ul> <li>Control HR.</li> <li>Cardioversion for SVT with hemodynamic compromise.</li> </ul> </td> </tr> <tr> <td>Normal HR (60 to 80 bpm)</td> <td> <p>Avoid tachycardia</p> <p>Avoid severe bradycardia</p> Avoid junctional rhythm</td> <td> <p>5-lead ECG</p> Pulse oximetry with visible waveform</td> <td> <p>Design an anesthetic that maintains a relatively slow HR (eg, an opioid-based technique).</p> <p>Prevent tachycardia by ensuring adequate depth of anesthesia and analgesia.</p> <p>Manage tachycardia related to hypotension with a vasoconstrictor (eg, phenylephrine, norepinephrine) and fluid administration.</p> Slow HR with beta blockers if necessary.</td> </tr> <tr> <td>Maintain afterload</td> <td>Avoid hypotension</td> <td>Intra-arterial BP</td> <td> <p>Administer a vasoconstrictor (eg, phenylephrine, norepinephrine) to manage hypotension.</p> Consider preemptive administration of a low-dose infusion of a vasoconstrictor (eg, phenylephrine, norepinephrine) during induction.</td> </tr> <tr> <td>Maintain preload</td> <td>Avoid hypovolemia</td> <td>Assess clinical response to fluid boluses</td> <td> <p>Maintain intravascular volume status.</p> Rapid resuscitation for hemorrhage.</td> </tr> <tr> <td>Maintain contractility</td> <td>Avoid doses of drugs that cause significant myocardial depression</td> <td>Hemodynamics</td> <td>If inotropic support needed, norepinephrine is preferred.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SVT: supraventricular tachycardia; ECG: electrocardiogram; HR: heart rate; bpm: beats per minute; BP: blood pressure.</div><div id=\"graphicVersion\">Graphic 114907 Version 1.0</div></div></div>"},"114908":{"type":"graphic_table","displayName":"Management of aortic or mitral regurgitation in cardiac surgery","title":"Key points for anesthetic and hemodynamic management of aortic or mitral regurgitation during cardiac surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key points for anesthetic and hemodynamic management of aortic or mitral regurgitation during cardiac surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Hemodynamic goals</td> <td class=\"subtitle1\">Avoid</td> <td class=\"subtitle1\">Monitor</td> <td class=\"subtitle1\">Intervention</td> </tr> <tr> <td>Normal to fast HR (80 to 100 bpm)</td> <td>Avoid bradycardia</td> <td> <p>5-lead ECG</p> Pulse oximetry with visible waveform</td> <td>Management of bradycardia: <ul> <li>Ephedrine. </li> <li>Glycopyrrolate if necessary. </li> <li>Low-dose infusion of dopamine or epinephrine if necessary. </li> </ul> </td> </tr> <tr> <td>Normal to low afterload</td> <td>Avoid hypertension</td> <td>Intra-arterial BP</td> <td> <p>Prevent hypertension by providing adequate anesthetic depth and effective analgesia.</p> Treat hypotension with careful titration of ephedrine.</td> </tr> <tr> <td>Normal to low preload</td> <td>Avoid hypervolemia</td> <td>Assess clinical response to small fluid boluses</td> <td> <p>Restrictive fluid management.</p> Intravenous nitroglycerin infusion for volume overload.</td> </tr> <tr> <td>Maintain contractility</td> <td>Avoid doses of drugs that cause significant myocardial depression</td> <td>Hemodynamics</td> <td>If inotropic support is needed, milrinone, dobutamine, or low-dose epinephrine is preferred.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HR: heart rate; bpm: beats per minute; ECG: electrocardiogram; BP: blood pressure.</div><div id=\"graphicVersion\">Graphic 114908 Version 1.0</div></div></div>"},"114909":{"type":"graphic_table","displayName":"Management of mitral stenosis during cardiac surgery","title":"Key points for anesthetic and hemodynamic management of mitral stenosis during cardiac surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key points for anesthetic and hemodynamic management of mitral stenosis during cardiac surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Hemodynamic goals</td> <td class=\"subtitle1\">Avoid</td> <td class=\"subtitle1\">Monitor</td> <td class=\"subtitle1\">Intervention</td> </tr> <tr> <td>Sinus rhythm</td> <td> <p>Avoid atrial fibrillation</p> Avoid tachyarrhythmias</td> <td>5-lead ECG</td> <td>Manage without delay new-onset atrial fibrillation or other SVT: <ul> <li>Control HR.</li> <li>Cardioversion for SVT with hemodynamic compromise (if no evidence of LA thrombus).</li> </ul> </td> </tr> <tr> <td>Slow to normal HR (50 to 70 bpm)</td> <td> <p>Avoid tachycardia</p> Avoid severe bradycardia</td> <td> <p>5-lead ECG</p> Pulse oximetry with visible waveform</td> <td> <p>Prevent pain-induced tachycardia by ensuring adequate anesthetic depth and effective analgesia.</p> <p>Design an anesthetic that maintains a relatively slow HR (eg, an opioid-based technique) and induce anesthesia slowly.</p> <p>Manage tachycardia related to hypotension with phenylephrine (or norepinephrine).</p> Slow HR with beta blockers if necessary.</td> </tr> <tr> <td>Maintain afterload</td> <td>Avoid hypotension</td> <td>Intra-arterial BP</td> <td>Administer a vasoconstrictor (eg, phenylephrine, norepinephrine) to manage hypotension.</td> </tr> <tr> <td rowspan=\"2\">Adequate preload</td> <td>Avoid hypervolemia</td> <td> <p>Clinical course and oxygenation</p> Development of flash pulmonary edema</td> <td>Management of pulmonary edema: <ul> <li>Treat hypoxemia related to pulmonary edema immediately with 100% oxygen, PEEP, and, if necessary, intubation and controlled ventilation.</li> </ul> </td> </tr> <tr> <td>Avoid hypovolemia</td> <td>Assess clinical response to fluid boluses</td> <td> <p>Maintain intravascular volume status.</p> Rapid resuscitation for hemorrhage.</td> </tr> <tr> <td>Maintain RV contractility</td> <td>Avoid doses of drugs that cause significant myocardial depression</td> <td>Hemodynamics</td> <td>If inotropic support is needed, milrinone or dobutamine may be used if SVR and systemic BP are maintained; low-dose epinephrine may be necessary.</td> </tr> <tr> <td>Minimize PVR (optimize oxygenation and ventilation)</td> <td> <p>Avoid hypoxemia</p> Avoid hypercarbia</td> <td> <p>Pulse oximetry with visible waveform</p> <p>Capnometry (end-tidal CO<sub>2</sub>)</p> Arterial blood gas analysis</td> <td>Minimize risk of hypoxemia and hypercarbia by: <ul> <li>Administering supplemental oxygen.</li> <li>Ensuring well-controlled ventilation.</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; SVT: supraventricular tachyarrhythmia; HR: heart rate; LA: left atrium; bpm: beats per minute; BP: blood pressure; PEEP: positive end-expiratory pressure; RV: right ventricular; PVR: pulmonary vascular resistance; CO<SUB>2</SUB>: carbon dioxide.</div><div id=\"graphicVersion\">Graphic 114909 Version 1.0</div></div></div>"},"114910":{"type":"graphic_table","displayName":"Management of aortic or mitral valve disease in cardiac surgery","title":"Key points for hemodynamic management during cardiac surgery in patients with aortic or mitral valve disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key points for hemodynamic management during cardiac surgery in patients with aortic or mitral valve disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup span=\"2\" width=\"12.5%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"12.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Valvular lesion</td> <td class=\"subtitle1\">Heart rate</td> <td class=\"subtitle1\">Heart rhythm</td> <td class=\"subtitle1\">Preload</td> <td class=\"subtitle1\">Afterload</td> <td class=\"subtitle1\">Contractility</td> <td class=\"subtitle1\">PVR</td> </tr> <tr> <td>Aortic stenosis</td> <td> <p>Normal HR at 60 to 80 bpm</p> <p>Avoid tachycardia</p> Avoid bradycardia</td> <td> <p>Maintain sinus rhythm</p> <p>Avoid SVT</p> Avoid AV dissociation</td> <td> <p>Maintain intravascular volume</p> Avoid hypovolemia</td> <td> <p>Maintain systolic BP &#62;100 mmHg, MAP &#62;70 mmHg, or both within 20% of baseline</p> Avoid hypotension</td> <td>Avoid myocardial depression</td> <td>&nbsp;</td> </tr> <tr> <td>Mitral stenosis</td> <td> <p>Slow to normal HR at 50 to 70 bpm</p> Avoid tachycardia</td> <td>Control ventricular rate regardless of rhythm</td> <td> <p>Maintain intravascular volume</p> <p>Avoid hypovolemia</p> Avoid hypervolemia</td> <td> <p>Maintain systolic BP &#62;100 mmHg, MAP &#62;70 mmHg, or both within 20% of baseline</p> Avoid hypotension</td> <td>Avoid myocardial depression</td> <td> <p>Avoid hypoxemia</p> Avoid hypercarbia</td> </tr> <tr> <td>Aortic regurgitation</td> <td> <p>Normal to fast HR at 80 to 100 bpm</p> Avoid bradycardia</td> <td>Maintain relatively fast HR regardless of rhythm</td> <td> <p>Maintain or reduce preload</p> Avoid hypervolemia</td> <td> <p>Maintain a low-normal systolic BP of approximately 100 to 120 mmHg or within 10% of baseline</p> Avoid hypertension</td> <td>Avoid myocardial depression</td> <td>&nbsp;</td> </tr> <tr> <td>Mitral regurgitation</td> <td> <p>Normal to fast HR at 80 to 100 bpm</p> <p>Avoid bradycardia</p> <em>(In patients with MR due to ischemic heart disease, maintain a slower HR at 60 to 80 bpm)</em></td> <td>Maintain relatively fast HR regardless of rhythm</td> <td> <p>Maintain or reduce preload</p> Avoid hypervolemia</td> <td> <p>Maintain a low-normal systolic BP of approximately 100 to 120 mmHg or within 10% of baseline</p> <p>Avoid hypertension</p> <em>(In patients with MR due to ischemic heart disease, maintain a normal BP approximating preoperative values)</em></td> <td>Avoid myocardial depression</td> <td> <p>Avoid hypoxemia</p> Avoid hypercarbia</td> </tr> <tr> <td>Mitral regurgitation due to hypertrophic cardiomyopathy with LVOT obstruction</td> <td> <p>Normal HR at 60 to 80 bpm</p> <p>Avoid tachycardia</p> Avoid bradycardia</td> <td> <p>Maintain sinus rhythm</p> <p>Avoid SVT</p> Avoid AV dissociation</td> <td> <p>Maintain intravascular volume</p> Avoid hypovolemia</td> <td> <p>Maintain systolic BP &#62;100 mmHg, MAP &#62;70 mmHg, or both within 20% of baseline</p> Treat hypotension with vasoconstrictors without inotropic properties (eg, phenylephrine, vasopressin)</td> <td> <p>Cautiously decrease contractility by deepening anesthesia or administering beta blockers</p> Avoid inotropic agents</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PVR: pulmonary vascular resistance; HR: heart rate; bpm: beats per minute; SVT: supraventricular tachycardia; AV: atrioventricular; BP: blood pressure; MAP: mean arterial pressure; MR: mitral regurgitation; LVOT: left ventricular outflow tract.</div><div id=\"graphicVersion\">Graphic 114910 Version 1.0</div></div></div>"},"114915":{"type":"graphic_figure","displayName":"Anserine bursa drawing","title":"Anserine bursa","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Anserine bursa</div><div class=\"cntnt\"><img style=\"width:598px; height:510px;\" src=\"images/RHEUM/114915_Anserinebursadrawing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing represents the medial view of the knee and demonstrates the relationship between the anserine bursa and the surrounding structures.</div><div id=\"graphicVersion\">Graphic 114915 Version 2.0</div></div></div>"},"114919":{"type":"graphic_algorithm","displayName":"Approach to management of purulent skin infection in adults","title":"Approach to management of drainable abscess or skin infection with purulent drainage in adults","html":"<div class=\"graphic\"><div style=\"width: 1458px\" class=\"figure\"><div class=\"ttl\">Approach to management of drainable abscess or skin infection with purulent drainage in adults</div><div class=\"cntnt\"><img style=\"width:1438px; height:1056px;\" src=\"images/ID/114919_Drainablskinabscessadult.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm outlines our approach to initial empiric antibiotic therapy and abscess management of patients with skin abscesses or skin infections with purulent drainage. It includes various appropriate antibiotic options depending on the patient presentation. The choice among them further depends on factors such as patient allergies or medication intolerance, expected toxicities or drug interactions, physician familiarity with the different antibiotics, expected local rates of resistance, cost, and convenience of administration.</div><div class=\"graphic_footnotes\">MRSA: methicillin-resistant <EM>S. aureus</EM>; IV: intravenously; MIC: minimum inhibitory concentration.<br />​* This includes a history of infective endocarditis, prosthetic valve or perivalvular material, and unrepaired congenital heart disease. Refer to other UpToDate content for more details.<br />¶ We suggest antibiotic therapy for all patients with skin abscesses. However, because many abscesses can be successfully treated with incision and drainage alone, it is reasonable to forgo antibiotic therapy in otherwise healthy patients who have small (eg, &lt;2 cm) abscesses without the features listed in the first box. An antibiotic-sparing approach may be particularly compelling in patients who have multiple antibiotic allergies or intolerances.<br />Δ The decision to administer antimicrobial therapy parenterally should be individualized based on clinical presentation and patient characteristics. Parenteral antimicrobial therapy is generally appropriate when any of these features are present. Comorbidities that increase the risk of severe or complicated infection, such as the presence of an immunocompromising condition (eg, neutropenia, recent organ transplant, advanced HIV infection, B cell or T cell deficiency, or use of immunosuppressive agents), should lower the threshold for parenteral therapy.<br /><FONT class=lozenge>◊</FONT> Wound cultures are not necessary in healthy patients who do not receive antibiotics. For patients receiving antibiotics for a purulent skin infection, we submit a drainage specimen for microbiologic testing when any of the following are present: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Severe local infection (eg, extensive cellulitis).</LI>&#xD;&#xA;<LI>Systemic signs of infection (eg, fever).</LI>&#xD;&#xA;<LI>History of recurrent or multiple abscesses.</LI>&#xD;&#xA;<LI>Failure of initial antibiotic therapy.</LI>&#xD;&#xA;<LI>Extremes of age (young infants or older adults).</LI>&#xD;&#xA;<LI>Immunocompromising condition.</LI>&#xD;&#xA;<LI>Indications for prophylaxis against infective endocarditis.</LI>&#xD;&#xA;<LI>The community patterns of <EM>S. aureus</EM> susceptibility are unknown or rapidly changing.</LI></UL>§ Five days of antibiotic therapy is generally sufficient; extension up to 14 days may be warranted for slow response to therapy. In cases of slow improvement, culture results, if available, should be evaluated to determine whether the chosen antimicrobial regimen is appropriate or warrants revision.<br />¥ Oral antibiotic dosing as follows (if two doses are listed for a given agent, the higher one is for patients with higher weights [eg, &gt;120 kg] or more severe illness): &#xD;&#xA;<UL>&#xD;&#xA;<LI>Amoxicillin 875 mg orally twice daily.</LI>&#xD;&#xA;<LI>Amoxicillin-clavulanate 875 mg orally twice daily.</LI>&#xD;&#xA;<LI>Clindamycin 300 to 450 mg orally four times daily.</LI>&#xD;&#xA;<LI>Ciprofloxacin 500 mg orally twice daily.</LI>&#xD;&#xA;<LI>Doxycycline 100 mg orally twice daily.</LI>&#xD;&#xA;<LI>Levofloxacin 750 mg orally once daily.</LI>&#xD;&#xA;<LI>Metronidazole 500 mg orally three times daily.</LI>&#xD;&#xA;<LI>Minocycline 200 mg orally once, then 100 mg orally twice daily.</LI>&#xD;&#xA;<LI>Trimethoprim-sulfamethoxazole 1 to 2 double-strength tablets orally twice daily.</LI></UL>‡ For oral anti-MRSA coverage, we generally favor trimethoprim-sulfamethoxazole, doxycycline, or minocycline because of the greater associated risk of <EM>Clostridium difficile</EM> infection with clindamycin. Other active options include linezolid, tedizolid, and delafloxacin, but these should be reserved for circumstances in which the other options cannot be used.<br />† Intravenous antibiotic dosing as follows (if two doses are listed for a given agent, the higher one is for patients with higher weights [eg, &gt;120 kg] or more severe illness): &#xD;&#xA;<UL>&#xD;&#xA;<LI>Ampicillin-sulbactam 3 g IV every 6 hours.</LI>&#xD;&#xA;<LI>Ceftriaxone 1 to 2 g IV every 24 hours.</LI>&#xD;&#xA;<LI>Ciprofloxacin 400 mg IV every 12 hours.</LI>&#xD;&#xA;<LI>Daptomycin 4 to 6 mg/kg IV every 24 hours.</LI>&#xD;&#xA;<LI>Levofloxacin 750 mg IV once daily.</LI>&#xD;&#xA;<LI>Metronidazole 500 mg IV every 8 hours.</LI>&#xD;&#xA;<LI>Piperacillin-tazobactam 3.375 or 4.5 g IV every 6 hours.</LI>&#xD;&#xA;<LI>Ticarcillin-clavulanate 3.1 g IV every 4 hours.</LI>&#xD;&#xA;<LI>Vancomcyin 15 to 20 mg/kg/dose IV every 8 to 12 hours (not to exceed 2 g per dose). &#xD;&#xA;<UL>&#xD;&#xA;<LI>A one-time 25 mg/kg loading dose is appropriate for severely ill patients.</LI>&#xD;&#xA;<LI>A target trough level of 15 to 20 mcg/mL is appropriate in patients with severe and deep-seated infections.</LI>&#xD;&#xA;<LI>A target trough of 10 to 15 mcg/mL is appropriate for nonsevere infections.</LI></UL></LI></UL>** Vancomycin is the preferred parenteral anti-MRSA option. Daptomycin is an acceptable alternative agent for patients who have prior infection or colonization with a MRSA isolate with MIC ≥2, do not respond to vancomycin, have prior treatment failure with vancomycin, or do not tolerate vancomycin. Additional alternative anti-MRSA agents include ceftaroline, linezolid, tedizolid, telavancin, dalbavancin, oritavancin, and delafloxacin; use of these agents is limited by high cost and, in some cases, availability. Refer to the UptoDate topic on the treatment of skin and soft tissue infection due to MRSA for further discussion of the approach to antibiotic selection.<br />¶¶ Because of uncertain streptococcal coverage with trimethoprim-sulfamethoxazole, doxycycline, or minocycline, we add amoxicillin to each of these agents to ensure coverage, although it is not clear that this is necessary. If added, amoxicillin can be discontinued if cultures do not grow <EM>Streptococcus</EM> species.</div><div id=\"graphicVersion\">Graphic 114919 Version 2.0</div></div></div>"},"114920":{"type":"graphic_table","displayName":"Patient-clinician communication: ASCO consensus guideline","title":"Patient-clinician communication: American Society of Clinical Oncology (ASCO) consensus guideline","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient-clinician communication: American Society of Clinical Oncology (ASCO) consensus guideline</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Key recommendations</td> </tr> <tr> <td class=\"subtitle2_single\"> <ol class=\"numbers_to_nine\"> <li>Core communication skills </li> </ol> </td> </tr> <tr> <td class=\"indent2\"><span style=\"float: left;\">1.1.</span> <p class=\"indent2\">Before each conversation, clinicians should review the patient's medical information, establish goals for the conversation, and anticipate the needs and responses of the patient and family.</p> </td> </tr> <tr> <td class=\"indent2\"><span style=\"float: left;\">1.2.</span> <p class=\"indent2\">At the beginning of conversations with patients, clinicians should explore the patient's understanding of their disease and collaboratively set an agenda with the patient after inquiring what the patient and family wish to address and explaining what the clinician wishes to address.</p> </td> </tr> <tr> <td class=\"indent2\"><span style=\"float: left;\">1.3.</span> <p class=\"indent2\">During patient visits, clinicians should engage in behaviors that actively foster trust, confidence in the clinician, and collaboration.</p> </td> </tr> <tr> <td class=\"indent2\"><span style=\"float: left;\">1.4.</span> <p class=\"indent2\">Clinicians should provide information that is timely and oriented to the patient's concerns and preferences for information. After providing information, clinicians should check for patient understanding and document important discussions in the medical record.</p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"><span style=\"float: left;\">1.5.</span> <p class=\"indent2\">When patients display emotion through verbal or nonverbal behavior, clinicians should respond empathically.</p> </td> </tr> <tr> <td class=\"subtitle2_single\"> <ol class=\"numbers_to_nine\" start=\"2\"> <li>Discussing goals of care and prognosis </li> </ol> </td> </tr> <tr> <td class=\"indent2\"><span style=\"float: left;\">2.1.</span> <p class=\"indent2\">Clinicians should provide diagnostic and prognostic information that is tailored to the patient's needs and that provides hope and reassurance without misleading the patient.</p> </td> </tr> <tr> <td class=\"indent2\"><span style=\"float: left;\">2.2.</span> <p class=\"indent2\">Clinicians should reassess a patient's goals, priorities, and desire for information whenever a significant change in the patient's care is being considered.</p> </td> </tr> <tr> <td class=\"indent2\"><span style=\"float: left;\">2.3.</span> <p class=\"indent2\">Clinicians should provide information in simple and direct terms.</p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"><span style=\"float: left;\">2.4.</span> <p class=\"indent2\">When providing serious news, clinicians should take additional steps to address the needs and responses of patients.</p> </td> </tr> <tr> <td class=\"subtitle2_single\"> <ol class=\"numbers_to_nine\" start=\"3\"> <li>Discussing treatment options and clinical trials </li> </ol> </td> </tr> <tr> <td class=\"indent2\"><span style=\"float: left;\">3.1.</span> <p class=\"indent2\">Before discussing specific treatment options with the patient, clinicians should clarify the goals of treatment (cure versus prolongation of survival versus improved quality of life) so that the patient understands likely outcomes and can relate the goals of treatment to their goals of care.</p> </td> </tr> <tr> <td class=\"indent2\"><span style=\"float: left;\">3.2.</span> <p class=\"indent2\">When reviewing treatment options with patients, clinicians should provide information about the potential benefits and burdens of any treatment (proportionality) and check the patient's understanding of these benefits and burdens.</p> </td> </tr> <tr> <td class=\"indent2\"><span style=\"float: left;\">3.3</span> <p class=\"indent2\">Clinicians should discuss treatment options in a way that preserves patient hope, promotes autonomy, and facilitates understanding.</p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"><span style=\"float: left;\">3.4.</span> <p class=\"indent2\">Clinicians should make patients aware of all treatment options, including clinical trials and a sole focus on palliative care. When appropriate, clinicians should discuss the option of initiating palliative care simultaneously with other treatment modalities. If clinical trials are available, clinicians should start treatment discussions with standard treatments available off trial and then move to a discussion of applicable clinical trials if the patient is interested.</p> </td> </tr> <tr> <td class=\"subtitle2_single\"> <ol class=\"numbers_to_nine\" start=\"4\"> <li>Discussing end-of-life care </li> </ol> </td> </tr> <tr> <td class=\"indent2\"><span style=\"float: left;\">4.1.</span> <p class=\"indent2\">Clinicians should use an organized framework to guide the bidirectional communication about end-of-life care with patients and families.</p> </td> </tr> <tr> <td class=\"indent2\"><span style=\"float: left;\">4.2.</span> <p class=\"indent2\">Clinicians should initiate conversations about patients' end-of-life preferences early in the course of incurable illness and readdress this topic periodically based on clinical events or patient preferences.</p> </td> </tr> <tr> <td class=\"indent2\"><span style=\"float: left;\">4.3.</span> <p class=\"indent2\">Clinicians should explore how a patient's culture, religion, or spiritual belief system affects their end-of-life decision making or care preferences.</p> </td> </tr> <tr> <td class=\"indent2\"><span style=\"float: left;\">4.4.</span> <p class=\"indent2\">Clinicians should recognize and respond empathically to grief and loss among patients, families, and themselves. Clinicians should refer patients and families to psychosocial team members (eg, social workers, counselors, psychologists, psychiatrists, and clergy) when appropriate.</p> </td> </tr> <tr> <td class=\"indent2\"><span style=\"float: left;\">4.5.</span> <p class=\"indent2\">Clinicians should identify and suggest local resources to provide robust support to patients, families, and loved ones transitioning to end-of-life care.</p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Gilligan T, Coyle N, Frankel RM, et al. Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline. J Clin Oncol 2017. Reprinted with permission © 2017 American Society of Clinical Oncology.</div><div id=\"graphicVersion\">Graphic 114920 Version 1.0</div></div></div>"},"114924":{"type":"graphic_diagnosticimage","displayName":"Intestinal TB – CT enteroclysis I","title":"Intestinal tuberculosis - CT enteroclysis I","html":"<div class=\"graphic\"><div style=\"width: 783px\" class=\"figure\"><div class=\"ttl\">Intestinal tuberculosis - CT enteroclysis I</div><div class=\"cntnt\"><img style=\"width:763px; height:392px;\" src=\"images/ID/114924_IntstnlTBCTenteroclyssI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 40-year-old male patient presented with recurrent episodes of abdominal pain for one year with an episode of partial bowel obstruction, which was treated conservatively. Coronal reformatted images from CT enteroclysis demonstrate contiguous ileocecal involvement with ileal stricture (arrows) and large pericecal and mesenteric lymph nodes (asterisk) and small bowel feces sign (delta). These features are suggestive of intestinal tuberculosis.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Vineet Ahuja, MD, DM.</div><div id=\"graphicVersion\">Graphic 114924 Version 1.0</div></div></div>"},"114925":{"type":"graphic_diagnosticimage","displayName":"Intestinal TB – CT enteroclysis II","title":"Intestinal tuberculosis – CT enteroclysis II","html":"<div class=\"graphic\"><div style=\"width: 779px\" class=\"figure\"><div class=\"ttl\">Intestinal tuberculosis &ndash; CT enteroclysis II</div><div class=\"cntnt\"><img style=\"width:759px; height:389px;\" src=\"images/ID/114925_IntstnlTBCTenteroclysII.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial (A) and coronal reformatted (B) images demonstrate short segment annular terminal ileal stricture (arrow) with contiguous ileocecal involvement (asterisk).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Vineet Ahuja, MD, DM.</div><div id=\"graphicVersion\">Graphic 114925 Version 1.0</div></div></div>"},"114926":{"type":"graphic_diagnosticimage","displayName":"Intestinal TB – CT abdomen","title":"Intestinal tuberculosis with interval resolution","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Intestinal tuberculosis with interval resolution</div><div class=\"cntnt\"><img style=\"width:593px; height:761px;\" src=\"images/ID/114926_IntestinaTBCTabdomen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial images from contrast-enhanced CT demonstrating (A) ileocecal involvement (arrows) with ulceration (asterisk) and (B) complete resolution of radiographic findings after six months of antituberculous therapy.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Vineet Ahuja, MD, DM.</div><div id=\"graphicVersion\">Graphic 114926 Version 1.0</div></div></div>"},"114927":{"type":"graphic_table","displayName":"Summary of genes associated with LQTS","title":"Summary of heritable arrhythmia syndrome susceptibility genes: Long QT syndrome (LQTS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of heritable arrhythmia syndrome susceptibility genes: Long QT syndrome (LQTS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Gene</td> <td class=\"subtitle1\">Locus</td> <td class=\"subtitle1\">Protein</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Major LQTS genes</td> </tr> <tr> <td class=\"indent1\"><em>KCNQ1</em> (LQT1)</td> <td>11p15.5</td> <td>I<sub>Ks</sub> potassium channel alpha subunit (KVLQT1, Kv7.1)</td> </tr> <tr> <td class=\"indent1\"><em>KCNH2</em> (LQT2)</td> <td>7q35-36</td> <td>I<sub>Kr</sub> potassium channel alpha subunit (HERG, Kv11.1)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><em>SCN5A</em> (LQT3)</td> <td>3p21-p24</td> <td>Cardiac sodium channel alpha subunit (NaV1.5)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Minor LQTS genes</td> </tr> <tr> <td class=\"indent1\"><em>AKAP9</em></td> <td>7q21-q22</td> <td>Yotiao</td> </tr> <tr> <td class=\"indent1\"><em>CACNA1C</em></td> <td>12p13.3</td> <td>Voltage gated L-type calcium channel (CaV1.2)</td> </tr> <tr> <td class=\"indent1\"><em>CALM1</em></td> <td>14q32.11</td> <td>Calmodulin 1</td> </tr> <tr> <td class=\"indent1\"><em>CALM2</em></td> <td>2p21</td> <td>Calmodulin 2</td> </tr> <tr> <td class=\"indent1\"><em>CALM3</em></td> <td>19q13.2-q13.3</td> <td>Calmodulin 3</td> </tr> <tr> <td class=\"indent1\"><em>CAV3</em></td> <td>3p25</td> <td>Caveolin-3</td> </tr> <tr> <td class=\"indent1\"><em>KCNE1</em></td> <td>21q22.1</td> <td>Potassium channel beta subunit (MinK)</td> </tr> <tr> <td class=\"indent1\"><em>KCNE2</em></td> <td>21q22.1</td> <td>Potassium channel beta subunit (MiRP1)</td> </tr> <tr> <td class=\"indent1\"><em>KCNJ5</em></td> <td>11q24.3</td> <td>Kir3.4 subunit of I<sub>KACH</sub> channel</td> </tr> <tr> <td class=\"indent1\"><em>SCN4B</em></td> <td>11q23.3</td> <td>Sodium channel beta 4 subunit</td> </tr> <tr> <td class=\"indent1\"><em>SNTA1</em></td> <td>20q11.2</td> <td>Syntrophin-alpha 1</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Tester DJ, Ackerman MJ. Genetics of cardiac arrhythmias. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 10th ed, Mann DL, Zipes DP, Libby P, et al (Eds), Elsevier, Philadelphia 2015.</div><div id=\"graphicVersion\">Graphic 114927 Version 1.0</div></div></div>"},"114942":{"type":"graphic_diagnosticimage","displayName":"Intestinal tuberculosis - Endoscopy 1","title":"Intestinal tuberculosis - Endoscopy","html":"<div class=\"graphic\"><div style=\"width: 737px\" class=\"figure\"><div class=\"ttl\">Intestinal tuberculosis - Endoscopy</div><div class=\"cntnt\"><img style=\"width:717px; height:298px;\" src=\"images/ID/114942_Intestnl_TB_Endoscpy1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These endoscopy images of intestinal tuberculosis demonstrate a patulous ileocecal valve, scar changes, and multiple ulcers.</div><div class=\"graphic_reference\">Courtesy of Vineet Ahuja, MD, DM.</div><div id=\"graphicVersion\">Graphic 114942 Version 1.0</div></div></div>"},"114943":{"type":"graphic_diagnosticimage","displayName":"Intestinal tuberculosis - Endoscopy 2","title":"Healed intestinal tuberculosis - Endoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Healed intestinal tuberculosis - Endoscopy</div><div class=\"cntnt\"><img style=\"width:297px; height:252px;\" src=\"images/ID/114943_Intestnl_TB_Endoscpy2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This endoscopy image of healed intestinal tuberculosis demonstrates cecal cicatrization.</div><div class=\"graphic_reference\">Courtesy of Vineet Ahuja, MD, DM.</div><div id=\"graphicVersion\">Graphic 114943 Version 1.0</div></div></div>"},"114951":{"type":"graphic_figure","displayName":"Appearance and associations of the three majors types of GN","title":"Histologic appearance and clinical associations of the three major pathogenic types of glomerulonephritis","html":"<div class=\"graphic\"><div style=\"width: 678px\" class=\"figure\"><div class=\"ttl\">Histologic appearance and clinical associations of the three major pathogenic types of glomerulonephritis</div><div class=\"cntnt\"><img style=\"width:658px; height:332px;\" src=\"images/NEPH/114951_Apprassc3majorstypesGN.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">GN: glomerulonephritis; GBM: glomerular basement membrane; ANCA: antineutrophil cytoplasmic autoantibody; SLE: systemic lupus erythematosus; MPGN: membranoproliferative glomerulonephritis; IgA: immunoglobulin A.</div><div class=\"graphic_reference\">Courtesy of Jai Radhakrishnan, MD, MS. Images courtesy of M. Barry Stokes, MD.</div><div id=\"graphicVersion\">Graphic 114951 Version 1.0</div></div></div>"},"114952":{"type":"graphic_figure","displayName":"Incompetent inspiratory valve vs incompetent expiratory valve","title":"Incompetent inspiratory valve versus incompetent expiratory valve","html":"<div class=\"graphic\"><div style=\"width: 655px\" class=\"figure\"><div class=\"ttl\">Incompetent inspiratory valve versus incompetent expiratory valve</div><div class=\"cntnt\"><img style=\"width:635px; height:323px;\" src=\"images/ANEST/114952_Incp_nspy_vl_vs_incp_xpy_vl.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Capnography can help distinguish an incompetent inspiratory valve from an incompetent expiratory valve.<br />(A) Normally, the inspiratory and expiratory valves prevent rebreathing.<br />(B) An incompetent <strong>inspiratory</strong> valve causes some rebreathing, because exhaled gas flows into the inspiratory limb, which is small. On inspiration, end-tidal gas is re-inhaled, followed by fresh gas. The result is a long expiratory capnogram, a normal inspired CO<sub>2</sub>, and a slow rise in end-tidal CO<sub>2</sub>.<br />(C) An incompetent <strong>expiratory</strong> valve causes more rebreathing, because the expiratory limb contains the reservoir bag or ventilator bellows. On inspiration, fresh gas from the inspiratory hose, and end-tidal gas from the expiratory hose is re-inhaled. The result is a normal length expiratory capnogram, elevated inspired CO<sub>2</sub>, and a more rapid rise in end-tidal CO<sub>2</sub>. Increasing the fresh gas flow does not decrease the inspired CO<sub>2</sub> (which it does when the CO<sub>2</sub> absorbent is exhausted).</div><div class=\"graphic_footnotes\">CO<SUB>2</SUB>: carbon dioxide.</div><div id=\"graphicVersion\">Graphic 114952 Version 1.0</div></div></div>"},"114954":{"type":"graphic_figure","displayName":"Mapleson capnograms","title":"Mapleson capnograms","html":"<div class=\"graphic\"><div style=\"width: 704px\" class=\"figure\"><div class=\"ttl\">Mapleson capnograms</div><div class=\"cntnt\"><img style=\"width:684px; height:322px;\" src=\"images/ANEST/114954_Mapleson_capnograms.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Capnography can help titrate the appropriate fresh gas flow when using a Mapleson breathing circuit, and can indicate a leaking or detached fresh gas hose.<br />(A) With very high fresh gas flow rates, there may be little or no rebreathing and the capnogram will look \"normal\". However, the fresh gas flow is higher than it needs to be in this case.<br />(B) When the fresh gas flow is optimal, there will be some inspired CO<SUB>2</SUB>, but the end-tidal CO<SUB>2</SUB> will be normal with modest hyperventilation. The distinctive shape shown in panel B is from a Mapleson D (Bain) circuit, where fresh gas is inhaled followed by some exhaled gas.<br />(C) When the fresh gas flow is too low, or when the fresh gas hose is broken or disconnected, there will be high inspired CO<SUB>2</SUB> and no amount of hyperventilation will prevent hypercarbia.</div><div class=\"graphic_footnotes\">CO<SUB>2</SUB>: carbon dioxide.</div><div id=\"graphicVersion\">Graphic 114954 Version 1.0</div></div></div>"},"114960":{"type":"graphic_figure","displayName":"Steeple sign capnogram","title":"Steeple sign capnogram","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Steeple sign capnogram</div><div class=\"cntnt\"><img style=\"width:517px; height:315px;\" src=\"images/ANEST/114960_Steeple_sign_capnogram.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A \"steeple sign\" capnogram occurs during positive pressure ventilation when there is&nbsp;a leak in the sample line of a sidestream capnography monitor.&nbsp;This occurs because air entrained through the leak dilutes the sampled carbon dioxide, and the magnitude of the leak varies with phasic pressure changes in the breathing circuit.</div><div class=\"graphic_reference\">From: Kodali BS. Capnography outside the operating rooms. Anesthesiology 2013; 118:192. DOI: <A href=\"http://anesthesiology.pubs.asahq.org/article.aspx?articleid=2034665\" target=_blank>10.1097/ALN.0b013e318278c8b6</A>. Copyright © 2013 American Society of Anesthesiologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 114960 Version 2.0</div></div></div>"},"114962":{"type":"graphic_waveform","displayName":"Pediatric PAH ECG","title":"<P style=\"MARGIN-BOTTOM: 0pt; unicode-bidi: embed; WORD-BREAK: normal; DIRECTION: ltr; TEXT-ALIGN: left; MARGIN-LEFT: 0in; MARGIN-TOP: 0pt; language: en-US; mso-line-break-override: none; punctuation-wrap: hanging\">Electrocardiogram in a young child with ","html":"<div class=\"graphic\"><div style=\"width: 797px\" class=\"figure\"><div class=\"ttl\"><P style=\"MARGIN-BOTTOM: 0pt; unicode-bidi: embed; WORD-BREAK: normal; DIRECTION: ltr; TEXT-ALIGN: left; MARGIN-LEFT: 0in; MARGIN-TOP: 0pt; language: en-US; mso-line-break-override: none; punctuation-wrap: hanging\">Electrocardiogram in a young child with </div><div class=\"cntnt\"><img style=\"width:777px; height:499px;\" src=\"images/PEDS/114962_PediatricPAHECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">ECG obtained in a 3 year-old child with pulmonary hypertension. Findings include: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Right atrial enlargement (arrow): The P wave in lead II is &gt;2.5 mm. This is sometimes referred to as \"P pulmonale.\"</LI>&#xD;&#xA;<LI>Right ventricular hypertrophy: Tall R waves in V1 and deep S waves in V5 and V6 suggest RVH. R wave amplitude in V1 is 30 mm&nbsp;(upper limit of normal for this age is 20 mm).</LI>&#xD;&#xA;<LI>Rightward axis deviation: QRS axis in this child is 125 (upper limit of normal for this age is 110).</LI></OL></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; RVH: right ventricular hypertrophy.</div><div id=\"graphicVersion\">Graphic 114962 Version 3.0</div></div></div>"},"114963":{"type":"graphic_movie","displayName":"Normal walking gait upper body motion","title":"Normal walking gait upper body motion","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Normal walking gait upper body motion</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SM/114963_Normwalkupprbdymotnvid.mp4\" style=\"width:704px;height:416px\"></div><img style=\"width:670px; height:465px;\" src=\"images/SM/114963_Normwalkupprbdymotnimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In normal walking gait, the head moves slightly in the vertical plane, shoulder height and arm swing are symmetric, and the torso moves minimally in the coronal plane.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114963 Version 1.0</div></div></div>"},"114964":{"type":"graphic_movie","displayName":"Walking gait with lateral pelvic tilt","title":"Walking gait with lateral pelvic tilt","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Walking gait with lateral pelvic tilt</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SM/114964_Walkgaitlatpelvctltvid.mp4\" style=\"width:704px;height:352px\"></div><img style=\"width:470px; height:670px;\" src=\"images/SM/114964_Walkgaitlatpelvctltimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this video clip, the patient demonstrates excessive lateral pelvic tilt, seen best during left foot stance when the pelvis tilts to the right and the hip adducts.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114964 Version 1.0</div></div></div>"},"114965":{"type":"graphic_picture","displayName":"Full hip flexion during walking gait","title":"Full hip flexion during walking gait","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Full hip flexion during walking gait</div><div class=\"cntnt\"><img style=\"width:474px; height:750px;\" src=\"images/SM/114965_Fullhipflexnwalkinggait.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the photograph above, the patient's right leg is in full hip flexion at touch down, while the left leg is in full hip extension.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114965 Version 1.0</div></div></div>"},"114967":{"type":"graphic_picture","displayName":"Start of hip extension during running gait","title":"Start of hip extension during running gait","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Start of hip extension during running gait</div><div class=\"cntnt\"><img style=\"width:458px; height:752px;\" src=\"images/SM/114967_Starthipextrunninggait.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During running gait, the hip begins to extend before touchdown occurs, as seen with the right leg in the photograph above.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114967 Version 1.0</div></div></div>"},"114968":{"type":"graphic_movie","displayName":"Knee motion during walking gait","title":"Knee motion during walking gait","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Knee motion during walking gait</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SM/114968_Kneemotionwalknggaitvid.mp4\" style=\"width:704px;height:416px\"></div><img style=\"width:756px; height:590px;\" src=\"images/SM/114968_Kneemotionwalknggaitimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal knee motion during walking gait is demonstrated in this video clip.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114968 Version 1.0</div></div></div>"},"114969":{"type":"graphic_picture","displayName":"Knee valgus during walking gait","title":"Knee valgus during walking gait","html":"<div class=\"graphic\"><div style=\"width: 779px\" class=\"figure\"><div class=\"ttl\">Knee valgus during walking gait</div><div class=\"cntnt\"><img style=\"width:759px; height:646px;\" src=\"images/SM/114969_Kneevalguswalkinggait.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These images above provide a contrast between normal knee motion (B) and slight valgus motion (A). In the image of the valgus knee, the patella lies medial to a line drawn between the hip and ankle joints. Note also that the knees are closer together as they pass one another in the patient with valgus knee.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114969 Version 1.0</div></div></div>"},"114970":{"type":"graphic_picture","displayName":"External tibial torsion","title":"External tibial torsion","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">External tibial torsion</div><div class=\"cntnt\"><img style=\"width:491px; height:752px;\" src=\"images/SM/114970_Externaltibialtorsion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above shows a patient with external tibial torsion causing toe-out. The vertical line drawn from the patella to the ground highlights the external torsion of the tibia, with the resulting outward orientation of both feet. </div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 114970 Version 1.0</div></div></div>"},"114971":{"type":"graphic_picture","displayName":"Dermoscopy of androgenetic alopecia","title":"Dermoscopy of androgenetic alopecia","html":"<div class=\"graphic\"><div style=\"width: 771px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of androgenetic alopecia</div><div class=\"cntnt\"><img style=\"width:751px; height:563px;\" src=\"images/DERM/114971_Dermoscopyandrgntcalopcia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Marked variability in the diameter of hair shafts.</div><div id=\"graphicVersion\">Graphic 114971 Version 1.0</div></div></div>"},"114973":{"type":"graphic_picture","displayName":"Dermoscopy of androgenetic alopecia 2","title":"Dermoscopy of androgenetic alopecia","html":"<div class=\"graphic\"><div style=\"width: 773px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of androgenetic alopecia</div><div class=\"cntnt\"><img style=\"width:753px; height:564px;\" src=\"images/DERM/114973_Drmscpyandrogntcalopecia2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hair diameter variability among hairs emerging from the same follicle.</div><div id=\"graphicVersion\">Graphic 114973 Version 1.0</div></div></div>"},"114974":{"type":"graphic_picture","displayName":"Dermoscopy of telogen effluvium","title":"Dermoscopy of telogen effluvium","html":"<div class=\"graphic\"><div style=\"width: 772px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of telogen effluvium</div><div class=\"cntnt\"><img style=\"width:752px; height:563px;\" src=\"images/DERM/114974_Dermoscpytelogeneffluvium.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Terminal hair shafts with uniform diameter and multiple short, regrowing hairs.</div><div id=\"graphicVersion\">Graphic 114974 Version 1.0</div></div></div>"},"114977":{"type":"graphic_picture","displayName":"Dermoscopy of alopecia areata yellow dots","title":"Dermoscopy of alopecia areata","html":"<div class=\"graphic\"><div style=\"width: 772px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of alopecia areata</div><div class=\"cntnt\"><img style=\"width:752px; height:563px;\" src=\"images/DERM/114977_Drmscpyalpciaartayllwdt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Round, yellow to yellow-pink dots.</div><div id=\"graphicVersion\">Graphic 114977 Version 1.0</div></div></div>"},"114978":{"type":"graphic_picture","displayName":"Dermoscopy of alopecia areata","title":"Dermoscopy of alopecia areata","html":"<div class=\"graphic\"><div style=\"width: 738px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of alopecia areata</div><div class=\"cntnt\"><img style=\"width:718px; height:537px;\" src=\"images/DERM/114978_Dermoscopyalopeciaareata.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Exclamation point hairs (arrow), broken hairs, and black dots (arrowhead).</div><div id=\"graphicVersion\">Graphic 114978 Version 1.0</div></div></div>"},"114979":{"type":"graphic_picture","displayName":"Dermoscopy of alopecia areata - broken hairs","title":"Dermoscopy of alopecia areata","html":"<div class=\"graphic\"><div style=\"width: 770px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of alopecia areata</div><div class=\"cntnt\"><img style=\"width:750px; height:562px;\" src=\"images/DERM/114979_Dermoscopyalpcartbrknhr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple broken hairs of different lengths in a patient with acute disease.</div><div id=\"graphicVersion\">Graphic 114979 Version 1.0</div></div></div>"},"114983":{"type":"graphic_algorithm","displayName":"Cervical cyto followup overvw","title":"Algorithm: Overview of follow-up of cervical cytology","html":"<div class=\"graphic\"><div style=\"width: 1199px\" class=\"figure\"><div class=\"ttl\">Algorithm: Overview of follow-up of cervical cytology</div><div class=\"cntnt\"><img style=\"width:1179px; height:461px;\" src=\"images/ONC/114983_Cervicacytofollwupovervw.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HPV: human papillomavirus; EC/TZ: endocervical/transformation zone; ASCCP: American Society for Colposcopy and Cervical Pathology.<br />* United States cervical cancer screening guidelines recommend screening for most women from age 21 to 65 years old. Screening may be initiated earlier for women with human immunodeficiency infection, immunocompromise, or in-utero exposure to diethylstilbestrol. For women 21 to 29 years old, cervical cytology alone is recommended. Cervical cytology and HPV cotesting are recommended for women ≥30 years old. HPV testing refers to a test for HPV strains that are high risk for causing cervical cancer.<br />¶ Quality indicators on a cervical cytology report include: Absent EC/TZ component, obscuring factors (eg, blood, inflammation), or interfering substances (eg, lubricant).<br />Δ Risk factors include: &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>A previous unexplained glandular abnormality (eg, atypical glandular cells with no finding of CIN or adenocarcinoma in situ on further evaluation).</LI>&#xD;&#xA;<LI>A positive high-risk HPV test within 12 months.</LI>&#xD;&#xA;<LI>Clinician's inability to clearly visualize the cervix or sample the endocervical canal.</LI>&#xD;&#xA;<LI>Immunosuppression (this is not considered a criterion for more frequent testing after a Pap with obscuring factors by some experts).</LI>&#xD;&#xA;<LI>Similar obscuring factor (blood or inflammation) in consecutive cervical cytology results.</LI>&#xD;&#xA;<LI>Insufficient previous screening. Some experts repeat a Pap at 12 months for these patients.</LI></UL><FONT class=lozenge>◊</FONT> The ASCCP publishes algorithms for the management of cytologic and histologic cervical abnormalities; refer to UpToDate topics on abnormal results of cervical cytology and cervical intraepithelial neoplasia.<br />§ For pregnant patients with partially obscuring blood or inflammation, it is preferred to repeat the cervical cytology postpartum.</div><div id=\"graphicVersion\">Graphic 114983 Version 1.0</div></div></div>"},"114984":{"type":"graphic_picture","displayName":"Dermoscopy of traction alopecia","title":"Dermoscopy of traction alopecia","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of traction alopecia</div><div class=\"cntnt\"><img style=\"width:562px; height:752px;\" src=\"images/DERM/114984_Dermoscoptractionalopecia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hair cast (arrow) at the periphery of a patch of alopecia.</div><div id=\"graphicVersion\">Graphic 114984 Version 1.0</div></div></div>"},"114985":{"type":"graphic_picture","displayName":"Dermoscopy of dissecting cellulitis of the scalp","title":"Dermoscopy of dissecting cellulitis of the scalp","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of dissecting cellulitis of the scalp</div><div class=\"cntnt\"><img style=\"width:535px; height:718px;\" src=\"images/DERM/114985_Drmscpydsctngcellltssclp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Black dots (arrow) and follicular keratotic plug (arrowhead).</div><div id=\"graphicVersion\">Graphic 114985 Version 1.0</div></div></div>"},"114986":{"type":"graphic_picture","displayName":"Dermoscopy of lichen planopilaris","title":"Dermoscopy of lichen planopilaris","html":"<div class=\"graphic\"><div style=\"width: 773px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of lichen planopilaris</div><div class=\"cntnt\"><img style=\"width:753px; height:563px;\" src=\"images/DERM/114986_Dermscpylichenplanopilars.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Loss of follicular ostia and peripilar casts (arrow).</div><div id=\"graphicVersion\">Graphic 114986 Version 1.0</div></div></div>"},"114987":{"type":"graphic_picture","displayName":"Dermoscopy of lichen planopilaris 2","title":"Dermoscopy of lichen planopilaris","html":"<div class=\"graphic\"><div style=\"width: 581px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of lichen planopilaris</div><div class=\"cntnt\"><img style=\"width:561px; height:752px;\" src=\"images/DERM/114987_Dermoscopylichenplnplrs2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Loss of follicular ostia and peripilar casts (arrow) surrounding tufts of hair.</div><div id=\"graphicVersion\">Graphic 114987 Version 1.0</div></div></div>"},"114988":{"type":"graphic_picture","displayName":"Dermoscopy of frontal fibrosing alopecia","title":"Dermoscopy of frontal fibrosing alopecia","html":"<div class=\"graphic\"><div style=\"width: 770px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of frontal fibrosing alopecia</div><div class=\"cntnt\"><img style=\"width:750px; height:421px;\" src=\"images/DERM/114988_Dermscpyftlfbrsgalopecia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripilar casts (arrow) and loss of vellus hairs.</div><div id=\"graphicVersion\">Graphic 114988 Version 1.0</div></div></div>"},"114989":{"type":"graphic_picture","displayName":"Dermoscopy of scalp discoid lupus erythematosus","title":"Dermoscopy of discoid lupus erythematosus on the scalp","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of discoid lupus erythematosus on the scalp</div><div class=\"cntnt\"><img style=\"width:562px; height:752px;\" src=\"images/DERM/114989_Dmspysclpdcdlpserythmts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse scaling, loss of pigment network, and follicular keratotic plugs.</div><div id=\"graphicVersion\">Graphic 114989 Version 1.0</div></div></div>"},"114990":{"type":"graphic_picture","displayName":"Dermoscopy of scalp discoid lupus erythematosus 2","title":"Dermoscopy of discoid lupus erythematosus on the scalp","html":"<div class=\"graphic\"><div style=\"width: 771px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of discoid lupus erythematosus on the scalp</div><div class=\"cntnt\"><img style=\"width:751px; height:563px;\" src=\"images/DERM/114990_Dmspyslpdcdlpserythmts2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Follicular, red dots.</div><div id=\"graphicVersion\">Graphic 114990 Version 1.0</div></div></div>"},"114991":{"type":"graphic_picture","displayName":"Dermoscopy of scalp discoid lupus erythematosus 3","title":"Dermoscopy of discoid lupus erythematosus on the scalp","html":"<div class=\"graphic\"><div style=\"width: 585px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of discoid lupus erythematosus on the scalp</div><div class=\"cntnt\"><img style=\"width:565px; height:754px;\" src=\"images/DERM/114991_Dmspyslpdcdlpserythmts3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Enlarged branching vessels and keratotic plugs.</div><div id=\"graphicVersion\">Graphic 114991 Version 1.0</div></div></div>"},"114992":{"type":"graphic_picture","displayName":"Dermoscopy of folliculitis decalvans","title":"Dermoscopy of folliculitis decalvans","html":"<div class=\"graphic\"><div style=\"width: 772px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of folliculitis decalvans</div><div class=\"cntnt\"><img style=\"width:752px; height:563px;\" src=\"images/DERM/114992_Dermoscopyfollcultsdclvns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tufts of hair surrounded by thick peripilar casts.</div><div id=\"graphicVersion\">Graphic 114992 Version 1.0</div></div></div>"},"114993":{"type":"graphic_picture","displayName":"Dermoscopy of central centrifugal cicatricial alopecia","title":"Dermoscopy of central centrifugal cicatricial alopecia","html":"<div class=\"graphic\"><div style=\"width: 581px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of central centrifugal cicatricial alopecia</div><div class=\"cntnt\"><img style=\"width:561px; height:753px;\" src=\"images/DERM/114993_Drmscpycntrlcntrfglcctrclalpc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gray-white halos (arrow) around follicular ostia and irregular distribution of pinpoint white dots (arrowhead).</div><div id=\"graphicVersion\">Graphic 114993 Version 1.0</div></div></div>"},"114994":{"type":"graphic_picture","displayName":"Dermoscopy of scalp psoriasis","title":"Dermoscopy of scalp psoriasis","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of scalp psoriasis</div><div class=\"cntnt\"><img style=\"width:754px; height:565px;\" src=\"images/DERM/114994_Dermoscopyscalppsoriasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Twisted capillary loops (arrow).</div><div id=\"graphicVersion\">Graphic 114994 Version 1.0</div></div></div>"},"114995":{"type":"graphic_picture","displayName":"Dermoscopy of tinea capitis - comma hair","title":"Dermoscopy of tinea capitis","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of tinea capitis</div><div class=\"cntnt\"><img style=\"width:754px; height:565px;\" src=\"images/DERM/114995_Dermscpytncptscommahair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Comma hair (arrow).</div><div id=\"graphicVersion\">Graphic 114995 Version 1.0</div></div></div>"},"114996":{"type":"graphic_picture","displayName":"Dermoscopy of pediculosis capitis - louse","title":"Dermoscopy of pediculosis capitis","html":"<div class=\"graphic\"><div style=\"width: 773px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of pediculosis capitis</div><div class=\"cntnt\"><img style=\"width:753px; height:565px;\" src=\"images/DERM/114996_Dermoscpypdclsscptslouse.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Head louse.</div><div id=\"graphicVersion\">Graphic 114996 Version 1.0</div></div></div>"},"114997":{"type":"graphic_picture","displayName":"Dermoscopy of pediculosis capitis - nit","title":"Dermoscopy of pediculosis capitis","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of pediculosis capitis</div><div class=\"cntnt\"><img style=\"width:754px; height:565px;\" src=\"images/DERM/114997_Dermoscopypdclsscaptsnit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Viable nit.</div><div id=\"graphicVersion\">Graphic 114997 Version 1.0</div></div></div>"}};